var title_f40_32_41472="Ofloxacin: Patient drug information";
var content_f40_32_41472=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ofloxacin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/20/30020?source=see_link\">",
"       Ofloxacin (ophthalmic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?16/6/16484?source=see_link\">",
"       Ofloxacin (otic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/29/30165?source=see_link\">",
"       Ofloxacin (systemic): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11811 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-D8D1174216-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_32_41472=[""].join("\n");
var outline_f40_32_41472=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/20/30020?source=related_link\">",
"      Ofloxacin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?16/6/16484?source=related_link\">",
"      Ofloxacin (otic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/29/30165?source=related_link\">",
"      Ofloxacin (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_32_41473="HPV DNA testing cervical cancer screening over 30";
var content_f40_32_41473=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F61527&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F61527&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 620px\">",
"   <div class=\"ttl\">",
"    Use of HPV DNA as an adjunct to cytology for cervical cancer screening in women 30 years and older",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 600px; height: 286px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Management of abnormal cytology is discussed in related topics in UpToDate (see \"Cervical cytology: Evaluation of atypical and malignant glandular cells\" and \"Cervical cytology: Evaluation of atypical squamous cells (ASC-US and ASC-H)\" and \"Cervical cytology: Evaluation of low grade squamous intraepithelial lesions\" and \"Cervical cytology: Evaluation of high grade squamous intraepithelial lesions\" and \"Cervical intraepithelial neoplasia: Management\").",
"    <div class=\"footnotes\">",
"     * Test only for high-risk (oncogenic) types of HPV.",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted from: The Journal of Lower Genital Tract Diseases Vol. 11 Issue 4, with the permission of ASCCP &copy; American Society for Colposcopy and Cervical Pathology 2007. No copies of the algorithms may be made without the prior consent of ASCCP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_32_41473=[""].join("\n");
var outline_f40_32_41473=null;
var title_f40_32_41474="Syncytial form nodular sclerosis HL";
var content_f40_32_41474=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F82231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F82231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Syncytial form of nodular sclerosis Hodgkin lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 204px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sheets of lacunar cells are clustered around a center area of necrosis in the syncytial form of nodular sclerosis Hodgkin lymphoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Weiss LM, Warnke RA, Hansmann ML, et al, Pathology of Hodgkin Lymphoma. In: Hodgkin Lymphoma, 2nd ed, Hoppe RT, Mauch PT, Armitage JO, et al, (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_32_41474=[""].join("\n");
var outline_f40_32_41474=null;
var title_f40_32_41475="Paraneoplastic pemphigus tongue";
var content_f40_32_41475=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F79518&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F79518&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Paraneoplastic pemphigus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erosions are present on the tongue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_32_41475=[""].join("\n");
var outline_f40_32_41475=null;
var title_f40_32_41476="Starting solid foods during infancy";
var content_f40_32_41476=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Starting solid foods during infancy (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?40/32/41476/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/32/41476/contributors\" id=\"au4794\">",
"       Teresa K Duryea, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/32/41476/contributors\" id=\"au1071\">",
"       David M Fleischer, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?40/32/41476/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/32/41476/contributors\" id=\"se4617\">",
"       Kathleen J Motil, MD, PhD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/32/41476/contributors\" id=\"se4584\">",
"       Jan E Drutz, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?40/32/41476/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/32/41476/contributors\" id=\"de5754\">",
"       Mary M Torchia, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?40/32/41476?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      SOLID FOODS OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     The practice of introducing complementary foods (solid foods and liquids other than breast milk or infant formula) during the first year of life has varied over time and across cultures. The American Academy of Pediatrics (AAP) and World Health Organization (WHO) currently recommend that complementary foods be introduced around six months of age [",
"     <a class=\"abstract\" href=\"mobipreview.htm?40/32/41476/abstract/1,2\">",
"      1,2",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     This article will review when and how to start giving complementary foods, including which foods should be avoided. More detailed information about starting solids is available separately. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/43/10938?source=see_link\">",
"      \"Introducing solid foods and vitamin and mineral supplementation during infancy\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Certain vitamins and minerals may be lacking in an infant&rsquo;s diet, especially in infants who were born prematurely. The importance of iron, fluoride, vitamin B12, and vitamin D will also be discussed here.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHEN SHOULD INFANTS START SOLIDS?",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Developmental milestones",
"     </span>",
"     &nbsp;&mdash;&nbsp;The best time to start solid foods depends not only on your child's age, but also on your child's ability to sit up, support the head, and meet other developmental milestones. These guidelines apply to all children, including those who have delays with gross motor skills. The infant should be able to do the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Sit with support",
"      </li>",
"      <li>",
"       Have good head and neck control",
"      </li>",
"      <li>",
"       Push up with straight elbows from lying face down",
"      </li>",
"      <li>",
"       Show readiness for varied textures of supplemental foods by placing their hands or toys in their mouth",
"      </li>",
"      <li>",
"       Lean forward and open the mouth when interested in food, and lean back and turn away when uninterested in the food or not hungry",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Additional skills are necessary before an infant should be allowed to progress to eating finger foods:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       By 8 to 10 months, infants begin to have the skills necessary to eat finger foods independently (can sit independently, grasp and release food, chew food [even without teeth], and swallow)",
"      </li>",
"      <li>",
"       By 12 months, fine motor skills improve, allowing the child to grasp pieces of food between two fingers",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Why wait to start solids?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Introducing solid foods before age four to six months is not helpful and could be harmful. Reasons that expert groups recommend delaying the introduction of solid foods include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Introducing solid foods before an infant is four to six months of age may interfere with the child's ability to take in an adequate number of calories or nutrients and may increase the risk of developing food allergies.",
"      </li>",
"      <li>",
"       Young infants do not have the coordination",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       skills to safely swallow solid foods, which could lead to aspiration (inhaling",
"       <span class=\"nowrap\">",
"        food/liquid",
"       </span>",
"       into the lungs).",
"      </li>",
"      <li>",
"       Infants have a reflex (called the extrusion reflex), which causes them to raise the tongue and push against any object that is placed between their lips. This reflex usually disappears between four and five months of age. Trying to spoon-feed a child who still has the extrusion reflex can be a frustrating and difficult experience for both the parent and the infant.",
"      </li>",
"      <li>",
"       By four months of age, most infants usually have doubled their birth weight. When your infant has doubled",
"       <span class=\"nowrap\">",
"        his/her",
"       </span>",
"       birth weight and weighs at least 13 pounds (5.9 kg), you may need to begin supplementing their liquid diet with additional foods to support growth and satisfy hunger.",
"      </li>",
"      <li>",
"       Delaying solid food intake until after an infant is four months of age may reduce the child's risk of developing atopic dermatitis (eczema).",
"      </li>",
"      <li>",
"       Withholding solid foods after the infant is six months of age may lead to decreased growth because the child may not consume adequate calories from breast milk or formula alone. In addition, delaying beyond six months may lead to the child's resistance to trying solid foods. Withholding solid foods until after the infant is six months of age does not appear to prevent the development of allergies or eczema.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      SOLID FOOD PRECAUTIONS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Foods to avoid",
"     </span>",
"     &nbsp;&mdash;&nbsp;Certain foods should not be given to any child under 12 months, including cow's milk, hard, round foods that could cause a child to choke (eg, nuts, grapes, raw carrots, or candies), and honey. Cow's milk is not recommended because it does not contain adequate iron; honey is not recommended due to the potential risk of exposure to a harmful bacterial toxin (botulism poisoning). (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/36/37448?source=see_link\">",
"      \"Botulism\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Food allergy concerns",
"     </span>",
"     &nbsp;&mdash;&nbsp;An infant is said to be at \"high risk\" for developing allergic disease if there is at least one first-degree relative (parent or sibling) with an allergic condition, including a documented food allergy, asthma, allergic rhinitis, or atopic dermatitis (eczema). (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/47/29429?source=see_link\">",
"      \"Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/23/15730?source=see_link\">",
"      \"Patient information: Atopic dermatitis (eczema) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Previously, parents were told to delay giving highly allergenic foods, such as eggs, peanuts, tree nuts, fish, and shellfish, for months or years longer than other foods. However, studies do not show enough evidence in support of waiting to introduce these foods [",
"     <a class=\"abstract\" href=\"mobipreview.htm?40/32/41476/abstract/3\">",
"      3",
"     </a>",
"     ]. Experts now recommend that high-risk infants be introduced to traditional supplemental foods between four and six months of age. (See",
"     <a class=\"local\" href=\"#H11\">",
"      'Pur&eacute;ed foods'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     If the infant has no signs of allergy (including eczema) with the initial foods, additional foods can be introduced gradually, including the highly allergenic foods (eg, cow&rsquo;s milk, eggs, peanuts and tree nuts [although not whole nuts because of choking risk], soy, wheat, fish, and shellfish). Whole cow's milk should not be given to any child until after age 12 months, but yogurt and cheese can be given before age one year. (See",
"     <a class=\"local\" href=\"#H6\">",
"      'Foods to avoid'",
"     </a>",
"     above.)",
"    </p>",
"    <p>",
"     The safest way to introduce highly allergenic foods has not been studied. It is possible for an allergic reaction to occur the first time the child eats a particular food. We recommend giving highly allergenic foods (eg, cow's milk, eggs, peanut butter, soy, wheat, fish, and shellfish) to high-risk children in the following manner (see",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/37/25175?source=see_link\">",
"      \"Introducing formula and solid foods to infants at risk for allergic disease\"",
"     </a>",
"     ):",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The infant can be given an initial taste of one of these foods at home, rather than at day care or at a restaurant",
"      </li>",
"      <li>",
"       If there is no apparent reaction, the food can be introduced in gradually increasing amounts",
"      </li>",
"      <li>",
"       If the infant has signs or symptoms of an allergic reaction or develops a skin rash after eating a food, consultation with your child's healthcare provider",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       allergist is suggested before other new foods are offered, especially the highly allergenic foods (see",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/47/29429?source=see_link\">",
"        \"Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       If an infant has a sibling with documented food allergy (eg, peanut allergy, which has a 7 percent risk of peanut allergy among siblings), has a previous food allergy, or has moderate to severe atopic dermatitis that is difficult to control, an allergy evaluation may be recommended prior to introducing the highly allergenic foods",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      TYPES OF SUPPLEMENTAL FOODS",
"     </span>",
"    </p>",
"    <p>",
"     There is no one food that is recommended as a first food. Single-ingredient foods should be introduced first, one at a time, every few days, to determine if the child has an allergic reaction. As solid foods are introduced, infants should consume no more than 28 to 32 ounces of formula per day. Breastfed children can continue to nurse on demand.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Cereal",
"     </span>",
"     &nbsp;&mdash;&nbsp;Single-grain infant cereal is a good first supplemental food because it supplies additional calories and iron. Rice cereal is traditionally offered first because it is widely available and is least likely to cause an allergic reaction. However, wheat products (in cereal or other foods) may be offered by six months of age.",
"    </p>",
"    <p>",
"     Infant cereals can be prepared by adding breast milk, infant formula, or water. The consistency should initially be thin, and may be made thicker over time. Cereal should be offered initially by spoon in small amounts (one teaspoon [5 mL]) at the end of breast- or bottle-feeding. Spoon-feeding helps to develop the infant's ability to coordinate mouth and swallowing movements as well as enhance future speech development. Gradually increase the amount of cereal to one to four tablespoons (15 to 60 mL) twice per day (",
"     <a class=\"graphic graphic_table graphicRef73992 \" href=\"mobipreview.htm?27/10/27821\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     If the child refuses or appears uninterested in the cereal, try again the following day using a thinner mixture.",
"    </p>",
"    <p>",
"     Cereal should not be added to a bottle unless this is recommended by a healthcare provider as a treatment for gastroesophageal reflux (GER). Feeding cereal from a bottle prevents the child from learning to eat with a spoon. Infants with GER should be given cereal from a spoon in addition to the cereal in a bottle. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/16/16643?source=see_link\">",
"      \"Patient information: Acid reflux (gastroesophageal reflux) in infants (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      Does cereal help a child sleep through the night?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most parents are eager for their infant to sleep through the night. However, there is no evidence that giving cereal to a child who is younger than four to six months old will help him or her to sleep better [",
"     <a class=\"abstract\" href=\"mobipreview.htm?40/32/41476/abstract/4,5\">",
"      4,5",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Pur&eacute;ed foods",
"     </span>",
"     &nbsp;&mdash;&nbsp;Single-ingredient pur&eacute;ed foods, including vegetables, fruits, and meats, should be introduced one at a time, every few days. If the child has no signs or symptoms of an allergic reaction, a second food may be added. Signs and symptoms of a food allergy include hives (skin welts) or other skin rash, facial swelling, vomiting, diarrhea, coughing, wheezing, difficulty breathing, weakness, or pale skin. Parents should consult the child's healthcare provider if any of these problems occur. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/47/29429?source=see_link\">",
"      \"Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The goal is to expose the infant to new flavors and textures of food. The amount eaten is less important. The order in which foods are introduced (vegetable, fruit, or meat first) is probably less important than the texture and consistency of the food.",
"    </p>",
"    <p>",
"     By the time an infant is eight months of age, we suggest that the child consume approximately",
"     <span class=\"nowrap\">",
"      1/2",
"     </span>",
"     cup (4 ounces) of vegetables and",
"     <span class=\"nowrap\">",
"      1/2",
"     </span>",
"     cup of fruit per day (",
"     <a class=\"graphic graphic_table graphicRef73992 \" href=\"mobipreview.htm?27/10/27821\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       First foods should be finely pur&eacute;ed, contain only one ingredient, and should not contain additives (salt, sugar). Vitamin C (also called ascorbic acid) is often added to commercially prepared infant foods.",
"      </li>",
"      <li>",
"       Second foods are pur&eacute;ed or strained, often contain two or more ingredients (eg, fruit and grain, meat and vegetable), and should not contain additives (salt, sugar). Combination foods may be given after the child tolerates the individual components. Once thin pur&eacute;es are tolerated, thicker pur&eacute;es can be introduced.",
"      </li>",
"      <li>",
"       Third foods are usually combinations of food types, some of which have texture to encourage chewing. Some are seasoned with spices, although foods should not contain added salt or sugar. Chunkier blends often contain pur&eacute;ed food with small pieces of pasta, vegetables, or meat.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Safety issues with jarred baby food",
"     </span>",
"     &nbsp;&mdash;&nbsp;Safety issues regarding jars of baby food include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       After opening a jar or container of baby food, store it carefully to avoid spoilage.",
"      </li>",
"      <li>",
"       Jars of infant foods, once opened, should be discarded after two to three days according to most manufacturers.",
"      </li>",
"      <li>",
"       Store-bought foods should be served from a bowl rather than out of the jar to avoid contaminating the unused portion. Food left in the bowl should be discarded.",
"      </li>",
"      <li>",
"       Jarred foods may be served cold, room temperature, or warm.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Preparing baby food at home",
"     </span>",
"     &nbsp;&mdash;&nbsp;You may choose to make your own pur&eacute;ed baby food for a variety of reasons (eg, freshness, increased variety and texture, cost, avoidance of preservatives, etc). The",
"     <a class=\"external\" href=\"file://www.fns.usda.gov/tn/Resources/feedinginfants-ch12.pdf\">",
"      United States Department of Agriculture",
"     </a>",
"     provides guidelines for safe preparation of baby food at home.",
"    </p>",
"    <p>",
"     It is important to be careful when preparing certain foods at home. Home-prepared spinach, beets, green beans, squash, and carrots should not be given to infants younger than four months of age because they may contain enough of a chemical (nitrates) to cause a condition that reduces the amount of oxygen carried by the blood (methemoglobinemia) [",
"     <a class=\"abstract\" href=\"mobipreview.htm?40/32/41476/abstract/6\">",
"      6",
"     </a>",
"     ]. In addition, home-prepared foods should not be given as infant food if they contain large amounts of added salt",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     sugar [",
"     <a class=\"abstract\" href=\"mobipreview.htm?40/32/41476/abstract/5\">",
"      5",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Finger foods",
"     </span>",
"     &nbsp;&mdash;&nbsp;As the child gains the ability to feed",
"     <span class=\"nowrap\">",
"      himself/herself,",
"     </span>",
"     a greater variety of \"adult\" foods can be offered, including finely chopped, soft foods (",
"     <a class=\"graphic graphic_table graphicRef73992 \" href=\"mobipreview.htm?27/10/27821\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Foods that are choking hazards are not recommended in children younger than four years. These foods include hot dogs, peanuts, tree nuts, grapes, raisins, raw carrots, popcorn, and round candies.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Fruit juice",
"     </span>",
"     &nbsp;&mdash;&nbsp;Juices may be introduced when an infant can drink from a cup, beginning at approximately six months of age. Before an infant reaches six months of age, fruit juice is not necessary or recommended (",
"     <a class=\"graphic graphic_table graphicRef73992 \" href=\"mobipreview.htm?27/10/27821\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Fruit juice should be labeled as 100 percent juice (as opposed to \"fruit drinks\"), and should have added vitamin C. The American Academy of Pediatrics (AAP) recommends the following guidelines:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Fruit juice should be offered only from a cup (not a bottle or sippy cup).",
"      </li>",
"      <li>",
"       A child should not drink more than four to six ounces of fruit juice per day. Individual servings may be diluted with water if desired.",
"      </li>",
"      <li>",
"       Fruit juice should be used as part of a meal or a snack and should not be sipped throughout the day or given at bedtime.",
"      </li>",
"      <li>",
"       Drinking too much juice can lead to overnutrition or undernutrition, diarrhea, gas, bloating, and dental cavities.",
"      </li>",
"      <li>",
"       Fruit juice consumed by infants and children should be pasteurized (heat treated to kill harmful bacteria). For example, infants should not be given fresh-pressed apple cider.",
"      </li>",
"      <li>",
"       Calcium-fortified juices provide a good source of calcium. However, juice should not be given in place of breast milk, formula, or cow's milk, because it lacks other important nutrients.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      VITAMIN AND MINERAL SUPPLEMENTS",
"     </span>",
"    </p>",
"    <p>",
"     Some children require vitamin or mineral supplements.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Iron",
"     </span>",
"     &nbsp;&mdash;&nbsp;Iron deficiency is the most common nutrient deficiency in the United States. The amount of iron required depends upon a child's gestational age and birth weight.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Premature and very low birth weight infants are at risk for iron deficiency, and should be given an iron supplement (in the form of multivitamin drops) beginning at one month of age and continuing until the child is at least 12 months of age.",
"      </li>",
"      <li>",
"       Infants who are not premature who are given iron-fortified formula usually do not need any additional iron supplementation. Low-iron formulas are not recommended in any situation and are no longer available in the United States.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     After four to six months of age, a full-term breastfed infant may not get an adequate amount of iron from breast milk alone. At this time, some form of iron supplementation (eg, iron-fortified infant cereal) is recommended. An average of two servings (2 ounces of dry cereal per serving) of iron-fortified cereal per day is sufficient to meet an infant's daily iron requirement. Additional iron can be given (in the form of multivitamin drops) if the infant cannot consume an adequate amount of iron-fortified cereal. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/19/1333?source=see_link\">",
"      \"Patient information: Breastfeeding guide (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     After solid foods have been introduced, at least one feeding per day should contain foods rich in vitamin C (eg, citrus fruits and juices, cantaloupe, strawberries, tomatoes, and dark green vegetables) to promote iron absorption from iron-rich foods (such as pur&eacute;ed meat) eaten during the same meal.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Fluoride",
"     </span>",
"     &nbsp;&mdash;&nbsp;Fluoride is a mineral that is often found in drinking water. Fluoride can reduce the risk that a young child will develop dental caries, also known as cavities. However, not all drinking water contains an adequate amount of fluoride.",
"    </p>",
"    <p>",
"     A fluoride supplement is recommended for children between six months and three years if the fluoride level in the local water supply is low. To determine the level of fluoride content in your water supply, call the water department or bottler, or arrange to have well water tested.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Vitamin B12",
"     </span>",
"     &nbsp;&mdash;&nbsp;The body requires a source of vitamin B12 to maintain blood cells; meat, eggs, and dairy products are the only food sources of vitamin B12. Low levels of vitamin B12 can lead to anemia, developmental delay, and other problems.",
"    </p>",
"    <p>",
"     A multivitamin supplement that includes B12 is recommended for breastfeeding infants of strict vegetarian (vegan) mothers, and for infants who are fed a vegetarian diet. Adequate B12 is available in most non-prescription infant vitamin drops and in certain brands of nutritional yeasts, most ready-to-eat cereals, many meat substitutes, and some milk alternatives. Fortified soy milk is a good source of B12 for children.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Vitamin D",
"     </span>",
"     &nbsp;&mdash;&nbsp;The body requires vitamin D to absorb calcium and phosphorus, which are essential minerals for the formation of bones. Inadequate levels of vitamin D in children can lead to a condition known as rickets, which causes bones to be fragile and to break easily. This is especially true in dark-skinned children.",
"    </p>",
"    <p>",
"     All infants, including those who breastfeed",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     bottle-feed, should be given a supplement containing 400 IU of vitamin D per day, starting within days of birth [",
"     <a class=\"abstract\" href=\"mobipreview.htm?40/32/41476/abstract/7\">",
"      7",
"     </a>",
"     ]. Vitamin D is included in most non-prescription infant vitamin drops. In some countries, it is possible to buy infant drops that contain only vitamin D.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your child's healthcare provider is the best source of information for questions and concerns related to your child's medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H28611207\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H28611214\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/27/4531?source=see_link\">",
"      Patient information: Weaning from breastfeeding (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/59/7091?source=see_link\">",
"      Patient information: Starting solid foods with babies (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/35/11827?source=see_link\">",
"      Patient information: Diet and health (The Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H28611270\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/47/29429?source=see_link\">",
"      Patient information: Food allergy symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/23/15730?source=see_link\">",
"      Patient information: Atopic dermatitis (eczema) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/16/16643?source=see_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux) in infants (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/19/1333?source=see_link\">",
"      Patient information: Breastfeeding guide (Beyond the Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H28611287\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28631?source=see_link\">",
"      Dietary history and recommended dietary intake in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/12/14538?source=see_link\">",
"      Etiology and evaluation of failure to thrive (undernutrition) in children younger than two years",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/37/25175?source=see_link\">",
"      Introducing formula and solid foods to infants at risk for allergic disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/43/10938?source=see_link\">",
"      Introducing solid foods and vitamin and mineral supplementation during infancy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/16/30985?source=see_link\">",
"      Management of failure to thrive (undernutrition) in children younger than two years",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/21/38233?source=see_link\">",
"      Poor weight gain in children older than two years of age",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/36/37448?source=see_link\">",
"      Botulism",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Medline Plus",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/infantandtoddlernutrition.html\">",
"      www.nlm.nih.gov/medlineplus/infantandtoddlernutrition.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       La Leche League",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.llli.org/NB/NBsolids.html\">",
"      www.llli.org/NB/NBsolids.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Academy of Pediatrics",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.healthychildren.org/english/ages-stages/baby/feeding-nutrition/pages/switching-to-solid-foods.aspx\">",
"      www.healthychildren.org/English/ages-stages/baby/feeding-nutrition/Pages/Switching-To-Solid-Foods.aspx",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Women, Infants, and Children Works Resource Center",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nal.usda.gov/wicworks/Topics/infant_nut_solids.html\">",
"      www.nal.usda.gov/wicworks/Topics/infant_nut_solids.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Food Allergy Research &amp; Education",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.foodallergy.org/\">",
"      www.foodallergy.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?40/32/41476/abstract/1-9\">",
"      1-9",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 21, 2013.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?40/32/41476?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41476/abstract/1\">",
"      Section on Breastfeeding. Breastfeeding and the use of human milk. Pediatrics 2012; 129:e827.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization: Complementary feeding. Available at: www.who.int/nutrition/topics/complementary_feeding/en/index.html (Accessed on April 28, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41476/abstract/3\">",
"      Boyce JA, Assa'ad A, Burks AW, et al. Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report. J Allergy Clin Immunol 2010; 126:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41476/abstract/4\">",
"      Macknin ML, Medendorp SV, Maier MC. Infant sleep and bedtime cereal. Am J Dis Child 1989; 143:1066.",
"     </a>",
"    </li>",
"    <li>",
"     Committee on Nutrition American Academy of Pediatrics. Complementary feeding. In: Pediatric Nutrition Handbook, 6th, American Academy of Pediatrics, Elk Grove Village, IL 2009. p.113.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41476/abstract/6\">",
"      Greer FR, Shannon M, American Academy of Pediatrics Committee on Nutrition, American Academy of Pediatrics Committee on Environmental Health. Infant methemoglobinemia: the role of dietary nitrate in food and water. Pediatrics 2005; 116:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41476/abstract/7\">",
"      Misra M, Pacaud D, Petryk A, et al. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics 2008; 122:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41476/abstract/8\">",
"      Muraro A, Dreborg S, Halken S, et al. Dietary prevention of allergic diseases in infants and small children. Part III: Critical review of published peer-reviewed observational and interventional studies and final recommendations. Pediatr Allergy Immunol 2004; 15:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41476/abstract/9\">",
"      Greer FR, Sicherer SH, Burks AW, et al. Effects of early nutritional interventions on the development of atopic disease in infants and children: the role of maternal dietary restriction, breastfeeding, timing of introduction of complementary foods, and hydrolyzed formulas. Pediatrics 2008; 121:183.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f40_32_41476=[""].join("\n");
var outline_f40_32_41476=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           SOLID FOODS OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHEN SHOULD INFANTS START SOLIDS?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           SOLID FOOD PRECAUTIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           TYPES OF SUPPLEMENTAL FOODS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           VITAMIN AND MINERAL SUPPLEMENTS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/10/27821\" title=\"table 1\">",
"           Infant feeding guide PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f40_32_41477="Modalities for the diagnosis of abdominal and thoracic cavity defects in peritoneal dialysis patients";
var content_f40_32_41477=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Modalities for the diagnosis of abdominal and thoracic cavity defects in peritoneal dialysis patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/32/41477/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/32/41477/contributors\">",
"     Madhukar Misra, MD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/32/41477/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/32/41477/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/32/41477/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/32/41477/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/32/41477/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of dialysis fluid in the abdominal cavity increases intra-abdominal pressure and may lead to the dialysis fluid leaking from acquired or congenital defects in the abdominal and thoracic wall. This may manifest as hydrothorax, hernia, or",
"    <span class=\"nowrap\">",
"     genital/abdominal",
"    </span>",
"    wall edema. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/22/7528?source=see_link\">",
"     \"Noninfectious complications of peritoneal dialysis catheters\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/23/22904?source=see_link\">",
"     \"Noninfectious complications of continuous peritoneal dialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41061?source=see_link\">",
"     \"Abdominal hernias in continuous peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Various diagnostic modalities were previously used to help diagnose these defects. In the 1970s, plain radiographs, contrast catheterograms, and peritoneographs were commonly utilized. However, since they were somewhat inaccurate and misleading [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41477/abstract/1\">",
"     1",
"    </a>",
"    ], these techniques have been replaced by radiological methods. These newer methods include nuclear isotope scans (peritoneal scintigraphy), CT scans (CT peritoneography or CTP) and MRI (MR peritoneography or MRP) using",
"    <span class=\"nowrap\">",
"     contrast/dye",
"    </span>",
"    materials.",
"   </p>",
"   <p>",
"    This topic review will discuss the diagnostic methods used to detect defects in the abdominal and thoracic wall among patients undergoing peritoneal dialysis. A review of general problems among peritoneal dialysis patients, including the clinical manifestations suggestive of a hernia or peritoneal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pleural leak, is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/22/7528?source=see_link\">",
"     \"Noninfectious complications of peritoneal dialysis catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PERITONEAL SCINTIGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peritoneal scintigraphy is a safe, accurate, and rapid way of diagnosing leaks in the peritoneal cavity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41477/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. Three to 5 millicuries of technetium 99m isotope per 0.5 to 2 L of dialysis solution is injected into the abdominal cavity. Multiple projections (anterior, lateral, posterior and oblique) are then taken to help separate a leak in the abdominal wall from the peritoneal fluid posterior to it [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41477/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although a significant dose of isotope is used, it is not absorbed from the peritoneum and almost all of the material drains out of the body after the procedure. The net dose of radiation is therefore only a fraction of the total dose instilled into the peritoneal cavity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41477/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Various radioligands that have been used include sulfur colloid, albumin colloid, tin colloid, and macroaggregated albumin colloid (MAA). The size of these molecules is larger than mesothelial pores in the diaphragm that communicate with the lymphatic vessels, thus preventing their uptake as well as maintaining good intraperitoneal concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41477/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To facilitate fluid egress out of the peritoneal cavity and thus enhance diagnostic sensitivity, a variety of measures can be employed to increase intra-abdominal pressures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41477/abstract/9\">",
"     9",
"    </a>",
"    ]. The patient should ambulate or (if non-ambulatory) be made to roll from side to side. Use of larger volumes, if tolerated, should also be advocated. Images are subsequently taken at regular time intervals, with most leaks being detected in two to six hours. Delayed scans (24 to 48 hours later) are advocated in small leaks or in initially equivocal studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41477/abstract/6,10\">",
"     6,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Peritoneal scintigraphy is not only useful in diagnosing leaks, hernias, and hydrothorax (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57933 \" href=\"mobipreview.htm?23/43/24243\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75319 \" href=\"mobipreview.htm?14/56/15235\">",
"     image 2",
"    </a>",
"    ) but can also demonstrate the inflow and distribution of dialysis fluid in the peritoneal cavity. In addition, it can facilitate repeated examination of the area of interest if clinically indicated. This technique has also been found to be useful in the diagnosis of adhesions in the peritoneal cavity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41477/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CT SCANS AND CT PERITONEOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT scans (CTS) and CT peritoneography (CTP) are accurate and reliable methods of diagnosing peritoneal defects. However, CTP, which is performed using dialysis fluid mixed with iodinated contrast, has a distinct advantage over CTS for diagnosing small leaks, adhesions, loculated fluid collections, intra-abdominal abscesses and pseudocysts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41477/abstract/10,12,13\">",
"     10,12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preparation for this diagnostic procedure is similar to that done for peritoneal scintigraphy. The dose of iodinated contrast used is approximately 50 mL per liter of dialysis fluid. Oral and intravenous contrast can be simultaneously given to diagnose any abscesses or tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41477/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Besides diagnosing leaks and defects in the abdominal and thoracic wall, quantification of dialysis fluid and its distribution with respect to catheter position in the peritoneal cavity can also be done with considerable diagnostic accuracy (this method slightly underestimates the volume of fluid) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41477/abstract/10\">",
"     10",
"    </a>",
"    ]. CTP is not effective in diagnosing fibrinous catheter obstruction or obstruction of the catheter by adhesions or omentum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41477/abstract/12\">",
"     12",
"    </a>",
"    ]. Cumulative radiation exposure may be of concern in pediatric populations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MRI AND MR PERITONEOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI and MR peritoneography (MRP) are additional modalities to help diagnose these anatomic defects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41477/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. Gadolinium-based dye was most commonly used.",
"   </p>",
"   <p>",
"    However, among patients with moderate to advanced renal failure (dialysis-dependent or estimated GFR less than 30",
"    <span class=\"nowrap\">",
"     mL/min),",
"    </span>",
"    the administration of gadolinium has been associated with the potentially severe syndrome of nephrogenic systemic fibrosis. In such patients, gadolinium-based imaging should be avoided, if possible. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=see_link\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Saline, or the dialysis solution itself, has also been used as contrast medium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41477/abstract/16\">",
"     16",
"    </a>",
"    ]. These fluids show up as a hyperintense image on T2 weighted images owing to its electrolyte content. The use of dialysis fluid as contrast avoids the risk of catheter contamination during the procedure. It also does not require the presence of specialized personnel to instill the dye into the peritoneum. In addition, the absence of dye makes the procedure cheaper. MRP provides multiplanar images and its diagnostic accuracy is similar to that of CTP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41477/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL METHODS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical methods of diagnosing hydrothorax and abdominal wall leaks may be easy to perform, but may not be sensitive enough to diagnose these defects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Thoracentesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thoracentesis is a simple, although invasive, method to diagnose hydrothorax. It is especially helpful in patients who are acutely symptomatic, a setting in which this procedure can be diagnostic as well as therapeutic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/23/12663?source=see_link\">",
"     \"Diagnostic thoracentesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The slight but real risks of thoracentesis make this procedure a less attractive method of diagnosis. It becomes an attractive option in cases of extreme symptoms due to large pleural effusions.",
"   </p>",
"   <p>",
"    If thoracentesis is performed, dialysate fluid in the pleura should have a higher concentration of glucose than plasma, and the concentrations of LDH and protein are consistent with a transudate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41477/abstract/17\">",
"     17",
"    </a>",
"    ]. A cell count and cultures (to exclude infection), and L and D isomers of lactate (if available) should also be performed. The L isomer of lactate is endogenous, while commercial dialysis solutions have both L and D isomers; as a result, if the D isomer of lactate is present in the pleural effusion, the source is the commercial dialysate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41477/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/7/16505?source=see_link\">",
"     \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Methylene blue dye",
"    </span>",
"    &nbsp;&mdash;&nbsp;Instillation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    dye into the peritoneum has also been found useful in diagnosing leaks. However, there have been some case reports of irritation to the abdominal viscera [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41477/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Clinical observation",
"    </span>",
"    &nbsp;&mdash;&nbsp;An easier, but relatively insensitive method of diagnosing hydrothorax, is to keep the abdomen dry overnight, and to repeat a chest radiograph in the morning to determine if the pleural effusion has decreased.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Biochemical analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biochemical analysis for glucose and lactate can be performed on the fluid that has leaked into the abdominal wall.",
"   </p>",
"   <p>",
"    Alternative peritoneal dialysis solutions, however, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/36/44612?source=see_link\">",
"     icodextrin",
"    </a>",
"    , may not contain glucose. In this setting, the addition of povidine-iodine to a fluid aspirate may result in a characteristic blue black color [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41477/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Different diagnostic modalities can be used alone or in combination to diagnose abdominal wall",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thoracic defects in PD patients. Based on sensitivity, specificity, and cost, we use and recommend CT peritoneography as the initial diagnostic modality to be utilized. It is the most commonly used modality in the United States and offers distinct advantage over plain CT scans.",
"   </p>",
"   <p>",
"    Although MR peritoneography has a similar sensitivity to CT peritoneography in diagnosing these defects, the administration of gadolinium among dialysis patients has been associated with the potentially severe syndrome of nephrogenic systemic fibrosis. In such patients, gadolinium-based imaging should therefore be avoided. MR peritoneography using dialysis fluid as a contrast medium may eventually offer a valuable, cheap and a user friendly alternative. However, further study in additional centers is required to validate its usefulness.",
"   </p>",
"   <p>",
"    Isotope scanning is principally used in patients who are allergic to iodinated contrast used in CT peritoneography.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41477/abstract/1\">",
"      Singal K, Segel DP, Bruns FJ, et al. Genital edema in patients on continuous ambulatory peritoneal dialysis. Report of 3 cases and review of the literature. Am J Nephrol 1986; 6:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41477/abstract/2\">",
"      Juergensen PH, Rizvi H, Caride VJ, et al. Value of scintigraphy in chronic peritoneal dialysis patients. Kidney Int 1999; 55:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41477/abstract/3\">",
"      Walker JV, Fish MB. Scintigraphic detection of abdominal wall and diaphragmatic peritoneal leaks in patients on continuous ambulatory peritoneal dialysis. J Nucl Med 1988; 29:1596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41477/abstract/4\">",
"      Goh, ASW, Le, GSL, Kee, SG, et al. Radionuclide detection of dialysate leakage in patients on CAPD. Ann Acad Med, 1994; 23:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41477/abstract/5\">",
"      Johnson J, Baum S, Smink RD Jr. Radionuclide imaging in the diagnosis of hernias related to peritoneal dialysis. Arch Surg 1987; 122:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41477/abstract/6\">",
"      Berman C, Velchik MG, Shusterman N, Alavi A. The clinical utility of the Tc-99m SC intraperitoneal scan in CAPD patients. Clin Nucl Med 1989; 14:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41477/abstract/7\">",
"      Johnson BF, Segasby CA, Holroyd AM, et al. A method for demonstrating subclinical inguinal herniae in patients undergoing peritoneal dialysis: the isotope 'peritoneoscrotogram'. Nephrol Dial Transplant 1987; 2:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41477/abstract/8\">",
"      Leak LV, Rahil K. Permeability of the diaphragmatic mesothelium: the ultrastructural basis for \"stomata\". Am J Anat 1978; 151:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41477/abstract/9\">",
"      Twardowski ZJ, Tully RJ, Ersoy FF, Dedhia NM. Computerized tomography with and without intraperitoneal contrast for determination of intraabdominal fluid distribution and diagnosis of complications in peritoneal dialysis patients. ASAIO Trans 1990; 36:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41477/abstract/10\">",
"      Sissons GR, Jones SM, Evans C, Richards AR. Scintigraphic detection of abdominal hernias associated with continuous ambulatory peritoneal dialysis. Br J Radiol 1991; 64:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41477/abstract/11\">",
"      Gudit S, Sudhakar P, Ram R, et al. Peritoneal scintigraphy in the diagnosis of adhesions. Perit Dial Int 2010; 30:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41477/abstract/12\">",
"      Hollett MD, Marn CS, Ellis JH, et al. Complications of continuous ambulatory peritoneal dialysis: evaluation with CT peritoneography. AJR Am J Roentgenol 1992; 159:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41477/abstract/13\">",
"      Lam MF, Lo WK, Chu FS, et al. Retroperitoneal leakage as a cause of ultrafiltration failure. Perit Dial Int 2004; 24:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41477/abstract/14\">",
"      Prokesch RW, Schima W, Schober E, et al. Complications of continuous ambulatory peritoneal dialysis: findings on MR peritoneography. AJR Am J Roentgenol 2000; 174:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41477/abstract/15\">",
"      Arbeiter KM, Aufricht C, Mueller T, et al. MRI in the diagnosis of a peritoneal leak in continuous ambulatory peritoneal dialysis. Pediatr Radiol 2001; 31:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41477/abstract/16\">",
"      Prischl FC, Muhr T, Seiringer EM, et al. Magnetic resonance imaging of the peritoneal cavity among peritoneal dialysis patients, using the dialysate as \"contrast medium\". J Am Soc Nephrol 2002; 13:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41477/abstract/17\">",
"      Tang S, Chui WH, Tang AW, et al. Video-assisted thoracoscopic talc pleurodesis is effective for maintenance of peritoneal dialysis in acute hydrothorax complicating peritoneal dialysis. Nephrol Dial Transplant 2003; 18:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41477/abstract/18\">",
"      Benz RL, Schleifer CR. Hydrothorax in continuous ambulatory peritoneal dialysis: successful treatment with intrapleural tetracycline and a review of the literature. Am J Kidney Dis 1985; 5:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41477/abstract/19\">",
"      O'Sullivan JC. Letter: Female sterility produced by investigation. Br Med J 1973; 4:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41477/abstract/20\">",
"      Camilleri B, Glancey G, Pledger D, Williams P. The icodextrin black line sign to confirm a pleural leak in a patient on peritoneal dialysis. Perit Dial Int 2004; 24:197.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1929 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-11D65C23BF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_32_41477=[""].join("\n");
var outline_f40_32_41477=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PERITONEAL SCINTIGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CT SCANS AND CT PERITONEOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MRI AND MR PERITONEOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL METHODS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Thoracentesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Methylene blue dye",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Clinical observation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Biochemical analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1929\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1929|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?23/43/24243\" title=\"diagnostic image 1\">",
"      Abdominal scintigram with leak",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?14/56/15235\" title=\"diagnostic image 2\">",
"      Scintigraphy hydrothorax",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41061?source=related_link\">",
"      Abdominal hernias in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/7/16505?source=related_link\">",
"      Diagnostic evaluation of a pleural effusion in adults: Initial testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/23/12663?source=related_link\">",
"      Diagnostic thoracentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/23/22904?source=related_link\">",
"      Noninfectious complications of continuous peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/22/7528?source=related_link\">",
"      Noninfectious complications of peritoneal dialysis catheters",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_32_41478="Superficial wound repair with tissue adhesives";
var content_f40_32_41478=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Superficial wound repair with tissue adhesives",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/32/41478/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/32/41478/contributors\">",
"     Rana Kronfol, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/32/41478/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/32/41478/contributors\">",
"     Anne M Stack, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/32/41478/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/32/41478/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/32/41478/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tissue adhesives were approved for minor wound repair in the United States in 1998, although they have been widely used in Europe and Canada for much longer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41478/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. They \"provide a simple, quick, painless and cost-effective way to manage many lacerations with cosmetic results that have been judged to be at least as good, or better than, the results achieved by traditional sutures\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41478/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most tissue adhesives are cyanoacrylate polymers, such as n-butyl-2-cyanoacrylate (eg, Histoacryl&reg;, PeriAcryl&reg;) or 2-octyl cyanoacrylate (eg, Dermabond&reg;, Surgiseal).",
"   </p>",
"   <p>",
"    Laceration repair with tissue adhesives is discussed here. Information concerning wound preparation and irrigation, topical and infiltrative anesthesia, and sutures and staples is found separately as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/51/32567?source=see_link\">",
"       \"Minor wound preparation and irrigation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/50/43817?source=see_link\">",
"       \"Topical anesthetics in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33689?source=see_link\">",
"       \"Infiltration of local anesthetics\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18553?source=see_link\">",
"       \"Closure of skin wounds with sutures\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/22/33124?source=see_link\">",
"       \"Closure of minor skin wounds with staples\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     WOUND HEALING WITH TISSUE ADHESIVES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although tissue adhesives other than the cyanoacrylates are available, this discussion will primarily be limited to cyanoacrylate polymers, since they are most commonly used for minor laceration repair.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Physiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyanoacrylate tissue adhesives are liquid monomers that undergo an exothermic reaction on exposure to moisture (eg, on the skin surface), changing to polymers that form a strong tissue bond. When applied to a laceration, the polymer binds the wound edges together to allow normal healing of the underlying tissue.",
"   </p>",
"   <p>",
"    Cyanoacrylates degrade into the toxic byproducts cyanoacetate and formaldehyde; these byproducts can cause an inflammatory response in the surrounding tissues that may compromise wound healing. The currently used cyanoacrylates (n-butyl-2-cyanoacrylate [Histoacryl&reg;, PeriAcryl&reg;], 2-octyl cyanoacrylate [eg, Dermabond&reg;, Surgiseal&reg;]) degrade relatively slowly, thereby generating smaller quantities of toxic byproducts and causing less inflammation than some other preparations.",
"   </p>",
"   <p>",
"    Compared with butyl-2-cyanoacrylate, 2-octyl cyanoacrylate appears to form a stronger bond, and the addition of plasticizers also allows it to form a flexible, more adherent bond [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41478/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Maximum bonding strength is achieved within 2.5 minutes of application [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41478/abstract/4\">",
"     4",
"    </a>",
"    ]. Compared with wounds closed with sutures, the tensile strength of wounds closed by tissue adhesives is less at the time of initial application, but equalizes by one week post-repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41478/abstract/1-5\">",
"     1-5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Advantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential advantages of using tissue adhesives compared with sutures include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41478/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Less painful application, and sometimes no need for local anesthetic injection",
"     </li>",
"     <li>",
"      More rapid application and repair time",
"     </li>",
"     <li>",
"      Cosmetically similar results at 12 months post-repair",
"     </li>",
"     <li>",
"      Waterproof barrier",
"     </li>",
"     <li>",
"      Antimicrobial properties",
"     </li>",
"     <li>",
"      Better acceptance by patients",
"     </li>",
"     <li>",
"      No need for suture removal or follow-up",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several randomized clinical trials in both children and adults have found that there is no significant difference in outcomes when either lacerations or surgical incisions are repaired with tissue adhesive versus standard wound closure (eg, sutures, adhesive strips) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41478/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Lacerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;With regard to lacerations, cosmetic results with tissue adhesives have been similar to standard wound closure in studies that have included either n-butyl-2-cyanoacrylate (Histoacryl&reg;, PeriAcryl&reg;) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41478/abstract/8-10\">",
"     8-10",
"    </a>",
"    ] or 2-octyl cyanoacrylate (Dermabond&reg;, Surgiseal&reg;) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41478/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. One study that compared n-butyl-2-cyanoacrylate with 2-octyl cyanoacrylate for closure of pediatric facial lacerations found no significant difference between them [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41478/abstract/15\">",
"     15",
"    </a>",
"    ]. In another study of 216 patients with small lacerations on the face or upper extremities, high viscosity 2-octyl cyanoacrylate alone achieved similar cosmetic appearance and no increased wound dehiscence when compared with mesh tape combined with 2-octyl cyanoacrylate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41478/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some circumstances, closure of lacerations with tissue adhesives may result in better cosmetic outcomes than sutures. As an example, a randomized study of 55 children with facial lacerations categorized the lacerations on the basis of orientation along Langer's lines: Langer (+) patients had lacerations that were &lt;20 degrees deviated from Langer's lines, while Langer (-) patients had lacerations that were &ge;20 degrees deviated from Langer's lines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41478/abstract/17\">",
"     17",
"    </a>",
"    ]. At two months follow-up, wound appearance was significantly worse for sutured Langer (-) compared with Langer (+) wounds. In contrast, cosmetic appearance of lacerations closed by tissue adhesive was comparable between Langer (-) and Langer (+) wounds. These findings suggest that tissue adhesives may be the preferred method of cutaneous closure for facial lacerations oriented against Langer's lines.",
"   </p>",
"   <p>",
"    Other outcomes to be considered when comparing closure of lacerations with tissue adhesives versus other standard methods of laceration closure include speed, pain, complications, and cost.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A systematic review of randomized trials concluded that application of tissue adhesives is significantly faster (average 5.7 minutes less) and less painful than standard wound closure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/32/41478/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      While no individual study has found a significant difference in complication rates between closure with tissue adhesives and standard laceration closure, pooling of data in the systematic review found a small but significant increased risk of wound dehiscence with use of tissue adhesives [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/32/41478/abstract/6\">",
"       6",
"      </a>",
"      ]. However, the clinical significance of this result is difficult to interpret.",
"     </li>",
"     <li>",
"      An economic analysis of n-butyl-2-cyanoacrylate (Histoacryl&reg;, PeriAcryl&reg;) versus standard wound repair of facial lacerations in children found that use of absorbable sutures was 2.4 times more costly than tissue adhesives, while nonabsorbable sutures were 6.8 times more costly because of the need for a repeat visit [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/32/41478/abstract/18\">",
"       18",
"      </a>",
"      ]. In countries where both n-butyl-2-cyanoacrylate (eg, Histoacryl&reg;, PeriAcryl&reg;) and 2-octyl cyanoacrylate (Dermabond&reg;, Surgiseal&reg;) are available, use of the former can result in significant cost savings when used as a multi-dose vial.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Surgical incisions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of eight randomized trials that evaluated the use of tissue adhesives for closure of surgical incisions concluded that there is no difference in rates of wound dehiscence or infection between use of tissue adhesives or sutures or adhesive tape [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41478/abstract/7\">",
"     7",
"    </a>",
"    ]. Some studies found that use of tissue adhesives resulted in better cosmetic outcomes.",
"   </p>",
"   <p>",
"    Findings were consistent in the studies that used either n-butyl-2-cyanoacrylate (Histoacryl&reg;, PeriAcryl&reg;) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41478/abstract/19-22\">",
"     19-22",
"    </a>",
"    ] or 2-octyl cyanoacrylate (Dermabond&reg;, Surgiseal&reg;) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41478/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. The surgeries encompassed a variety of procedures including inguinal and femoral hernia repair, testicular surgery, lymph node biopsy, hand and wrist surgery, benign skin lesions, blepharoplasty, phlebectomy, and elective laparoscopic surgery. A retrospective chart review concluded that tissue adhesives could be used to close incisions from inguinal surgery in children in diapers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41478/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Notably absent from the studies listed above were procedures involving incisions in areas of high tension (eg, elbow and knee). Patients whose health status may have put them at high risk for impaired wound healing also were excluded from these studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     INDICATIONS AND CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tissue adhesives may be used to repair skin lacerations that have good wound approximation with no wound tension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41478/abstract/2-4,28\">",
"     2-4,28",
"    </a>",
"    ]. The ideal laceration is clean and linear. Complex stellate lesions or crush injuries should not be closed with tissue adhesives since good wound approximation is difficult to achieve.",
"   </p>",
"   <p>",
"    Tissue adhesives are marketed as replacing sutures that are 5-0 or smaller in diameter, as excess tension is often present in wounds requiring larger-caliber sutures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41478/abstract/1-4,29\">",
"     1-4,29",
"    </a>",
"    ]. Placement of subcutaneous sutures in wounds under tension may reduce the tension sufficiently to allow use of tissue adhesives for cutaneous closure.",
"   </p>",
"   <p>",
"    Tissue adhesives are not recommended for lacerations of the hands, feet, or joints unless the affected areas are immobilized, since repetitive movements could cause the adhesive bond to break before sufficient tensile strength is achieved.",
"   </p>",
"   <p>",
"    Tissue adhesives are not recommended for the oral mucosa or other mucosal surfaces or areas of high moisture such as the axillae and perineum.",
"   </p>",
"   <p>",
"    Lacerations involving the hairline or vermilion border require more precision, and should be repaired with traditional sutures. Scalp wounds can be closed with tissue adhesive, but hair around the wound may interfere with the adhesive. Patients should also be aware that they can wash but cannot scrub the area for 7 to 10 days.",
"   </p>",
"   <p>",
"    Puncture wounds and most bites should not be closed with either adhesives or conventional sutures because of the increased risk of infection. Similarly, lacerations with infected, devitalized, or contaminated tissue should not be closed.",
"   </p>",
"   <p>",
"    Patients with diabetes mellitus, chronic vascular disease, peripheral vascular disease, decubitus ulcers, prolonged steroid use, history of keloids, bleeding diathesis, allergy to adhesives (or formaldehyde), or any condition that delays wound healing should be treated with traditional methods and not with tissue adhesives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41478/abstract/2,3,30\">",
"     2,3,30",
"    </a>",
"    ]. Tissue adhesives are not thought to protect against the development of keloids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41478/abstract/31\">",
"     31",
"    </a>",
"    ], although there are no data suggesting they increase keloid formation.",
"   </p>",
"   <p>",
"    More recent applications for tissue adhesives include fixation of peripheral nerve catheters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41478/abstract/32\">",
"     32",
"    </a>",
"    ], closure of laparoscopic port-site incisions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41478/abstract/33\">",
"     33",
"    </a>",
"    ], and repair of lacerations during competitive athletics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41478/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TECHNIQUE OF APPLICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wounds should be prepared for closure in the same manner as wounds to be closed by sutures. Thorough wound irrigation and cleansing are as important for wounds closed by tissue adhesives as for any other method of wound closure. The patient should be positioned to minimize leakage of the adhesive into adjacent structures such as the eye or eyelashes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/51/32567?source=see_link\">",
"     \"Minor wound preparation and irrigation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Deep lacerations, particularly to the torso and extremities, should have subcutaneous sutures placed prior to application of tissue adhesive. Failure to strengthen such wounds with subcutaneous sutures may increase the risk of wound dehiscence and adversely affect the cosmetic result, since the adhesive typically peels off within 5 to 10 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41478/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After cleansing and placement of subcutaneous sutures if necessary, tissue adhesive is applied as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The wound edges should be well apposed or slightly everted using the fingers or tissue forceps. Complete hemostasis is required because blood oozing from the wound interferes with adherence of the adhesive to the skin. Any tissue or hair that extrudes through or overlies the wound edges will also interfere with the adhesive.",
"     </li>",
"     <li>",
"      Some tissue adhesives (eg, Dermabond&reg;, Surgiseal&reg;) are packaged in a plastic, single-use vial with a foam tip applicator at one end. The vial should be crushed to begin the polymerization process then squeezed to force the adhesive to permeate the foam tip applicator. The vial must be used in the next few minutes or polymerization within the vial tip will prevent use. The vial should be squeezed gently to avoid dripping of the adhesive, and squeezing should stop as soon as a drop begins to form at the tip.",
"     </li>",
"     <li>",
"      Once the tip is saturated, it should be swiped gently over the wound edges in a single motion, spreading a thin film over them (",
"      <a class=\"graphic graphic_figure graphicRef82996 \" href=\"mobipreview.htm?5/22/5474\">",
"       figure 1",
"      </a>",
"      ). The applicator tip should never be pressed into the wound, since this may cause a foreign body reaction that prevents normal wound healing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/32/41478/abstract/11\">",
"       11",
"      </a>",
"      ]. If this occurs, the adhesive should be wiped off, using petroleum jelly or antibiotic ointment if needed to loosen the polymer. The wound should then be re-cleansed and reclosed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/32/41478/abstract/2,3,13\">",
"       2,3,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The adhesive should be allowed to dry for 30 to 40 seconds while continuing to hold the wound edges together to allow complete polymerization. This first layer reaches full tensile strength in approximately two minutes. If wound edges are not well aligned after the first application, the adhesive can be wiped away with gauze; this needs to occur within about 10 seconds, or the adhesive will be too polymerized to wipe away [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/32/41478/abstract/2\">",
"       2",
"      </a>",
"      ]. Application of antibiotic ointment or petroleum jelly for 30 minutes will allow polymer removal if necessary.",
"     </li>",
"     <li>",
"      The application process is repeated three to four times in an oval pattern around the wound to encompass a greater surface area on the skin. Wound closure strength is enhanced by extending the application 5 to 10 mm beyond the margin of the incision [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/32/41478/abstract/4\">",
"       4",
"      </a>",
"      ]. These subsequent layers typically take longer to dry than the first layer because less moisture is available for polymerization. The wound should not be touched until complete drying has occurred, which may take as long as five minutes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This process is exothermic and the patient should be warned of a sensation of warmth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41478/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     AFTERCARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;No external bandages are necessary over a wound closed by tissue adhesives. The adhesive itself acts as a water-resistant bandage. Antibiotic ointment should not be used as it can break down the adhesive prematurely.",
"   </p>",
"   <p>",
"    Patients may shower while the adhesive is on the skin, but should not soak or scrub the area for 7 to 10 days. Wet skin should be gently patted dry. Children should not take baths.",
"   </p>",
"   <p>",
"    The adhesive will peel off when the epithelial layer sloughs off, usually by 5 to 10 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41478/abstract/1-4,35\">",
"     1-4,35",
"    </a>",
"    ]. Antibiotic ointment or petroleum jelly can be applied to the wound if the adhesive does not come off on its own.",
"   </p>",
"   <p>",
"    No follow-up visit is required unless there are signs of infection or nonhealing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most complications of tissue adhesives relate to leakage in unwanted areas. Care should be taken to prevent leakage of the adhesive onto the glove or the forceps, since that can glue them to the",
"    <span class=\"nowrap\">",
"     wound/patient.",
"    </span>",
"    Using vinyl gloves tends to reduce this complication, as adhesion to vinyl gloves is substantially weaker than rubber latex gloves [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41478/abstract/13\">",
"     13",
"    </a>",
"    ]. If adhesion occurs, mild tension is usually enough to separate the bond. The adhesive sticks less well to metal than to plastic forceps, but use of metal forceps may be limited because they can cause increased pain.",
"   </p>",
"   <p>",
"    Squeezing the vial too forcefully can result in adhesive draining away from the wound. This should be wiped off before it hardens. If it has set, it can be removed by application of petroleum jelly, acetone, or antibiotic ointment. Gauze can be used in the vicinity of the tissue adhesive to prevent adhesive runoff, but it should be moistened to decrease the probability of adherence to the skin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41478/abstract/13\">",
"     13",
"    </a>",
"    ]. Some authors recommend applying a protective periphery or \"wall\" of ointment around the wound to prevent runoff and adhesion. Moistened gauze should be squeezed well, however, because it cannot wet the skin where the adhesive is applied.",
"   </p>",
"   <p>",
"    The eyes should be well protected for lacerations near the eye. If adhesive gets into the eye or eyelid, or glues the eyelashes together, generous amounts of ophthalmic antibiotic ointment should be placed on the eyelid to break down the adhesive and an ophthalmologist should be consulted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41478/abstract/13,36\">",
"     13,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     COST",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dermabond costs approximately $24 per vial, while sutures cost $5 per package. However, when the time of the procedure, follow-up appointment for suture removal, and cost of suture kit and suture removal kits are factored in, the cost is quite similar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41478/abstract/2\">",
"     2",
"    </a>",
"    ]. As mentioned above, in countries where both n-butyl-2-cyanoacrylate (eg, Histoacryl&reg; PeriAcryl&reg;) and 2-octyl cyanoacrylate (eg, Dermabond&reg;, Surgiseal&reg;) are available, use of the former can result in significant cost savings when used as a multi-dose vial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The currently used tissue adhesives include butyl-2-cyanoacrylate (eg, Histoacryl&reg;, PeriAcryl&reg;) and 2-octyl cyanoacrylate (eg, Dermabond&reg;, Surgiseal&reg;). For laceration repair, cosmetic outcomes are similar for tissue adhesives and sutures; some studies have found that tissue adhesives have better cosmetic outcomes. Application of tissue adhesives is faster than sutures and probably cheaper. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Physiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tissue adhesives may be used to repair skin lacerations that have good wound approximation with no wound tension. The ideal laceration is clean and linear. Placement of subcutaneous sutures in wounds under tension may reduce the tension sufficiently to allow use of tissue adhesives for cutaneous closure. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Indications and contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tissue adhesives are not recommended for lacerations of the hands, feet, or joints unless the affected areas are immobilized. Tissue adhesives also are not recommended for the oral mucosa or other mucosal surfaces or areas of high moisture such as the axillae and perineum. Lacerations involving the hairline or vermilion border require more precision and should be repaired with traditional sutures. Patients with diabetes mellitus, chronic vascular disease, peripheral vascular disease, decubitus ulcers, prolonged steroid use, history of keloids, bleeding diathesis, allergy to adhesives (or formaldehyde), or any condition that delays wound healing should be treated with traditional methods and not with tissue adhesives. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Indications and contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The technique for applying tissue adhesives to superficial skin lacerations is described (",
"      <a class=\"graphic graphic_figure graphicRef82996 \" href=\"mobipreview.htm?5/22/5474\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Technique of application'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No external bandages are necessary over a wound closed by tissue adhesives. The adhesive itself acts as a water-resistant bandage. Antibiotic ointment should not be used as it can break down the adhesive prematurely. The adhesive will peel off when the epithelial layer sloughs off, usually by 5 to 10 days. Antibiotic ointment or petroleum jelly can be applied to the wound if the adhesive does not come off on its own. No follow-up visit is required unless there are signs of infection or nonhealing. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Aftercare'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most complications of tissue adhesives relate to leakage in unwanted areas. Tissue adhesive can be wiped away from these areas within 10 seconds. Alternatively, application of antibiotic ointment or petroleum jelly can break down the adhesive to allow removal. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41478/abstract/1\">",
"      Capellan O, Hollander JE. Management of lacerations in the emergency department. Emerg Med Clin North Am 2003; 21:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41478/abstract/2\">",
"      Bruns TB, Worthington JM. Using tissue adhesive for wound repair: a practical guide to dermabond. Am Fam Physician 2000; 61:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41478/abstract/3\">",
"      Pearson AS, Wolford RW. Management of skin trauma. Prim Care 2000; 27:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41478/abstract/4\">",
"      Toriumi DM, Bagal AA. Cyanoacrylate tissue adhesives for skin closure in the outpatient setting. Otolaryngol Clin North Am 2002; 35:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41478/abstract/5\">",
"      Yamamoto LG. Preventing adverse events and outcomes encountered using dermabond. Am J Emerg Med 2000; 18:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41478/abstract/6\">",
"      Farion K, Osmond MH, Hartling L, et al. Tissue adhesives for traumatic lacerations in children and adults. Cochrane Database Syst Rev 2002; :CD003326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41478/abstract/7\">",
"      Coulthard P, Worthington H, Esposito M, et al. Tissue adhesives for closure of surgical incisions. Cochrane Database Syst Rev 2004; :CD004287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41478/abstract/8\">",
"      Barnett P, Jarman FC, Goodge J, et al. Randomised trial of histoacryl blue tissue adhesive glue versus suturing in the repair of paediatric lacerations. J Paediatr Child Health 1998; 34:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41478/abstract/9\">",
"      Quinn JV, Drzewiecki A, Li MM, et al. A randomized, controlled trial comparing a tissue adhesive with suturing in the repair of pediatric facial lacerations. Ann Emerg Med 1993; 22:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41478/abstract/10\">",
"      Simon HK, McLario DJ, Bruns TB, et al. Long-term appearance of lacerations repaired using a tissue adhesive. Pediatrics 1997; 99:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41478/abstract/11\">",
"      Quinn J, Wells G, Sutcliffe T, et al. A randomized trial comparing octylcyanoacrylate tissue adhesive and sutures in the management of lacerations. JAMA 1997; 277:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41478/abstract/12\">",
"      Bruns TB, Robinson BS, Smith RJ, et al. A new tissue adhesive for laceration repair in children. J Pediatr 1998; 132:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41478/abstract/13\">",
"      Singer AJ, Hollander JE, Valentine SM, et al. Prospective, randomized, controlled trial of tissue adhesive (2-octylcyanoacrylate) vs standard wound closure techniques for laceration repair. Stony Brook Octylcyanoacrylate Study Group. Acad Emerg Med 1998; 5:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41478/abstract/14\">",
"      Zempsky WT, Parrotti D, Grem C, Nichols J. Randomized controlled comparison of cosmetic outcomes of simple facial lacerations closed with Steri Strip Skin Closures or Dermabond tissue adhesive. Pediatr Emerg Care 2004; 20:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41478/abstract/15\">",
"      Osmond MH, Quinn JV, Sutcliffe T, et al. A randomized, clinical trial comparing butylcyanoacrylate with octylcyanoacrylate in the management of selected pediatric facial lacerations. Acad Emerg Med 1999; 6:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41478/abstract/16\">",
"      Singer AJ, Chale S, Giardano P, et al. Evaluation of a novel wound closure device: a multicenter randomized controlled trial. Acad Emerg Med 2011; 18:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41478/abstract/17\">",
"      Simon HK, Zempsky WT, Bruns TB, Sullivan KM. Lacerations against Langer's lines: to glue or suture? J Emerg Med 1998; 16:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41478/abstract/18\">",
"      Osmond MH, Klassen TP, Quinn JV. Economic comparison of a tissue adhesive and suturing in the repair of pediatric facial lacerations. J Pediatr 1995; 126:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41478/abstract/19\">",
"      Cheng W, Saing H. A prospective randomized study of wound approximation with tissue glue in circumcision in children. J Paediatr Child Health 1997; 33:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41478/abstract/20\">",
"      Keng TM, Bucknall TE. A clinical trial of tissue adhesive (histoacryl) in skin closure of groin wounds. Med J Malaysia 1989; 44:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41478/abstract/21\">",
"      Sinha S, Naik M, Wright V, et al. A single blind, prospective, randomized trial comparing n-butyl 2-cyanoacrylate tissue adhesive (Indermil) and sutures for skin closure in hand surgery. J Hand Surg Br 2001; 26:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41478/abstract/22\">",
"      Ozturan O, Miman MC, Aktas D, Oncel S. Butylcyanoacrylate tissue adhesive for columellar incision closure. J Laryngol Otol 2001; 115:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41478/abstract/23\">",
"      Toriumi DM, O'Grady K, Desai D, Bagal A. Use of octyl-2-cyanoacrylate for skin closure in facial plastic surgery. Plast Reconstr Surg 1998; 102:2209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41478/abstract/24\">",
"      Greene D, Koch RJ, Goode RL. Efficacy of octyl-2-cyanoacrylate tissue glue in blepharoplasty. A prospective controlled study of wound-healing characteristics. Arch Facial Plast Surg 1999; 1:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41478/abstract/25\">",
"      Shamiyeh A, Schrenk P, Stelzer T, Wayand WU. Prospective randomized blind controlled trial comparing sutures, tape, and octylcyanoacrylate tissue adhesive for skin closure after phlebectomy. Dermatol Surg 2001; 27:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41478/abstract/26\">",
"      Maartense S, Bemelman WA, Dunker MS, et al. Randomized study of the effectiveness of closing laparoscopic trocar wounds with octylcyanoacrylate, adhesive papertape or poliglecaprone. Br J Surg 2002; 89:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41478/abstract/27\">",
"      Ferlise VJ, Ankem MK, Barone JG. Use of cyanoacrylate tissue adhesive under a diaper. BJU Int 2001; 87:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41478/abstract/28\">",
"      Bernard L, Doyle J, Friedlander SF, et al. A prospective comparison of octyl cyanoacrylate tissue adhesive (dermabond) and suture for the closure of excisional wounds in children and adolescents. Arch Dermatol 2001; 137:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41478/abstract/29\">",
"      Bruns TB, Simon HK, McLario DJ, et al. Laceration repair using a tissue adhesive in a children's emergency department. Pediatrics 1996; 98:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41478/abstract/30\">",
"      Edmonson MB. Foreign body reactions to dermabond. Am J Emerg Med 2001; 19:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41478/abstract/31\">",
"      Maw JL, Quinn JV, Wells GA, et al. A prospective comparison of octylcyanoacrylate tissue adhesive and suture for the closure of head and neck incisions. J Otolaryngol 1997; 26:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41478/abstract/32\">",
"      Klein SM, Nielsen KC, Buckenmaier CC 3rd, et al. 2-octyl cyanoacrylate glue for the fixation of continuous peripheral nerve catheters. Anesthesiology 2003; 98:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41478/abstract/33\">",
"      Matin SF. Prospective randomized trial of skin adhesive versus sutures for closure of 217 laparoscopic port-site incisions. J Am Coll Surg 2003; 196:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41478/abstract/34\">",
"      Perron AD, Garcia JA, Parker Hays E, Schafermeyer R. The efficacy of cyanoacrylate-derived surgical adhesive for use in the repair of lacerations during competitive athletics. Am J Emerg Med 2000; 18:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41478/abstract/35\">",
"      Hollander JE, Singer AJ. Laceration management. Ann Emerg Med 1999; 34:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41478/abstract/36\">",
"      Resch KL, Hick JL. Preliminary experience with 2-octylcyanoacrylate in a pediatric emergency department. Pediatr Emerg Care 2000; 16:328.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6337 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-C50D28AF5E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_32_41478=[""].join("\n");
var outline_f40_32_41478=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      WOUND HEALING WITH TISSUE ADHESIVES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Physiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Advantages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Lacerations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Surgical incisions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      INDICATIONS AND CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TECHNIQUE OF APPLICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      AFTERCARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      COST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6337\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6337|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/22/5474\" title=\"figure 1\">",
"      Application of tissue adhesive",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/22/33124?source=related_link\">",
"      Closure of minor skin wounds with staples",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/7/18553?source=related_link\">",
"      Closure of skin wounds with sutures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33689?source=related_link\">",
"      Infiltration of local anesthetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/51/32567?source=related_link\">",
"      Minor wound preparation and irrigation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/50/43817?source=related_link\">",
"      Topical anesthetics in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_32_41479="Blood supply to the colon and rectum";
var content_f40_32_41479=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F73756&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F73756&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Blood supply to the colon and rectum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 558px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The blood supply to the colon originates from the superior mesenteric artery and the inferior mesenteric artery. The blood supply to the rectum originates from the superior rectal artery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_32_41479=[""].join("\n");
var outline_f40_32_41479=null;
var title_f40_32_41480="Clinical features and diagnosis of diabetic ketoacidosis in children";
var content_f40_32_41480=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features and diagnosis of diabetic ketoacidosis in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/32/41480/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/32/41480/contributors\">",
"     George S Jeha, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/32/41480/contributors\">",
"     Morey W Haymond, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/32/41480/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/32/41480/contributors\">",
"     Joseph I Wolfsdorf, MB, BCh",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/32/41480/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/32/41480/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/32/41480/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic ketoacidosis (DKA) is the leading cause of morbidity and mortality in children with type 1 diabetes mellitus. DKA can less commonly occur in children with type 2 diabetes mellitus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14874?source=see_link\">",
"     \"Classification of diabetes mellitus and genetic diabetic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In recent years, the incidence and prevalence of type 2 diabetes mellitus have increased across all ethnic groups. This has been coupled with an increasing awareness that children with type 2 diabetes mellitus can present with ketosis or DKA, particularly in obese African American adolescents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14874?source=see_link&amp;anchor=H270106199#H270106199\">",
"     \"Classification of diabetes mellitus and genetic diabetic syndromes\", section on 'DKA in type 2 diabetes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical features and diagnosis of DKA in children will be reviewed here. This discussion is primarily based upon the large collective experience of children with type 1 diabetes mellitus. There is limited experience in the assessment and diagnosis of DKA in children with type 2 diabetes mellitus, although the same principles should apply. The management of diabetes in children, treatment of DKA in children and the epidemiology and pathogenesis of DKA are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/9/40090?source=see_link\">",
"     \"Management of type 1 diabetes mellitus in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/28/7626?source=see_link\">",
"     \"Treatment and complications of diabetic ketoacidosis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/16/44295?source=see_link\">",
"     \"Epidemiology and pathogenesis of diabetic ketoacidosis and hyperosmolar hyperglycemic state\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consensus statements from the European Society for Paediatric",
"    <span class=\"nowrap\">",
"     Endocrinology/Lawson",
"    </span>",
"    Wilkins Pediatric Endocrine Society",
"    <span class=\"nowrap\">",
"     (ESPE/LWPES)",
"    </span>",
"    in 2004, the American Diabetes Association (ADA) in 2006, and the International Society for Pediatric and Adolescent Diabetes (ISPAD) in 2007 defined the following biochemical criteria for the diagnosis of DKA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperglycemia, blood glucose of &gt;200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (11",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    AND",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Metabolic acidosis, defined as a venous pH &lt;7.3",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      plasma bicarbonate &lt;15",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      (15",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The severity of DKA can be categorized according to the degree of acidosis as mild, moderate, or severe, (pH 7.2-7.3, pH 7.1-7.2, or pH &lt;7.1, respectively) (",
"    <a class=\"graphic graphic_table graphicRef72608 \" href=\"mobipreview.htm?11/13/11483\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    These abnormalities are accompanied by hyperketosis (concentration of total ketone bodies &gt;5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and hyperosmolality. The clinical manifestations of DKA are related to the degree of hyperosmolality, volume depletion, and acidosis.",
"   </p>",
"   <p>",
"    Hyperosmolar hyperglycemic state (HHS) is a hyperglycemia emergency which is distinguished from classic DKA by marked hyperglycemia (plasma glucose &gt;600",
"    <span class=\"nowrap\">",
"     mg/dL),",
"    </span>",
"    serum CO2 &gt;15",
"    <span class=\"nowrap\">",
"     mmol/L,",
"    </span>",
"    absent to mild ketonemia and ketonuria, and effective serum osmolality &gt;320",
"    <span class=\"nowrap\">",
"     mOsm/L.",
"    </span>",
"    HHS occurs most commonly in adults with poorly controlled type 2 diabetes, but has also been reported in African-American adolescents with type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Recognition of HHS is important because it is reported to be associated with more severe dehydration and difficult to manage hypotension than typically occurs in DKA. As in DKA, management of HHS requires carefully monitored fluid and electrolyte management, and it has been suggested that patients may require higher rates of fluid administration than are typically used in DKA. Management of HHS is discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/48/15114?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Fluid replacement'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;DKA is frequently the initial presentation of children with new onset type 1 diabetes mellitus. In a surveillance study of almost 3000 episodes of DKA in the United Kingdom, 38 percent occurred in patients at the time of initial diagnosis of diabetes mellitus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/14\">",
"     14",
"    </a>",
"    ]. In other studies from Europe and North America, the frequency of DKA as the initial presentation for type 1 diabetes mellitus is approximately 25 percent (range from 15 to 67 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/9,15\">",
"     9,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although population-based studies are lacking, the incidence of DKA as the initial presentation in type 2 diabetes mellitus varies considerably. In a systematic review, factors associated with increased risk for having DKA at presentation are younger age (&lt;5 years), ethnic minority status, diagnostic error, lack of health insurance (in the United States), lower body mass index, and delayed treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/16\">",
"     16",
"    </a>",
"    ]. In different studies, 4 percent of Canadian aboriginal children, 25 percent of Irish children, 30 percent of Mexican-American children and more than 40 percent of obese African-American adolescents with type 2 diabetes mellitus initially present in DKA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/1-6\">",
"     1-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, DKA and its complications are the most common cause of hospitalization, mortality, and morbidity in children with established type 1 diabetes mellitus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Initial presentation of type 1 diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who are young (&lt;6 years of age) or from a low socioeconomic background are at increased risk for DKA at initial presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/17-22\">",
"     17-22",
"    </a>",
"    ]. The data supporting these conclusions are illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective study from Germany reviewed 2121 newly diagnosed children with type 1 diabetes mellitus, 558 of whom (26 percent) presented in DKA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/17\">",
"       17",
"      </a>",
"      ]. The incidence of DKA was higher (36 percent) in children less than five years of age.",
"     </li>",
"     <li>",
"      The importance of socioeconomic status was illustrated in a review of 139 patients with newly diagnosed type 1 diabetes mellitus seen at a single center in the United States [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/18\">",
"       18",
"      </a>",
"      ]. The investigators used the lack of private insurance as a proxy for low socioeconomic status. A disproportionate number of children having either Medicaid or no insurance presented in DKA compared to those with private insurance (62 versus 34 percent). Children less than five years of age were also at increased risk for DKA (relative risk 2.7 compared to older children).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     In established type 1 diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of DKA in children who are known to have type 1 diabetes mellitus was 8 episodes per 100 person years in the largest reported prospective study in which 1243 American children were followed for five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/23\">",
"     23",
"    </a>",
"    ]. Risk factors for recurrent DKA included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Higher A1C values and higher reported insulin requirements",
"     </li>",
"     <li>",
"      Female adolescents, with the highest risk in female adolescents over 13 years of age",
"     </li>",
"     <li>",
"      Children over 13 years of age, regardless of gender, who are underinsured",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      have a history of psychiatric disorders",
"     </li>",
"     <li>",
"      Longer duration of diabetes mellitus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Almost 60 percent of DKA episodes occurred in only 5 percent of children. Similar findings were noted in the United Kingdom surveillance study cited above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/14\">",
"     14",
"    </a>",
"    ]. Patients with known diabetes mellitus who had four or more episodes of DKA (4.8 percent of patients) accounted for 35 percent of all episodes.",
"   </p>",
"   <p>",
"    Thus, a small group of patients consume a disproportionate amount of healthcare resources and costs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/23\">",
"     23",
"    </a>",
"    ]. The identification of these patients at high risk for recurrence of DKA and the establishment of a comprehensive diabetes treatment program may reduce the rates of DKA and possibly healthcare costs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/24\">",
"     24",
"    </a>",
"    ]. Such a program should emphasize compliance with management recommendations, including adherence to the insulin regimen and the use of home glucose monitoring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Type 2 diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although less common, ketosis and DKA can occur in children with type 2 diabetes mellitus, particularly in African-American children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. In a retrospective review of 69 patients (between 9 and 18 years of age) who presented with DKA at a tertiary center, 13 percent had type 2 diabetes mellitus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/5\">",
"     5",
"    </a>",
"    ]. At presentation, there was no difference in the serum pH level but patients with type 2 diabetes mellitus compared to those with type 1 diabetes mellitus had higher blood glucose levels. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14874?source=see_link&amp;anchor=H270106199#H270106199\">",
"     \"Classification of diabetes mellitus and genetic diabetic syndromes\", section on 'DKA in type 2 diabetes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PRECIPITATING FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent episodes of DKA with established type 1 diabetes mellitus are primarily the result of underlying poor metabolic control and frequently missed insulin injections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/23\">",
"     23",
"    </a>",
"    ]. Omission of insulin injections is particularly common among adolescents.",
"   </p>",
"   <p>",
"    Stress is also an important precipitating factor. Stress increases the secretion of catecholamines, cortisol, and glucagon, which promote both glucose and ketoacid production. As an example, infection can precede an episode of DKA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/16/44295?source=see_link\">",
"     \"Epidemiology and pathogenesis of diabetic ketoacidosis and hyperosmolar hyperglycemic state\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, medications such as corticosteroids, atypical antipsychotics,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/11/13492?source=see_link\">",
"     diazoxide",
"    </a>",
"    , and high dose thiazides, have precipitated DKA in individuals not previously diagnosed with type 1 diabetes mellitus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical diagnosis of diabetes in a previously healthy child requires a high index of suspicion. Signs and symptoms of DKA are related to the degree of hyperosmolality, volume depletion, and acidosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The earliest symptoms are related to hyperglycemia. Older children and adolescents typically present with polyuria (due to the glucose-induced osmotic diuresis), polydipsia (due to the increased urinary losses), and fatigue. Other findings include weight loss, nocturia (with or without secondary enuresis), daytime enuresis, and vaginal or cutaneous moniliasis. Hypovolemia may be severe if the urinary losses are not replaced.",
"   </p>",
"   <p>",
"    In infants, the diagnosis is more difficult because the patients are not toilet trained and they cannot express thirst. As a result, polyuria may not be detected and polydipsia is not apparent. However, decreased energy and activity, irritability, weight loss, and physical signs of dehydration are common findings. In addition, severe Candida diaper rash or otherwise unexplained metabolic acidosis or hypovolemia should heighten the suspicion for diabetes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/33/37401?source=see_link\">",
"     \"Overview of diaper dermatitis in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of other clinical findings may be seen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Polyphagia usually occurs early in the course of the illness. However, once insulin deficiency becomes more severe and ketoacidosis develops, appetite is suppressed. Some patients present with anorexia, nausea, vomiting, and abdominal pain, which at times can mimic appendicitis or gastroenteritis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/3/32826?source=see_link\">",
"       \"Acute appendicitis in children: Clinical manifestations and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hyperventilation and deep (Kussmaul) respirations represent the respiratory compensation for metabolic acidosis. Hyperpnea results from an increase in minute volume (rate x tidal volume) and can be increased by tidal volume alone without an increase in respiratory rate. As a result, the patient's chest excursion as well as respiratory rate should be carefully observed. In infants, the hyperpnea may be manifested only by tachypnea. Patients may also have a fruity breath secondary to exhaled acetone.",
"     </li>",
"     <li>",
"      Although children with DKA are volume depleted, they are less likely to show the classic signs of hypovolemia such as dry oral mucous membranes and decreased skin turgor than patients with the same degree of weight loss from vomiting or diarrhea due to gastroenteritis. This important distinction is a reflection of water loss in excess of sodium with a glucosuria-induced osmotic diuresis and water loss from hyperventilation. Water is freely distributed between the extracellular and intracellular fluids. As a result, water loss produces less extracellular fluid volume depletion than salt and water loss. Water loss also is largely responsible for the marked rise in plasma osmolality.",
"     </li>",
"     <li>",
"      Neurologic findings, ranging from drowsiness, lethargy, and obtundation to coma, are related to the severity of hyperosmolality",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      to the degree of acidosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/26\">",
"       26",
"      </a>",
"      ]. Cerebral edema occurs in 0.5 to 1 percent of cases of DKA in children, and is the leading cause of mortality. The clinician should be vigilant for early signs of cerebral edema and should treat promptly if cerebral edema is suspected (",
"      <a class=\"graphic graphic_table graphicRef53017 \" href=\"mobipreview.htm?3/3/3132\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/37/16983?source=see_link\">",
"       \"Cerebral edema in children with diabetic ketoacidosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Fluid and electrolyte deficits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies estimating water and electrolyte losses in DKA were conducted in the 1940s and 1950s. Most included adults, but one was a detailed study of a 10-year-old female [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. The data from the available studies are consistent with the following average losses in severe DKA:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Water &mdash; 70 (range 30 to 100)",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"     </li>",
"     <li>",
"      Sodium &mdash; 5 to 13",
"      <span class=\"nowrap\">",
"       mEq/kg",
"      </span>",
"     </li>",
"     <li>",
"      Potassium &mdash; 6 to 7",
"      <span class=\"nowrap\">",
"       mEq/kg",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is difficult to assess clinically the degree of dehydration in children presenting with DKA as these children are less likely to show the classic signs of hypovolemia because of chronic and acute losses of intracellular and extracellular water as compared with children with more acute causes of dehydration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/30\">",
"     30",
"    </a>",
"    ]. Children with DKA generally present with a 5 to 10 percent fluid deficit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/4,7\">",
"     4,7",
"    </a>",
"    ]. Initial fluid management is based on the assumption of a 5 to 7 percent deficit for moderate DKA, and 10 percent dehydration for severe DKA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/9\">",
"     9",
"    </a>",
"    ]. This recommendation is consistent with the above studies that assessed fluid and electrolyte losses. However, to minimize risks for cerebral edema and electrolyte imbalances, hypovolemia should be corrected gradually. The maximal volume of isotonic solution used for initial treatment is 10",
"    <span class=\"nowrap\">",
"     mL/kg,",
"    </span>",
"    unless the patient is objectively hypotensive. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Signs and symptoms'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial laboratory testing should include serum testing for glucose, electrolytes, creatinine and urea nitrogen, blood gases, and hematocrit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Direct measurement of beta-hydroxybutyrate in the blood should also be performed if possible; accurate bedside meters for this measurement are available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/31\">",
"     31",
"    </a>",
"    ]. The diagnosis of DKA is confirmed by the findings of hyperglycemia, a high anion gap acidosis, ketonuria, and ketonemia. Treatment of these abnormalities is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/28/7626?source=see_link\">",
"     \"Treatment and complications of diabetic ketoacidosis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Serum glucose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum glucose is, by definition, greater than 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (11",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. This degree of hyperglycemia exceeds the renal tubular threshold for glucose reabsorption, resulting in an osmotic diuresis with polyuria and subsequent volume depletion. Glucosuria also predisposes to candidal infections in diapered children and adolescent girls.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Acid-base status",
"    </span>",
"    &nbsp;&mdash;&nbsp;The second criterion for the diagnosis of DKA is a serum bicarbonate &lt;15",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    or a venous pH &lt;7.3. Insulin deficiency and increased plasma concentrations of glucagon, cortisol and epinephrine increase glucose production, lipolysis and ketogenesis which collectively contribute to the development of both the hyperglycemia and the ketoacidosis. Acetoacetic acid is the initial ketone formed and it may be reduced to beta-hydroxybutyric acid (another organic acid) or decarboxylated to acetone, which will be detected as a ketone but does not contribute to the acidosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/16/44295?source=see_link\">",
"     \"Epidemiology and pathogenesis of diabetic ketoacidosis and hyperosmolar hyperglycemic state\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The severity of metabolic acidosis is dependent upon three factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rate of ketoacid production",
"     </li>",
"     <li>",
"      The duration of increased ketoacid production; the acidosis will be less severe in patients who present early due, for example, to abdominal pain or an underlying infection that precipitated the DKA",
"     </li>",
"     <li>",
"      The rate of acid excretion in the urine. Patients with relatively normal renal function can markedly increase acid excretion, thereby minimizing the severity of the acidosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/32\">",
"       32",
"      </a>",
"      ]. The magnitude of this effect was illustrated in a study of patients with DKA: ketone production averaged 51",
"      <span class=\"nowrap\">",
"       mEq/h,",
"      </span>",
"      while net acid excretion with the ketoacid anions averaged 15",
"      <span class=\"nowrap\">",
"       mEq/h",
"      </span>",
"      or 30 percent of the acid load [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/33\">",
"       33",
"      </a>",
"      ]. The conversion of acetoacetic acid to acetone can neutralize another 15 to 25 percent of the acid load [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The adequacy of the compensatory respiratory alkalosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Conventional urine screening tests for ketones are performed with",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/52/40773?source=see_link\">",
"     nitroprusside",
"    </a>",
"    impregnated strips or tablets (Acetest). Nitroprusside reacts with acetoacetate and acetone but not beta-hydroxybutyrate. In DKA, beta-hydroxybutyrate makes up 75 percent of the circulating ketones. Thus, clinical testing with nitroprusside may underestimate the severity of ketoacidosis and ketonuria. On the other hand, during recovery beta-hydroxybutyrate is converted to acetoacetate and acetone, which persist for a longer period. As a result, urine testing may give a false impression of persistent ketoacidosis. Therefore, direct measurement of beta-hydroxybutyrate should be used whenever possible.",
"   </p>",
"   <p>",
"    Blood testing for beta-hydroxybutyrate may be available both in the clinical chemistry laboratory, and more importantly, at points of care such as emergency departments and physician's offices, as well as at home (Precision Xtra&trade;, Abbott Laboratories). The meter measures a current produced during oxidation of beta-hydroxybutyrate to acetoacetate, and is accurate in children and adults in a variety of clinical settings for plasma beta-hydroxybutyrate concentrations of up to 5 to 7",
"    <span class=\"nowrap\">",
"     mMol/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Anion Gap (AG) is useful in estimating the severity of ketosis, and the normalization of the anion gap is a direct measure of the resolution of ketoacidemia. However, the anion gap may also underestimate the degree of acidosis. The loss of ketoacid anions in the urine (as the sodium and potassium salts of beta-hydroxybutyrate and to a lesser degree acetoacetate) lowers the anion gap without affecting the plasma bicarbonate concentration or therefore the degree of acidosis.",
"   </p>",
"   <p>",
"    When insulin is given to patients with diabetic ketoacidosis, metabolism of the ketoacid anions results in the regeneration of HCO3- and correction of the metabolic acidosis. For this reason, ketoacid anions have been called \"potential bicarbonate,\" and their loss in the urine represents the loss of HCO3-. As a result, a normal AG acidosis is typically seen during the treatment phase of diabetic ketoacidosis due to the urinary loss of these bicarbonate precursors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/11/6330?source=see_link&amp;anchor=H13#H13\">",
"     \"Approach to the child with metabolic acidosis\", section on 'Overlap'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The serum anion gap is calculated from the following formula in units of",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     mmol/L:",
"    </span>",
"   </p>",
"   <p>",
"    &nbsp; Serum anion gap &nbsp;= &nbsp;Serum sodium &nbsp;- &nbsp;(Serum chloride + bicarbonate)",
"   </p>",
"   <p>",
"    The normal value in children is 12&plusmn;2",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Serum sodium",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum sodium concentration is affected by hyperglycemia. The magnitude of this effect is determined by two major factors.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperglycemia will increase the plasma osmolality, resulting in osmotic water movement out of the cells which lowers the serum sodium by dilution. Theoretical calculations suggest that the serum sodium should be lowered by 1.6",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      for every 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.5",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      elevation in serum glucose [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/36\">",
"       36",
"      </a>",
"      ]. There is no experimental verification of this estimate in children. Experimental data in adults suggest that a better overall estimate is a reduction in serum sodium of 2.4",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      for every 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.5",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      elevation of plasma glucose [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The direct effect of hyperglycemia to lower the serum sodium is counteracted to a variable degree by the glucosuria-induced osmotic diuresis. The diuresis results in water loss in excess of sodium and potassium, which will tend to raise the serum sodium concentration and plasma osmolality. Inadequate water intake, which may be a particular problem in hot weather and in infants and young children who cannot independently access water, prevents partial correction of the hyperosmolality and can even lead to hypernatremia despite the presence of hyperglycemia. On the other hand, consumption of large volumes of dilute fluid, since thirst is stimulated by hyperosmolality, can contribute to hyponatremia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A third factor that can affect the measured serum sodium concentration represents a laboratory artifact. Hyperlipidemia can cause pseudohyponatremia by reducing the fraction of plasma that is water. As a result, the amount of sodium in the specimen is reduced and the measured plasma sodium concentration will be lower, even though the physiologically important plasma water sodium concentration and plasma osmolality are not affected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/38\">",
"     38",
"    </a>",
"    ]. Ion-selective electrodes have been used to measure directly the plasma water sodium concentration in this setting, but they have been shown to have variable accuracy and are not routinely used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/20/21832?source=see_link&amp;anchor=H5#H5\">",
"     \"Evaluation of the patient with hyponatremia\", section on 'Serum osmolality'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Serum potassium",
"    </span>",
"    &nbsp;&mdash;&nbsp;The osmotic diuresis and increased ketoacid excretion promote urinary potassium loss, while vomiting and diarrhea, if present, increase gastrointestinal potassium losses. In adults, average potassium losses during DKA are 3 to 5",
"    <span class=\"nowrap\">",
"     mEq/kg;",
"    </span>",
"    the estimated potassium loss in children has been less well studied but average losses appear to be 6 to 7",
"    <span class=\"nowrap\">",
"     mEq/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potassium losses will tend to produce hypokalemia. However, the combination of insulin deficiency, which impairs potassium entry into the cells, and hyperosmolality, which pulls water and potassium out of the cells, tends to raise the serum potassium concentration. Ketoacidosis itself appears to have little effect on transcellular potassium movement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/18/25891?source=see_link\">",
"     \"Potassium balance in acid-base disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of these counteracting effects, the serum potassium at the time of presentation can be normal, increased, or decreased. Regardless of the initial level, therapy with insulin and fluids will predictably lower the serum potassium concentration, which needs to be monitored carefully. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/28/7626?source=see_link\">",
"     \"Treatment and complications of diabetic ketoacidosis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Serum phosphate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with DKA are typically in negative phosphate balance because of decreased phosphate intake and phosphaturia caused by the glucosuria-induced osmotic diuresis. Despite the presence of phosphate depletion, at presentation the serum phosphate concentration is usually normal or even high because both insulin deficiency and metabolic acidosis cause a shift of phosphate out of the cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/39\">",
"     39",
"    </a>",
"    ]. This transcellular shift is reversed and the true state of phosphate balance is unmasked after treatment with insulin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/48/15114?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Phosphate depletion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Blood urea nitrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with severe hypovolemia often have elevated blood urea nitrogen concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/40\">",
"     40",
"    </a>",
"    ]. This finding at presentation may have predictive value since it is a risk factor for cerebral edema during therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Assessment of severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;At presentation, the following clinical and laboratory findings may be used to estimate the severity of DKA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acid-base status &mdash; The venous pH and serum bicarbonate concentration directly reflect the severity of the acidosis (",
"      <a class=\"graphic graphic_table graphicRef72608 \" href=\"mobipreview.htm?11/13/11483\">",
"       table 1",
"      </a>",
"      ). The respiratory rate also may be helpful, since the magnitude of the respiratory compensation is directly related to the severity of the acidosis.",
"     </li>",
"     <li>",
"      Ketosis &mdash; The magnitude of the anion gap is another measure of the severity of the ketosis and can be a helpful estimate of acidosis. A very large anion gap may also reflect decreased renal perfusion, which limits ketoacid excretion. Measurement of plasma beta-hydroxybutyrate is now widely available and is a direct method for monitoring the degree of ketoacidemia. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Acid-base status'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neurologic status &mdash; Severe neurologic compromise at presentation is a poor prognostic indicator, in part because such patients are at increased risk for developing cerebral edema during therapy. This was illustrated in a retrospective multicenter study of 61 children with DKA and cerebral edema; all patients who either died or survived in a persistent vegetative state presented with Glasgow coma score &le;7 (score of 6 to 7 includes an abnormal or absent purposeful response to pain) (",
"      <a class=\"graphic graphic_table graphicRef59662 \" href=\"mobipreview.htm?2/58/2989\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/42\">",
"       42",
"      </a>",
"      ]. Because of the high morbidity and mortality of cerebral edema, it is important to recognize and treat at the earliest signs of neurologic compromise (",
"      <a class=\"graphic graphic_table graphicRef53017 \" href=\"mobipreview.htm?3/3/3132\">",
"       table 2",
"      </a>",
"      ). The pathophysiology and treatment of cerebral edema in children with DKA is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/37/16983?source=see_link\">",
"       \"Cerebral edema in children with diabetic ketoacidosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Volume status &mdash; Estimated fluid deficit, (generally 5-10% fluid deficit).",
"     </li>",
"     <li>",
"      Duration of symptoms &mdash; A long duration of symptoms, as well as depressed level of consciousness or compromised circulation, is evidence of severe DKA and should prompt close monitoring for potential complications of DKA, such as cerebral edema [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. Symptoms of cerebral edema typically occur several hours after the initiation of treatment for DKA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/9\">",
"       9",
"      </a>",
"      ]. The presence of such symptoms at presentation indicates a poor neurologic prognosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon the severity of presentation, the clinician can ascertain the appropriate clinical setting in which to treat the child. As an example, mild DKA without vomiting may be safely managed in an ambulatory setting under close supervision and with appropriate monitoring by an experienced diabetes team. On the other hand, a patient with severe DKA should be managed in a pediatric intensive care unit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41480/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/28/7626?source=see_link\">",
"     \"Treatment and complications of diabetic ketoacidosis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/2/36898?source=see_link\">",
"       \"Patient information: Diabetic ketoacidosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2992631\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diabetic ketoacidosis (DKA) is the leading cause of morbidity and mortality in children with type 1 diabetes mellitus. DKA also can occur in children with type 2 diabetes mellitus, particularly in obese African-American adolescents.",
"     </li>",
"     <li>",
"      DKA is diagnosed when patients with diabetes mellitus exhibit BOTH",
"      <strong>",
"       hyperglycemia",
"      </strong>",
"      (blood glucose of &gt;200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [11",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      and",
"      <strong>",
"       metabolic acidosis",
"      </strong>",
"      (venous pH &lt;7.3",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      plasma bicarbonate &lt;15",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      [15",
"      <span class=\"nowrap\">",
"       mmol/L]),",
"      </span>",
"      caused by severe hyperketonemia (concentration of total ketone bodies &gt;5",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      DKA is the presenting feature of new onset type 1 diabetes mellitus in approximately 30 to 40 percent of cases. Children who are younger (eg, under six years of age) or from a lower socioeconomic status are more likely to have DKA when they present with type 1 diabetes mellitus. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Initial presentation of type 1 diabetes mellitus'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Presenting symptoms of DKA in older children and adolescents include polyuria, polydipsia, and fatigue. Other findings include weight loss, nocturia (with or without secondary enuresis), daytime enuresis, and vaginal or cutaneous moniliasis. Infants tend to present with decreased energy and activity, irritability, weight loss, and physical signs of dehydration; a severe Candida diaper rash is common. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Signs and symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial laboratory testing should include serum testing for glucose, electrolytes, creatinine and urea nitrogen, blood gases, and hematocrit. Direct measurement of beta-hydroxybutyrate in the blood should also be performed if possible. The diagnosis of DKA is confirmed by the findings of hyperglycemia, a high anion gap acidosis, significant ketonemia, and metabolic acidosis. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The venous pH and serum bicarbonate concentration directly reflect the severity of the acidosis (",
"      <a class=\"graphic graphic_table graphicRef72608 \" href=\"mobipreview.htm?11/13/11483\">",
"       table 1",
"      </a>",
"      ). Neurologic status should also be formally assessed at presentation and periodically during treatment (",
"      <a class=\"graphic graphic_table graphicRef53017 \" href=\"mobipreview.htm?3/3/3132\">",
"       table 2",
"      </a>",
"      ), because cerebral edema is an important cause of morbidity and mortality in patients with DKA. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Assessment of severity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hyperosmolar hyperglycemic state (HHS) is a hyperglycemia emergency which is distinguished from classic DKA by marked hyperosmolality (effective osmolality of &gt;320",
"      <span class=\"nowrap\">",
"       mOsm/L)",
"      </span>",
"      due to severe hyperglycemia (plasma glucose &gt;600",
"      <span class=\"nowrap\">",
"       mg/dL),",
"      </span>",
"      in the absence of severe metabolic acidosis (serum CO2 &gt;15",
"      <span class=\"nowrap\">",
"       mmol/L,",
"      </span>",
"      absent to small ketonemia and ketonuria). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/55/4986?source=see_link\">",
"       \"Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/1\">",
"      Pinhas-Hamiel O, Dolan LM, Zeitler PS. Diabetic ketoacidosis among obese African-American adolescents with NIDDM. Diabetes Care 1997; 20:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/2\">",
"      Scott CR, Smith JM, Cradock MM, Pihoker C. Characteristics of youth-onset noninsulin-dependent diabetes mellitus and insulin-dependent diabetes mellitus at diagnosis. Pediatrics 1997; 100:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/3\">",
"      Banerji MA. Impaired beta-cell and alpha-cell function in African-American children with type 2 diabetes mellitus--\"Flatbush diabetes\". J Pediatr Endocrinol Metab 2002; 15 Suppl 1:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/4\">",
"      Neufeld ND, Raffel LJ, Landon C, et al. Early presentation of type 2 diabetes in Mexican-American youth. Diabetes Care 1998; 21:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/5\">",
"      Sapru A, Gitelman SE, Bhatia S, et al. Prevalence and characteristics of type 2 diabetes mellitus in 9-18 year-old children with diabetic ketoacidosis. J Pediatr Endocrinol Metab 2005; 18:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/6\">",
"      Sellers EA, Dean HJ. Diabetic ketoacidosis: a complication of type 2 diabetes in Canadian aboriginal youth. Diabetes Care 2000; 23:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/7\">",
"      Dunger DB, Sperling MA, Acerini CL, et al. ESPE/LWPES consensus statement on diabetic ketoacidosis in children and adolescents. Arch Dis Child 2004; 89:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/8\">",
"      Dunger DB, Sperling MA, Acerini CL, et al. European Society for Paediatric Endocrinology/Lawson Wilkins Pediatric Endocrine Society consensus statement on diabetic ketoacidosis in children and adolescents. Pediatrics 2004; 113:e133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/9\">",
"      Wolfsdorf J, Glaser N, Sperling MA, American Diabetes Association. Diabetic ketoacidosis in infants, children, and adolescents: A consensus statement from the American Diabetes Association. Diabetes Care 2006; 29:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/10\">",
"      Wolfsdorf J, Craig ME, Daneman D, et al. Diabetic ketoacidosis. Pediatr Diabetes 2007; 8:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/11\">",
"      Rosenbloom AL. Hyperglycemic hyperosmolar state: an emerging pediatric problem. J Pediatr 2010; 156:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/12\">",
"      Carchman RM, Dechert-Zeger M, Calikoglu AS, Harris BD. A new challenge in pediatric obesity: pediatric hyperglycemic hyperosmolar syndrome. Pediatr Crit Care Med 2005; 6:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/13\">",
"      Bhowmick SK, Levens KL, Rettig KR. Hyperosmolar hyperglycemic crisis: an acute life-threatening event in children and adolescents with type 2 diabetes mellitus. Endocr Pract 2005; 11:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/14\">",
"      Edge JA, Hawkins MM, Winter DL, Dunger DB. The risk and outcome of cerebral oedema developing during diabetic ketoacidosis. Arch Dis Child 2001; 85:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/15\">",
"      Klingensmith GJ, Tamborlane WV, Wood J, et al. Diabetic ketoacidosis at diabetes onset: still an all too common threat in youth. J Pediatr 2013; 162:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/16\">",
"      Usher-Smith JA, Thompson MJ, Sharp SJ, Walter FM. Factors associated with the presence of diabetic ketoacidosis at diagnosis of diabetes in children and young adults: a systematic review. BMJ 2011; 343:d4092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/17\">",
"      Neu A, Willasch A, Ehehalt S, et al. Ketoacidosis at onset of type 1 diabetes mellitus in children--frequency and clinical presentation. Pediatr Diabetes 2003; 4:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/18\">",
"      Mallare JT, Cordice CC, Ryan BA, et al. Identifying risk factors for the development of diabetic ketoacidosis in new onset type 1 diabetes mellitus. Clin Pediatr (Phila) 2003; 42:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/19\">",
"      Rosenbauer J, Icks A, Giani G. Clinical characteristics and predictors of severe ketoacidosis at onset of type 1 diabetes mellitus in children in a North Rhine-Westphalian region, Germany. J Pediatr Endocrinol Metab 2002; 15:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/20\">",
"      Quinn M, Fleischman A, Rosner B, et al. Characteristics at diagnosis of type 1 diabetes in children younger than 6 years. J Pediatr 2006; 148:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/21\">",
"      Roche EF, Menon A, Gill D, Hoey H. Clinical presentation of type 1 diabetes. Pediatr Diabetes 2005; 6:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/22\">",
"      Rewers A, Klingensmith G, Davis C, et al. Presence of diabetic ketoacidosis at diagnosis of diabetes mellitus in youth: the Search for Diabetes in Youth Study. Pediatrics 2008; 121:e1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/23\">",
"      Rewers A, Chase HP, Mackenzie T, et al. Predictors of acute complications in children with type 1 diabetes. JAMA 2002; 287:2511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/24\">",
"      Hoffman WH, O'Neill P, Khoury C, Bernstein SS. Service and education for the insulin-dependent child. Diabetes Care 1978; 1:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/25\">",
"      Flood RG, Chiang VW. Rate and prediction of infection in children with diabetic ketoacidosis. Am J Emerg Med 2001; 19:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/26\">",
"      Edge JA, Roy Y, Bergomi A, et al. Conscious level in children with diabetic ketoacidosis is related to severity of acidosis and not to blood glucose concentration. Pediatr Diabetes 2006; 7:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/27\">",
"      DARROW DC, PRATT EL. Retention of water and electrolyte during recovery in a patient with diabetic acidosis. J Pediatr 1952; 41:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/28\">",
"      Atchley DW, Loeb RF, Richards DW, et al. ON DIABETIC ACIDOSIS: A Detailed Study of Electrolyte Balances Following the Withdrawal and Reestablishment of Insulin Therapy. J Clin Invest 1933; 12:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/29\">",
"      BUTLER AM, TALBOT NB. Metabolic studies in diabetic coma. Trans Assoc Am Physicians 1947; 60:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/30\">",
"      Koves IH, Neutze J, Donath S, et al. The accuracy of clinical assessment of dehydration during diabetic ketoacidosis in childhood. Diabetes Care 2004; 27:2485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/31\">",
"      Bashford J, Acerini CL. How to use near-patient capillary ketone meters. Arch Dis Child Educ Pract Ed 2012; 97:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/32\">",
"      Adrogu&eacute; HJ, Eknoyan G, Suki WK. Diabetic ketoacidosis: role of the kidney in the acid-base homeostasis re-evaluated. Kidney Int 1984; 25:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/33\">",
"      Owen OE, Licht JH, Sapir DG. Renal function and effects of partial rehydration during diabetic ketoacidosis. Diabetes 1981; 30:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/34\">",
"      Ham MR, Okada P, White PC. Bedside ketone determination in diabetic children with hyperglycemia and ketosis in the acute care setting. Pediatr Diabetes 2004; 5:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/35\">",
"      Wallace TM, Meston NM, Gardner SG, Matthews DR. The hospital and home use of a 30-second hand-held blood ketone meter: guidelines for clinical practice. Diabet Med 2001; 18:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/36\">",
"      Katz MA. Hyperglycemia-induced hyponatremia--calculation of expected serum sodium depression. N Engl J Med 1973; 289:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/37\">",
"      Hillier TA, Abbott RD, Barrett EJ. Hyponatremia: evaluating the correction factor for hyperglycemia. Am J Med 1999; 106:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/38\">",
"      Weisberg LS. Pseudohyponatremia: a reappraisal. Am J Med 1989; 86:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/39\">",
"      Kebler R, McDonald FD, Cadnapaphornchai P. Dynamic changes in serum phosphorus levels in diabetic ketoacidosis. Am J Med 1985; 79:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/40\">",
"      Harris GD, Fiordalisi I. Physiologic management of diabetic ketoacidemia. A 5-year prospective pediatric experience in 231 episodes. Arch Pediatr Adolesc Med 1994; 148:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/41\">",
"      Glaser N, Barnett P, McCaslin I, et al. Risk factors for cerebral edema in children with diabetic ketoacidosis. The Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. N Engl J Med 2001; 344:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41480/abstract/42\">",
"      Marcin JP, Glaser N, Barnett P, et al. Factors associated with adverse outcomes in children with diabetic ketoacidosis-related cerebral edema. J Pediatr 2002; 141:793.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5809 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.131.240.2-0CE6B713CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_32_41480=[""].join("\n");
var outline_f40_32_41480=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2992631\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Initial presentation of type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      In established type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PRECIPITATING FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Fluid and electrolyte deficits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Serum glucose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Acid-base status",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Serum sodium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Serum potassium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Serum phosphate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Blood urea nitrogen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Assessment of severity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2992631\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5809\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5809|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/13/11483\" title=\"table 1\">",
"      Assessment of severity of diabetic ketoacidosis in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/3/3132\" title=\"table 2\">",
"      DKA neuro state children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/58/2989\" title=\"table 3\">",
"      Glasgow and pediatric coma scales",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/3/32826?source=related_link\">",
"      Acute appendicitis in children: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/11/6330?source=related_link\">",
"      Approach to the child with metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/37/16983?source=related_link\">",
"      Cerebral edema in children with diabetic ketoacidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/33/14874?source=related_link\">",
"      Classification of diabetes mellitus and genetic diabetic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/55/4986?source=related_link\">",
"      Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/16/44295?source=related_link\">",
"      Epidemiology and pathogenesis of diabetic ketoacidosis and hyperosmolar hyperglycemic state",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/20/21832?source=related_link\">",
"      Evaluation of the patient with hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/9/40090?source=related_link\">",
"      Management of type 1 diabetes mellitus in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/33/37401?source=related_link\">",
"      Overview of diaper dermatitis in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/2/36898?source=related_link\">",
"      Patient information: Diabetic ketoacidosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/18/25891?source=related_link\">",
"      Potassium balance in acid-base disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/28/7626?source=related_link\">",
"      Treatment and complications of diabetic ketoacidosis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/48/15114?source=related_link\">",
"      Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_32_41481="Selective estrogen receptor modulators for osteoporosis";
var content_f40_32_41481=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Selective estrogen receptor modulators for osteoporosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/32/41481/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/32/41481/contributors\">",
"     Harold N Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/32/41481/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/32/41481/contributors\">",
"     Clifford J Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/32/41481/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/32/41481/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/32/41481/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The selective estrogen receptor modulators (SERMS) bind with high affinity to the estrogen receptor and have estrogen agonist and antagonist properties that vary depending upon the individual target organ [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Some SERMS, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    , have estrogen activity in bone and, therefore, prevent bone loss, improve bone mineral density, and decrease the risk of fracture.",
"   </p>",
"   <p>",
"    The use of SERMS for the treatment of osteoporosis will be discussed here. The mechanisms of action of SERMS and their role in breast cancer prevention are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/2/7210?source=see_link\">",
"     \"Mechanisms of action of selective estrogen receptor modulators\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44246?source=see_link\">",
"     \"Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20106?source=see_link\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An overview of the approach to therapy of osteoporosis in postmenopausal women and the prevention of osteoporosis are also reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/21/33113?source=see_link\">",
"     \"Prevention of osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RALOXIFENE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     Raloxifene",
"    </a>",
"    inhibits bone resorption and reduces the risk of vertebral fracture. For postmenopausal women who are candidates for and desire pharmacological therapy for",
"    <strong>",
"     prevention",
"    </strong>",
"    of osteoporosis, bisphosphonates or raloxifene are reasonable options. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/21/33113?source=see_link\">",
"     \"Prevention of osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We favor bisphosphonates over",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    for the",
"    <strong>",
"     treatment",
"    </strong>",
"    of osteoporosis because they increase bone mineral density (BMD) more than raloxifene and, in randomized trials, they decrease the incidence of hip fractures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link&amp;anchor=H20#H20\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Choice of drug'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    is a reasonable alternative to bisphosphonates for postmenopausal women with osteoporosis (low bone mineral density [T score &lt;-2.5] and no fragility fractures) who cannot tolerate or are not candidates for any bisphosphonates or for postmenopausal women with osteoporosis who are also at high risk for invasive breast cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link&amp;anchor=H20#H20\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Choice of drug'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     Raloxifene",
"    </a>",
"    has estrogen activity in bone and other systems but not in reproductive tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/3\">",
"     3",
"    </a>",
"    ]. In ovariectomized animals, raloxifene preserves bone density, lowers serum total cholesterol, and inhibits aortic cholesterol accumulation, without causing endometrial hyperplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism responsible for the apparent tissue-selective activity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    is incompletely understood. In vitro studies suggest that raloxifene has different effects than estradiol at the estrogen receptor, including differential modulation of DNA response elements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/6\">",
"     6",
"    </a>",
"    ], causing a different conformational change in the transactivation domain of the ligand-binding region [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/2/7210?source=see_link\">",
"     \"Mechanisms of action of selective estrogen receptor modulators\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Bone mineral density",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several trials demonstrating a beneficial effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    on bone mineral density (BMD) (",
"    <a class=\"graphic graphic_figure graphicRef73629 \" href=\"mobipreview.htm?1/32/1551\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/8-12\">",
"     8-12",
"    </a>",
"    ]. In a meta-analysis of seven trials (four treatment, three prevention) examining the effects of raloxifene versus placebo on bone mineral density, raloxifene increased bone mineral density of the lumbar spine (weighted mean difference [WMD] 1.8, 95% CI 1.5-2.1) and hip (WMD 2.1, 95% CI 1.7-2.5) after two years of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a three-year analysis of the two largest prevention trials, 1145 postmenopausal women without osteoporosis were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    versus placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/10\">",
"     10",
"    </a>",
"    ]. All groups received 400 to 600 mg of elemental calcium, while dietary vitamin D was not supplemented. Women assigned to raloxifene had significant increases in lumbar spine BMD compared with placebo (mean difference 2.6 percent). Biochemical markers of bone turnover were suppressed to the normal premenopausal range in raloxifene-treated women.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     Raloxifene",
"    </a>",
"    is also effective for the treatment of established osteoporosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/11,12,14-17\">",
"     11,12,14-17",
"    </a>",
"    ]. In the largest trial, the Multiple Outcomes of Raloxifene Evaluation (MORE) trial, 7705 postmenopausal women with osteoporosis were randomly assigned to raloxifene (60 or 120 mg) or placebo daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/14\">",
"     14",
"    </a>",
"    ]. Lumbar spine and femoral neck BMD increased from 2.0 to 2.7 percent in the raloxifene groups compared with placebo.",
"   </p>",
"   <p>",
"    Smoking, which reduces the efficacy of estrogen by accelerating its metabolism, did not interfere with the antiosteoporotic effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Fracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     Raloxifene",
"    </a>",
"    reduces the risk of vertebral fracture; however, it has not been shown to reduce nonvertebral fractures. As an example, in a meta-analysis of trials comparing raloxifene to placebo, raloxifene consistently reduced the risk of vertebral fracture in postmenopausal women (odds ratio [OR] 0.6, 95% CI 0.5-0.7) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/19\">",
"     19",
"    </a>",
"    ]. In the largest trial, the MORE trial, a subset of 6828 of the women had lumbar spine x-rays at baseline and after 36 months of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/11\">",
"     11",
"    </a>",
"    ]. Among the women receiving 60 mg and 120 mg raloxifene, 6.6 and 5.4 percent, respectively, had new vertebral fractures, compared with 10.1 percent in the placebo group; the risk of nonvertebral fractures was similar in the three groups.",
"   </p>",
"   <p>",
"    After four years of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    treatment (60 mg per day), the cumulative relative risk [RR] for one or more vertebral fractures was 0.64 (95 % CI 0.53-0.76) compared with placebo (",
"    <a class=\"graphic graphic_figure graphicRef70865 \" href=\"mobipreview.htm?15/4/15425\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/12\">",
"     12",
"    </a>",
"    ]. No reduction in the risk of nonvertebral fractures was seen. However, in a post hoc analysis, a decrease in nonvertebral fracture risk was seen in the subgroup of women with the most severe vertebral fractures at baseline (severity determined by radiographic decrease in vertebral height) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/15\">",
"     15",
"    </a>",
"    ]. In the Continuing Outcomes Relevant to Evista (CORE) study, the benefits of raloxifene on BMD and nonvertebral fracture risk in a subgroup of patients with vertebral fractures were still measurable after seven years of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the RUTH trial, which is described below,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    also reduced the risk of vertebral fractures (HR 0.65; absolute risk reduction 1.3 per 1000) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/20\">",
"     20",
"    </a>",
"    ]. In this trial, fracture was a secondary outcome. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Coronary heart disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Potency",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     Raloxifene",
"    </a>",
"    appears to be a less potent antiresorptive agent than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    or estrogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a one-year study of 331 postmenopausal women with osteoporosis,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      (10",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      increased BMD more than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"       raloxifene",
"      </a>",
"      (60",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a three-year trial of 619 hysterectomized postmenopausal women randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"       raloxifene",
"      </a>",
"      60",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      conjugated estrogen 0.625",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      or placebo, beneficial effects on bone density were seen with both drugs, although the effect of estrogen was more marked (4.6 percent increase in spine BMD versus no change or 2 percent decrease with raloxifene and placebo, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/24\">",
"       24",
"      </a>",
"      ]. Hot flashes and leg cramps were more common in the raloxifene group, while breast tenderness was more common with estrogen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is not known if the greater efficacy in increasing BMD with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    and estrogen translates into greater fracture reduction. There are no fracture trials directly comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    with a bisphosphonate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    resulted in a greater increase in BMD when compared with either drug alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/21\">",
"     21",
"    </a>",
"    ]. However, the benefit of combined versus monotherapy for fracture reduction is unknown. We do not suggest combination bisphosphonate-raloxifene therapy, as the additional BMD benefits are small, the reduction in fracture risk above that with either agent alone is unknown, and there are additional costs and side effects of taking two agents.",
"   </p>",
"   <p>",
"    Some trials have reported that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    (either taken concurrently or prior to PTH) does not suppress the BMD response to PTH as much as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    . Patients previously treated with raloxifene have a good BMD response to PTH, but the optimal management (continue versus discontinue raloxifene) is unclear. This topic is reviewed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15786?source=see_link&amp;anchor=H17#H17\">",
"     \"Parathyroid hormone therapy for osteoporosis\", section on 'Combination therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike bisphosphonates, SERMS do not have a prolonged duration of action in the skeleton, and there is no residual benefit on BMD after discontinuation of therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=see_link&amp;anchor=H11271460#H11271460\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'Alendronate'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one trial, women who had completed a five year course of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    experienced significant decreases in lumbar spine and femoral neck BMD (2.4 and 3.0 percent, respectively) one year after discontinuation of raloxifene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/25\">",
"     25",
"    </a>",
"    ]. The rate of bone loss was similar to that of placebo treated patients. Thus, in women who are tolerating raloxifene well and who are having a good response (improvement or stable BMD), we suggest not stopping therapy. Safety and efficacy data from clinical trials extend for eight years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/16\">",
"     16",
"    </a>",
"    ] and, therefore, some clinicians prefer to discontinue raloxifene after eight years and switch to an alternative anti-osteoporosis agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Effects in premenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     Raloxifene",
"    </a>",
"    is",
"    <strong>",
"     not",
"    </strong>",
"    effective for the prevention or treatment of osteoporosis in premenopausal women. In a two-year study of 37 premenopausal women at risk for breast cancer, raloxifene significantly decreased lumbar spine BMD by 3.5 percent and total hip BMD by 1.0 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/26\">",
"     26",
"    </a>",
"    ]. The decrease in BMD was associated with an increase in all markers of bone turnover. After stopping raloxifene for one year, BMD increased by 1.4 percent and 1.7 percent in the spine and hip, respectively. Therefore, raloxifene, like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , has opposite effects on bone in pre- and postmenopausal women. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Tamoxifen'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     General",
"    </span>",
"    &nbsp;&mdash;&nbsp;In clinical trials, hot flushes, leg cramps, and peripheral edema were more common with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    than with placebo, occurring in 8 to 25, 5 to 10, and 5 to 14 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/8,10,11,14,20\">",
"     8,10,11,14,20",
"    </a>",
"    ]. There was no difference in endometrial thickness, or in complaints of breast pain or vaginal bleeding between the active treatment and placebo groups.",
"   </p>",
"   <p>",
"    In the MORE trial,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    therapy was not associated with an increased risk of either gallbladder disease or cataracts (risks that are increased with estrogen and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    use, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. However, an increased risk of gallbladder disease was seen with raloxifene in the RUTH trial, described below (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Coronary heart disease'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Venous thromboembolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     Raloxifene",
"    </a>",
"    increases the risk of venous thromboembolic (VTE) events, as has been described for both estrogen and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/11,14,20,28\">",
"     11,14,20,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29258?source=see_link&amp;anchor=H18#H18\">",
"     \"Postmenopausal hormone therapy and cardiovascular risk\", section on 'Venous thromboembolism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The magnitude of this effect is illustrated by the results of a meta-analysis of nine trials (24,523 postmenopausal women), in which therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    was associated with an increase in the risk of deep venous thrombosis and pulmonary embolism (ORs 1.5, 95% CI 1.1-2.1 and 1.9, 95% CI 1.0-3.5, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one of the largest trials,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     Raloxifene",
"    </a>",
"    Use for The Heart (RUTH) Trial, 10,101 postmenopausal women (mean age 67 years) with CHD or risk factors for CHD were randomly assigned to raloxifene (60",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/20\">",
"     20",
"    </a>",
"    ]. The two primary outcomes were coronary events and invasive breast cancer. Raloxifene was associated with an increased risk of venous thromboembolism (103 versus 71 events, HR 1.44, 95% CI 1.1-1.9, absolute risk increase 1.2 per 1000). (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Coronary heart disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In the STAR trial, which compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    for the prevention of breast cancer, the risk of thromboembolic events (deep venous thrombosis, pulmonary embolism) was lower with raloxifene than with tamoxifen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/27\">",
"     27",
"    </a>",
"    ]. This trial is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44246?source=see_link&amp;anchor=H31421397#H31421397\">",
"     \"Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention\", section on 'Raloxifene'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the RUTH trial,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    was not associated with an increased risk in overall stroke risk but was associated with an increased risk of fatal stroke (59 versus 39 events, HR 1.49, 95% CI 1.0-2.2, absolute risk increase 0.7 per 1000 woman-years) compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/20\">",
"     20",
"    </a>",
"    ]. In a post hoc analysis, the increased risk of fatal stroke was greater in women who had a high baseline risk of stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/30\">",
"     30",
"    </a>",
"    ]. In the STAR trial, stroke risk was similar in the raloxifene and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Coronary heart disease'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44246?source=see_link&amp;anchor=H2423700#H2423700\">",
"     \"Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention\", section on 'Choice of tamoxifen versus raloxifene'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other effects",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Coronary heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    decreases serum concentrations of total and low-density lipoprotein (LDL) cholesterol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/8,31\">",
"     8,31",
"    </a>",
"    ], it does",
"    <strong>",
"     not",
"    </strong>",
"    decrease the risk of coronary heart disease (CHD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/20,32,33\">",
"     20,32,33",
"    </a>",
"    ]. In Raloxifene Use for The Heart (RUTH) Trial, 10,101 postmenopausal women (mean age 67 years) with CHD or its risk factors were randomly assigned to raloxifene (60",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/20\">",
"     20",
"    </a>",
"    ]. The two primary outcomes were coronary events and invasive breast cancer. After a mean treatment period of 5.6 years, the following results were seen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"       Raloxifene",
"      </a>",
"      had no significant effect on the risk of coronary events when compared with placebo (HR 0.95). In a post hoc analysis of the original dataset, the incidence of coronary events among women &lt;60 years of age was significantly lower in the raloxifene group compared with placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/34\">",
"       34",
"      </a>",
"      ]. However, these data should be interpreted with caution, as they were based upon a post hoc subgroup analysis and a small number of events (50 versus 84).",
"     </li>",
"     <li>",
"      The absolute rates of events that were decreased (vertebral fractures and breast cancer) were similar to the absolute rates of events that were increased (venous thromboembolic events and fatal stroke).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the STAR trial, the risk of CHD was similar in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/27\">",
"     27",
"    </a>",
"    ]. This trial is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44246?source=see_link&amp;anchor=H2423700#H2423700\">",
"     \"Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention\", section on 'Choice of tamoxifen versus raloxifene'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a study of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    therapy in 12 postmenopausal women with a history of hypertriglyceridemia while on oral estrogen, 3 of the 12 developed severe hypertriglyceridemia (&ge;1000",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [&ge;11.3",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    while taking raloxifene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/35\">",
"     35",
"    </a>",
"    ]. This subset of susceptible women should be monitored closely if raloxifene is subsequently prescribed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The MORE trial showed that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    was associated with a substantially reduced risk of invasive breast cancers, a secondary endpoint of the study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/14\">",
"     14",
"    </a>",
"    ]. In the RUTH trial described above, raloxifene reduced the risk of invasive breast cancer (HR 0.56; absolute risk reduction 1.2 cases per 1000 women per year). The benefit was primarily due to a decreased risk of estrogen-receptor-positive breast cancers. This topic is reviewed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44246?source=see_link\">",
"     \"Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the",
"    <span class=\"nowrap\">",
"     MORE/CORE",
"    </span>",
"    trial, which recruited postmenopausal women with osteoporosis, mortality was recorded as an adverse event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/11\">",
"     11",
"    </a>",
"    ]. Overall mortality was lower among patients in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    group (45 versus 65 deaths, HR 0.68, 95% CI 0.46-0.99) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/36\">",
"     36",
"    </a>",
"    ]. In the RUTH trial, which recruited postmenopausal women with CHD or its risk factors, overall mortality was a secondary endpoint, and coronary death was a component of the primary composite endpoint [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/20\">",
"     20",
"    </a>",
"    ]. There was no difference in overall or coronary mortality rates between the raloxifene and placebo groups (554 versus 595 deaths, HR for overall and coronary mortality 0.92, 95% CI 0.82-1.03 and 0.78-1.09, respectively). However, there was a significant increase in cerebrovascular mortality (39 versus 59 deaths, HR 1.49 [95% CI 1.00-2.24]). In a post-hoc pooled analysis of mortality data from",
"    <span class=\"nowrap\">",
"     MORE/CORE",
"    </span>",
"    and RUTH, overall mortality was lower among women receiving raloxifene (HR 0.9, 95% CI 0.8-1.0), primarily due to a lower rate of noncardiovascular deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These data suggest that treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    has the most favorable risk-benefit profile in postmenopausal women at high risk for vertebral compression fractures and breast cancer but a less favorable profile in women at high risk for thromboembolic disease and stroke. When considering raloxifene therapy, the individual's risk of disease and personal preference are important for weighing the potential benefits and risks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Cognitive function",
"    </span>",
"    &nbsp;&mdash;&nbsp;An analysis of data from the MORE trial showed that the risk of cognitive decline was no different with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    versus placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Genitourinary effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike estrogen and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    is not associated with vaginal bleeding and, unlike estrogen, it does not increase the risk of endometrial hyperplasia or cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/2,27,28,38,39\">",
"     2,27,28,38,39",
"    </a>",
"    ]. In a secondary analysis of the MORE trial, neither endometrial hyperplasia nor endometrial cancer risk was increased with raloxifene compared with placebo (RR 1.3, 95% CI 0.4-5.1 and RR 0.9, 95% CI 0.3-2.7, for endometrial hyperplasia and cancer, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the STAR trial, the lower number of endometrial cancers in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    as compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    groups (23 of 4712 versus 36 of the 4732) was not statistically significant (relative risk 0.62, 95% CI 0.35-1.08) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/27\">",
"     27",
"    </a>",
"    ]. However, more than one-half of enrolled women had undergone hysterectomy and were not at risk for endometrial cancer. Fewer women receiving raloxifene underwent hysterectomy for non-cancer reasons (111 versus 244). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44246?source=see_link&amp;anchor=H2423700#H2423700\">",
"     \"Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention\", section on 'Choice of tamoxifen versus raloxifene'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    does not appear to affect vaginal symptoms (dryness or dyspareunia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/40\">",
"     40",
"    </a>",
"    ], nor does it have any effect on urinary incontinence symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     TAMOXIFEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;In postmenopausal women with estrogen-dependent breast cancer,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    provides some protection against postmenopausal bone loss, presumably due to its partial agonist activity (",
"    <a class=\"graphic graphic_figure graphicRef56681 \" href=\"mobipreview.htm?32/36/33357\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. In contrast, net bone loss is reported in many studies in which tamoxifen was administered to premenopausal women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. In premenopausal women, tamoxifen, like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    , blocks estrogen action on bone and causes a decrease in bone density. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42553?source=see_link&amp;anchor=H15#H15\">",
"     \"Evaluation and treatment of premenopausal osteoporosis\", section on 'Chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In postmenopausal women, the increase in bone density with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    (about 1.2 percent in the lumbar spine at two years) is substantially less than that with estrogen or a bisphosphonate such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    (5 to 7 percent at two years). Tamoxifen prevents fracture in postmenopausal women, as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 Trial is the only prospective study of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      in which fracture risk was examined. In this study, 13,328 women were randomly assigned to tamoxifen (20",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or placebo, with the primary objective to determine whether tamoxifen reduced the incidence of invasive breast cancer in high-risk women. In the latest report, with seven years follow-up, women receiving tamoxifen had significantly fewer fractures of the hip, radius, and spine (80 versus 116 in the placebo group, combined RR 0.68, 95 percent CI 0.51 to 0.92) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/42\">",
"       42",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44246?source=see_link\">",
"       \"Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a population-based analysis, women aged 50 or older who were diagnosed with an osteoporotic fracture (vertebral, wrist, hip) in Manitoba Canada from 1996 to 2004 were each compared with three controls without fracture, matched for age, ethnicity, and comorbidity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/46\">",
"       46",
"      </a>",
"      ]. Current",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      use, which was identified in 105 fracture cases and 459 controls, was associated with lower osteoporotic fracture rates (OR 0.68, 95% CI 0.55-0.84). In contrast, past tamoxifen use was unrelated to osteoporotic fracture risk.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite reasonable data to suggest efficacy,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    is not considered a first line SERM for the prevention or treatment of osteoporosis, primarily due to a greater number of endometrial adverse effects with tamoxifen compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    . Unlike tamoxifen, raloxifene is not associated with vaginal bleeding or an increased risk of endometrial hyperplasia or cancer. We therefore do not use tamoxifen for the prevention or treatment of osteoporosis. However, if a postmenopausal woman is taking tamoxifen for the prevention or treatment of breast cancer, it may lower her risk of osteoporosis.",
"   </p>",
"   <p>",
"    In contrast, premenopausal women who are taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    are at risk of developing osteoporosis and, therefore, require monitoring of bone mineral density. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42553?source=see_link&amp;anchor=H15#H15\">",
"     \"Evaluation and treatment of premenopausal osteoporosis\", section on 'Chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     EMERGING SERMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several SERMS in clinical trials for the treatment and prevention of postmenopausal osteoporosis, including bazedoxifene and lasofoxifene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. They have been shown to act as skeletal agonists and breast and uterine antagonists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/49-54\">",
"     49-54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Bazedoxifene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bazedoxifene is effective in preventing and treating osteoporosis. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a two-year randomized trial of bazedoxifene,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"       raloxifene",
"      </a>",
"      , or placebo in 1583 postmenopausal women with osteopenia (T-score of the lumbar spine or femoral neck between -1.0 and -2.5 or other risk factors), women randomly assigned to bazedoxifene or raloxifene similarly maintained spine and hip BMD, whereas women in the placebo group had significant bone loss at both sites (between group differences of approximately 1.5 and 1.6 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a three-year randomized trial in 6847 postmenopausal women with osteoporosis, the cumulative incidence of new vertebral fractures was significantly lower in women randomly assigned to bazedoxifene (20 or 40 mg daily) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"       raloxifene",
"      </a>",
"      (60 mg daily) versus placebo (fracture rates of 2.3, 2.5, 2.3 versus 4.1 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/54\">",
"       54",
"      </a>",
"      ]. The risk of nonvertebral fractures was not decreased in the raloxifene or bazedoxifene groups compared with controls.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In both trials, hot flashes and leg cramps were the most common adverse events, occurring in up to 24 and 12 percent of subjects, respectively. The rates of endometrial hyperplasia, cancer, and polyps were low and similar among the groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/55,56\">",
"     55,56",
"    </a>",
"    ], but the rate of DVT was slightly but significantly higher in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    and bazedoxifene groups compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/54\">",
"     54",
"    </a>",
"    ]. In one of the trials, 753 of 6847 women underwent periodic transvaginal ultrasonography to assess endometrial safety and 444 had mammography to assess breast density [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/55,57\">",
"     55,57",
"    </a>",
"    ]. After two years, the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There were no between group differences in mean endometrial thickness (2.26, 2.51, 2.56, and 2.26 mm in the bazedoxifene 20 mg, bazedoxifene 40 mg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"       raloxifene",
"      </a>",
"      60 mg, and placebo groups, respectively) or mean change from baseline in endometrial thickness (-0.07, 0.10, 0.16, and -0.08 mm, respectively).",
"     </li>",
"     <li>",
"      The incidence of ovarian cancer was low. There was evidence of a significant increase in the incidence of ovarian cancer with bazedoxifene 20 mg (five cases). However, there were no cases with bazedoxifene 40 mg, which seems to make a causal relationship unlikely.",
"     </li>",
"     <li>",
"      Changes in breast density were low and not significantly different among the four groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Bazedoxifene/conjugated estrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;A combination of bazedoxifene and conjugated estrogen",
"    <span class=\"nowrap\">",
"     (BZA/CE)",
"    </span>",
"    is under investigation for the treatment of postmenopausal vasomotor symptoms and osteoporosis prevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a two-year trial of",
"    <span class=\"nowrap\">",
"     BZA/CE",
"    </span>",
"    (in varying doses),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    , or placebo in 3397 postmenopausal women with BMD T-scores between -1 and -2.5, bone mineral density of the lumbar spine and total hip increased significantly with",
"    <span class=\"nowrap\">",
"     BZA/CE",
"    </span>",
"    and raloxifene compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/58\">",
"     58",
"    </a>",
"    ]. The greatest improvement in BMD was seen with the formulation of",
"    <span class=\"nowrap\">",
"     BZA/CE",
"    </span>",
"    that contained the lowest dose BZA (10 mg) combined with the highest dose CE (0.625 mg). These results are not surprising, given the known beneficial effects of CE on BMD; the lowest dose of BZA did not negate these effects.",
"   </p>",
"   <p>",
"    In women who were more than five years post menopause, formulations of",
"    <span class=\"nowrap\">",
"     BZA/CE",
"    </span>",
"    containing BZA 10 or 20 mg with CE 0.45 or 0.625 mg resulted in greater increases in lumbar spine BMD than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    (between group difference 1.2 to 1.6 percent).",
"   </p>",
"   <p>",
"    In addition, combinations with the lower doses (10 or 20 mg) of bazedoxifene with either 0.45 or 0.625 mg of CE significantly improved indices of vaginal atrophy and reduced the daily number of hot flushes (mean change -9 versus -2.4 and -5.3 for placebo and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    groups, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/60\">",
"     60",
"    </a>",
"    ]. The incidence of venous thromboembolic events was low and similar among the groups. The incidence of endometrial hyperplasia was not increased in the groups taking at least 20 mg of BZA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/53/25434?source=see_link\">",
"     \"Menopausal hot flashes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Lasofoxifene",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the Postmenopausal Evaluation and Risk-Reduction With Lasofoxifene (PEARL) trial, over 8500 postmenopausal women with osteoporosis (T-score below -2.5) were randomly assigned to lasofoxifene (0.25 or 0.5 mg daily) versus placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/61\">",
"     61",
"    </a>",
"    ]. All subjects received calcium (1000 mg) and vitamin D (400 to 800 int. units) daily. The primary endpoint for the first three years of the five-year trial was radiographic vertebral fractures. Nonvertebral fracture and estrogen receptor (ER) positive breast cancer were coprimary endpoints through five years.",
"   </p>",
"   <p>",
"    After three years, patients treated with either dose of lasofoxifene had fewer vertebral fractures (13.5 versus 23 per 1000 patient-years, in the 0.5 mg and placebo groups, respectively, HR 0.58, 95% CI 0.45-0.73). After five years, the reduction in vertebral fracture was similar, and patients randomly assigned to 0.5 mg daily also had significantly fewer non vertebral fractures (18.7 versus 24.5 per 1000 person-years, HR 0.76, 95% CI 0.64-0.91). There was no effect on the incidence of hip fracture.",
"   </p>",
"   <p>",
"    There was also a reduction in the incidence of ER positive breast cancer (0.3 versus 1.7 per 1000 person-years in the 0.5 mg and placebo groups, respectively, HR 0.19, 95% CI 0.07-0.56). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44246?source=see_link\">",
"     \"Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After five years, there was a reduction in major coronary heart disease (5.1 versus 7.5 cases per 1000 person-years in the 0.5 mg and placebo groups, respectively, HR 0.68, 95% CI 0.50-0.93) and in stroke (2.5 versus 3.9 cases per 1000 person-years, HR 0.64, 95% CI 0.41-0.99), and there was no difference in the incidence of fatal strokes, which occurred in seven and five patients in the lasofoxifene 0.5 mg and placebo groups, respectively. There was an increase in venous thrombotic events (HR 2.1, 95% CI 1.2-3.6). There was also an unexplained small (just reaching statistical significance) increase in all-cause mortality in the 0.25 mg group but not in the 0.5 mg group, which seems to make a causal relationship unlikely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/61,62\">",
"     61,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Leg cramps, hot flushes, endometrial hypertrophy, uterine polyps, and vaginal candidiasis were significantly more common in women assigned to lasofoxifene than placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/61,62\">",
"     61,62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Lasofoxifene versus raloxifene",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no trials directly comparing lasofoxifene and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    . Compared with raloxifene trials, the lasofoxifene trial showed similar reductions in vertebral fractures and risk of ER-positive breast cancer, and similar increases in the risk of thromboembolic events, hot flashes, and leg cramps. After five years, lasofoxifene was associated with a decrease in non-vertebral fractures, whereas raloxifene has not been shown to have any effect. Neither SERM reduces the risk of hip fracture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although lasofoxifene decreased the risk of major coronary heart disease (CHD) and stroke, the number of events in these categories was small and the confidence intervals wide, suggesting that studies in a high-risk group (larger number of CHD events) are warranted to confirm these finding. Lasofoxifene has not been studied in women with CHD or its risk factors. In the RUTH trial,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    was associated with an increased risk of fatal stroke, an increase that was greater in women who had a high baseline risk of stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/20,30\">",
"     20,30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Coronary heart disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Neither drug significantly increases endometrial hyperplasia or endometrial cancer. However, lasofoxifene may have more endometrial side effects. In the lasofoxifene trials, endometrial hyperplasia was confirmed in more women in the lasofoxifene group (six versus none in the placebo group) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/64\">",
"     64",
"    </a>",
"    ]. The mean increase in endometrial thickness was approximately 1.5 mm, compared with 0.01 mm in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/32/41481/abstract/14,64\">",
"     14,64",
"    </a>",
"    ]. In addition, lasofoxifene use was associated with a significant increase in cystic echotexture on transvaginal ultrasound (due to benign cystic atrophy), endometrial hypertrophy, vaginal bleeding, and uterine polyps. In contrast, raloxifene has not been shown to increase endometrial thickness or vaginal bleeding.",
"   </p>",
"   <p>",
"    Thus, lasofoxifene appears to have similar or better skeletal and cardiovascular benefits but worse endometrial risks than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    . The uterine adverse effects of lasofoxifene require further investigation with long-term follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A SERM is a therapeutic option for the management of osteoporosis. Other pharmacologic options and candidates for pharmacologic therapy for prevention and treatment of osteoporosis are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Candidates for therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/21/33113?source=see_link\">",
"     \"Prevention of osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the majority of postmenopausal women, we suggest",
"      <strong>",
"       not",
"      </strong>",
"      using pharmacological therapy for prevention of osteoporosis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/21/33113?source=see_link\">",
"       \"Prevention of osteoporosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For postmenopausal women who are candidates for and desire pharmacological therapy for",
"      <strong>",
"       prevention",
"      </strong>",
"      of osteoporosis, we suggest bisphosphonates or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"       raloxifene",
"      </a>",
"      as first-line choices (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/21/33113?source=see_link\">",
"       \"Prevention of osteoporosis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      There are nonskeletal considerations with raloxifene that may play an important role in the selection of patients for therapy: a reduction in breast cancer risk, but an increase in thromboembolic events and hot flashes, and no apparent effect on heart disease or the endometrium. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Adverse effects'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Other effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the treatment of osteoporosis in postmenopausal women, we suggest bisphosphonates over",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"       raloxifene",
"      </a>",
"      as first-line therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link&amp;anchor=H20#H20\">",
"       \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Choice of drug'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      We favor bisphosphonates over raloxifene for the",
"      <strong>",
"       treatment",
"      </strong>",
"      of osteoporosis because they increase bone mineral density (BMD) more than raloxifene and in randomized trials, decrease the incidence of hip fracture. However, raloxifene is a reasonable alternative to bisphosphonates for postmenopausal women with osteoporosis who are also at high risk for invasive breast cancer. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link&amp;anchor=H20#H20\">",
"       \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Choice of drug'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"       raloxifene",
"      </a>",
"      for postmenopausal women with osteoporosis (low bone mineral density [T score &lt;-2.5] and no fragility fractures) who cannot tolerate or are not candidates for any bisphosphonates (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link&amp;anchor=H20#H20\">",
"       \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Choice of drug'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In premenopausal women,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6390?source=see_link\">",
"       raloxifene",
"      </a>",
"      blocks estrogen action on bone and causes a decrease in bone density and, therefore, it should not be used for the prevention or treatment of osteoporosis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Effects in premenopausal women'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       Tamoxifen",
"      </a>",
"      is not a first-line SERM for the prevention or treatment of osteoporosis. However, if a postmenopausal woman is taking tamoxifen for the prevention or treatment of breast cancer, it should decrease her risk of osteoporosis. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Tamoxifen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In contrast,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      blocks estrogen action on bone and causes a decrease in bone density in premenopausal women. Thus, premenopausal women who are taking tamoxifen require monitoring of bone mineral density. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42553?source=see_link&amp;anchor=H15#H15\">",
"       \"Evaluation and treatment of premenopausal osteoporosis\", section on 'Chemotherapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/1\">",
"      Cosman F, Lindsay R. Selective estrogen receptor modulators: clinical spectrum. Endocr Rev 1999; 20:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/2\">",
"      Riggs BL, Hartmann LC. Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice. N Engl J Med 2003; 348:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/3\">",
"      Khovidhunkit W, Shoback DM. Clinical effects of raloxifene hydrochloride in women. Ann Intern Med 1999; 130:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/4\">",
"      Black LJ, Sato M, Rowley ER, et al. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 1994; 93:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/5\">",
"      Bjarnason NH, Haarbo J, Byrjalsen I, et al. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits. Circulation 1997; 96:1964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/6\">",
"      Yang NN, Venugopalan M, Hardikar S, Glasebrook A. Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene. Science 1996; 273:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/7\">",
"      Brzozowski AM, Pike AC, Dauter Z, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997; 389:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/8\">",
"      Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/9\">",
"      Meunier PJ, Vignot E, Garnero P, et al. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group. Osteoporos Int 1999; 10:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/10\">",
"      Johnston CC Jr, Bjarnason NH, Cohen FJ, et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med 2000; 160:3444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/11\">",
"      Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/12\">",
"      Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002; 87:3609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/13\">",
"      Cranney A, Tugwell P, Zytaruk N, et al. Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev 2002; 23:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/14\">",
"      Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999; 281:2189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/15\">",
"      Delmas PD, Genant HK, Crans GG, et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 2003; 33:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/16\">",
"      Siris ES, Harris ST, Eastell R, et al. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res 2005; 20:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/17\">",
"      Lufkin EG, Whitaker MD, Nickelsen T, et al. Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res 1998; 13:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/18\">",
"      Chapurlat RD, Ewing SK, Bauer DC, Cummings SR. Influence of smoking on the antiosteoporotic efficacy of raloxifene. J Clin Endocrinol Metab 2001; 86:4178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/19\">",
"      Seeman E, Crans GG, Diez-Perez A, et al. Anti-vertebral fracture efficacy of raloxifene: a meta-analysis. Osteoporos Int 2006; 17:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/20\">",
"      Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/21\">",
"      Johnell O, Scheele WH, Lu Y, et al. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002; 87:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/22\">",
"      Sambrook PN, Geusens P, Ribot C, et al. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International. J Intern Med 2004; 255:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/23\">",
"      Prestwood KM, Gunness M, Muchmore DB, et al. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J Clin Endocrinol Metab 2000; 85:2197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/24\">",
"      Reid IR, Eastell R, Fogelman I, et al. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women. Arch Intern Med 2004; 164:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/25\">",
"      Neele SJ, Evertz R, De Valk-De Roo G, et al. Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone 2002; 30:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/26\">",
"      Eng-Wong J, Reynolds JC, Venzon D, et al. Effect of raloxifene on bone mineral density in premenopausal women at increased risk of breast cancer. J Clin Endocrinol Metab 2006; 91:3941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/27\">",
"      Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006; 295:2727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/28\">",
"      Grady D, Ettinger B, Moscarelli E, et al. Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstet Gynecol 2004; 104:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/29\">",
"      Adomaityte J, Farooq M, Qayyum R. Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis. Thromb Haemost 2008; 99:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/30\">",
"      Barrett-Connor E, Cox DA, Song J, et al. Raloxifene and risk for stroke based on the framingham stroke risk score. Am J Med 2009; 122:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/31\">",
"      Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998; 279:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/32\">",
"      Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002; 287:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/33\">",
"      Ensrud K, Genazzani AR, Geiger MJ, et al. Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis. Am J Cardiol 2006; 97:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/34\">",
"      Collins P, Mosca L, Geiger MJ, et al. Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors. Circulation 2009; 119:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/35\">",
"      Carr MC, Knopp RH, Brunzell JD, et al. Effect of raloxifene on serum triglycerides in women with a history of hypertriglyceridemia while on oral estrogen therapy. Diabetes Care 2005; 28:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/36\">",
"      Grady D, Cauley JA, Stock JL, et al. Effect of Raloxifene on all-cause mortality. Am J Med 2010; 123:469.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/37\">",
"      Yaffe K, Krueger K, Sarkar S, et al. Cognitive function in postmenopausal women treated with raloxifene. N Engl J Med 2001; 344:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/38\">",
"      Goldstein SR, Scheele WH, Rajagopalan SK, et al. A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Obstet Gynecol 2000; 95:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/39\">",
"      Neven P, Quail D, L&eacute;vrier M, et al. Uterine effects of estrogen plus progestin therapy and raloxifene: adjudicated results from the EURALOX study. Obstet Gynecol 2004; 103:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/40\">",
"      Davies GC, Huster WJ, Lu Y, et al. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol 1999; 93:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/41\">",
"      Waetjen LE, Brown JS, Modelska K, et al. Effect of raloxifene on urinary incontinence: a randomized controlled trial. Obstet Gynecol 2004; 103:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/42\">",
"      Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005; 97:1652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/43\">",
"      Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/44\">",
"      Sverrisd&oacute;ttir A, Fornander T, Jacobsson H, et al. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol 2004; 22:3694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/45\">",
"      Powles TJ, Hickish T, Kanis JA, et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996; 14:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/46\">",
"      Cooke AL, Metge C, Lix L, et al. Tamoxifen use and osteoporotic fracture risk: a population-based analysis. J Clin Oncol 2008; 26:5227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/47\">",
"      Stump AL, Kelley KW, Wensel TM. Bazedoxifene: a third-generation selective estrogen receptor modulator for treatment of postmenopausal osteoporosis. Ann Pharmacother 2007; 41:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/48\">",
"      Chaki O. [Next generation selective estrogen receptor modulators]. Clin Calcium 2006; 16:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/49\">",
"      Komm BS, Kharode YP, Bodine PV, et al. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 2005; 146:3999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/50\">",
"      Draper MW, Plouffe L Jr. Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet Gynecol 2005; 106:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/51\">",
"      McClung MR, Siris E, Cummings S, et al. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. Menopause 2006; 13:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/52\">",
"      Ke HZ, Foley GL, Simmons HA, et al. Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats. Endocrinology 2004; 145:1996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/53\">",
"      Miller PD, Chines AA, Christiansen C, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 2008; 23:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/54\">",
"      Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008; 23:1923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/55\">",
"      Archer DF, Pinkerton JV, Utian WH, et al. Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause 2009; 16:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/56\">",
"      Pinkerton JV, Archer DF, Utian WH, et al. Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis. Menopause 2009; 16:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/57\">",
"      Harvey JA, Holm MK, Ranganath R, et al. The effects of bazedoxifene on mammographic breast density in postmenopausal women with osteoporosis. Menopause 2009; 16:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/58\">",
"      Lindsay R, Gallagher JC, Kagan R, et al. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 2009; 92:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/59\">",
"      Pickar JH, Yeh IT, Bachmann G, Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril 2009; 92:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/60\">",
"      Lobo RA, Pinkerton JV, Gass ML, et al. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 2009; 92:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/61\">",
"      Cummings SR, Ensrud K, Delmas PD, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010; 362:686.",
"     </a>",
"    </li>",
"    <li>",
"     The Pink Sheet 2008; 70:11.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/32/41481/abstract/63\">",
"      Becker C. Another selective estrogen-receptor modulator for osteoporosis. N Engl J Med 2010; 362:752.",
"     </a>",
"    </li>",
"    <li>",
"     Reproductive Health Drugs Advisory Committee Briefing Document - FABLYN (lasofoxifene tartrate) 0.5 mg Tablets. September 8, 2008. www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4381b1-02-Pfizer.pdf (Accessed on June 16, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2068 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-298F256B3B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_32_41481=[""].join("\n");
var outline_f40_32_41481=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RALOXIFENE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Bone mineral density",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Potency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Effects in premenopausal women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - General",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Venous thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Breast cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Mortality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Cognitive function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Genitourinary effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      TAMOXIFEN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      EMERGING SERMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Bazedoxifene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Bazedoxifene/conjugated estrogen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Lasofoxifene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Lasofoxifene versus raloxifene",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/2068\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2068|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/32/1551\" title=\"figure 1\">",
"      Bone density with raloxifene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/4/15425\" title=\"figure 2\">",
"      Vertebral fracture raloxifene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/36/33357\" title=\"figure 3\">",
"      Tamoxifen in osteoporosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20106?source=related_link\">",
"      Adjuvant endocrine therapy for hormone receptor-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=related_link\">",
"      Bisphosphonates in the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/35/42553?source=related_link\">",
"      Evaluation and treatment of premenopausal osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/2/7210?source=related_link\">",
"      Mechanisms of action of selective estrogen receptor modulators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/53/25434?source=related_link\">",
"      Menopausal hot flashes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15786?source=related_link\">",
"      Parathyroid hormone therapy for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/36/29258?source=related_link\">",
"      Postmenopausal hormone therapy and cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/21/33113?source=related_link\">",
"      Prevention of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44246?source=related_link\">",
"      Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_32_41482="Acute anteroapical MI tutorial";
var content_f40_32_41482=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52433&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52433&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1264px;\">",
"  <div class=\"figure\" style=\"width: 550px\">",
"   <div class=\"ttl\">",
"    Acute anteroapical transmural myocardial infarction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 530px; height: 166px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    ST elevation is present in V3 and V4 in patients with an anteroapical infarct.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 594px\">",
"   <div class=\"ttl\">",
"    Normal ECG",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 594px; height: 337px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFRAlIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD2S80nTV1SxVdN08K18VYDSjgj7M5wV9MgHb6jdUlto+mGWzzpmnnMcec6YWz8knUfxfUdeD/CajvLq1bVLHFu2FvjkHRpxx9mfgLjJ5OdvX+LpUlte2plswbeQ5jjznR52z8knUY+b6jrwf4TVLl1PqZOtyLWXw9n3fkVLbSdON/Ip06wKi1smAOmE8mSTJ9ycDJ/ixgVbTR9M3S/8SzT/wDWJ/zDCf8Alsw/D0x3Hy9RVW2u7b7fI5gfBtbIf8gmcnPmSZzx3z16P0HQ1aS9td0v+jyf6xP+YPOf+WzD0444x3Hy9RQuUqq613Zy6dH2XkVLLStOexuGbTrAsGvgCdMORicgc9sDgH+EcGjW9K06PRdRePTrBXW1vGVl0wqQQeCD2I7H+HoaLG7tksbgG3fO6+OV0mf/AJ7tjnHBHr/B0PNGt3ds+i6iq27hja3gBOkzrg545IwMep4XoaXu8padb2y1l8T6Pu/It32j6YFuMaZp4xI3TTCmP3Oe/TnnHY/N0qO80nTV1SxVdN08K18VYDSjgj7M5wV9MgHb6jdUl9e2oW4xbyDEjdNHnTH7nPdePXHY/N0qO8urVtUscW7YW+OQdGnHH2Z+AuMnk529f4ulN8tjKDrW3l8L6Pt6Elto+mGWzzpmnnMcec6YWz8knUfxfUdeD/CaqW2k6cb+RTp1gVFrZMAdMJ5MkmT7k4GT/FjAq3bXtqZbMG3kOY4850eds/JJ1GPm+o68H+E1Vtru2+3yOYHwbWyH/IJnJz5kmc8d89ej9B0ND5blJ1ve1lsuj7+haTR9M3S/8SzT/wDWJ/zDCf8Alsw/D0x3Hy9RVSy0rTnsbhm06wLBr4AnTDkYnIHPbA4B/hHBq2l7a7pf9Hk/1if8wec/8tmHpxxxjuPl6iqljd2yWNwDbvndfHK6TP8A892xzjgj1/g6Hmj3bgnWs9Zbro+z8g1vStOj0XUXj06wV1tbxlZdMKkEHgg9iOx/h6Grd9o+mBbjGmaeMSN00wpj9znv055x2PzdKqa3d2z6LqKrbuGNreAE6TOuDnjkjAx6nhehq3fXtqFuMW8gxI3TR50x+5z3Xj1x2PzdKFy3BOtyrWW8uj8vIjvNJ01dUsVXTdPCtfFWA0o4I+zOcFfTIB2+o3VJbaPphls86Zp5zHHnOmFs/JJ1H8X1HXg/wmo7y6tW1Sxxbthb45B0accfZn4C4yeTnb1/i6VJbXtqZbMG3kOY4850eds/JJ1GPm+o68H+E0Ll1Jk63ItZfD2fd+RUttJ0438inTrAqLWyYA6YTyZJMn3JwMn+LGBVtNH0zdL/AMSzT/8AWJ/zDCf+WzD8PTHcfL1FVba7tvt8jmB8G1sh/wAgmcnPmSZzx3z16P0HQ1aS9td0v+jyf6xP+YPOf+WzD0444x3Hy9RQuUqq613Zy6dH2XkVLLStOexuGbTrAsGvgCdMORicgc9sDgH+EcGjW9K06PRdRePTrBXW1vGVl0wqQQeCD2I7H+HoaLG7tksbgG3fO6+OV0mf/nu2OccEev8AB0PNGt3ds+i6iq27hja3gBOkzrg545IwMep4XoaXu8padb2y1l8T6Pu/It32j6YFuMaZp4xI3TTCmP3Oe/TnnHY/N0qO80nTV1SxVdN08K18VYDSjgj7M5wV9MgHb6jdUl9e2oW4xbyDEjdNHnTH7nPdePXHY/N0qO8urVtUscW7YW+OQdGnHH2Z+AuMnk529f4ulN8tjKDrW3l8L6Pt6Elto+mGWzzpmnnMcec6YWz8knUfxfUdeD/CaqW2k6cb+RTp1gVFrZMAdMJ5MkmT7k4GT/FjAq3bXtqZbMG3kOY4850eds/JJ1GPm+o68H+E1Vtru2+3yOYHwbWyH/IJnJz5kmc8d89ej9B0ND5blJ1ve1lsuj7+haTR9M3S/wDEs0//AFif8wwn/lsw/D0x3Hy9RVSy0rTnsbhm06wLBr4AnTDkYnIHPbA4B/hHBq2l7a7pf9Hk/wBYn/MHnP8Ay2YenHHGO4+XqKqWN3bJY3ANu+d18crpM/8Az3bHOOCPX+DoeaPduCdaz1luuj7PyDW9K06PRdRePTrBXW1vGVl0wqQQeCD2I7H+Hoat32j6YFuMaZp4xI3TTCmP3Oe/TnnHY/N0qprd3bPouoqtu4Y2t4ATpM64OeOSMDHqeF6Grd9e2oW4xbyDEjdNHnTH7nPdePXHY/N0oXLcE63KtZby6Py8iO80nTV1SxVdN08K18VYDSjgj7M5wV9MgHb6jdUlto+mGWzzpmnnMcec6YWz8knUfxfUdeD/AAmo7y6tW1Sxxbthb45B0accfZn4C4yeTnb1/i6VJbXtqZbMG3kOY4850eds/JJ1GPm+o68H+E0Ll1Jk63ItZfD2fd+RUttJ0438inTrAqLWyYA6YTyZJMn3JwMn+LGBVtNH0zdL/wASzT/9Yn/MMJ/5bMPw9Mdx8vUVVtru2+3yOYHwbWyH/IJnJz5kmc8d89ej9B0NWkvbXdL/AKPJ/rE/5g85/wCWzD0444x3Hy9RQuUqq613Zy6dH2XkVLLStOexuGbTrAsGvgCdMORicgc9sDgH+EcGjW9K06PRdRePTrBXW1vGVl0wqQQeCD2I7H+HoaLG7tksbgG3fO6+OV0mf/nu2OccEev8HQ80a3d2z6LqKrbuGNreAE6TOuDnjkjAx6nhehpe7ylp1vbLWXxPo+78i3faPpgW4xpmnjEjdNMKY/c579Oecdj83So7zSdNXVLFV03TwrXxVgNKOCPsznBX0yAdvqN1SX17ahbjFvIMSN00edMfuc9149cdj83So7y6tW1Sxxbthb45B0accfZn4C4yeTnb1/i6U3y2MoOtbeXwvo+3oSW2j6YZbPOmaecxx5zphbPySdR/F9R14P8ACaqW2k6cb+RTp1gVFrZMAdMJ5MkmT7k4GT/FjAq3bXtqZbMG3kOY4850eds/JJ1GPm+o68H+E1Vtru2+3yOYHwbWyH/IJnJz5kmc8d89ej9B0ND5blJ1ve1lsuj7+haTR9M3S/8AEs0//WJ/zDCf+WzD8PTHcfL1FVLLStOexuGbTrAsGvgCdMORicgc9sDgH+EcGraXtrul/wBHk/1if8wec/8ALZh6cccY7j5eoqpY3dsljcA2753Xxyukz/8APdsc44I9f4Oh5o924J1rPWW66Ps/INb0rTo9F1F49OsFdbW8ZWXTCpBB4IPYjsf4ehq3faPpgW4xpmnjEjdNMKY/c579Oecdj83Sqmt3ds+i6iq27hja3gBOkzrg545IwMep4Xoat317ahbjFvIMSN00edMfuc9149cdj83ShctwTrcq1lvLo/LyI7zSdNXVLFV03TwrXxVgNKOCPsznBX0yAdvqN1SW2j6YZbPOmaecxx5zphbPySdR/F9R14P8JqO8urVtUscW7YW+OQdGnHH2Z+AuMnk529f4ulSW17amWzBt5DmOPOdHnbPySdRj5vqOvB/hNC5dSZOtyLWXw9n3fkVLbSdON/Ip06wKi1smAOmE8mSTJ9ycDJ/ixgVbTR9M3S/8SzT/APWJ/wAwwn/lsw/D0x3Hy9RVW2u7b7fI5gfBtbIf8gmcnPmSZzx3z16P0HQ1aS9td0v+jyf6xP8AmDzn/lsw9OOOMdx8vUULlKqutd2cunR9l5FSy0rTnsbhm06wLBr4AnTDkYnIHPbA4B/hHBo1vStOj0XUXj06wV1tbxlZdMKkEHgg9iOx/h6Gixu7ZLG4Bt3zuvjldJn/AOe7Y5xwR6/wdDzRrd3bPouoqtu4Y2t4ATpM64OeOSMDHqeF6Gl7vKWnW9stZfE+j7vyLd9o+mBbjGmaeMSN00wpj9znv055x2PzdKjvNJ01dUsVXTdPCtfFWA0o4I+zOcFfTIB2+o3VJfXtqFuMW8gxI3TR50x+5z3Xj1x2PzdKjvLq1bVLHFu2FvjkHRpxx9mfgLjJ5OdvX+LpTfLYyg61t5fC+j7ehJbaPphls86Zp5zHHnOmFs/JJ1H8X1HXg/wmqltpOnG/kU6dYFRa2TAHTCeTJJk+5OBk/wAWMCrdte2plswbeQ5jjznR52z8knUY+b6jrwf4TVW2u7b7fI5gfBtbIf8AIJnJz5kmc8d89ej9B0ND5blJ1ve1lsuj7+haTR9M3S/8SzT/APWJ/wAwwn/lsw/D0x3Hy9RVSy0rTnsbhm06wLBr4AnTDkYnIHPbA4B/hHBq2l7a7pf9Hk/1if8AMHnP/LZh6cccY7j5eoqpY3dsljcA2753Xxyukz/892xzjgj1/g6Hmj3bgnWs9Zbro+z8g1vStOj0XUXj06wV1tbxlZdMKkEHgg9iOx/h6Grd9o+mBbjGmaeMSN00wpj9znv055x2PzdKqa3d2z6LqKrbuGNreAE6TOuDnjkjAx6nhehq3fXtqFuMW8gxI3TR50x+5z3Xj1x2PzdKFy3BOtyrWW8uj8vIjvNJ01dUsVXTdPCtfFWA0o4I+zOcFfTIB2+o3VJbaPphls86Zp5zHHnOmFs/JJ1H8X1HXg/wmo7y6tW1Sxxbthb45B0accfZn4C4yeTnb1/i6VJbXtqZbMG3kOY4850eds/JJ1GPm+o68H+E0Ll1Jk63ItZfD2fd+RUttJ0438inTrAqLWyYA6YTyZJMn3JwMn+LGBVtNH0zdL/xLNP/ANYn/MMJ/wCWzD8PTHcfL1FVba7tvt8jmB8G1sh/yCZyc+ZJnPHfPXo/QdDVpL213S/6PJ/rE/5g85/5bMPTjjjHcfL1FC5SqrrXdnLp0fZeRUstK057G4ZtOsCwa+AJ0w5GJyBz2wOAf4RwaNb0rTo9F1F49OsFdbW8ZWXTCpBB4IPYjsf4ehosbu2SxuAbd87r45XSZ/8Anu2OccEev8HQ80a3d2z6LqKrbuGNreAE6TOuDnjkjAx6nhehpe7ylp1vbLWXxPo+78i3faPpgW4xpmnjEjdNMKY/c579Oecdj83So7zSdNXVLFV03TwrXxVgNKOCPsznBX0yAdvqN1cZ8Wb5FvvBaWgeFpPFtjE2LOS1LIyEMvzAZUgkFffnhhXZ3l1atqlji3bC3xyDo044+zPwFxk8nO3r/F0ofKctGtVlOULy92L/ABXoSW2j6YZbPOmaecxx5zphbPySdR/F9R14P8JqpbaTpxv5FOnWBUWtkwB0wnkySZPuTgZP8WMCrdte2plswbeQ5jjznR52z8knUY+b6jrwf4TVW2u7b7fI5gfBtbIf8gmcnPmSZzx3z16P0HQ03y3N063vay2XR9/QtJo+mbpf+JZp/wDrE/5hhP8Ay2Yfh6Y7j5eoqpZaVpz2NwzadYFg18ATphyMTkDntgcA/wAI4NW0vbXdL/o8n+sT/mDzn/lsw9OOOMdx8vUVUsbu2SxuAbd87r45XSZ/+e7Y5xwR6/wdDzR7twTrWest10fZ+Qa3pWnR6LqLx6dYK62t4ysumFSCDwQexHY/w9DVu+0fTAtxjTNPGJG6aYUx+5z36c847H5ulVNbu7Z9F1FVt3DG1vACdJnXBzxyRgY9TwvQ1bvr21C3GLeQYkbpo86Y/c57rx647H5ulC5bgnW5VrLeXR+XkR3mk6auqWKrpunhWvirAaUcEfZnOCvpkA7fUbqkttH0wy2edM085jjznTC2fkk6j+L6jrwf4TXndxrNwf2jbbTjJIdIXS/tAtP7Ok2iTDru8jG/OCf59BXolte2plswbeQ5jjznR52z8knUY+b6jrwf4TQuXUyVSrOneLlorbdm/IqW2k6cb+RTp1gVFrZMAdMJ5MkmT7k4GT/FjAq2mj6Zul/4lmn/AOsT/mGE/wDLZh+HpjuPl6iqttd232+RzA+Da2Q/5BM5OfMkznjvnr0foOhq5b3NtLO8awMGaaNRv0mZQMzsOSRhR9e3y9jQuU0qusm3eXTo+y8jxnxIiReItUjjRUjW6lVVRNgUBzgBf4R7dqKPEhVvEWqFBtU3UpA8sx4G8/wnlfoeRRXG9z9Bofwo37L8j2u+dv7V079xP/x/njzrjP8Ax6ycfdznvnrjjGOa4fxLqN7b/Fz4Z2cE95HaXMF6Z7eO4nVJ9luShYAZOCSRgEDJweTXW3lxc/2pYFk08f6cSuNYlIP+jOOW8vgdfm65+XpzUltcXgls8xaeMRx5zq0q4+STqfL+X6DpkD+I12J7n5vVoSlTS8l1Xd+YWrN/aUv7qY/6JY/8tZv+esv+z37Y4H8OTVxGO6X91N/rE/5azf8APZv9n8Oec8j5sisi2nuhfyfu7Df9lsgQdVkAGJJP9jr1yP4eozmraXF5ul/daf8A6xP+YtKP+WzH/nnzxznsPm6mmmaVaTu9O3Vdl5hp7N9guP3Uw+e//wCWs3/PdvVe3fPB/iwaNeZv7C1P91N/x6XnWWb1/wB3t3zwf4sGqtjcXX2GcJHYMN1911WTOTO3GNnPfA/jHJxSa3PdHRdRDx2AU2t4CV1WRjyew2cn0H8XU0r+6aKk/bJ2+0+q7vzNe+Ylbj91MMyN1lmOP3Puv48844+7zUV87f2rp37if/j/ADx51xn/AI9ZOPu5z3z1xxjHNQX1xeFbjEWnnMjYxq0r5/c47x8+me5+XpUd5cXP9qWBZNPH+nErjWJSD/ozjlvL4HX5uufl6c029DGnSdtvsvqu3qaFszedZ/upj+7j6SzDPySdMLx+GRwccE4p2rN/aUv7qY/6JY/8tZv+esv+z37Y4H8OTRbXF4JbPMWnjEcec6tKuPkk6ny/l+g6ZA/iNVLae6F/J+7sN/2WyBB1WQAYkk/2OvXI/h6jOaG9S1SfvadF1Xf1NdGO6X91N/rE/wCWs3/PZv8AZ/DnnPI+bIqnp7N9guP3Uw+e/wD+Ws3/AD3b1Xt3zwf4sGhLi83S/utP/wBYn/MWlH/LZj/zz545z2HzdTVWxuLr7DOEjsGG6+66rJnJnbjGznvgfxjk4ovqJUnZ6dV1XZ+Za15m/sLU/wB1N/x6XnWWb1/3e3fPB/iwauXzErcfuphmRussxx+591/HnnHH3eayNbnujouoh47AKbW8BK6rIx5PYbOT6D+Lqat31xeFbjEWnnMjYxq0r5/c47x8+me5+XpQnqCpPlWnWXVeXmT3zt/aunfuJ/8Aj/PHnXGf+PWTj7uc989ccYxzUtszedZ/upj+7j6SzDPySdMLx+GRwccE4z7y4uf7UsCyaeP9OJXGsSkH/RnHLeXwOvzdc/L05qS2uLwS2eYtPGI4851aVcfJJ1Pl/L9B0yB/EaE9yZUnyLT7Pdd35has39pS/upj/olj/wAtZv8AnrL/ALPftjgfw5NY/j/xE3hnwzfaiiyxyiaGON3WaWNGa4YAvlo1VeSNzyIAec7jtp9hrBk8QXmn+TCt/DZafIQ2ousRjMkvIbbncCDlduFxkHPFaqXF5ul/daf/AKxP+YtKP+WzH/nnzxznsPm6mhMU4+0vyeS3XRLzPAr/AMZeJpPC2heJ7WK7lXxTYXuhpZW+oS28Vrfy3TlLlNxIYnkY7bBufJrL8Saj4k03xF4p0W51vWJYLCKwtG1mXUblILFjGhkeS3BIcTsjIfM+UO43MM5r6Hsbi6+wzhI7BhuvuuqyZyZ24xs574H8Y5OKTW57o6LqIeOwCm1vASuqyMeT2Gzk+g/i6mp+yQsFN1Fd3fN3Xn56XNe+Ylbj91MMyN1lmOP3Puv48844+7zUV87f2rp37if/AI/zx51xn/j1k4+7nPfPXHGMc1BfXF4VuMRaecyNjGrSvn9zjvHz6Z7n5elR3lxc/wBqWBZNPH+nErjWJSD/AKM45by+B1+brn5enNU3oaU6Ttt9l9V29TQtmbzrP91Mf3cfSWYZ+STphePwyODjgnFO1Zv7Sl/dTH/RLH/lrN/z1l/2e/bHA/hyaLa4vBLZ5i08YjjznVpVx8knU+X8v0HTIH8RqpbT3Qv5P3dhv+y2QIOqyADEkn+x165H8PUZzQ3qWqT97Touq7+prox3S/upv9Yn/LWb/ns3+z+HPOeR82RVPT2b7Bcfuph89/8A8tZv+e7eq9u+eD/Fg0JcXm6X91p/+sT/AJi0o/5bMf8AnnzxznsPm6mqtjcXX2GcJHYMN1911WTOTO3GNnPfA/jHJxRfUSpOz06rquz8y1rzN/YWp/upv+PS86yzev8Au9u+eD/Fg1cvmJW4/dTDMjdZZjj9z7r+PPOOPu81ka3PdHRdRDx2AU2t4CV1WRjyew2cn0H8XU1bvri8K3GItPOZGxjVpXz+5x3j59M9z8vShPUFSfKtOsuq8vMnvnb+1dO/cT/8f54864z/AMesnH3c575644xjmpbZm86z/dTH93H0lmGfkk6YXj8Mjg44Jxn3lxc/2pYFk08f6cSuNYlIP+jOOW8vgdfm65+XpzUltcXgls8xaeMRx5zq0q4+STqfL+X6DpkD+I0J7kypPkWn2e67vzC1Zv7Sl/dTH/RLH/lrN/z1l/2e/bHA/hyauIx3S/upv9Yn/LWb/ns3+z+HPOeR82RWRbT3Qv5P3dhv+y2QIOqyADEkn+x165H8PUZzVtLi83S/utP/ANYn/MWlH/LZj/zz545z2HzdTQmVVpO707dV2XmGns32C4/dTD57/wD5azf8929V7d88H+LBo15m/sLU/wB1N/x6XnWWb1/3e3fPB/iwaq2NxdfYZwkdgw3X3XVZM5M7cY2c98D+McnFJrc90dF1EPHYBTa3gJXVZGPJ7DZyfQfxdTSv7poqT9snb7T6ru/M175iVuP3UwzI3WWY4/c+6/jzzjj7vNRXzt/aunfuJ/8Aj/PHnXGf+PWTj7uc989ccYxzUF9cXhW4xFp5zI2MatK+f3OO8fPpnufl6Vl+LdefQrU6veQW0lvZXElyyW+qyu7qtpITj5B2z83r8vTmnJqxjCm0rv8Alf2l29TR1W1udR0iWysp7mxuriy8mG7jectC7RShZFAAOQTuAU9uDgkjyn4Rajr3irVdRlvZtT0z+xdLtvDtxGt89yZrxJSWus7WQOuCAGVhl+C2CD6lo+pT3tvpd3BHYeTNbwyqX1WVCAY3Iz+7yp5HHbOP4jUdtPdC/k/d2G/7LZAg6rIAMSSf7HXrkfw9RnNDauiHh+eXP2S6rXX1OZ+A+o3up/CrRbzUp72+u5SxkuJrid3ci8lAJODnpgc8Y4yciux09m+wXH7qYfPf/wDLWb/nu3qvbvng/wAWDQlxebpf3Wn/AOsT/mLSj/lsx/5588c57D5upqrY3F19hnCR2DDdfddVkzkztxjZz3wP4xycUX1RdOhKMOXzXVdn5lrXmb+wtT/dTf8AHpedZZvX/d7d88H+LBq5fMStx+6mGZG6yzHH7n3X8eeccfd5rI1ue6Oi6iHjsAptbwErqsjHk9hs5PoP4upq3fXF4VuMRaecyNjGrSvn9zjvHz6Z7n5elCepSpPlWnWXVeXmT3zt/aunfuJ/+P8APHnXGf8Aj1k4+7nPfPXHGMc1LbM3nWf7qY/u4+kswz8knTC8fhkcHHBOM+8uLn+1LAsmnj/TiVxrEpB/0Zxy3l8Dr83XPy9Oaktri8EtnmLTxiOPOdWlXHySdT5fy/QdMgfxGhPcmVJ8i0+z3Xd+YWrN/aUv7qY/6JY/8tZv+esv+z37Y4H8OTVxGO6X91N/rE/5azf89m/2fw55zyPmyKyLae6F/J+7sN/2WyBB1WQAYkk/2OvXI/h6jOatpcXm6X91p/8ArE/5i0o/5bMf+efPHOew+bqaEyqtJ3enbquy8w09m+wXH7qYfPf/APLWb/nu3qvbvng/xYNGvM39han+6m/49LzrLN6/7vbvng/xYNVbG4uvsM4SOwYbr7rqsmcmduMbOe+B/GOTik1ue6Oi6iHjsAptbwErqsjHk9hs5PoP4uppX900VJ+2Tt9p9V3fma98xK3H7qYZkbrLMcfufdfx55xx93mor52/tXTv3E//AB/njzrjP/HrJx93Oe+euOMY5qC+uLwrcYi085kbGNWlfP7nHePn0z3Py9KjvLi5/tSwLJp4/wBOJXGsSkH/AEZxy3l8Dr83XPy9OabehjTpO232X1Xb1NC2ZvOs/wB1Mf3cfSWYZ+STphePwyODjgnFO1Zv7Sl/dTH/AESx/wCWs3/PWX/Z79scD+HJotri8EtnmLTxiOPOdWlXHySdT5fy/QdMgfxGqltPdC/k/d2G/wCy2QIOqyADEkn+x165H8PUZzQ3qWqT97Touq7+prox3S/upv8AWJ/y1m/57N/s/hzznkfNkVT09m+wXH7qYfPf/wDLWb/nu3qvbvng/wAWDQlxebpf3Wn/AOsT/mLSj/lsx/5588c57D5upqrY3F19hnCR2DDdfddVkzkztxjZz3wP4xycUX1EqTs9Oq6rs/Mta8zf2Fqf7qb/AI9LzrLN6/7vbvng/wAWDVy+Ylbj91MMyN1lmOP3Puv48844+7zWRrc90dF1EPHYBTa3gJXVZGPJ7DZyfQfxdTVu+uLwrcYi085kbGNWlfP7nHePn0z3Py9KE9QVJ8q06y6ry8ye+dv7V079xP8A8f54864z/wAesnH3c575644xjmpbZm86z/dTH93H0lmGfkk6YXj8Mjg44Jxn3lxc/wBqWBZNPH+nErjWJSD/AKM45by+B1+brn5enNSW1xeCWzzFp4xHHnOrSrj5JOp8v5foOmQP4jQnuTKk+RafZ7ru/Moapa3Oo2urWNlPc2F1c6XbQw3cck5aB2aYLIAAOQSCACMEfKc15P4D1rx1qNrrWp21hfXGpaBYw6B/ZlxqLyJeailxukuHIIAZQeQTltx2vmvT/wC2/s3iS106VbMXt7ZW7xINRm27YpG3ksI8KR5i8HG3OVzzjYS4vN0v7rT/APWJ/wAxaUf8tmP/ADz545z2HzdTQmRWoupK8Xtbquy8+h5v8B9S1u70jxZbeIW1S6u7PVL2Jrm6lIG4iMvGERmCFWyzKPkzIMMa9I15m/sLU/3U3/HpedZZvX/d7d88H+LBqrY3F19hnCR2DDdfddVkzkztxjZz3wP4xycUmtz3R0XUQ8dgFNreAldVkY8nsNnJ9B/F1NK/umtHDypzjF62l3Xn5nn/AMebp4/Evw/jVZo2PiKGYbnduVEX98Dnn64PpjPqV87f2rp37if/AI/zx51xn/j1k4+7nPfPXHGMc1498bLuc/Er4XxTLaqra8rhob17jo9qOrKOOTz36fw16teXFz/algWTTx/pxK41iUg/6M45by+B1+brn5enNDZy4eDdWcbbLuv5fU0LZm86z/dTH93H0lmGfkk6YXj8Mjg44JxTtWb+0pf3Ux/0Sx/5azf89Zf9nv2xwP4cmi2uLwS2eYtPGI4851aVcfJJ1Pl/L9B0yB/EaqW090L+T93Yb/stkCDqsgAxJJ/sdeuR/D1Gc029TrVJ+9p0XVd/U10Y7pf3U3+sT/lrN/z2b/Z/DnnPI+bIqnp7N9guP3Uw+e//AOWs3/PdvVe3fPB/iwaEuLzdL+60/wD1if8AMWlH/LZj/wA8+eOc9h83U1Vsbi6+wzhI7BhuvuuqyZyZ24xs574H8Y5OKL6iVJ2enVdV2fmWteZv7C1P91N/x6XnWWb1/wB3t3zwf4sGrl8xK3H7qYZkbrLMcfufdfx55xx93msjW57o6LqIeOwCm1vASuqyMeT2Gzk+g/i6mrd9cXhW4xFp5zI2MatK+f3OO8fPpnufl6UJ6gqT5Vp1l1Xl5nm9y0Z/artWRJDINEw6ebMWBy/GdgccbT0P1xwPVLZm86z/AHUx/dx9JZhn5JOmF4/DI4OOCceG6Xczt+1vrLHySUskAD3rrGP9GiOBLgtjk4OOfQZr2a2uLwS2eYtPGI4851aVcfJJ1Pl/L9B0yB/EaUXuc1GDlSuuz6rvLzC1Zv7Sl/dTH/RLH/lrN/z1l/2e/bHA/hyauIx3S/upv9Yn/LWb/ns3+z+HPOeR82RWRbT3Qv5P3dhv+y2QIOqyADEkn+x165H8PUZzVtLi83S/utP/ANYn/MWlH/LZj/zz545z2HzdTTTOmrSd3p26rsvM8c8T8+JdWJBH+lzcEkkfOe55/Pmik8SEt4i1Qtt3G6lJ2SGRfvnoxALD3I5orje5+h4f+FH0X5Htd9cy/wBq6eft8Gft5O77QmM/ZZBnPl9O2cYzxjPNS208gmsyLyFdscYBM6DbhJOD8nGM45zjI65BFe8tb8atYA3+rljqBAJW13A/ZX5HyY3Y/DB9afaWl959ht1HVs+VFt2ra5xslxjKdOuM84znnFdae+h+cSjDkWsfh8+78iC1nkGpSgXkIxaWIx56cYllwPudup9O+7pVxJ5N0v8ApkIzIh/16c/vmOfuevP0OeQcDPtbW9+3OovtV4tLA7gttyPNk2jlOmenfJO7jFW47S+3z/8AEx1b/Wx5wtr1+0P1+TrnPtnOeMU0/IqrGF3rHp37LyINPnkNhcA3kJy9+Meehzmdsj7nfqPXtt6Ua9PIdC1MfbITm0vBjz05yeR9zv1Hr229KjsrW9awuD9u1VRnUARttsf687ifkz15bHf7vFGuWt6uiakzX+qsotL0lWW2wRnkHCZx645/u0r+7saKMPbLWPxPv3fkaF9PIy3GbyF8yMeJ0Of3OM8IM8cdueOvNRX1zL/aunn7fBn7eTu+0JjP2WQZz5fTtnGM8YzzRqNpfbLndqOrf61s71tev2c9cJ1x6cY96ZeWt+NWsAb/AFcsdQIBK2u4H7K/I+TG7H4YPrQ3psYwjC28fhfft6Fi2nkE1mReQrtjjAJnQbcJJwfk4xnHOcZHXIIp2s8g1KUC8hGLSxGPPTjEsuB9zt1Pp33dKntLS+8+w26jq2fKi27Vtc42S4xlOnXGecZzziqlra3v251F9qvFpYHcFtuR5sm0cp0z075J3cYpt67FKMPe1jsu/wDN6Ggk8m6X/TIRmRD/AK9Of3zHP3PXn6HPIOBT0+eQ2FwDeQnL34x56HOZ2yPud+o9e23pSXnn6fZ6he3mq6rFa2oE88hW1wiJNIzMfk7YJ47g54xUGkLcXmifa7bUtTa1uI72aJ1FsVkjeUsHB2cqwIYkdc/LxRfXYEqdmrx3Xfs/Isa9PIdC1MfbITm0vBjz05yeR9zv1Hr229KuX08jLcZvIXzIx4nQ5/c4zwgzxx254681Q160vU0bU86hqkiLaX2QVttrDdznCA49cYP92rWo2l9sud2o6t/rWzvW16/Zz1wnXHpxj3oT12BRhyx1jvLv5eQX1zL/AGrp5+3wZ+3k7vtCYz9lkGc+X07ZxjPGM81LbTyCazIvIV2xxgEzoNuEk4PycYzjnOMjrkEV7y1vxq1gDf6uWOoEAlbXcD9lfkfJjdj8MH1p9paX3n2G3UdWz5UW3atrnGyXGMp064zzjOecUk99CZRhyLWPw+fd+Rxmju5+LmsSC4jXZo2nISZQB/rpCBnaRxjnjjB64Oe4SeTdL/pkIzIh/wBenP75jn7nrz9DnkHA4Lw7Hcy/FPxFGt3e+bDpulJ5iLD5mC7sAcrtxyMcZ+7nvXcR2l9vn/4mOrf62POFtev2h+vydc59s5zximn5GFGMLSu18Xn39CDT55DYXAN5CcvfjHnoc5nbI+536j17belGvTyHQtTH2yE5tLwY89Ocnkfc79R69tvSo7K1vWsLg/btVUZ1AEbbbH+vO4n5M9eWx3+7xRrlrerompM1/qrKLS9JVltsEZ5BwmceuOf7tK/u7Haow9stY/E+/d+RoX08jLcZvIXzIx4nQ5/c4zwgzxx254681FfXMv8Aaunn7fBn7eTu+0JjP2WQZz5fTtnGM8YzzRqNpfbLndqOrf61s71tev2c9cJ1x6cY96ZeWt+NWsAb/Vyx1AgEra7gfsr8j5Mbsfhg+tDemxjCMLbx+F9+3oWLaeQTWZF5Cu2OMAmdBtwknB+TjGcc5xkdcginazyDUpQLyEYtLEY89OMSy4H3O3U+nfd0qe0tL7z7DbqOrZ8qLbtW1zjZLjGU6dcZ5xnPOKqWtre/bnUX2q8WlgdwW25HmybRynTPTvkndxim3rsUow97WOy7/wA3oaCTybpf9MhGZEP+vTn98xz9z15+hzyDgU9PnkNhcA3kJy9+Meehzmdsj7nfqPXtt6VPHaX2+f8A4mOrf62POFtev2h+vydc59s5zxiqlla3rWFwft2qqM6gCNttj/XncT8mevLY7/d4ovrsCjCz1juu/Z+RJr08h0LUx9shObS8GPPTnJ5H3O/Uevbb0q5fTyMtxm8hfMjHidDn9zjPCDPHHbnjrzWfrlrerompM1/qrKLS9JVltsEZ5BwmceuOf7tW9RtL7Zc7tR1b/Wtnetr1+znrhOuPTjHvQnrsCjDlWsd5d/LyC+uZf7V08/b4M/byd32hMZ+yyDOfL6ds4xnjGealtp5BNZkXkK7Y4wCZ0G3CScH5OMZxznGR1yCK95a341awBv8AVyx1AgEra7gfsr8j5Mbsfhg+tPtLS+8+w26jq2fKi27Vtc42S4xlOnXGecZzziknvoTKMORax+Hz7vyILWeQalKBeQjFpYjHnpxiWXA+526n077ulXEnk3S/6ZCMyIf9enP75jn7nrz9DnkHAz7W1vftzqL7VeLSwO4LbcjzZNo5Tpnp3yTu4xVuO0vt8/8AxMdW/wBbHnC2vX7Q/X5Ouc+2c54xTT8iqsYXesenfsvIg0+eQ2FwDeQnL34x56HOZ2yPud+o9e23pRr08h0LUx9shObS8GPPTnJ5H3O/Uevbb0qOytb1rC4P27VVGdQBG22x/rzuJ+TPXlsd/u8Ua5a3q6JqTNf6qyi0vSVZbbBGeQcJnHrjn+7Sv7uxoow9stY/E+/d+RoX08jLcZvIXzIx4nQ5/c4zwgzxx254681xfxsmeTwHrKvcRT7luPlWZWyfsUgDcKOnr04xjvXX6jaX2y53ajq3+tbO9bXr9nPXCdcenGPeuH+Oy3lr8P8AWZJbvUJRvkXFwsG0E2rjPyKDux+GPeiT02OblhyOzj8Mu/b0Ou8MNNb6RoUT3sQkisrZCTOnykROMElOMcjnPUdcgh9rPINSlAvIRi0sRjz04xLLgfc7dT6d93SprOxvo5rBFv8AVVKxRKqottwAkuAu5OnXG7nGc84qra2t79udRfarxaWB3BbbkebJtHKdM9O+Sd3GKG9tCqMYcj1jtHv3XkaCTybpf9MhGZEP+vTn98xz9z15+hzyDgU9PnkNhcA3kJy9+Meehzmdsj7nfqPXtt6VPHaX2+f/AImOrf62POFtev2h+vydc59s5zxiqlla3rWFwft2qqM6gCNttj/XncT8mevLY7/d4p312LUYWesd137PyJNenkOhamPtkJzaXgx56c5PI+536j17belXL6eRluM3kL5kY8Toc/ucZ4QZ447c8deaz9ctb1dE1Jmv9VZRaXpKsttgjPIOEzj1xz/dq3qNpfbLndqOrf61s71tev2c9cJ1x6cY96E9dgUYcq1jvLv5eQX1zL/aunn7fBn7eTu+0JjP2WQZz5fTtnGM8YzzUttPIJrMi8hXbHGATOg24STg/JxjOOc4yOuQRXvLW/GrWAN/q5Y6gQCVtdwP2V+R8mN2PwwfWn2lpfefYbdR1bPlRbdq2ucbJcYynTrjPOM55xST30JlGHItY/D5935EFrPINSlAvIRi0sRjz04xLLgfc7dT6d93SriTybpf9MhGZEP+vTn98xz9z15+hzyDgZ9ra3v251F9qvFpYHcFtuR5sm0cp0z075J3cYq3HaX2+f8A4mOrf62POFtev2h+vydc59s5zximn5FVYwu9Y9O/ZeRBp88hsLgG8hOXvxjz0Ocztkfc79R69tvSjXp5DoWpj7ZCc2l4MeenOTyPud+o9e23pUdla3rWFwft2qqM6gCNttj/AF53E/Jnry2O/wB3ijXLW9XRNSZr/VWUWl6SrLbYIzyDhM49cc/3aV/d2NFGHtlrH4n37vyNC+nkZbjN5C+ZGPE6HP7nGeEGeOO3PHXmor65l/tXTz9vgz9vJ3faExn7LIM58vp2zjGeMZ5o1G0vtlzu1HVv9a2d62vX7OeuE649OMe9MvLW/GrWAN/q5Y6gQCVtdwP2V+R8mN2PwwfWhvTYxhGFt4/C+/b0LFtPIJrMi8hXbHGATOg24STg/JxjOOc4yOuQRTtZ5BqUoF5CMWliMeenGJZcD7nbqfTvu6VPaWl959ht1HVs+VFt2ra5xslxjKdOuM84znnFVLW1vftzqL7VeLSwO4LbcjzZNo5Tpnp3yTu4xTb12KUYe9rHZd/5vQ0Enk3S/wCmQjMiH/Xpz++Y5+568/Q55BwKenzyGwuAbyE5e/GPPQ5zO2R9zv1Hr229KnjtL7fP/wATHVv9bHnC2vX7Q/X5Ouc+2c54xVSytb1rC4P27VVGdQBG22x/rzuJ+TPXlsd/u8UX12BRhZ6x3Xfs/Ik16eQ6FqY+2QnNpeDHnpzk8j7nfqPXtt6Vcvp5GW4zeQvmRjxOhz+5xnhBnjjtzx15rP1y1vV0TUma/wBVZRaXpKsttgjPIOEzj1xz/dq3qNpfbLndqOrf61s71tev2c9cJ1x6cY96E9dgUYcq1jvLv5eQX1zL/aunn7fBn7eTu+0JjP2WQZz5fTtnGM8YzzUttPIJrMi8hXbHGATOg24STg/JxjOOc4yOuQRXvLW/GrWAN/q5Y6gQCVtdwP2V+R8mN2PwwfWn2lpfefYbdR1bPlRbdq2ucbJcYynTrjPOM55xST30JlGHItY/D5935HC61Ix+Mfg5jPGSmkTAMJFITEkXBO3jHuDj3rv0nk3S/wCmQjMiH/Xpz++Y5+568/Q55BwPP9Wtblvi94QQ3V60i6NK6yMId6jzYQNuF24z03DPPNd3HaX2+f8A4mOrf62POFtev2h+vydc59s5zximn5GFKMPfu18Xn5eRBp88hsLgG8hOXvxjz0Ocztkfc79R69tvSjXp5DoWpj7ZCc2l4MeenOTyPud+o9e23pUdla3rWFwft2qqM6gCNttj/XncT8mevLY7/d4o1y1vV0TUma/1VlFpekqy22CM8g4TOPXHP92lf3djtUYe2Wsfiffu/I8r+PUpf4m/ClpJVl/4nhJdHDA/PZ9CAB29BXr99cy/2rp5+3wZ+3k7vtCYz9lkGc+X07ZxjPGM815j8XLSCX4heC11K7ma8t79J7Y3LRrIZGu9NTaAgCn5DIcDJwCe1el3lrfjVrAG/wBXLHUCAStruB+yvyPkxux+GD60mzzsKo+1qXa+H9OmmxBquvW+gaX/AGtqeoRwWVlbxvLIJA2wbXUDAjJzlguME5YDnIIo+Fdfg11P7Q0+8xbSW1rGomPlMDHcTIQVaMEbWVs+nXLdK5/xLa3Gr/EPwL4fmu7y5t44TrM8LCEOpgUrbum0AbRJITh8g7OQelU/hBa3dvdeLdKS6u4hp+pxqn2fyTujllaeMt5inBxLxjjOc5FNvXY1jUi6ko+7bRX87p9vXp0PSUnk3S/6ZCMyIf8AXpz++Y5+568/Q55BwKenzyGwuAbyE5e/GPPQ5zO2R9zv1Hr229KnjtL7fP8A8THVv9bHnC2vX7Q/X5Ouc+2c54xVSytb1rC4P27VVGdQBG22x/rzuJ+TPXlsd/u8U767HQows9Y7rv2fkSa9PIdC1MfbITm0vBjz05yeR9zv1Hr229KuX08jLcZvIXzIx4nQ5/c4zwgzxx254681n65a3q6JqTNf6qyi0vSVZbbBGeQcJnHrjn+7VvUbS+2XO7UdW/1rZ3ra9fs564Trj04x70J67Aow5VrHeXfy8jwLwXftd/tb+ILlbqPcqzxecZQFyiIn3ipH8OPu/TFfQdnJM1xZLHdR7/LjC4mX5cJJx9w4xkjHOMjrkEfPfwoXUbn9onxc8kl88o1G5jN2I4mmXa06qu9lKDKoRtHBC8D5Rj3+zsb1pLMjU9UBSGEqAlrlvlkAC5T3JGewbPOKUXvoclJR9hq1t19ZeWxRXUY7XWIILjUraGW8t7SK2je4RTKySOWVQU5KBlJAyVDAnOQK0knk3S/6ZCMyIf8AXpz++Y5+568/Q55BwPA/E2jJ8QPCvi7xbcajdynRrTydDkwoWOKByzTgoQCZJI5Y1IUEKoLdQa9j8J3F/rfhrTdVN/qim/t7W7IRbXA8yQuOqerce+c8YpplRqKpOXNZbW312V9vR9N0eU+JyW8S6sxYOTdzEsCCD855yAM/kKKPE4ZfEurLI0jOLuUM0m3cTvPJ28Z+nHpRXE9z9Ow/8KPovyPar6xX+1dPX7LP/wAf5XHl2+f+PWQ49M9/THvUttaK01mPs8x3RxnASHnKSHjP0788HPOKz7zSdNXVLFV03TwrXxVgNKOCPsznBX0yAdvqN1SW2j6YZbPOmaecxx5zphbPySdR/F9R14P8JrtTep+dSceRav4f5fN+YWtoDqUp+zzHNpYnISHndLKO/r27n+LiuD+NN4dKt/DIjeS2M3iKzRidinYJZSeV7fIAe34AV2NtpOnG/kU6dYFRa2TAHTCeTJJk+5OBk/xYwK8Y/aVmi0m98JQ2ltb29ub57yYx2/kr+6lCqWGO3mkdQB06ild2Zlj2vZys+3TyXme5afaKLC4P2eYYe/OSkPG2dh29O+OR/DxRr1oo0LUz9nmGLS8OdkPG047enfuP4eKx9Q/4R3QdEub3xBHpOn2yteDzrrTynWVjGFzySVHygAkDgA1wOqLL8Q7C/l8O20WgeHNOWW6i1aLT2SfUzsDhI0IHlxLu5ds9UA/iou+WxrKvCNZKLbfM9Leb8/xPYr6zCLcf6PMu2RhykIx+53dvz44x/tVFfWK/2rp6/ZZ/+P8AK48u3z/x6yHHpnv6Y9685+GWoQ6tY6joPiSx03/hL9JuJYruIacqPKgQhJlVQMIcp/CPmIbviu9u9G08ajZlNLsfL+2EyY0ltuz7O45H93fjj+9g023YmlVptXUvsv7Pl6l62tFaazH2eY7o4zgJDzlJDxn6d+eDnnFU7W0B1KU/Z5jm0sTkJDzullHf17dz/FxVYW2g291ax3NtpETrGm9ZLAZBCuDkd+SuT3JU9q5DWvGPgDw/cXLanfaBmKG0iNvFZiaUSB5C4KKScgAbiQARtHHFDbuU6lOKk3Lounn6mv8AFi5g0f4ZeMbqeGVU+wS2wJSL5WmeSFc7RkcsBx6H+HFXPh9bB/hn4WkMEhJ0GJtwSLHEMfPPOB+fpXEfFZ/DOvfDLWotCudDmkuZ7SCOWzt1JUveDoyn5flz9QMdjWf4V8feGYvBmgWa6Jc63e22kw291LYaMbkRSeVGAHkyMsowMjO3OMHsXdzhdWnHE8zlpbt/wfxPXtY09pdH1COG0uHka1uwqrHCSSDgYAGeOnHP93imQ3Om6paXVxpM8V5Ak7xmW3e3kVWEOSpKZwR1wO3+1XlN1o2ueN7TUr+6tD4T8Lpazy2trbWKR3t6oGT5rrkxIclSobplTwQSa94WsPhh4lfXNM0hJvB89uLTU4Tas5s5FQCO4VXO4/e+YAsRhnweABSdzf270f2LvW2vTpfbbr8j2G604PqdkPs8iql6chltwT/oz/KB3OSDgcY56gkOtrRWmsx9nmO6OM4CQ85SQ8Z+nfng55xXm9/8Q/hml1ZyQ6locoa480RQaRJI0qGErt2qpx8xB2tjkE9sUweN/DzbP7M8Ianqc8USfuYPDbku3K4O7Az8wOTgHb6gBkm9RvE0eVL2nTt6+Zc8KRiX4teL0MMh2WWkjG2Mn5tx78YO768jPeu+W0XdNm3mwJEH3IOP3zD+mOOMjn5cV84R6d4k1PxR4y1eGKHQNW0mytLqPRY4kvIJwEfbHKANpdgCQwGMyds12XizULHxPoHhTS/D1lYwTeMnUGa3tU8y1tlLSXOxuR5iKQpA5/hHK01JnPTrwjGbu977b6+p1kPjLwdaRz28/iHSEn8y64+2WhwWlZkyQeODz3HQYo1Pxp4NutKvoYPEejGWS3uFQG9s1yzfc53e/PcdsDNXvD3hbQ9P8NjT7fSdPNtAt3CofTCWYJKVUsx6tgD5jyO+Sak8R+GdBl0nUJ5dD0h5o7O6CSNpA3KF4XDEcYAAB/gAxRrynTGWI9qr2vzdnvqU5fHngmczLB4i0rdvO0Nc2q5HlkDof73p2560/wAXeKvDWgaroq6pdSIbm8ZoUgto7h3T7ORkLErE/M69Bjn1BrY1nw/o13a3MF1o+lzQ+Yf3b6T8vEJI4PA55x2PzdKwtG+Hnhbwxr0M2iaTDA13dG3mD21xKrR+Q8mzY7kBd4Vtvqqt0AobdjOnKt5bPo9rEVt8RPBhs7W+k1KVLM3K6eXexKk3IVsptaPI6rywA65OQK6i3ssapMGtpw32SxzmOHqZZQevPPbPP97ivnvw74bHi74hjR9Zthc6WNe1m4vECu5dAkRjZthDffuODkdfrXeXHwl0W0S5PhH7Vo+pRWUcsBiEssUss29MSpN5iMo2ggqASfunIFDbFTrVXzWV1on96/rc9TS0BaX/AEeY4kQfch4zMw/pjjjI5+XFcvP4i8NaK1zY6vq9hYXyyXe63ubi1jkXdKzISpIIBXnPoRt4Nctpni3TE8DeJL7X9D0zT/Efh+PbqGnSWiL+/DEpsflQkhKqpOc/dG7ALafwx8GafpngtJNTs7e81q+huZdSubvTy8ss/mAsCxJyFYYB4AxkgFjRdtlPEOelHW7vqn29X5/cXtT8YeDrrSLqODxJohkntbgRhr+yXlvuA/Nx156EdsDNXdQ8XeEYmdDr+ko7sWjDXloMr5WBjB/vHtx6fNUeueD/AAymi6k6eHNDVxaXh3Loqg5B4OccEY4P8PQ1Yu/BPhWKG6SPwxoKKzMhC6KqZHk5wTj15wehAboKavcalX5Vt16PyLniC503TIrbVdQfyNLt7vzJblxb+WiNbsFJPTlmUDsdwx8xFc9p3xF8GXXh+51+LUmbSdNMMV5L9lUMjuGC4jZNzAllwcHOGz93iO3+Fvg7SvEun3dposBb7a6LFPbTzQoDA8h2xOxUfMAQAMjAI4rhfGkdi/jXWdKvYYDHrN34eiKCLy/NJmcvkBTvYgPksRnrk8KVdoxr16tOnFtLZd/P0PYNJFtfXH2q0Vp7eaysXSWMQMrhpZRkHuD27/3uK0ktAWl/0eY4kQfch4zMw/pjjjI5+XFeXw/CPRrW4uYvDeo6voO61t5DHaiSWGWSR3AMscu9ZApUEAYz0BBq98MbxdVj1bR/E+l6LH4k0a6itrpYbDcJ1L7lnCgDaGDfdwM4wAvAAm9jodV83LV0emyutl5o6zzLHTdJuJ9QdbSESX/7yc28a5Wdu5x0745H8PFYus+MPB0miaiIvEmiM5trpVUX9kSWOduAGyfw5/u8VzngXwxpfjLSJfFXiTTjd/bpb250yzvLWTybK03qsSLCCIlJCbi4BzuBJJOa63W/CHhmPRNRaPw5oaMlreMpXRVUqQeCDjgjsf4eho15RU61WrUjOKWstLp+Zcj17w7qN1PaaZq2n3V2CziGC5tHfZ5Oc7UOcZI5HH/Aq5z4+qlj8OtYlKXUA3vDuWOLPzWzgKdmDgluccbSTgnir/ij4a+E9T0u6tF0PT7FhKxiuLDTTaywsItwZXH3eQDg5Hc5HFeR+P8AUzbfCbXNB1S1sYfFmizxW94RYBWuLdh5aXKluSrgoSSAVkYH5SVok3YzjVai1U0vF2030/A+j3t0m1GJhbzEShHxsgOcrIeOx6d/Q5521nWtoDqUp+zzHNpYnISHndLKO/r27n+LiuDt/A+veIYrGHxRe6focJQebb+H9KKzMCrFd08oY7l287FGdx5O0YmT4eodQjNv4o8SiSOK3kYXYF/GwlkYPtWdHCudmd44boF45G2XGq0vcTasunn66/erbnoSWgLS/wCjzHEiD7kPGZmH9MccZHPy4qnp9oosLg/Z5hh785KQ8bZ2Hb0745H8PFefyfDfXIy8emeNPKgVkGLvwzbXL7jKVJ3bVIHy/dPqVqBvh1rDia703xrfCWSKeKf+09HjvVVopSoMCsqrAh5+RRhAcZ4FF3fYtVXa3K7X7Ls/7x02ueJdE/tnVPCoaUaymlXd2UKQbQASAueu/aC2ByFGRgYz1t9ZhFuP9HmXbIw5SEY/c7u358cY/wBqvHPFfgez0PV/DGs31/Je3013dwX9/cWEcQINi0YKqoUKqC3DIgB2Etls4q74Z8Jf8JjoI8ReJ7m7it9UY3MGh2DS29lbwmPfFkR7d0mACWJ6EdgcibuYQxMmuS3vXelumnU9BvbzSD4psNKN3bLqQuzJ9jaa0ExTyHXhCcn5j0Ax17g41ba0VprMfZ5jujjOAkPOUkPGfp354OecVwWtfDHw9HpEGj6DY2mlzvfq8N8ulmedJEiaZCWlDMy71GUJyVLchTVeHwd4puriESaz4ds1G1Y/s/hjzfMTa2HcO33zgkgZGTkE7eC71L9pNRXtF00sr997tHc2toDqUp+zzHNpYnISHndLKO/r27n+LiriWgLS/wCjzHEiD7kPGZmH9MccZHPy4rzux8P+JraeOAS+E78hLZpZbnw/KhEbuwBAR9rMMH03jA3HtZ0vQvFUk0g1KDwPBGcZaDQriYq/mkBQDIny/eOcg9FwegE32NKlZN7S6fZXZf3jr9PtFFhcH7PMMPfnJSHjbOw7enfHI/h4rnfF3inw9pt+fDl5cTRazfxSwW8P2ZGDSSyGOFWdVKrlgRkkYxwQKwBovjJYXu7WDwVcsxmha0m0eeKKPEjLJKJAWf5WC4HQKSPkIAPM+MPC2qaQY9c1yfT5rm71nTRHbWVrLDBa+TMVIj3H+JpXOO2TwCQFSbtYzr4mUXzwTTTb1Vl182e531mEW4/0eZdsjDlIRj9zu7fnxxj/AGqwfFOteH9C1rToNav7WwlN5u8u5ktY22GBlBwe25hz938a4LQNE/4TnU/EerarJcWOjW2pTada6Xpgltba4WBTmWQx7Wcsw4GRt+ftXWH4deFLKU2cOjWzJqN7Kl1LNazzTSq9s7MDI7GTG4Btu7hgHptuwoVaktae1nun210V/lqdhBZf6RaI9tPkpHlfLhySVk9fp354OecVStbQHUpT9nmObSxOQkPO6WUd/Xt3P8XFef6b8ONbsnt7ex8XQvaHDRC/8Nx3cyqwdgHkJBlIxjdjnOeijFez+H/iQzSRyeNYWlEFpIrDwrbbMM7jBXbzjb94Eb845xQ3K+xtGq7Sunsui7/4j1NLRS8w+zzHbIg+5BxmZhj9MccZ6/Liqmn2iiwuD9nmGHvzkpDxtnYdvTvjkfw8V5/NqWreFriRfGXhzTdT8PwhEXWdN0tibcK7sxmtySVViHyU+UcLwW+WpZXfiLxFazXPhjwlo1jpipNNHPr2mSRyXivKzDyghbaixlSHbpkAcAmld3JWJp2abd7rTl12fmd/41uLDRvCerX2p77a1jtboGV0hwG3hFHAznLAcc5IC1NpeoaZ4h0NdX0My3GnXDuYZjBHGGAiPYgMOQT0HHP3q4+w8Ga34gvtM/4S608MWmn214b02ek6fPvnK7sRSyNtG1XKHGCp284wAfOfhjbya7oPg7Qob6PTgul3uqXU0NrBNPOqXIhjjy6MUA2v82COuQcHDu7mKxTU+R3trbTVtv1/U+gr+zRdT08NbTBRflTmO36fZZDj09/THvS6clvdvaNbq06FUBMQgYE7ZMj07d+eDnnFcLN8LdEa6htNYvdZ1q1uL85gvnnWFCIpJQVhhMaD5iRtC8AkgAE1n3vg688L63HqHgTw/peo2t/bKLjSruNo4Ibgg7bhFKnjarBlUqG+UgfLlRN6lyq1EldaW6J3662/NXNi9tgfjB4dURyDdoMjldseWzcQDIxwc5/i/Gu3S0BaX/R5jiRB9yHjMzD+mOOMjn5cV4nb3zeH/itpkfj6Tw3Y2tzoX7p4LZoLUsZ43ZXEjfOQIj83G7gdcV3SeJ/h3mU/214P270IO2IjHmsT/FwNuOO4wvahNk0JwtK7a97t6eZ02n2iiwuD9nmGHvzkpDxtnYdvTvjkfw8Ua9aKNC1M/Z5hi0vDnZDxtOO3p37j+HisjSR4dvILuKBdGnniku42RLIMyFpm8tTzwSoO30AxVLXNU8HRPfaQt34dj1o29wsdoLZVnMjt+6VVznecjaOoBHBzmld8p2+0pqsm5fa7eb8zzb45u8fxr8E2irsWK4t5FSRUGC1xDnO35cfKP617lqVpHHqNiZLeZUW+YMWS3GALWRue3v6Y96+ffizZ2tz8bbFLOyVI7G80mzaOG3MURaaR5DmPsSFX67TXbW6p8SLtY7Gwh0jwVcXU1uL+xth9o1QKhBjUKN0EJ8qTdht7qwGAGYgbZ51Csoubjq9enlvvojV+F9q3iHXdS8W3VrdFL147PTN8Ma5sY0cq6BwCBJJvfkdAD1xUfhO3SD4v+MoZYZjNe2ek3UYKxksiqYiRkYxkgDn655x2ljoekxmwjj0rTUjWKIBF0r5QNknGB16DpwcAj7teeeL5LLwx480rW7/S1k8Of2PFaXsyacZIrRvOaSKRkGSQ2JVLKMHdz1pttGk4KCUr7NN6d73692eopaAtL/o8xxIg+5DxmZh/THHGRz8uKp6faKLC4P2eYYe/OSkPG2dh29O+OR/DxXC23xA+G9w0n2SbT7rLBsW+gzy7VErHnanGR27jA4xmmWnjfwCv+jXsmn2kk32kxyXujS26Es5dF8yRQoIXgZOF6DPFF3c3WJoWa5+q6eT8zvdetFGhamfs8wxaXhzsh42nHb079x/DxVy+swi3H+jzLtkYcpCMfud3b8+OMf7VclqV/wCEZvDuqXVnc+HXjitbhjNDbphCx/dncDhSeNp7dOasWuo+DNamubfRbrw1f3ALS+XZ26OwTysbsAkhc/kfmoTdzRThypc3WXT08zzj4axx3fxgvJEDFZpbpkhjSNsr9r1DruOARtHBHIOeMDPYfFzV5tF8ETJpMVx/bOoLb6bZKsS5ea4V1GwoM7tu5lPXKjPO2vKPA/iKy0rX7vVdWSKezdZHFoqi5W5ma6vxHGiA4kYs2FI4Gd2cAmvS/CvhTU9Z8Xafr/izTLLSbezjEdlokFuLmMlonVppnUASsfm244AOQeGzKvrY86E+agoRettdL6Xfn+htweFrDSPC95oun206WUOjWsKtIIstuaYM7Ec5YknjnJOcDAp/wmhkn+GfhiS4tZlf+zrNRiOLld21T83PzKBj17/LitS00vTxqDgWFiAtrZMMaaeCZJMkEdzgZI+9gAdK828L6/4Q8F2Vz4f8UwQ6ZJZahcW9nJqOlSv9pt0uWZXWQg5AR1XBOcLj0JaujprOFKqruyslt5R8zP8AE67PEurIFK7buYYIAI+c+nH5cUVzGt+OPC0us38lnqlv9me4kaLy4XRdhY4wuPlGMcdqK5XF3Pv6GZ4NU4p1o7L7S/zPWvEem6/ea/v07xP9htZLwrDD/wAIk8jW/wDo7HI3ffPUbSD13Y4zUVhoeutqlub3xvq76eyLiKDwvGkwBEhGZDCwcjABYIA3XAxx3l87f2rp37if/j/PHnXGf+PWTj7uc989ccYxzUtszedZ/upj+7j6SzDPySdMLx+GRwccE46knqfBypw5E7S2/m83/XY81i8G20+rfa7rxN4ykuY2gu4JlhlUwmRmVkEQi8nZtVQcx4k+YewzvHvg7UfEfgi8s59TuNQ16OD7HBJ/Y0trBIr3kTs7KqMVkxbr0OP4QoIr0+1Zv7Sl/dTH/RLH/lrN/wA9Zf8AZ79scD+HJq4jHdL+6m/1if8ALWb/AJ7N/s/hzznkfNkUKLYq2Go3a5ZdOq7LyPLvDPw08E6TEl0dIuby+t1nVZ7qzu5uYnKh8H5AxwCTtAU8YHSu61u7tn0XUVW3cMbW8AJ0mdcHPHJGBj1PC9DVvT2b7Bcfuph89/8A8tZv+e7eq9u+eD/Fg0a8zf2Fqf7qb/j0vOss3r/u9u+eD/Fg0WfKdFKnTp1UoRa97uvPyOa8c+FPCniq4F1rmkTT3NszRxSx6deW7Knl79uUxxkHg5xuZhgE1g3Hwp+H63ttH/Yd4yvcmJi8OpZx5LPkDzMk7gOOTjJ6V6ffMStx+6mGZG6yzHH7n3X8eeccfd5qK+dv7V079xP/AMf54864z/x6ycfdznvnrjjGOaGnY540aMtXB7P+Xt6Hn1p8Mvh6HtlHhklXVHO6wvZDllcnknJ6DkHnt0OdjQdF8N6RcXCadoVrbxS2tnvCaHKS2ZJA275ckEHGejDgdK662ZvOs/3Ux/dx9JZhn5JOmF4/DI4OOCcU7Vm/tKX91Mf9Esf+Ws3/AD1l/wBnv2xwP4cmm07ouNKkua0Hsv5e68jj77wL4NurpLu20JNPv7SZXtbix0e4gMUnmkB8IACRtUgNnkYHOSb/AIF03TfC/gy00e0hldbSG6jaY6VcFpXWTBkJwdpJycZ+TO09K61GO6X91N/rE/5azf8APZv9n8Oec8j5siqens32C4/dTD57/wD5azf8929V7d88H+LBos7hGlSi3OMWne267PyKmt3ds+i6iq27hja3gBOkzrg545IwMep4Xoat317ahbjFvIMSN00edMfuc9149cdj83SjXmb+wtT/AHU3/HpedZZvX/d7d88H+LBq5fMStx+6mGZG6yzHH7n3X8eeccfd5oV7miceVaPeXVeXkUb29t31GwXyHKLqDttOj3GPmt3JwuOcsclRznLdKdbXtqZbMG3kOY4850eds/JJ1GPm+o68H+E1PfO39q6d+4n/AOP88edcZ/49ZOPu5z3z1xxjHNS2zN51n+6mP7uPpLMM/JJ0wvH4ZHBxwTgV9SXyqmkk/h7ru/I8w8F3EI+LXjqVonMbQaQAv2GVzny+coBuHfno2ePvCr+geBfDujeKZdatDrB8qZmtbB7CdrO0MsgWQxxlMqW8vn5sEMVxwMReBTn4s/EJvLcssejKMPIDjys9QM8/kOMZwM+iox3S/upv9Yn/AC1m/wCezf7P4c855HzZFFmctOEJXck9JO2q7+hkWN3bJY3ANu+d18crpM//AD3bHOOCPX+DoeaNbu7Z9F1FVt3DG1vACdJnXBzxyRgY9TwvQ1b09m+wXH7qYfPf/wDLWb/nu3qvbvng/wAWDRrzN/YWp/upv+PS86yzev8Au9u+eD/Fg0teU9BNe2Wj+J9V3fkF9e2oW4xbyDEjdNHnTH7nPdePXHY/N0qO8urVtUscW7YW+OQdGnHH2Z+AuMnk529f4ulaF8xK3H7qYZkbrLMcfufdfx55xx93mor52/tXTv3E/wDx/njzrjP/AB6ycfdznvnrjjGOabvYxptW2fwvqu3oeP8AgVYk/aD8UTGN/skVpDthWxeZQ88EDs5RPm3Hye47knBHPp9td232+RzA+Da2Q/5BM5OfMkznjvnr0foOhrh/hZp96fid451m6jkaJ7u2soipZd2y3JI+QFhhWj7c5PXnHoVqzf2lL+6mP+iWP/LWb/nrL/s9+2OB/Dk0tTLC2UJ6P71/N5o4zxF4Q03WfG+k+IoZ7ywnsJk+0x2+j3H+mqt0HiVz0UI8YPA3MDsyNox1Fjd2yWNwDbvndfHK6TP/AM92xzjgj1/g6HmtdGO6X91N/rE/5azf89m/2fw55zyPmyKp6ezfYLj91MPnv/8AlrN/z3b1Xt3zwf4sGnZ8xrCEIqTUXq11XZ+RU1u7tn0XUVW3cMbW8AJ0mdcHPHJGBj1PC9DVu+vbULcYt5BiRumjzpj9znuvHrjsfm6Ua8zf2Fqf7qb/AI9LzrLN6/7vbvng/wAWDVy+Ylbj91MMyN1lmOP3Puv48844+7zQr3KTjyrR7y6ry8jPvLq1bVLHFu2FvjkHRpxx9mfgLjJ5OdvX+LpXjXiH7NefHvw9YTq6rcfYNRQC1fOLeG6JBjI3NlsdPvZyOte4Xzt/aunfuJ/+P88edcZ/49ZOPu5z3z1xxjHNeV3mmm7/AGnPDVw0EjC08OfaQEMmT80sYJIBYDL9hjoBxS1OLG2dOmkn07d5f12PQ7a7tvt8jmB8G1sh/wAgmcnPmSZzx3z16P0HQ1y3jLwrHr2sJq+i61qvh7WIYzZtc2mjTSCSBpn+UoQNrBsFWBBHI5IGOztWb+0pf3Ux/wBEsf8AlrN/z1l/2e/bHA/hyauIx3S/upv9Yn/LWb/ns3+z+HPOeR82RTSdjrxEYT0kn06rsvI53w1HZaP4ZttMhW7mhsYLm2ikm0yd5DHHJsTc+3G4KAM4GzoQOlW9bu7Z9F1FVt3DG1vACdJnXBzxyRgY9TwvQ1b09m+wXH7qYfPf/wDLWb/nu3qvbvng/wAWDRrzN/YWp/upv+PS86yzev8Au9u+eD/Fg0teU1jyqqkk/i7ru/IL69tQtxi3kGJG6aPOmP3Oe68euOx+bpXkP7UWm6Te+B7jVRY7NTtLuKKK4/s+a2IjYLlCzAAjPO05OcsMZNe1XzErcfuphmRussxx+591/HnnHH3ea85/aTw/wg8Rl4nUi4tipdpXwd8Q/jUYOM8/exx0ptOxx1pQVL3ovZ9Vv06HdW17amWzBt5DmOPOdHnbPySdRj5vqOvB/hNVba7tvt8jmB8G1sh/yCZyc+ZJnPHfPXo/QdDWtbM3nWf7qY/u4+kswz8knTC8fhkcHHBOKdqzf2lL+6mP+iWP/LWb/nrL/s9+2OB/Dk0O90dKcfe0ey6rv6Al7a7pf9Hk/wBYn/MHnP8Ay2YenHHGO4+XqKqWN3bJY3ANu+d18crpM/8Az3bHOOCPX+Doea10Y7pf3U3+sT/lrN/z2b/Z/DnnPI+bIqnp7N9guP3Uw+e//wCWs3/PdvVe3fPB/iwaNbgnHlej3XVdn5HlX7S166fD20udMaW0urTUzcCVbKa2Yf6yP5WK9R5gI5G0A98V6Fo8Nronhmx0sRzv9hgS1DnSZwx2WwXOSvHTP1+bpUfxE0C18TeGZbLUfPhtYZHu5GCyTMVimV2UBgACQpXOR97Lc8Ho75iVuP3UwzI3WWY4/c+6/jzzjj7vNCTuc1OCjVc+V2fmu/p6GfeXVq2qWOLdsLfHIOjTjj7M/AXGTyc7ev8AF0qS2vbUy2YNvIcxx5zo87Z+STqMfN9R14P8Jqe+dv7V079xP/x/njzrjP8Ax6ycfdznvnrjjGOaltmbzrP91Mf3cfSWYZ+STphePwyODjgnAr6m8muRaP4e67vyMm2u7b7fI5gfBtbIf8gmcnPmSZzx3z16P0HQ1aS9td0v+jyf6xP+YPOf+WzD0444x3Hy9RRas39pS/upj/olj/y1m/56y/7Pftjgfw5NXEY7pf3U3+sT/lrN/wA9m/2fw55zyPmyKFcqq1d6Pp1XZeRkWN3bJY3ANu+d18crpM//AD3bHOOCPX+Doea4346X0MPw4vbuGKRJLS4juAwsZLcjbeRdC4AY88Dt0Nd7p7N9guP3Uw+e/wD+Ws3/AD3b1Xt3zwf4sGuN+PkQufhH4ijceUBE0geVpnGVuo2wPkOCdu3PAyfmIoV+UxxlnGej3l1Xn5EPwgunT4VaS+pxySXsxnuZJBp8shfzfMlB8xRt/jBx24Pau0vLq1bVLHFu2FvjkHRpxx9mfgLjJ5OdvX+LpVTwtp02i+CtK0u5ikE9naxW8h3Sgb1tQrcbcdQT9OPu81rXzt/aunfuJ/8Aj/PHnXGf+PWTj7uc989ccYxzQ07Dw6jGCVn8L6rt6EFte2plswbeQ5jjznR52z8knUY+b6jrwf4TVW2u7b7fI5gfBtbIf8gmcnPmSZzx3z16P0HQ1rWzN51n+6mP7uPpLMM/JJ0wvH4ZHBxwTinas39pS/upj/olj/y1m/56y/7Pftjgfw5NDvdGqcfe0ey6rv6Al7a7pf8AR5P9Yn/MHnP/AC2YenHHGO4+XqKqWN3bJY3ANu+d18crpM//AD3bHOOCPX+Doea10Y7pf3U3+sT/AJazf89m/wBn8Oec8j5siqens32C4/dTD57/AP5azf8APdvVe3fPB/iwaNbgnHlej3XVdn5FfVr+FNKvngiljmW2uyjjSp0KsDwQ2PlI7N/B0NeKfA2aK58Q+ILp2lkXTIH09EWywAJLi8m/1cYIXseDhc+gFe568zf2Fqf7qb/j0vOss3r/ALvbvng/xYNeafA2xW3sfG12LeRXn8RXke8GRQURDjGBtOC7d/UHjJo15jnqJOdJ2e8u3kej3l1atqlji3bC3xyDo044+zPwFxk8nO3r/F0qW0v7QTWe60kcGOLIOk3H9189F+Y8deh6/wANTXzt/aunfuJ/+P8APHnXGf8Aj1k4+7nPfPXHGMc1LbM3nWf7qY/u4+kswz8knTC8fhkcHHBOBX1Np8vItH8Pdd35HAXX9mXXxV0pmheWRfDrGeF9OkwFN3bhGKFcyZJcEjOcdu/UQRaPFcTSx6XEknEW9dCmzsadty8Lwp2rle4AXqK5RXP/AAvq1GybI8KQ/L5kuP8Aj9XkcZ5xjA4HGCTxXoSMd0v7qb/WJ/y1m/57N/s/hzznkfNkUWZzU4QfM5Rb97y8vI4F/Bfgq902eO58L2HD3jBoNCliYbZztG5FBGBx1wo+VhV7UdA8Lw+CbzRItBg/spYrmb7KdIuI0aRSArs4wQ2FA8wtlRwTXSaezfYLj91MPnv/APlrN/z3b1Xt3zwf4sGjXmb+wtT/AHU3/HpedZZvX/d7d88H+LBpWfKdXsaLq2cH8T/l7vyPHfiXo3h7wRo2k3mkWt5GyeJNPkuZ7iC5EkiRIxUeZMSBgEgKMcYPSur+EsFppnw/8E26wSMMrcNu06WfJltXkOGUYYbnJ2jkdexqv+0zZpd/CfWbmRbiKSwvbe5i/eyEbyUjwwdeeJGPZunbr2mkW4sLDwzZxWnlJbyRxLHBJOEULZMuF4J7dclseo5pNM4sOoxrysnblfbt6WLdte2plswbeQ5jjznR52z8knUY+b6jrwf4TVW2u7b7fI5gfBtbIf8AIJnJz5kmc8d89ej9B0Na1szedZ/upj+7j6SzDPySdMLx+GRwccE4p2rN/aUv7qY/6JY/8tZv+esv+z37Y4H8OTVO90dycfe0ey6rv6Al7a7pf9Hk/wBYn/MHnP8Ay2YenHHGO4+XqKp2d1ajT7lHt3IY3+QNInIIMzcZxgcHH+z0PNbCMd0v7qb/AFif8tZv+ezf7P4c855HzZFU9PZvsFx+6mHz3/8Ay1m/57t6r2754P8AFg0a3D3XF6PddV2fkcjrnhDwY9hdXCeF9PjuIoLt43TQJYgGGQCSFA43HBPC4GeQCNHxXoHh3WY2a502WC6gmzBd2el3NrPDiHokiAFRgYKnj+LGBW7rzN/YWp/upv8Aj0vOss3r/u9u+eD/ABYNXL5iVuP3UwzI3WWY4/c+6/jzzjj7vNFncz9lRcVeD3l/L5eR85a9pml6H8cfCfh3R7FxYQvY3EcTWsmQIjcMxaN/nJJfdjvyR1FfQNte2plswbeQ5jjznR52z8knUY+b6jrwf4TXluu2hm/ay8PzGOTMWjtMEYy5PE6cNt3nrnOOMegzXr9qXMtoVgnYLFGTiSfptkGeF4HPbj0yCcCucWEslU0f3r/L/gGRbXdt9vkcwPg2tkP+QTOTnzJM547569H6DoauQ6hAjT7Iply6KcaRcdPPbjpwOBx3GF6im2rN/aUv7qY/6JY/8tZv+esv+z37Y4H8OTVxGO6X91N/rE/5azf89m/2fw55zyPmyKEnY9GtyttNPp1XZeR5D4g8QasuvaksGqahHELmUIiyyRBRvOAEJyv+6enSis7xPz4l1YkEf6XNwSSR857nn8+aK423c+9oYai6UfcWy6Lsev3lxc/2pYFk08f6cSuNYlIP+jOOW8vgdfm65+XpzUltcXgls8xaeMRx5zq0q4+STqfL+X6DpkD+I1PfXMv9q6eft8Gft5O77QmM/ZZBnPl9O2cYzxjPNS208gmsyLyFdscYBM6DbhJOD8nGM45zjI65BHYk9dT4CT9xe6vh7y7syLae6F/J+7sN/wBlsgQdVkAGJJP9jr1yP4eozmraXF5ul/daf/rE/wCYtKP+WzH/AJ588c57D5upotZ5BqUoF5CMWliMeenGJZcD7nbqfTvu6VcSeTdL/pkIzIh/16c/vmOfuevP0OeQcASZVV6v3V06vsjJsbi6+wzhI7BhuvuuqyZyZ24xs574H8Y5OKTW57o6LqIeOwCm1vASuqyMeT2Gzk+g/i6mrenzyGwuAbyE5e/GPPQ5zO2R9zv1Hr229KNenkOhamPtkJzaXgx56c5PI+536j17belKz5TRP98vdXxPq+7C+uLwrcYi085kbGNWlfP7nHePn0z3Py9KjvLi5/tSwLJp4/04lcaxKQf9Gcct5fA6/N1z8vTmtC+nkZbjN5C+ZGPE6HP7nGeEGeOO3PHXmor65l/tXTz9vgz9vJ3faExn7LIM58vp2zjGeMZ5ptO25jTenwr4X1l2ILa4vBLZ5i08YjjznVpVx8knU+X8v0HTIH8RqpbT3Qv5P3dhv+y2QIOqyADEkn+x165H8PUZzWvbTyCazIvIV2xxgEzoNuEk4PycYzjnOMjrkEU7WeQalKBeQjFpYjHnpxiWXA+526n077ulDTvuUn8XurZdX3BLi83S/utP/wBYn/MWlH/LZj/zz545z2HzdTVWxuLr7DOEjsGG6+66rJnJnbjGznvgfxjk4rWSeTdL/pkIzIh/16c/vmOfuevP0OeQcCnp88hsLgG8hOXvxjz0Ocztkfc79R69tvSizuCfuv3Vuur7Mqa3PdHRdRDx2AU2t4CV1WRjyew2cn0H8XU1bvri8K3GItPOZGxjVpXz+5x3j59M9z8vSjXp5DoWpj7ZCc2l4MeenOTyPud+o9e23pVy+nkZbjN5C+ZGPE6HP7nGeEGeOO3PHXmhJ3BP3V7q3l1fkZ95cXP9qWBZNPH+nErjWJSD/ozjlvL4HX5uufl6c1JbXF4JbPMWnjEcec6tKuPkk6ny/l+g6ZA/iNT31zL/AGrp5+3wZ+3k7vtCYz9lkGc+X07ZxjPGM81LbTyCazIvIV2xxgEzoNuEk4PycYzjnOMjrkECT11Jk/cXur4e8u7PN/AstwvxJ+IbMlqtwTooKNeNEuBATkMEyeCCeOM5zwM94lxebpf3Wn/6xP8AmLSj/lsx/wCefPHOew+bqah05IrbVb17d7KGW4gsZZnRo1eRgzqN7eXklVVRgk7QO+cVpJPJul/0yEZkQ/69Of3zHP3PXn6HPIOA0jONN0k4uK3vu+tmZNjcXX2GcJHYMN1911WTOTO3GNnPfA/jHJxSa3PdHRdRDx2AU2t4CV1WRjyew2cn0H8XU1b0+eQ2FwDeQnL34x56HOZ2yPud+o9e23pRr08h0LUx9shObS8GPPTnJ5H3O/Uevbb0qbPlOpP98vdXxPq+7C+uLwrcYi085kbGNWlfP7nHePn0z3Py9KjvLi5/tSwLJp4/04lcaxKQf9Gcct5fA6/N1z8vTmtC+nkZbjN5C+ZGPE6HP7nGeEGeOO3PHXmor65l/tXTz9vgz9vJ3faExn7LIM58vp2zjGeMZ5ptO25jTenwr4X1l2MLw9YXumaxf3QlsXi1KaC6MJ1Jo1hcW3lN8wizkiNc5J28AfeObdtPdC/k/d2G/wCy2QIOqyADEkn+x165H8PUZzWvbTyCazIvIV2xxgEzoNuEk4PycYzjnOMjrkEU7WeQalKBeQjFpYjHnpxiWXA+526n077ulDi7ocUoqSUV06v+YEuLzdL+60//AFif8xaUf8tmP/PPnjnPYfN1NVbG4uvsM4SOwYbr7rqsmcmduMbOe+B/GOTitZJ5N0v+mQjMiH/Xpz++Y5+568/Q55BwKenzyGwuAbyE5e/GPPQ5zO2R9zv1Hr229KLO40/dfurddX2ZU1ue6Oi6iHjsAptbwErqsjHk9hs5PoP4upq3fXF4VuMRaecyNjGrSvn9zjvHz6Z7n5elGvTyHQtTH2yE5tLwY89Ocnkfc79R69tvSrl9PIy3GbyF8yMeJ0Of3OM8IM8cdueOvNCTuCfur3VvLq/Iz7y4uf7UsCyaeP8ATiVxrEpB/wBGcct5fA6/N1z8vTmqdvp0X/CS2OuGx00aqtill9pOsTAiH53KH5ML8wB4GRkDJB41765l/tXTz9vgz9vJ3faExn7LIM58vp2zjGeMZ5qW2nkE1mReQrtjjAJnQbcJJwfk4xnHOcZHXIIEnqTOzgrxXw95eZkW090L+T93Yb/stkCDqsgAxJJ/sdeuR/D1Gc1bS4vN0v7rT/8AWJ/zFpR/y2Y/88+eOc9h83U0Ws8g1KUC8hGLSxGPPTjEsuB9zt1Pp33dKuJPJul/0yEZkQ/69Of3zHP3PXn6HPIOAJMqq9X7q6dX2Rk2NxdfYZwkdgw3X3XVZM5M7cY2c98D+McnFJrc90dF1EPHYBTa3gJXVZGPJ7DZyfQfxdTVvT55DYXAN5CcvfjHnoc5nbI+536j17belGvTyHQtTH2yE5tLwY89Ocnkfc79R69tvSlZ8pon++Xur4n1fdhfXF4VuMRaecyNjGrSvn9zjvHz6Z7n5elee/tGTTyfCPxGJltAvn25Bh1B7gn95F/CyDI/2uueK9Ovp5GW4zeQvmRjxOhz+5xnhBnjjtzx15qDUpWk1LTxJeWzj+0C3zTxkZFq/wA3+rx7Zx14xnmm07HJOn7WHIklo+r6akVtcXgls8xaeMRx5zq0q4+STqfL+X6DpkD+I1Utp7oX8n7uw3/ZbIEHVZABiST/AGOvXI/h6jOa2bS4ZZLbN1DnyogrG4UeXhX6/J2GRg5xuHXIIo2s8g1KUC8hGLSxGPPTjEsuB9zt1Pp33dKGnc3Tvze6tl1fdeYJcXm6X91p/wDrE/5i0o/5bMf+efPHOew+bqaq2NxdfYZwkdgw3X3XVZM5M7cY2c98D+McnFayTybpf9MhGZEP+vTn98xz9z15+hzyDgU9PnkNhcA3kJy9+Meehzmdsj7nfqPXtt6UWdwT91+6t11fZlTW57o6LqIeOwCm1vASuqyMeT2Gzk+g/i6mrd9cXhW4xFp5zI2MatK+f3OO8fPpnufl6Ua9PIdC1MfbITm0vBjz05yeR9zv1Hr229KuX08jLcZvIXzIx4nQ5/c4zwgzxx254680JO4J+6vdW8ur8jPvLi5/tSwLJp4/04lcaxKQf9Gcct5fA6/N1z8vTmpLa4vBLZ5i08YjjznVpVx8knU+X8v0HTIH8Rqe+uZf7V08/b4M/byd32hMZ+yyDOfL6ds4xnjGealtp5BNZkXkK7Y4wCZ0G3CScH5OMZxznGR1yCBJ66kyfuL3V8PeXdmRbT3Qv5P3dhv+y2QIOqyADEkn+x165H8PUZzVtLi83S/utP8A9Yn/ADFpR/y2Y/8APPnjnPYfN1NFrPINSlAvIRi0sRjz04xLLgfc7dT6d93SriTybpf9MhGZEP8Ar05/fMc/c9efoc8g4Akyqr1furp1fZGTY3F19hnCR2DDdfddVkzkztxjZz3wP4xycUazc3Y0e/JSxUC2uzuTVZGYc5BA2DJ7gZ+bqcVa0+eQ2FwDeQnL34x56HOZ2yPud+o9e23pRr08h0LUx9shObS8GPPTnJ5H3O/Uevbb0pWfKXvWScV8T6vuwvri8K3GItPOZGxjVpXz+5x3j59M9z8vSo7y4uf7UsCyaeP9OJXGsSkH/RnHLeXwOvzdc/L05rQvp5GW4zeQvmRjxOhz+5xnhBnjjtzx15qK+uZf7V08/b4M/byd32hMZ+yyDOfL6ds4xnjGeabTtuZU3p8K+F9ZdiC2uLwS2eYtPGI4851aVcfJJ1Pl/L9B0yB/EaqW090L+T93Yb/stkCDqsgAxJJ/sdeuR/D1Gc1r208gmsyLyFdscYBM6DbhJOD8nGM45zjI65BFO1nkGpSgXkIxaWIx56cYllwPudup9O+7pQ077lJ/F7q2XV9wS4vN0v7rT/8AWJ/zFpR/y2Y/88+eOc9h83U1Vsbi6+wzhI7BhuvuuqyZyZ24xs574H8Y5OK1knk3S/6ZCMyIf9enP75jn7nrz9DnkHAp6fPIbC4BvITl78Y89DnM7ZH3O/Uevbb0os7gn7r91brq+zKmtz3R0XUQ8dgFNreAldVkY8nsNnJ9B/F1NQ2OmpollfW2lWenQxTXk906pq8r7nkjLMQDH0ycf+O+prR16eQ6FqY+2QnNpeDHnpzk8j7nfqPXtt6Vcvp5GW4zeQvmRjxOhz+5xnhBnjjtzx15os7ismotwW8ur8jPvLi5/tSwLJp4/wBOJXGsSkH/AEZxy3l8Dr83XPy9Oaktri8EtnmLTxiOPOdWlXHySdT5fy/QdMgfxGp765l/tXTz9vgz9vJ3faExn7LIM58vp2zjGeMZ5qW2nkE1mReQrtjjAJnQbcJJwfk4xnHOcZHXIIEnrqKT9xe6vh7y7s82WW8/4XpbM0dmGXwrAoX+0JAuPtuSd+zIOQflxhQMg8YrvUuLzdL+60//AFif8xaUf8tmP/PPnjnPYfN1NZ9rp1r/AMJhJrJni/tFdLsrNZDdAbYvPkcrt2YzuVSc5IwOSCQdxJ5N0v8ApkIzIh/16c/vmOfuevP0OeQcBpMzjB0+ZOK3vu+tmZNjcXX2GcJHYMN1911WTOTO3GNnPfA/jHJxSa3PdHRdRDx2AU2t4CV1WRjyew2cn0H8XU1b0+eQ2FwDeQnL34x56HOZ2yPud+o9e23pRr08h0LUx9shObS8GPPTnJ5H3O/Uevbb0qbPlOpP98vdXxPq+7OL+OcVxqXww8QWb/Y4/tF1Zxq8WoSXBBaeBc7SoyOfvZz2rsLye4Gp2H7rTUUXxKBNWkC/8ezjqIxgdfmHcbcYo8U2K61Zm2u79WgS+hu2jSaJhM0IWRVbMXKlkUHG3ONvck2765l/tXTz9vgz9vJ3faExn7LIM58vp2zjGeMZ5ocWcdCDVSUnFax7vsQW1xeCWzzFp4xHHnOrSrj5JOp8v5foOmQP4jVS2nuhfyfu7Df9lsgQdVkAGJJP9jr1yP4eozmte2nkE1mReQrtjjAJnQbcJJwfk4xnHOcZHXIIp2s8g1KUC8hGLSxGPPTjEsuB9zt1Pp33dKbTvudCfxe6tl1fcEuLzdL+60//AFif8xaUf8tmP/PPnjnPYfN1NVbG4uvsM4SOwYbr7rqsmcmduMbOe+B/GOTitZJ5N0v+mQjMiH/Xpz++Y5+568/Q55BwKenzyGwuAbyE5e/GPPQ5zO2R9zv1Hr229KLO4J+6/dW66vsyprc90dF1EPHYBTa3gJXVZGPJ7DZyfQfxdTVu+uLwrcYi085kbGNWlfP7nHePn0z3Py9KNenkOhamPtkJzaXgx56c5PI+536j17belXL6eRluM3kL5kY8Toc/ucZ4QZ447c8deaEncE/dXureXV+R5fNO0n7TkD3X2NZo/DhFsPt8hjY+c2f32zcDgv27Y716La3V6stp+7sADFGG/wCJvKo+7JwT5fy8447cD+I1gX3hwf8AC3NP8Yf2vB9o8g6X5PmJjb5cknmb9uMfw/d6/r1drcypLabb2JP3Ua589AAAsnB+TjHoc4yOuQQJPU5401Tg2o7q+78/67mPbT3Qv5P3dhv+y2QIOqyADEkn+x165H8PUZzVtLi83S/utP8A9Yn/ADFpR/y2Y/8APPnjnPYfN1NFrPINSlAvIRi0sRjz04xLLgfc7dT6d93SriTybpf9MhGZEP8Ar05/fMc/c9efoc8g4AkzoqvV+6unV9keH+JCW8RaoW27jdSk7JDIv3z0YgFh7kc0UviclvEurMWDk3cxLAgg/OecgDP5CiuN7n6Hh/4UfRfkez3lrfjVrAG/1csdQIBK2u4H7K/I+TG7H4YPrT7S0vvPsNuo6tnyotu1bXONkuMZTp1xnnGc84ovrFf7V09fss//AB/lceXb5/49ZDj0z39Me9S21orTWY+zzHdHGcBIecpIeM/Tvzwc84rrUVqfnEprkXw/D2Xdmfa2t79udRfarxaWB3BbbkebJtHKdM9O+Sd3GKtx2l9vn/4mOrf62POFtev2h+vydc59s5zxioLW0B1KU/Z5jm0sTkJDzullHf17dz/FxVxLQFpf9HmOJEH3IeMzMP6Y44yOflxTSRVWau/h+z0XZGfZWt61hcH7dqqjOoAjbbY/153E/Jnry2O/3eKNctb1dE1Jmv8AVWUWl6SrLbYIzyDhM49cc/3ak0+0UWFwfs8ww9+clIeNs7Dt6d8cj+HijXrRRoWpn7PMMWl4c7IeNpx29O/cfw8UrLlNFNe2Xw/E+i7sn1G0vtlzu1HVv9a2d62vX7OeuE649OMe9MvLW/GrWAN/q5Y6gQCVtdwP2V+R8mN2PwwfWrF9ZhFuP9HmXbIw5SEY/c7u358cY/2qivrFf7V09fss/wDx/lceXb5/49ZDj0z39Me9EkrGMJq32fhfRdgtLS+8+w26jq2fKi27Vtc42S4xlOnXGecZzziqlra3v251F9qvFpYHcFtuR5sm0cp0z075J3cYrQtrRWmsx9nmO6OM4CQ85SQ8Z+nfng55xVO1tAdSlP2eY5tLE5CQ87pZR39e3c/xcU2lcpTXvfDsui/mJ47S+3z/APEx1b/Wx5wtr1+0P1+TrnPtnOeMVUsrW9awuD9u1VRnUARttsf687ifkz15bHf7vFaCWgLS/wCjzHEiD7kPGZmH9MccZHPy4qnp9oosLg/Z5hh785KQ8bZ2Hb0745H8PFFlcFUVn8O66LsyPXLW9XRNSZr/AFVlFpekqy22CM8g4TOPXHP92reo2l9sud2o6t/rWzvW16/Zz1wnXHpxj3qDXrRRoWpn7PMMWl4c7IeNpx29O/cfw8VcvrMItx/o8y7ZGHKQjH7nd2/PjjH+1Qkrgqi5V8O8ui8iveWt+NWsAb/Vyx1AgEra7gfsr8j5Mbsfhg+tPtLS+8+w26jq2fKi27Vtc42S4xlOnXGecZzzii+sV/tXT1+yz/8AH+Vx5dvn/j1kOPTPf0x71LbWitNZj7PMd0cZwEh5ykh4z9O/PBzzikorUmU1yL4fh7LuzPtbW9+3OovtV4tLA7gttyPNk2jlOmenfJO7jFW47S+3z/8AEx1b/Wx5wtr1+0P1+TrnPtnOeMVBa2gOpSn7PMc2lichIed0so7+vbuf4uKuJaAtL/o8xxIg+5DxmZh/THHGRz8uKaSKqzV38P2ei7Iz7K1vWsLg/btVUZ1AEbbbH+vO4n5M9eWx3+7xRrlrerompM1/qrKLS9JVltsEZ5BwmceuOf7tSafaKLC4P2eYYe/OSkPG2dh29O+OR/DxRr1oo0LUz9nmGLS8OdkPG047enfuP4eKVlymimvbL4fifRd2T6jaX2y53ajq3+tbO9bXr9nPXCdcenGPemXlrfjVrAG/1csdQIBK2u4H7K/I+TG7H4YPrVi+swi3H+jzLtkYcpCMfud3b8+OMf7VRX1iv9q6ev2Wf/j/ACuPLt8/8eshx6Z7+mPeiSVjGE1b7PwvouwWlpfefYbdR1bPlRbdq2ucbJcYynTrjPOM55xVS1tb37c6i+1Xi0sDuC23I82TaOU6Z6d8k7uMVoW1orTWY+zzHdHGcBIecpIeM/Tvzwc84qna2gOpSn7PMc2lichIed0so7+vbuf4uKbSuUpr3vh2XRfzE8dpfb5/+Jjq3+tjzhbXr9ofr8nXOfbOc8YqpZWt61hcH7dqqjOoAjbbY/153E/Jnry2O/3eK0EtAWl/0eY4kQfch4zMw/pjjjI5+XFU9PtFFhcH7PMMPfnJSHjbOw7enfHI/h4osrgqis/h3XRdmR65a3q6JqTNf6qyi0vSVZbbBGeQcJnHrjn+7VvUbS+2XO7UdW/1rZ3ra9fs564Trj04x71Br1oo0LUz9nmGLS8OdkPG047enfuP4eKuX1mEW4/0eZdsjDlIRj9zu7fnxxj/AGqElcFUXKvh3l0XkV7y1vxq1gDf6uWOoEAlbXcD9lfkfJjdj8MH1p9paX3n2G3UdWz5UW3atrnGyXGMp064zzjOecUX1iv9q6ev2Wf/AI/yuPLt8/8AHrIceme/pj3qW2tFaazH2eY7o4zgJDzlJDxn6d+eDnnFJRWpMprkXw/D2Xdmfa2t79udRfarxaWB3BbbkebJtHKdM9O+Sd3GKtx2l9vn/wCJjq3+tjzhbXr9ofr8nXOfbOc8YqC1tAdSlP2eY5tLE5CQ87pZR39e3c/xcVcS0BaX/R5jiRB9yHjMzD+mOOMjn5cU0kVVmrv4fs9F2Rn2VretYXB+3aqozqAI222P9edxPyZ68tjv93ijXLW9XRNSZr/VWUWl6SrLbYIzyDhM49cc/wB2pNPtFFhcH7PMMPfnJSHjbOw7enfHI/h4o160UaFqZ+zzDFpeHOyHjacdvTv3H8PFKy5TRTXtl8PxPou7J9RtL7Zc7tR1b/Wtnetr1+znrhOuPTjHvTLy1vxq1gDf6uWOoEAlbXcD9lfkfJjdj8MH1qxfWYRbj/R5l2yMOUhGP3O7t+fHGP8AaqK+sV/tXT1+yz/8f5XHl2+f+PWQ49M9/THvRJKxjCat9n4X0XYLS0vvPsNuo6tnyotu1bXONkuMZTp1xnnGc84qpa2t79udRfarxaWB3BbbkebJtHKdM9O+Sd3GK0La0VprMfZ5jujjOAkPOUkPGfp354OecVTtbQHUpT9nmObSxOQkPO6WUd/Xt3P8XFNpXKU173w7Lov5ieO0vt8//Ex1b/Wx5wtr1+0P1+TrnPtnOeMVUsrW9awuD9u1VRnUARttsf687ifkz15bHf7vFaCWgLS/6PMcSIPuQ8ZmYf0xxxkc/Liqen2iiwuD9nmGHvzkpDxtnYdvTvjkfw8UWVwVRWfw7rouzI9ctb1dE1Jmv9VZRaXpKsttgjPIOEzj1xz/AHat6jaX2y53ajq3+tbO9bXr9nPXCdcenGPeoNetFGhamfs8wxaXhzsh42nHb079x/DxVy+swi3H+jzLtkYcpCMfud3b8+OMf7VCSuCqLlXw7y6LyK95a341awBv9XLHUCAStruB+yvyPkxux+GD60+0tL7z7DbqOrZ8qLbtW1zjZLjGU6dcZ5xnPOKL6xX+1dPX7LP/AMf5XHl2+f8Aj1kOPTPf0x71LbWitNZj7PMd0cZwEh5ykh4z9O/PBzzikorUmU1yL4fh7LuzPtbW9+3OovtV4tLA7gttyPNk2jlOmenfJO7jFW47S+3z/wDEx1b/AFsecLa9ftD9fk65z7ZznjFQWtoDqUp+zzHNpYnISHndLKO/r27n+LiriWgLS/6PMcSIPuQ8ZmYf0xxxkc/Limkiqs1d/D9nouyM+ytb1rC4P27VVGdQBG22x/rzuJ+TPXlsd/u8Ua5a3q6JqTNf6qyi0vSVZbbBGeQcJnHrjn+7Umn2iiwuD9nmGHvzkpDxtnYdvTvjkfw8Ua9aKNC1M/Z5hi0vDnZDxtOO3p37j+HilZcpopr2y+H4n0Xdk+o2l9sud2o6t/rWzvW16/Zz1wnXHpxj3pl5a341awBv9XLHUCAStruB+yvyPkxux+GD61YvrMItx/o8y7ZGHKQjH7nd2/PjjH+1UV9Yr/aunr9ln/4/yuPLt8/8eshx6Z7+mPeiSVjGE1b7PwvouwWlpfefYbdR1bPlRbdq2ucbJcYynTrjPOM55xVS1tb37c6i+1Xi0sDuC23I82TaOU6Z6d8k7uMVoW1orTWY+zzHdHGcBIecpIeM/Tvzwc84qna2gOpSn7PMc2lichIed0so7+vbuf4uKbSuUpr3vh2XRfzE8dpfb5/+Jjq3+tjzhbXr9ofr8nXOfbOc8YqpZWt61hcH7dqqjOoAjbbY/wBedxPyZ68tjv8Ad4rQS0BaX/R5jiRB9yHjMzD+mOOMjn5cVT0+0UWFwfs8ww9+clIeNs7Dt6d8cj+HiiyuCqKz+HddF2ZHrlrerompM1/qrKLS9JVltsEZ5BwmceuOf7tW9RtL7Zc7tR1b/Wtnetr1+znrhOuPTjHvUGvWijQtTP2eYYtLw52Q8bTjt6d+4/h4q5fWYRbj/R5l2yMOUhGP3O7t+fHGP9qhJXBVFyr4d5dF5Fe8tb8atYA3+rljqBAJW13A/ZX5HyY3Y/DB9afaWl959ht1HVs+VFt2ra5xslxjKdOuM84znnFF9Yr/AGrp6/ZZ/wDj/K48u3z/AMeshx6Z7+mPepba0VprMfZ5jujjOAkPOUkPGfp354OecUlFakymuRfD8PZd2Z9ra3v251F9qvFpYHcFtuR5sm0cp0z075J3cYq3HaX2+f8A4mOrf62POFtev2h+vydc59s5zxioLW0B1KU/Z5jm0sTkJDzullHf17dz/FxVxLQFpf8AR5jiRB9yHjMzD+mOOMjn5cU0kVVmrv4fs9F2Rn2VretYXB+3aqozqAI222P9edxPyZ68tjv93ijXLW9XRNSZr/VWUWl6SrLbYIzyDhM49cc/3ak0+0UWFwfs8ww9+clIeNs7Dt6d8cj+HijXrRRoWpn7PMMWl4c7IeNpx29O/cfw8UrLlNFNe2Xw/E+i7sn1G0vtlzu1HVv9a2d62vX7OeuE649OMe9MvLW/GrWAN/q5Y6gQCVtdwP2V+R8mN2PwwfWrF9ZhFuP9HmXbIw5SEY/c7u358cY/2qivrFf7V09fss//AB/lceXb5/49ZDj0z39Me9EkrGMJq32fhfRdgtLS+8+w26jq2fKi27Vtc42S4xlOnXGecZzziqlra3v251F9qvFpYHcFtuR5sm0cp0z075J3cYrQtrRWmsx9nmO6OM4CQ85SQ8Z+nfng55xVO1tAdSlP2eY5tLE5CQ87pZR39e3c/wAXFNpXKU173w7Lov5ieO0vt8//ABMdW/1secLa9ftD9fk65z7ZznjFVLK1vWsLg/btVUZ1AEbbbH+vO4n5M9eWx3+7xWgloC0v+jzHEiD7kPGZmH9MccZHPy4qnp9oosLg/Z5hh785KQ8bZ2Hb0745H8PFFlcFUVn8O66LsyPXLW9XRNSZr/VWUWl6SrLbYIzyDhM49cc/3at6jaX2y53ajq3+tbO9bXr9nPXCdcenGPeoNetFGhamfs8wxaXhzsh42nHb079x/DxVy+swi3H+jzLtkYcpCMfud3b8+OMf7VCSuCqLlXw7y6LyK95a341awBv9XLHUCAStruB+yvyPkxux+GD60+0tL7z7DbqOrZ8qLbtW1zjZLjGU6dcZ5xnPOKL6xX+1dPX7LP8A8f5XHl2+f+PWQ49M9/THvUttaK01mPs8x3RxnASHnKSHjP0788HPOKSitSZTXIvh+Hsu7M+1tb37c6i+1Xi0sDuC23I82TaOU6Z6d8k7uMVbjtL7fP8A8THVv9bHnC2vX7Q/X5Ouc+2c54xUFraA6lKfs8xzaWJyEh53Syjv69u5/i4q4loC0v8Ao8xxIg+5DxmZh/THHGRz8uKaSKqzV38P2ei7I8Q8Thl8S6ssjSM4u5QzSbdxO88nbxn6celFHiddniXVkCldt3MMEAEfOfTj8uKK4nufouH/AIUfRfkev3mk6auqWKrpunhWvirAaUcEfZnOCvpkA7fUbqkttH0wy2edM085jjznTC2fkk6j+L6jrwf4TUd5dWrapY4t2wt8cg6NOOPsz8BcZPJzt6/xdK5rVvFjWHxA8EaLBZwvZ6rBO1y8ulTmQGKFmXYvBfJb5iARwDxiuxcup+eVJ1Y0025bLo+ra7G9baTpxv5FOnWBUWtkwB0wnkySZPuTgZP8WMCraaPpm6X/AIlmn/6xP+YYT/y2Yfh6Y7j5eorjPhR4qfxR4Ys9a1Szgju7i3gR1tdLmkT5LqdMgjd1CjJz8xyo5Bx2aXtrul/0eT/WJ/zB5z/y2YenHHGO4+XqKFylSnVmuaLlZ8vR9l5FSy0rTnsbhm06wLBr4AnTDkYnIHPbA4B/hHBo1vStOj0XUXj06wV1tbxlZdMKkEHgg9iOx/h6Gixu7ZLG4Bt3zuvjldJn/wCe7Y5xwR6/wdDzRrd3bPouoqtu4Y2t4ATpM64OeOSMDHqeF6Gl7vKap1vbLWXxPo+78i3faPpgW4xpmnjEjdNMKY/c579Oecdj83So7zSdNXVLFV03TwrXxVgNKOCPsznBX0yAdvqN1SX17ahbjFvIMSN00edMfuc9149cdj83So7y6tW1Sxxbthb45B0accfZn4C4yeTnb1/i6U3y2MoOtbeXwvo+3oSW2j6YZbPOmaecxx5zphbPySdR/F9R14P8JqpbaTpxv5FOnWBUWtkwB0wnkySZPuTgZP8AFjAq3bXtqZbMG3kOY4850eds/JJ1GPm+o68H+E1Vtru2+3yOYHwbWyH/ACCZyc+ZJnPHfPXo/QdDQ+W5Sdb3tZbLo+/oWk0fTN0v/Es0/wD1if8AMMJ/5bMPw9Mdx8vUVUstK057G4ZtOsCwa+AJ0w5GJyBz2wOAf4Rwatpe2u6X/R5P9Yn/ADB5z/y2YenHHGO4+XqKqWN3bJY3ANu+d18crpM//Pdsc44I9f4Oh5o924J1rPWW66Ps/INb0rTo9F1F49OsFdbW8ZWXTCpBB4IPYjsf4ehq3faPpgW4xpmnjEjdNMKY/c579Oecdj83Sqmt3ds+i6iq27hja3gBOkzrg545IwMep4Xoat317ahbjFvIMSN00edMfuc9149cdj83ShctwTrcq1lvLo/LyI7zSdNXVLFV03TwrXxVgNKOCPsznBX0yAdvqN1SW2j6YZbPOmaecxx5zphbPySdR/F9R14P8JqO8urVtUscW7YW+OQdGnHH2Z+AuMnk529f4ulSW17amWzBt5DmOPOdHnbPySdRj5vqOvB/hNC5dSZOtyLWXw9n3fkVLbSdON/Ip06wKi1smAOmE8mSTJ9ycDJ/ixgVbTR9M3S/8SzT/wDWJ/zDCf8Alsw/D0x3Hy9RVW2u7b7fI5gfBtbIf8gmcnPmSZzx3z16P0HQ1W8Q+JdO0DRtQ1O7tZGgtnjLD+zWi4Nwy/elKIvUcMwyPlHIoXKOq6yb1l06PsvIsWWlac9jcM2nWBYNfAE6YcjE5A57YHAP8I4NGt6Vp0ei6i8enWCutreMrLphUgg8EHsR2P8AD0NeV3vxdtrCwGoLBZ22h6lo+oXWlz3Wmy75tQFy2Lc7WIwqlPmHyqSRuNbPhjxpqeuz+MNI8QaTZ2NzpmmRMUt9PlLLNNBvlVzkhQr5CscADuetL3eUmniZTrqMZN+9+d2vwPRr/R9MVbgDTNPB3sRjTCnHknpnoMg8eo3dKrPZaNcarYpZ2mlShrtnZYtMLAxiB1JKj+EPgY/vc1Zvr21C3GLeQYkbpo86Y/c57rx647H5ulR3l1atqlji3bC3xyDo044+zPwFxk8nO3r/ABdKb5bBB17by2fR9vQkttH0wy2edM085jjznTC2fkk6j+L6jrwf4TVS20nTjfyKdOsCotbJgDphPJkkyfcnAyf4sYFW7a9tTLZg28hzHHnOjztn5JOox831HXg/wmqttd232+RzA+Da2Q/5BM5OfMkznjvnr0foOhofLctOt72stl0ff0LSaPpm6X/iWaf/AKxP+YYT/wAtmH4emO4+XqKqWWlac9jcM2nWBYNfAE6YcjE5A57YHAP8I4NW0vbXdL/o8n+sT/mDzn/lsw9OOOMdx8vUVUsbu2SxuAbd87r45XSZ/wDnu2OccEev8HQ80e7cE61nrLddH2fkGt6Vp0ei6i8enWCutreMrLphUgg8EHsR2P8AD0NW77R9MC3GNM08YkbpphTH7nPfpzzjsfm6VU1u7tn0XUVW3cMbW8AJ0mdcHPHJGBj1PC9DVu+vbULcYt5BiRumjzpj9znuvHrjsfm6ULluCdblWst5dH5eRHeaTpq6pYqum6eFa+KsBpRwR9mc4K+mQDt9RuqS20fTDLZ50zTzmOPOdMLZ+STqP4vqOvB/hNR3l1atqlji3bC3xyDo044+zPwFxk8nO3r/ABdKktr21MtmDbyHMcec6PO2fkk6jHzfUdeD/CaFy6kydbkWsvh7Pu/IqW2k6cb+RTp1gVFrZMAdMJ5MkmT7k4GT/FjAq2mj6Zul/wCJZp/+sT/mGE/8tmH4emO4+XqKq213bfb5HMD4NrZD/kEzk58yTOeO+evR+g6GrSXtrul/0eT/AFif8wec/wDLZh6cccY7j5eooXKVVda7s5dOj7LyKllpWnPY3DNp1gWDXwBOmHIxOQOe2BwD/CODRreladHouovHp1grra3jKy6YVIIPBB7Edj/D0NFjd2yWNwDbvndfHK6TP/z3bHOOCPX+DoeaNbu7Z9F1FVt3DG1vACdJnXBzxyRgY9TwvQ0vd5S063tlrL4n0fd+RbvtH0wLcY0zTxiRummFMfuc9+nPOOx+bpUd5pOmrqliq6bp4Vr4qwGlHBH2Zzgr6ZAO31G6pL69tQtxi3kGJG6aPOmP3Oe68euOx+bpUd5dWrapY4t2wt8cg6NOOPsz8BcZPJzt6/xdKb5bGUHWtvL4X0fb0JLbR9MMtnnTNPOY4850wtn5JOo/i+o68H+E1UttJ0438inTrAqLWyYA6YTyZJMn3JwMn+LGBUeq6lLBpEs2j6ebvU0st9rbyaTPtmmEUpRW4GQWCgnIB65G01514U+IWoeKrt28L2ekXzR6BYm6lfT7kR2+pGY/uWKhmKbTISQp37AoYZzQ+W5E69SEuSTld2tp2foeqJo+mbpf+JZp/wDrE/5hhP8Ay2Yfh6Y7j5eoqpZaVpz2NwzadYFg18ATphyMTkDntgcA/wAI4Nc74A8V3Guy6293bWt1pcN1Cmn6rZaPcLDfIZD5hVCXKhXDJncQ4G0cqa6Kxu7ZLG4Bt3zuvjldJn/57tjnHBHr/B0PNHu3Lpzqzg5Jy3XTyfkGt6Vp0ei6i8enWCutreMrLphUgg8EHsR2P8PQ1bvtH0wLcY0zTxiRummFMfuc9+nPOOx+bpVTW7u2fRdRVbdwxtbwAnSZ1wc8ckYGPU8L0NW769tQtxi3kGJG6aPOmP3Oe68euOx+bpQuW5SdblWst5dH5eRHeaTpq6pYqum6eFa+KsBpRwR9mc4K+mQDt9RuqS20fTDLZ50zTzmOPOdMLZ+STqP4vqOvB/hNR3l1atqlji3bC3xyDo044+zPwFxk8nO3r/F0qS2vbUy2YNvIcxx5zo87Z+STqMfN9R14P8JoXLqTJ1uRay+Hs+78ipbaTpxv5FOnWBUWtkwB0wnkySZPuTgZP8WMCraaPpm6X/iWaf8A6xP+YYT/AMtmH4emO4+XqKq213bfb5HMD4NrZD/kEzk58yTOeO+evR+g6GrSXtrul/0eT/WJ/wAwec/8tmHpxxxjuPl6ihcpVV1ruzl06PsvIqWWlac9jcM2nWBYNfAE6YcjE5A57YHAP8I4NGt6Vp0ei6i8enWCutreMrLphUgg8EHsR2P8PQ0WN3bJY3ANu+d18crpM/8Az3bHOOCPX+DoeaNbu7Z9F1FVt3DG1vACdJnXBzxyRgY9TwvQ0vd5S063tlrL4n0fd+RbvtH0wLcY0zTxiRummFMfuc9+nPOOx+bpUd5pOmrqliq6bp4Vr4qwGlHBH2Zzgr6ZAO31G6pL69tQtxi3kGJG6aPOmP3Oe68euOx+bpUd5dWrapY4t2wt8cg6NOOPsz8BcZPJzt6/xdKb5bGUHWtvL4X0fb0JLbR9MMtnnTNPOY4850wtn5JOo/i+o68H+E1UttJ0438inTrAqLWyYA6YTyZJMn3JwMn+LGBVu2vbUy2YNvIcxx5zo87Z+STqMfN9R14P8JqrbXdt9vkcwPg2tkP+QTOTnzJM547569H6DoaHy3KTre9rLZdH39C0mj6Zul/4lmn/AOsT/mGE/wDLZh+HpjuPl6iqllpWnPY3DNp1gWDXwBOmHIxOQOe2BwD/AAjg1bS9td0v+jyf6xP+YPOf+WzD0444x3Hy9RVSxu7ZLG4Bt3zuvjldJn/57tjnHBHr/B0PNHu3BOtZ6y3XR9n5BreladHouovHp1grra3jKy6YVIIPBB7Edj/D0NW77R9MC3GNM08YkbpphTH7nPfpzzjsfm6VU1u7tn0XUVW3cMbW8AJ0mdcHPHJGBj1PC9DVu+vbULcYt5BiRumjzpj9znuvHrjsfm6ULluCdblWst5dH5eRHeaTpq6pYqum6eFa+KsBpRwR9mc4K+mQDt9RuqS20fTDLZ50zTzmOPOdMLZ+STqP4vqOvB/hNR3l1atqlji3bC3xyDo044+zPwFxk8nO3r/F0qS2vbUy2YNvIcxx5zo87Z+STqMfN9R14P8ACaFy6kydbkWsvh7Pu/IqW2k6cb+RTp1gVFrZMAdMJ5MkmT7k4GT/ABYwKtpo+mbpf+JZp/8ArE/5hhP/AC2Yfh6Y7j5eorG1XUJrex1W50fT/tepppls1pBJpUwEswaUqrHjhjgFsgN0BGDXnOl/FHXvEtjcS+DNG0vVriDSbS4uI10+bEWovdfNb5Lj5PL8wg9DtC7ieCLlJxFapCXLeV3a33K56pZaVpz2NwzadYFg18ATphyMTkDntgcA/wAI4NGt6Vp0ei6i8enWCutreMrLphUgg8EHsR2P8PQ1ynw98V/2odfsNTRI9S055/Os10KSOWDzGMilik0y85IHIKbGBzkE9Xrd3bPouoqtu4Y2t4ATpM64OeOSMDHqeF6Gl7vKa051Z1FJOVuZ9PN+QarBoNvqKafJZ6Yl5defLDENNKMyRwpvI9ADInB7nd0Bqe80nTV1SxVdN08K18VYDSjgj7M5wV9MgHb6jdXJ+JbuI/FLQisEqwpYakcfYZUGSlt0iI3Dtz2znoK6y8urVtUscW7YW+OQdGnHH2Z+AuMnk529f4ulD5bHPQqV5c13LRNbPsvLckttH0wy2edM085jjznTC2fkk6j+L6jrwf4TVS20nTjfyKdOsCotbJgDphPJkkyfcnAyf4sYFW7a9tTLZg28hzHHnOjztn5JOox831HXg/wmqttd232+RzA+Da2Q/wCQTOTnzJM547569H6Doab5bm6db3tZbLo+/oWk0fTN0v8AxLNP/wBYn/MMJ/5bMPw9Mdx8vUVUstK057G4ZtOsCwa+AJ0w5GJyBz2wOAf4Rwatpe2u6X/R5P8AWJ/zB5z/AMtmHpxxxjuPl6iqljd2yWNwDbvndfHK6TP/AM92xzjgj1/g6Hmj3bgnWs9Zbro+z8g1vStOj0XUXj06wV1tbxlZdMKkEHgg9iOx/h6Grd9o+mBbjGmaeMSN00wpj9znv055x2PzdKqa3d2z6LqKrbuGNreAE6TOuDnjkjAx6nhehq3fXtqFuMW8gxI3TR50x+5z3Xj1x2PzdKFy3BOtyrWW8uj8vIoJFoF/qkKafb6TMINUe1uEj0wnY62zkoy9Rg4O09xuq/baPphls86Zp5zHHnOmFs/JJ1H8X1HXg/wmuJ8D6nZX3iDxDcRQuY18VzwlW06RyPLsVjI8teVG5ThTzgZ/hNdtbXtqZbMG3kOY4850eds/JJ1GPm+o68H+E0ly63MKdSvUpKV5bdn3l5FS20nTjfyKdOsCotbJgDphPJkkyfcnAyf4sYFW00fTN0v/ABLNP/1if8wwn/lsw/D0x3Hy9RVW2u7b7fI5gfBtbIf8gmcnPmSZzx3z16P0HQ1bF9as8ubd+JIxxo0/TzmHTbxx27/d6g01ym9V1r6OXTo+y8jxrxIiReItUjjRUjW6lVVRNgUBzgBf4R7dqKPEhVvEWqFBtU3UpA8sx4G8/wAJ5X6HkUVxvc/QKH8KN+y/I9rvnb+1dO/cT/8AH+ePOuM/8esnH3c575644xjmqcmj2F7r2g6rdWMsmoabERaS+fcKUEkbq+Ao6EAcYIGOO5C3lxc/2pYFk08f6cSuNYlIP+jOOW8vgdfm65+XpzUltcXgls8xaeMRx5zq0q4+STqfL+X6DpkD+I12prU/OZ0W4K6+z3Xd+ZneFNHsPDsS6Xo1jLbWEFraGOJZ7hgC08zsckE8sxPUgE/Lk8Vuox3S/upv9Yn/AC1m/wCezf7P4c855HzZFZFtPdC/k/d2G/7LZAg6rIAMSSf7HXrkfw9RnNYdr4tvJPiZe+GPs1oUj01NQ8wX0uA4vNm0vjldrg525B575oTVhV4qm0mt3FLVdl5nT6ezfYLj91MPnv8A/lrN/wA929V7d88H+LBo15m/sLU/3U3/AB6XnWWb1/3e3fPB/iwaq2NxdfYZwkdgw3X3XVZM5M7cY2c98D+McnFJrc90dF1EPHYBTa3gJXVZGPJ7DZyfQfxdTSv7puqT9snb7T6ru/M175iVuP3UwzI3WWY4/c+6/jzzjj7vNRXzt/aunfuJ/wDj/PHnXGf+PWTj7uc989ccYxzUF9cXhW4xFp5zI2MatK+f3OO8fPpnufl6VHeXFz/algWTTx/pxK41iUg/6M45by+B1+brn5enNNvQxp0nbb7L6rt6mhbM3nWf7qY/u4+kswz8knTC8fhkcHHBOKdqzf2lL+6mP+iWP/LWb/nrL/s9+2OB/Dk0W1xeCWzzFp4xHHnOrSrj5JOp8v5foOmQP4jVS2nuhfyfu7Df9lsgQdVkAGJJP9jr1yP4eozmhvUtUn72nRdV39TXRjul/dTf6xP+Ws3/AD2b/Z/DnnPI+bIqnp7N9guP3Uw+e/8A+Ws3/PdvVe3fPB/iwa5H4ha7qWmf8I/HC8Nut/4hsbSVrbUJJHaM3Duyj5BwQgBOeh/2yK6SxuLr7DOEjsGG6+66rJnJnbjGznvgfxjk4ov7xnFNuULbNdV1T8y1rzN/YWp/upv+PS86yzev+72754P8WDVy+Ylbj91MMyN1lmOP3Puv48844+7zWRrc90dF1EPHYBTa3gJXVZGPJ7DZyfQfxdTVu+uLwrcYi085kbGNWlfP7nHePn0z3Py9KE9S1SfKtOsuq8vMnvnb+1dO/cT/APH+ePOuM/8AHrJx93Oe+euOMY5qW2ZvOs/3Ux/dx9JZhn5JOmF4/DI4OOCcZ95cXP8AalgWTTx/pxK41iUg/wCjOOW8vgdfm65+XpzUltcXgls8xaeMRx5zq0q4+STqfL+X6DpkD+I0J7kypPkWn2e67vzC1Zv7Sl/dTH/RLH/lrN/z1l/2e/bHA/hyai1rR7DXbf7PqljLOkV1FcRMJ7hHhlWdyro6gMrckbgQeT3LCuQ+F2tX2qaZdzXFzDeXiT+TM9xevb7dl7cBVUBSCoTb0wFHTmu0S4vN0v7rT/8AWJ/zFpR/y2Y/88+eOc9h83U0J6EuPtY81tHy9V2Xmc9p3g/QR4a07TP7Ib7Do95d3dhEbi5IglS4cowyOdu48E4OfmwadrnhTSEl13XIbO+g1O7tp3uZodQvIxOYxtTzEUhHCgYwwwcndgk51bG4uvsM4SOwYbr7rqsmcmduMbOe+B/GOTik1ue6Oi6iHjsAptbwErqsjHk9hs5PoP4uppXXKaxw6VVJR05u67vzNe+Ylbj91MMyN1lmOP3Puv48844+7zUV87f2rp37if8A4/zx51xn/j1k4+7nPfPXHGMc1BfXF4VuMRaecyNjGrSvn9zjvHz6Z7n5elR3lxc/2pYFk08f6cSuNYlIP+jOOW8vgdfm65+XpzTb0Ip0nbb7L6rt6mhbM3nWf7qY/u4+kswz8knTC8fhkcHHBOKdqzf2lL+6mP8Aolj/AMtZv+esv+z37Y4H8OTRbXF4JbPMWnjEcec6tKuPkk6ny/l+g6ZA/iNVLae6F/J+7sN/2WyBB1WQAYkk/wBjr1yP4eozmhvUtUn72nRdV39TXRjul/dTf6xP+Ws3/PZv9n8Oec8j5siqens32C4/dTD57/8A5azf8929V7d88H+LBoS4vN0v7rT/APWJ/wAxaUf8tmP/ADz545z2HzdTVWxuLr7DOEjsGG6+66rJnJnbjGznvgfxjk4ovqJUnZ6dV1XZ+Za15m/sLU/3U3/HpedZZvX/AHe3fPB/iwauXzErcfuphmRussxx+591/HnnHH3eayNbnujouoh47AKbW8BK6rIx5PYbOT6D+Lqat31xeFbjEWnnMjYxq0r5/c47x8+me5+XpQnqCpPlWnWXVeXmT3zt/aunfuJ/+P8APHnXGf8Aj1k4+7nPfPXHGMc1LbM3nWf7qY/u4+kswz8knTC8fhkcHHBOM+8uLn+1LAsmnj/TiVxrEpB/0Zxy3l8Dr83XPy9Oaktri8EtnmLTxiOPOdWlXHySdT5fy/QdMgfxGhPcmVJ8i0+z3Xd+YWrN/aUv7qY/6JY/8tZv+esv+z37Y4H8OTVxGO6X91N/rE/5azf89m/2fw55zyPmyKyLae6F/J+7sN/2WyBB1WQAYkk/2OvXI/h6jOatpcXm6X91p/8ArE/5i0o/5bMf+efPHOew+bqaEyqtJ3enbquy8w09m+wXH7qYfPf/APLWb/nu3qvbvng/xYNGvM39han+6m/49LzrLN6/7vbvng/xYNVbG4uvsM4SOwYbr7rqsmcmduMbOe+B/GOTik1ue6Oi6iHjsAptbwErqsjHk9hs5PoP4uppX900VJ+2Tt9p9V3fma98xK3H7qYZkbrLMcfufdfx55xx93mor52/tXTv3E//AB/njzrjP/HrJx93Oe+euOMY5qC+uLwrcYi085kbGNWlfP7nHePn0z3Py9KwvFeqahb+IvC8UMtrCtxrJVxFqDSrIos5ThnZAVHGNwyeo7DLb0OWV6UOZrpbddbLv5nU2zN51n+6mP7uPpLMM/JJ0wvH4ZHBxwTjk7Twjoapr2mppcyWWsJbXV/HHdXSfaJJJZN7EryA+ANoO3GQM5IroLa4vBLZ5i08YjjznVpVx8knU+X8v0HTIH8RqpbT3Qv5P3dhv+y2QIOqyADEkn+x165H8PUZzQ2rm3sW+a66Lqu/qO8OaFY+H7eS20qC/jtlMMaRSaheTJEiTOFVA+4KMcYGOnduBZ09m+wXH7qYfPf/APLWb/nu3qvbvng/xYNCXF5ul/daf/rE/wCYtKP+WzH/AJ588c57D5upqrY3F19hnCR2DDdfddVkzkztxjZz3wP4xycUXVwjRai0l1XVdn5lrXmb+wtT/dTf8el51lm9f93t3zwf4sGrl8xK3H7qYZkbrLMcfufdfx55xx93muU1rxGWv9T8PvbwLdDSLq+Mg1GUoYmlZBtJQBmyp+X+Ick1v31xeFbjEWnnMjYxq0r5/c47x8+me5+XpQmrijC8VbvLqvLzJ752/tXTv3E//H+ePOuM/wDHrJx93Oe+euOMY5qW2ZvOs/3Ux/dx9JZhn5JOmF4/DI4OOCcZ95cXP9qWBZNPH+nErjWJSD/ozjlvL4HX5uufl6c1JbXF4JbPMWnjEcec6tKuPkk6ny/l+g6ZA/iNCe4pUnyLT7Pdd35has39pS/upj/olj/y1m/56y/7Pftjgfw5NXEY7pf3U3+sT/lrN/z2b/Z/DnnPI+bIrItp7oX8n7uw3/ZbIEHVZABiST/Y69cj+HqM5q2lxebpf3Wn/wCsT/mLSj/lsx/5588c57D5upoTKq0nd6duq7LzDT2b7Bcfuph89/8A8tZv+e7eq9u+eD/Fg0a8zf2Fqf7qb/j0vOss3r/u9u+eD/Fg1Vsbi6+wzhI7BhuvuuqyZyZ24xs574H8Y5OKoeJtdS1ibTbprFLq/tNQMCJqUzlgmCx/1e3oRgMRv+tK65S+S1ZN/wA38y7vzOlvmJW4/dTDMjdZZjj9z7r+PPOOPu81FfO39q6d+4n/AOP88edcZ/49ZOPu5z3z1xxjHNQX1xeFbjEWnnMjYxq0r5/c47x8+me5+XpUd5cXP9qWBZNPH+nErjWJSD/ozjlvL4HX5uufl6c029DKnSdtvsvqu3qaFszedZ/upj+7j6SzDPySdMLx+GRwccE4p2rN/aUv7qY/6JY/8tZv+esv+z37Y4H8OTRbXF4JbPMWnjEcec6tKuPkk6ny/l+g6ZA/iNVLae6F/J+7sN/2WyBB1WQAYkk/2OvXI/h6jOaG9S1SfvadF1Xf1NdGO6X91N/rE/5azf8APZv9n8Oec8j5siqens32C4/dTD57/wD5azf8929V7d88H+LBoS4vN0v7rT/9Yn/MWlH/AC2Y/wDPPnjnPYfN1NVbG4uvsM4SOwYbr7rqsmcmduMbOe+B/GOTii+olSdnp1XVdn5lrXmb+wtT/dTf8el51lm9f93t3zwf4sGrl8xK3H7qYZkbrLMcfufdfx55xx93msbxBeSQ6Bqkt42nwWqWd40sv9pzSeWmcltojJbAycD72M9atXN5dTQSyRR6eyO5ZSNVlbIMHBwY+fqe/wAvShPUSjtHrr9pd15lq+dv7V079xP/AMf54864z/x6ycfdznvnrjjGOaltmbzrP91Mf3cfSWYZ+STphePwyODjgnGfeXFz/algWTTx/pxK41iUg/6M45by+B1+brn5enNSW1xeCWzzFp4xHHnOrSrj5JOp8v5foOmQP4jQnuKVJ8i0+z3Xd+YWrN/aUv7qY/6JY/8ALWb/AJ6y/wCz37Y4H8OTWYPCWhNpuvaa+j+ZY6xdm6voXmuGE0rzHcxyCQflXGMYK5X5sgYHhHXtau/HvjPTLx7N7fTl0oW0Ul6YvKV4y7AOse5xkk/N9zJ212SXF5ul/daf/rE/5i0o/wCWzH/nnzxznsPm6mhNEOPtryt1tuull38jK8K6DpujQarcafYTJdXst4bq5kuLmWWbZKVXe7gswVRjBOOSTgk51deZv7C1P91N/wAel51lm9f93t3zwf4sGqtjcXX2GcJHYMN1911WTOTO3GNnPfA/jHJxSa3PdHRdRDx2AU2t4CV1WRjyew2cn0H8XU0r+6dEaNqysvtPqu78zkdclZfj7Zjym+fQblSGZyy8oc5Zd3b244J25r0C+dv7V079xP8A8f54864z/wAesnH3c575644xjmvNdWuLg/tCqqGylb/hF5H2fbHZEYzFTiXbuYkKvBGOce9d/eXFz/algWTTx/pxK41iUg/6M45by+B1+brn5enNDehx4WHNz2/vLdfyrz/H8TQtmbzrP91Mf3cfSWYZ+STphePwyODjgnFO1Zv7Sl/dTH/RLH/lrN/z1l/2e/bHA/hyaLa4vBLZ5i08YjjznVpVx8knU+X8v0HTIH8RqpbT3Qv5P3dhv+y2QIOqyADEkn+x165H8PUZzTb1OpUn72nRdV39TXRjul/dTf6xP+Ws3/PZv9n8Oec8j5siqens32C4/dTD57//AJazf8929V7d88H+LBoS4vN0v7rT/wDWJ/zFpR/y2Y/88+eOc9h83U1Vsbi6+wzhI7BhuvuuqyZyZ24xs574H8Y5OKL6iVJ2enVdV2fmWteZv7C1P91N/wAel51lm9f93t3zwf4sGrl8xK3H7qYZkbrLMcfufdfx55xx93msjW57o6LqIeOwCm1vASuqyMeT2Gzk+g/i6mrd9cXhW4xFp5zI2MatK+f3OO8fPpnufl6UJ6gqT5Vp1l1Xl5nnfwjc/wBseKQI5CR421A7VeUEfuH4yF3Z+vPB45OPULZm86z/AHUx/dx9JZhn5JOmF4/DI4OOCceT/CWVhrfip4PIYHxnfkGa8eHP7mTGWAJ7n5vXA/iJHpltcXgls8xaeMRx5zq0q4+STqfL+X6DpkD+I0ovc5qEHKhFrs+q/ml5has39pS/upj/AKJY/wDLWb/nrL/s9+2OB/Dk1cRjul/dTf6xP+Ws3/PZv9n8Oec8j5sisi2nuhfyfu7Df9lsgQdVkAGJJP8AY69cj+HqM5q2lxebpf3Wn/6xP+YtKP8Alsx/5588c57D5upppnTVpO707dV2XmeOeJ+fEurEgj/S5uCSSPnPc8/nzRSeJCW8RaoW27jdSk7JDIv3z0YgFh7kc0Vxvc/Q8P8Awo+i/I9rvrmX+1dPP2+DP28nd9oTGfssgzny+nbOMZ4xnmpbaeQTWZF5Cu2OMAmdBtwknB+TjGcc5xkdcgiveWt+NWsAb/Vyx1AgEra7gfsr8j5Mbsfhg+tPtLS+8+w26jq2fKi27Vtc42S4xlOnXGecZzziutPfQ/OJRhyLWPw+fd+RBazyDUpQLyEYtLEY89OMSy4H3O3U+nfd0rzDQriWT9pzxCZLtZPK0ZAjeerCMfaYG64woyS33R97djnn0u1tb37c6i+1Xi0sDuC23I82TaOU6Z6d8k7uMV5Z4Ps7l/2g/Fd60lwskqy2gnVYxIWiksD3GwthxnjHPQChMxxnIqkEmt4/kt9D1fT55DYXAN5CcvfjHnoc5nbI+536j17belGvTyHQtTH2yE5tLwY89Ocnkfc79R69tvSo7K1vWsLg/btVUZ1AEbbbH+vO4n5M9eWx3+7xXEfF/wAcjwZZ29nLc6re3N8LhJ4v9HC21s0oRppNsZOC7BQPl3HOGXAyX93Y6ZypUqnPJxspPv3fkej308jLcZvIXzIx4nQ5/c4zwgzxx254681FfXMv9q6eft8Gft5O77QmM/ZZBnPl9O2cYzxjPNJqFretHck6jqpBkY5ZbXB/0c9cJ6enGPem3lrfjVrAG/1csdQIBK2u4H7K/I+TG7H4YPrQ3psRCMLbx+F9+3oWLaeQTWZF5Cu2OMAmdBtwknB+TjGcc5xkdcginazyDUpQLyEYtLEY89OMSy4H3O3U+nfd0qe0tL7z7DbqOrZ8qLbtW1zjZLjGU6dcZ5xnPOKqWtre/bnUX2q8WlgdwW25HmybRynTPTvkndxim3rsUow97WOy7/zeh5x8dLxxqHgaAyLIX8SW0u5WDY2ySdwB1356d88dB6Xp88hsLgG8hOXvxjz0Ocztkfc79R69tvSvIvjvb36eL/h9ve+ubcaqZ5WlSM+UEuo03HywABumUZP8TYHavWbK1vWsLg/btVUZ1AEbbbH+vO4n5M9eWx3+7xSv7xhSUHUqareP5S8iTXp5DoWpj7ZCc2l4MeenOTyPud+o9e23pVy+nkZbjN5C+ZGPE6HP7nGeEGeOO3PHXmuQ+J+tXXhjwnNP9tvJ7y9eWws7W6+zrHcTSyhdjMqggY3Mx3L907WHWmeA9W17xL4XvbrXL25TUbfUbqyuFtYoEi3xIyfdZSwOByM4xnHOKaeuxSnT5lT0+1rrbppt5HW31zL/AGrp5+3wZ+3k7vtCYz9lkGc+X07ZxjPGM81LbTyCazIvIV2xxgEzoNuEk4PycYzjnOMjrkEV7y1vxq1gDf6uWOoEAlbXcD9lfkfJjdj8MH1p9paX3n2G3UdWz5UW3atrnGyXGMp064zzjOecUk99C5RhyLWPw+fd+R5l+z6Db+HdQMNyiQy3e9N8ioSou5wDgqemMnHA9+lepJPJul/0yEZkQ/69Of3zHP3PXn6HPIOBwvws0ltP07ULDTrm/ihtb2SENF5JLhdTu1UtvU84UY2gDPXiu1jtL7fP/wATHVv9bHnC2vX7Q/X5Ouc+2c54xRF6bGcIwdNXa+zv6LyINPnkNhcA3kJy9+Meehzmdsj7nfqPXtt6Ua9PIdC1MfbITm0vBjz05yeR9zv1Hr229KjsrW9awuD9u1VRnUARttsf687ifkz15bHf7vFGuWt6uiakzX+qsotL0lWW2wRnkHCZx645/u0X93Y6lGHtlrH4n37vyNC+nkZbjN5C+ZGPE6HP7nGeEGeOO3PHXmor65l/tXTz9vgz9vJ3faExn7LIM58vp2zjGeMZ5o1G0vtlzu1HVv8AWtnetr1+znrhOuPTjHvTLy1vxq1gDf6uWOoEAlbXcD9lfkfJjdj8MH1ob02MYRhbePwvv29CxbTyCazIvIV2xxgEzoNuEk4PycYzjnOMjrkEU7WeQalKBeQjFpYjHnpxiWXA+526n077ulT2lpfefYbdR1bPlRbdq2ucbJcYynTrjPOM55xVS1tb37c6i+1Xi0sDuC23I82TaOU6Z6d8k7uMU29dilGHvax2Xf8Am9DQSeTdL/pkIzIh/wBenP75jn7nrz9DnkHAp6fPIbC4BvITl78Y89DnM7ZH3O/Uevbb0qeO0vt8/wDxMdW/1secLa9ftD9fk65z7ZznjFVLK1vWsLg/btVUZ1AEbbbH+vO4n5M9eWx3+7xRfXYFGFnrHdd+z8iTXp5DoWpj7ZCc2l4MeenOTyPud+o9e23pVy+nkZbjN5C+ZGPE6HP7nGeEGeOO3PHXms/XLW9XRNSZr/VWUWl6SrLbYIzyDhM49cc/3at6jaX2y53ajq3+tbO9bXr9nPXCdcenGPehPXYFGHKtY7y7+XkF9cy/2rp5+3wZ+3k7vtCYz9lkGc+X07ZxjPGM81LbTyCazIvIV2xxgEzoNuEk4PycYzjnOMjrkEV7y1vxq1gDf6uWOoEAlbXcD9lfkfJjdj8MH1p9paX3n2G3UdWz5UW3atrnGyXGMp064zzjOecUk99CZRhyLWPw+fd+RBazyDUpQLyEYtLEY89OMSy4H3O3U+nfd0q4k8m6X/TIRmRD/r05/fMc/c9efoc8g4Gfa2t79udRfarxaWB3BbbkebJtHKdM9O+Sd3GKtx2l9vn/AOJjq3+tjzhbXr9ofr8nXOfbOc8Ypp+RVWMLvWPTv2XkQafPIbC4BvITl78Y89DnM7ZH3O/Uevbb0o16eQ6FqY+2QnNpeDHnpzk8j7nfqPXtt6VHZWt61hcH7dqqjOoAjbbY/wBedxPyZ68tjv8Ad4o1y1vV0TUma/1VlFpekqy22CM8g4TOPXHP92lf3djRRh7Zax+J9+78jQvp5GW4zeQvmRjxOhz+5xnhBnjjtzx15rlfG8rv4w8FFriKTGtO3mCVSFP2KXnIQADjrgj5enBz0uo2l9sud2o6t/rWzvW16/Zz1wnXHpxj3rzT44a43g/WPB+tXt9dStba6GaO7jjP7owBZWBiA5CsODnqvHDAtvTY8/EqCo3TW3T1XkeoW08gmsyLyFdscYBM6DbhJOD8nGM45zjI65BFO1nkGpSgXkIxaWIx56cYllwPudup9O+7pU9paX3n2G3UdWz5UW3atrnGyXGMp064zzjOecVUtbW9+3OovtV4tLA7gttyPNk2jlOmenfJO7jFDeux2KMPe1jsu/8AN6Ggk8m6X/TIRmRD/r05/fMc/c9efoc8g4FPT55DYXAN5CcvfjHnoc5nbI+536j17belTx2l9vn/AOJjq3+tjzhbXr9ofr8nXOfbOc8YqpZWt61hcH7dqqjOoAjbbY/153E/Jnry2O/3eKL67Aows9Y7rv2fkeey35ufi542Tzo1a38NmAsZF/eBpHc4O3nO/oMZ7Yr1K+nkZbjN5C+ZGPE6HP7nGeEGeOO3PHXmvEfDsr3Xxn+LRhuLjcmmlZGj8os/loqOHyMdQd2zBz0xXp3xF1ebwp4V1nWb3UdSK2zNsSZLcrLM0G2ONtiZ+ZiqkjgKc5BGaSer0OajKHsnNtbyf5eRga38Rp4vGyWtjZyXunWOrWtldX63CoI7mdGiyv7kh0RSoY8cyKAP4j39tPIJrMi8hXbHGATOg24STg/JxjOOc4yOuQR4r4/0LVfh/wDBXy/tVxPqUOqwXt60Yi8qe53LM8hO3exyoILZG1RkZGB7JZ2t6ZrApqOrHMUW0qtr02S4xlOmM4zzjOecUJ76Cpx921SUdY3Xprpt0IbWeQalKBeQjFpYjHnpxiWXA+526n077ulXEnk3S/6ZCMyIf9enP75jn7nrz9DnkHAz7W1vftzqL7VeLSwO4LbcjzZNo5Tpnp3yTu4xVuO0vt8//Ex1b/Wx5wtr1+0P1+TrnPtnOeMU0/I6qsYXesenfsvIg0+eQ2FwDeQnL34x56HOZ2yPud+o9e23pXmnj+4ll+LmjwtcwlYdC1OdT5y87/MU4+UZzt4AGTyeB09HsrW9awuD9u1VRnUARttsf687ifkz15bHf7vFeI+Jr03X7RtxaCe8eex0W7gldlj3ljHNKQcDbjbIASAO+OcGpb90isoqrGzXx/q/I9+vp5GW4zeQvmRjxOhz+5xnhBnjjtzx15ryH4u+ONa07xa7eH7m5mXw2I9RvRbvG0c0kqqBE5MYx/o6ztuAP3hxkZr1XWIri3tr2a71bUoII3d5ZZ/sqogFuSWYhOMLkk9NvvXmfhbQbvxZ4Hur+9kv1ufF+oXd00RjhHlpJbTLCuSNxxEEI5wA5xhuacnoc9SMZWhFr4W9PJenc9VtrhvOs2jv7cqI49ridQANkmOSnHXvn7w65BFO1nkGpSgXkIxaWIx56cYllwPudup9O+7pXPfCW5uNZ8DeE7y21PU3U2MEX7tbfho0ljZRvTPBVhz6NyflJ3bW1vftzqL7VeLSwO4LbcjzZNo5Tpnp3yTu4xQ3todNPklBtuOqj37ryNBJ5N0v+mQjMiH/AF6c/vmOfuevP0OeQcCnp88hsLgG8hOXvxjz0Ocztkfc79R69tvSp47S+3z/APEx1b/Wx5wtr1+0P1+TrnPtnOeMVUsrW9awuD9u1VRnUARttsf687ifkz15bHf7vFO+uxSjCz1juu/Z+Rynx01mXTPhV4gkW5jkaaCW1CrIr8SzIjdEGMhievOMjHQ9dZmaHQ4IJZ0R0jVWjMq7gRbbSMbM/wCz168dfmry79qBb63+GccZubydbrUHgK3Cw4ABeUkeWoOf3POTjnjivVbm0u/ssu2+1NE3nC+Xbqo/0fpgpuHH/jv+1QnrsclNQddq60X6+hyPxQnvtX1XQfDWm6zc2dzf6ibm4vLKfDQW0UOJH8xUHl7i6RhjxliNp72/hXrF5eaQ9rfanLPeaNqNxpMtxdTIHYwtKEJYx/N+7eMFyMknnk8Y+g282ufGDWNejluZVsbmLQrW/iMBmLJbzS3CsMeXkO6LkLjCf3uTN8OLa8svG3i3SIp7+FFvLXUo5Ilh3y/aLQgk78rwYmxgDjOf4QEmZ8qvGd1Zpr0Wv4XX47Iq/Dy4Y/FX4lFJo4OdGGGdUzthIzgqc4xnP4nPSvSEnk3S/wCmQjMiH/Xpz++Y5+568/Q55BwPO/h3BdP46+ICw3N1Eq3Wl5NvHb7nPkJgszrk+oA4BJ45Nd/HaX2+f/iY6t/rY84W16/aH6/J1zn2znPGKafkbUIw5Hdrfz7+hBp88hsLgG8hOXvxjz0Ocztkfc79R69tvSjXp5DoWpj7ZCc2l4MeenOTyPud+o9e23pUdla3rWFwft2qqM6gCNttj/XncT8mevLY7/d4o1y1vV0TUma/1VlFpekqy22CM8g4TOPXHP8AdpX93Y7VGHtlrH4n37vyPMbe5ku/2ofERMyObbQPL80SAg5ER+8FAP38dB6dea9ZvrmX+1dPP2+DP28nd9oTGfssgzny+nbOMZ4xnmvKdPd3/aC8U22+4N2tnNvvMRCZlNtZYVsLswu1h06Mcc8n1O8tb8atYA3+rljqBAJW13A/ZX5HyY3Y/DB9aV9Njz8EoNTu19r8vTb+rGfr3izTPC1vYXmuazb2UBEUaM0gY52uAMLGTxnng4B5PcXLWeQalKBeQjFpYjHnpxiWXA+526n077ulebf8I/8A8LC+IWr2WrXN7c6Xo+mx6TCWhiV45rmIvI8bhdpKogU5BID+uM7PwevrrXfBWjXcV9qgK6bYW7lfs7HdFNLFj5kz95CRnnJO4kYNNvXY1pzUpzi+W2nfpJeR3iTybpf9MhGZEP8Ar05/fMc/c9efoc8g4FPT55DYXAN5CcvfjHnoc5nbI+536j17belTx2l9vn/4mOrf62POFtev2h+vydc59s5zxiqlla3rWFwft2qqM6gCNttj/XncT8mevLY7/d4p312N1GFnrHdd+z8iTXp5DoWpj7ZCc2l4MeenOTyPud+o9e23pVy+nkZbjN5C+ZGPE6HP7nGeEGeOO3PHXms/XLW9XRNSZr/VWUWl6SrLbYIzyDhM49cc/wB2reo2l9sud2o6t/rWzvW16/Zz1wnXHpxj3oT12BRhyrWO8u/l5Hk3wLuVF/r4S6SP/irLqRiZFXrBKM/MpB4H6+4I9et5nWe0xewjbHGA3nqAuEk9U4xnvnGR1yCPCf2XYLuXw+bhbi5SS41pnJthEWybWQ5JkB5+917Fu+017hbWt6stif7R1UYiiIIW16bJemU6YzjPbOecUovc5aEYuhFtrZ7+svIz01i2t/EcGny6vZJfXdlatBbG6j8xlieRmO3ZkBQSefRuW2kDWSeTdL/pkIzIh/16c/vmOfuevP0OeQcD5ySCS4063+JE0LWt/wD29Y36Xc8iqw07e1tHG+cAcR7iVwrBueFXH0RHaX2+f/iY6t/rY84W16/aH6/J1zn2znPGKafkOFRVHLnsvh+7p0fRI8V8Tkt4l1Ziwcm7mJYEEH5zzkAZ/IUUeJwy+JdWWRpGcXcoZpNu4neeTt4z9OPSiuJ7n6dh/wCFH0X5HtV9Yr/aunr9ln/4/wArjy7fP/HrIceme/pj3qW2tFaazH2eY7o4zgJDzlJDxn6d+eDnnFeaS+PvBE1zbzW2nl4FufNOzw5NiWMwsowMcjcVbB+vXikufGGkTYs/DHhGfVdeEapDZyaE0KFwj/NK0m0BOmT1JA44rsUnqfmksTQ5Eufp2835noFraA6lKfs8xzaWJyEh53Syjv69u5/i4rxv4dwtF8XdT2pcyfadV1mORCyYQLc2wHy42n7qrjoOO1bGmeLbDRLxbP4l6DYaDeP5UUN4mmGTT7lVkYiWOTJZSynBDDooJIzheQv5mtPFHgu58N6TbeITd6z4gngsYJEjhuovPwCrEFdm2PcOvCj2pXZzYqvTqTjKLejV9NVZLzPebK2SLTbqR4ZUVGv2LMkAChZ25J9B37j+HivJ7vw8PFngvx14zvIZBHq2l3P9lK+AYbO3O9CQQuPMkXzMBeAUwcFhVhNC8SeNdOFnq/h7T/CukeZdNevauZL2dQ75hR0TakYbajZP3eMgEg+k6npmnWejXT2+naerW1nciLOl52CPAQc5GFAAGeFAwaetjoqweJquOqV3unu79L7L+kLotzHrPhew1aOKRlvYI7nd5USAb7USYxkkYJzjJ+pbmr99Yr/aunr9ln/4/wArjy7fP/HrIceme/pj3rybRLa58AaRdaJqfgTUNU0y2v54tO1CwsY7yeeN97IJUZ1dCqsO2MgenOuLzxJcX9u5+GOj2ifazshuLhVeX92wCsscThRsy+3JwVzk8AjbsKjXgopXd+V3XL5ep6PbWitNZj7PMd0cZwEh5ykh4z9O/PBzziqdraA6lKfs8xzaWJyEh53Syjv69u5/i4ri7K18W2traSXfhDwXqFyiITFamaLzh8+MB4CAdpyTk5MeR6Vzsei+PtP1RtS/s/wzrI8qFpNChtPJjCMdsRinePJclXL7iFI4BbOFbbuae3S5tJdPs+fqRfGu8EXimyti1xCmmWQv3Eapu2vq1pHkqpAcfuuFPG5R0ABHren2iiwuD9nmGHvzkpDxtnYdvTvjkfw8V8+/FnTb26g8V+Jv+EduNCtLLSLWzRZ7WONjO+opLuTy3YDC/LuzxgoeRXc6b4J17xDpFvea3rcGkxXNnJNLYaRoqRSQSEhmQzuHdWUkqcY2EY+XpSTfMc1GrFTmo3d2nt/i89Nya9hHi7xp4guTAx0jwna3cFtJE0ZE166ZkLFflIiRlQryQzkg9hf8Fwiw8Z/EXRWBeSHVBqPSMuBc2vmHP0K/w8dcc7a3P+EW0TQvCVzZ6bplnHHb2V2EdtPYyEg8MXPJb/aP3e9Y3jTwhdweJU1/wnZaU8rI9leWF3bSQW0qmPMU20K2GiZnY9GK5wRxRre5py8kYVHdu8r2XotNfQ7i+sV/tXT1+yz/APH+Vx5dvn/j1kOPTPf0x70qxQwi3luI3jhWFJJHZYAoXZIS2Txj5c5bsDnnFecN4V8YG7tTdah4Whnkm8sQweHHeMSeUzHOSCVCg4GOTglf4qUfD3VtYe2s/EOt2KaTIUM66Vo5tJ54tkn7syhshW5D4zuUdcZwJvXQqdf93on8Pb1/vFXwL458JhtQe71eK3W6vrmS3luYhDFKn9oXEhKyzKEPyTRnAbPJ3DAOOs8S+M/Cfha4lh17VILScMjeRiF5QvmMclFBYZXGOMH/AHcVx3wI0vT9T+GFlDe2NrPDcWiJIJLJnLK17cqQWHqAo9wAo5Fd94S8I6D4T88eH9LtbNzIgMq2cjykecwwXYlscD5Sf9nqDTjexmvaxilFpq0ej7I5S1+J/gSDTpmOtRu5knCpFAkjsZZHaLCIpboOSB8pIHy5Ap+p/EvwHc6HP5WvQE3NvIkarCsjhpQTHmNELjAB3cZU4HGRnudPA/sy+TZHtme/81fsTgP++K/Nz6cZP3Rwai1u3gj0DV1SC3VZba7kkC2DLvYNkMfcHoT93vS15TdOu6yu0nzdn33OKufi98PZNyWesTTSSSERxppzb2yhUDaIwfvc8DGOfvVDqXxQ8Ni/smi0vxLLtuPOVF0UBpFaJ40VQUAJdyu0fdO4dGzj0rVUSaG+jmjhkjllJkVrFwHIgGM5/wB1eD0wG6Cs+80nTV1SxVdN08K18VYDSjgj7M5wV9MgHb6jdTlexFNTa1nbR/Zv09Tzrwr8VbO9h0Yap4f1n7VPZtcXI06xW7SAJLPD82F3fM0XGQcZ5Jxkaf8AwsPwta3sj3Y1mF2gtozG+iyhgyM7P1i6EMMdz34rk/gB4df/AISvxpPfwJPp1vqsmnW6zwfaFDRtM7DYPTzFPQfeJHQ16vbaTpxv5FOnWBUWtkwB0wnkySZPuTgZP8WMClduxnhnUqU3Jza2+zfr6nNx/FHwCbeSc64qjz0iMJtcTq3mMSvk+X5h+XAyqlc8E4wKq2fxO8BxW88f9r3JYG5dmGkzYj3yF4937nI+U8+mOOK7e00XSre9urq30vTormULBJKmlkO8ZnbKEjnacD5T1wF6iq1lpWnPY3DNp1gWDXwBOmHIxOQOe2BwD/CODTd7msY1GnedldfZ8n5nIah8TPBd7ptza2l5fyXd1DcR20I0iXdOzfcK/ueRg8nqO2BTrv4t+BcsBe3yAhpWZ9LdRCuzaN/7vjMhC5Hy++ea7DWtOsYtA1NYrGyQfZruTC6cV+ZSdrexGTg/wZI71durCyhV/JsrOPyZ2kj2ac0exvJByv8AdPyqfXIDdBQua41GfKvf6v7Pp5nDN8RvDN5LHeW9n4heytrnz/OGhsVlgMTJ5qkR427mz82OATjdXLeHPizeRazPpnifwvqU2qh0aHT9E09ZpooPJV8Sq5yZB5q7jgDIbIGBj1m80nTV1SxVdN08K18VYDSjgj7M5wV9MgHb6jdXk/g7RY7j9pXxPcTWUMlhDplrFslgMqhmt4dv7sdeI3x27+hpamFdVIqFpt3X8ttNfPXqdHbePtMW+M1z4c8XwQNFbRPLJoR2xlXcuzYUnGGHqTg5zU//AAtTwHEJjc6tNbOpVzFcae0cgXzT0VowWOCOEz3yMAV09tpOnG/kU6dYFRa2TAHTCeTJJk+5OBk/xYwKsnRNKkkDSaVpzmCUGItpefLLSsrbf7uQACO4AXqKaub1YzT0nfb7Nui8zj4fiJ4LtIJIZr++SVjcSKDo044lfzIj/qM42sDntn5eKj1H4keC7nTLu3+238M8sE8arLo0w2s33M4hPGOuOR2xXV2Wlac9jcM2nWBYNfAE6YcjE5A57YHAP8I4NGt6Vp0ei6i8enWCutreMrLphUgg8EHsR2P8PQ0teU0UJ+1S9o7838vm/M527+IOizbDpejeKdQt5pW/0i30J/LiTy8B2yikjOThAThWOAcZ87+J3iLQfHmuaPoeiQTz3pXU1kt7uyaGS2lFkyqjLhRvEmTgZwUB4z83uN9o+mBbjGmaeMSN00wpj9znv055x2PzdK4fxpaWyfGr4bQx21usJbVIzGlgyqV+yIdpTuuWY7f9pj/FTd7HFiIv2S99v/t23VeZ0/w9vh4j8K+HNUdTcS3lnA8zQxQhTLskEgAIxw6sOf7p9FrRtbQHUpT9nmObSxOQkPO6WUd/Xt3P8XFcCPhWV1UDSPEdxpujX0gup7GPRopWjZw5ZYJGBMaHBwApUHkDqAmlfDNLK6kW08VeIHmFtbsHvrWG9A8zcgGJYW4Xy1IwfmGVGKTbN6dSUYtNPZX0815q9/kelpaAtL/o8xxIg+5DxmZh/THHGRz8uKp6faKLC4P2eYYe/OSkPG2dh29O+OR/DxXBSfDbU5jNZv4rlOlyOiyldCgS7Cl5FYRzKg2ZJB+7kbQoPBqr4f8ADvivQLLylg8M+KLCBLiHdf2UtpdsUkKlt4R1PIxljkccjmnd32LVayaaluvs+T/vHIfDGFZvFfi/USA6ahol/fqYwhRR9uuFyN38PydRzXeNCPiD4li1OzjZvBOjTs9tL5cam/v0R/3iMvWGLHBGAzZxuxx5FrXhq60S0g8LXLquqT6FaWW9QcrLNqshcAnkcO6k8ZGR0OK+lrvRtLjhkRNM09UiPloq6YUCqtvhVGfugADA7Y3dKSvc4cI+f91N2Su3pfXTTfyKXjrQ5dU0m60y1gmSe8NzaRkrCuGexlAyV56nPHGPeqXwr1FPEvgrw1qPlySyS2kUcxWKEbpUWRJDgju0ZPPof9mte80nTV1SxVdN08K18VYDSjgj7M5wV9MgHb6jdXJH4Z2i6lNcaLrF/pQ1CRbqa3TT47mBZWRyzJHLG2CSBnaQp44wgwK+rOyrpyzjd+7Z6eb6X/U7G1tAdSlP2eY5tLE5CQ87pZR39e3c/wAXFXEtAWl/0eY4kQfch4zMw/pjjjI5+XFeXyfCTTbrVmkHiXxXGwS3uCFMYT947DaFEIXA2nHGGyABxVt/C3i2zO2wu/CepBSkbG/8PPCfvld37tjySCSOAfugcbQ032LqVddU+nTyX947nT7RRYXB+zzDD35yUh42zsO3p3xyP4eK8J8U6XbxfHVr2HLyS3GqW7gKmR5WkQMAcccGRgQOmDjmuxOl+LtJtPtkGmeHPEsRFwk9mNMNjMjCTazRSMWUgNk/NjCjACkgDjtdOo6P4z8O+I/EGkW+m380mu6gLKKDd5EcGnxJEm4EgkCAMMHCMSeOlTq42MMTX9+M7PSV7NW6+rO68aXcnjS9uPDHheCSbSFuDHreqLtjSFUUM1rG8eA0jKrBwpKqr8gsTj0C402KG/0uCK0nWNL7ylXZBkAWjkD0z39Me9cX8LtB023+FugbrC1eSS0SdnlsvMctJb+YTv8AqxOO33u1dZeaTpq6pYqum6eFa+KsBpRwR9mc4K+mQDt9Rupu9jXDpW529XF9PL1OT+DUUCQazotvbKltpOtXFtbwRLGWWB988e4P7SYBPB2HrgV2FraA6lKfs8xzaWJyEh53Syjv69u5/i4rjte+HsuoeIYdV8PazHolzd21vHdq2hpepN5cbrGwWQHBCjadvDAA4BUms8eA9flv5dvjG1TckEhjTwlBtRHkYKELM3IweTktwCW7DbRNKbpxcGn06dL6dUempaAtL/o8xxIg+5DxmZh/THHGRz8uKp6faKLC4P2eYYe/OSkPG2dh29O+OR/DxXDXXhTxVY3M/wDYt54c1S3aYbV1nQ9kkamQgfNAqhjkHjavB284wKlv8O9S1OzvbjVPF+rWk7/aAtto1u9naxGOQqwMfIcMc5LdFwvAAAd3fYp1nZqMXut1bo/NlX9oRoUs9H06WKdRPDrNyFZIwhMNlMASUIOQZBwQR1xgcHo/GPiKWCOPQfDkMl14svoPOh/cwtFZxmJA1zPgEoi79wypDEAYJJxxfiPwl4gttC1q/wDEJ0Z49K0TVYYLuytGgku/MUKGkj8sKjAK2cMQNyqAOSd/wBZQatrvjvV7m3tplbUY9OG6HzgGtrPacEcDlvw6/wAJpK9zgi28Q46pS8tbel/1Or8M+ELXwrp2haNbQ3cwgvWEksiws8sjW0juxJzyWJOCSAMdxWY8cWl/F3QIvKuVHiHSnDITERLLbgMhVTxwkshO4Z6Y5znpLzSdNXVLFV03TwrXxVgNKOCPsznBX0yAdvqN1ZPiPwLoniaws7K4hfT3AhkjvNNtWhuIjtk3bWAO7cuVOQQwOcfLkCud1aC9lDkeyX2fN+ZmfDu0SXxX48l+zTM51CxQyKYmUj7PF8uGGQeTznByMgYOe5S0BaX/AEeY4kQfch4zMw/pjjjI5+XFeP8Aw+8K3Op3Hi43niC+82DWFiSSPTbWRCTFEASrQsFwCg2rtDBQABmtyPwN4ihecReJtMnTzgV+1eFYiwHmOApKFR15PyjoFHQimm+xjRqWg7p79r9f8R3Gn2iiwuD9nmGHvzkpDxtnYdvTvjkfw8Ua9aKNC1M/Z5hi0vDnZDxtOO3p37j+HivP28HeJLqzlMHiDRbcD7SCy+FlLZVyrcs5A+bp/dGB8vSqupfCt9MhvNV0vxVqzXywzyTJqFik9tIqcMqxBUEZY4IZSCnI6nNK75TrVb96pWl8T+yu+3xEHhiCNvjL4juQp+eXUrcARoxBiisOD/CuMn7vPBArovFfjXRknitvC8kOu68Loi20+zNvMWYwmMbygKoodwWLEKAD/FXnfi/whdadrXhfw9PckyeINQ1O41UWaG3ieMi2maKNCAyR7YkGCSflPOCBXtEfh3RdMurK007R9LtbaTUP3kUWkFVfbayY3KOuOuDzn5qNbHBhPaLmitFr0u9u3oVfh74TPhzRrO0ufOvNRu3+3X9yPLf7TcyiRpJBvHQ4AGQDhBkZxXKfBZoo217w9NAY73R7pYfKVYxuikuppUkVX52ssy4wMdM8V6BbaPphls86Zp5zHHnOmFs/JJ1H8X1HXg/wmuN8T/DnSPFGt2VxJcX2lS2VlbIr6Tb+Q0iySvuVyVYMMqCOME5x3pu+h1ezUP4b2S6dL+u97fid8loC0v8Ao8xxIg+5DxmZh/THHGRz8uKp6faKLC4P2eYYe/OSkPG2dh29O+OR/DxXntv8GNKWV2n8ReKLgKBEqvKyAZdk3fIqncMbuc5PHOCKh0b4S29pbXM9t4q8SGYfaVX7TDHOgMUjIpIkiI56t0x0OOMF3c1U/de+66eT8z0jXrRRoWpn7PMMWl4c7IeNpx29O/cfw8VPrJh0qzvr6a1fyrQvK4kECrtSAuQSBx0zxxjn71eZ6p8O9VksZptW8VytFZQzXEX9laMunSSSRtkF5EywGeMKQFwOhputfDXWLNdZtdE1q3udLvleNk1qwluJ4GaEhjHMTvHB4DE4IDeppXdzKdSTp2Sdve6a9Ol9vn8jK/Z4sYo7BIIEaaL7baSYjVCA0ml72HzjruJz24P+zW3471GDxZqmn/Dvw1Nv1DUYw2r3ESqxsrVVy4BXgNJnZ85PUBsZU1xPg3wTPd+O9T8KalNO/hrTpYbWeSGOWKS8m+xKArbfm8vbCSYwwOXUncBx7P4b8H+HdDjgttL0XT4IZhFJIDpzyb22S4LZJL4ycducjABoV7Oxy0/aToxjskvO+7/4Y574k+GYtS+HniTS7KyukVNEs2toLaOLrG8jRooALEExqoA+Y9D2rpPBVy2u+EtI1aeAGa+tLW5kFukWxWkYllGeRzlceoweMU+z0vTxqLYsLEbbWydf+JaThjLJk59TgZP8WAB0rhbf4fa1obXNj4VvdF/sYShoI9U0hp5oMy42BwBld28gNk4wmWwcCujrrWp1LxvayWi7JW6+pgeJ12eJdWQKV23cwwQAR859OPy4orB1Xw3qcGqXkNx44uhNHM6P5Xh+BE3BiDtXzRgZ6DA+gorla13Pt6OZSVOK9hUei6L/AOSPfby6tW1Sxxbthb45B0accfZn4C4yeTnb1/i6VJbXtqZbMG3kOY4850eds/JJ1GPm+o68H+E1PfO39q6d+4n/AOP88edcZ/49ZOPu5z3z1xxjHNS2zN51n+6mP7uPpLMM/JJ0wvH4ZHBxwTjrV9T42TXItH8Pdd35GKstjcXUy3Fn5sUlpZBkfR5nz+9kzkY5zxz0foOlZ97oWi33iPQ9XeO/hm0EvHZwQaXKsBWVzGQ6bCcBVAVQV/u84retWb+0pf3Ux/0Sx/5azf8APWX/AGe/bHA/hyauIx3S/upv9Yn/AC1m/wCezf7P4c855HzZFCTHWUHK7T+z1XZeRkWN3bJY3ANu+d18crpM/wDz3bHOOCPX+DoeaNbu7Z9F1FVt3DG1vACdJnXBzxyRgY9TwvQ1b09m+wXH7qYfPf8A/LWb/nu3qvbvng/xYNGvM39han+6m/49LzrLN6/7vbvng/xYNLXlNU17ZaP4n1Xd+QX17ahbjFvIMSN00edMfuc9149cdj83So7y6tW1Sxxbthb45B0accfZn4C4yeTnb1/i6VoXzErcfuphmRussxx+591/HnnHH3eaivnb+1dO/cT/APH+ePOuM/8AHrJx93Oe+euOMY5pu9jGm1bZ/C+q7ehBbXtqZbMG3kOY4850eds/JJ1GPm+o68H+E1Vtru2+3yOYHwbWyH/IJnJz5kmc8d89ej9B0Na1szedZ/upj+7j6SzDPySdMLx+GRwccE4p2rN/aUv7qY/6JY/8tZv+esv+z37Y4H8OTQ73RScfe0ey6rv6Fe8/svUba5tdQ05bq1eSPdDPok0iNidiMqVx2HB64C9RTLG7tksbgG3fO6+OV0mf/nu2OccEev8AB0PNa6Md0v7qb/WJ/wAtZv8Ans3+z+HPOeR82RVPT2b7Bcfuph89/wD8tZv+e7eq9u+eD/Fg0a3Bctm7PddV2fkVNbu7Z9F1FVt3DG1vACdJnXBzxyRgY9TwvQ1bvr21C3GLeQYkbpo86Y/c57rx647H5ulGvM39han+6m/49LzrLN6/7vbvng/xYNXL5iVuP3UwzI3WWY4/c+6/jzzjj7vNCvcE48q0e8uq8vIz7y6tW1Sxxbthb45B0accfZn4C4yeTnb1/i6VNY3ds91YKIJQWSIZOmTLyVk5LEY9Pm6cA9FNS3zt/aunfuJ/+P8APHnXGf8Aj1k4+7nPfPXHGMc0kkrRwxOI5MrboQTJLjiOTnpwPpxwcHBYgV9SKjXslo/h7rz8jy/9n24gj+HGk+ZCWP2eMfLp0s3/AC+3P8SjB4IH+193qDXpSXtrul/0eT/WJ/zB5z/y2YenHHGO4+XqK8//AGeyy/DnSAYpT/okJ4eUf8vlyeirjnt+YycivTEY7pf3U3+sT/lrN/z2b/Z/DnnPI+bIojexMWuSN09o9V2XkZFjd2yWNwDbvndfHK6TP/z3bHOOCPX+DoeaNbu7Z9F1FVt3DG1vACdJnXBzxyRgY9TwvQ1c0zc9nMnlyLukvhlppsDNw3JyuMDvng/xYNN112Ohal+5mH+iXnWWbjn/AHccd+x/iwaWvKdCcfbpWfxPqu78hb69tQtxi3kGJG6aPOmP3Oe68euOx+bpUd5dWrapY4t2wt8cg6NOOPsz8BcZPJzt6/xdK0L5iVuP3UwzI3WWY4/c+6/jzzjj7vNRXzt/aunfuJ/+P88edcZ/49ZOPu5z3z1xxjHNN3sZU2rbP4X1Xb0Od8HaPpHhuW6FiNTnGqXh1OcXemzShZZUfcqAIPk+UY6k9cnbWjbXdt9vkcwPg2tkP+QTOTnzJM547569H6Doa1rZm86z/dTH93H0lmGfkk6YXj8Mjg44JxTtWb+0pf3Ux/0Sx/5azf8APWX/AGe/bHA/hyaGndDgoRUlFPp1X83oCXtrul/0eT/WJ/zB5z/y2YenHHGO4+XqKqWN3bJY3ANu+d18crpM/wDz3bHOOCPX+Doea10Y7pf3U3+sT/lrN/z2b/Z/DnnPI+bIqnp7N9guP3Uw+e//AOWs3/PdvVe3fPB/iwaNbjTjyvR7rquz8iprd3bPouoqtu4Y2t4ATpM64OeOSMDHqeF6Grd9e2oW4xbyDEjdNHnTH7nPdePXHY/N0o15m/sLU/3U3/HpedZZvX/d7d88H+LBq5fMStx+6mGZG6yzHH7n3X8eeccfd5oV7gnHlWj3l1Xl5GfeXVq2qWOLdsLfHIOjTjj7M/AXGTyc7ev8XSqmk2ukWWszajb2Uy3epJbNdO2l3LiTy4pFT5cY4GeVAyTnsa1r52/tXTv3E/8Ax/njzrjP/HrJx93Oe+euOMY5qW2ZvOs/3Ux/dx9JZhn5JOmF4/DI4OOCcCT1ImouEbp/D3Xn5GTbXdt9vkcwPg2tkP8AkEzk58yTOeO+evR+g6GrSXtrul/0eT/WJ/zB5z/y2YenHHGO4+XqKLVm/tKX91Mf9Esf+Ws3/PWX/Z79scD+HJq4jHdL+6m/1if8tZv+ezf7P4c855HzZFCuXVau9H06rsvIyLG7tksbgG3fO6+OV0mf/nu2OccEev8AB0PNGt3ds+i6iq27hja3gBOkzrg545IwMep4Xoat6ezfYLj91MPnv/8AlrN/z3b1Xt3zwf4sGjXmb+wtT/dTf8el51lm9f8Ad7d88H+LBpa8pomvbLR/E+q7vyC+vbULcYt5BiRumjzpj9znuvHrjsfm6VwfjK5tj8bPhwwt2MayamCp0uZM5tI8YjK7mwecDp1OAa9IvmJW4/dTDMjdZZjj9z7r+PPOOPu81wni8NJ8bfh6whmzEdTcjzZs820S9du7v2GeeeMGm72OGu17NaPp1XdeR19te2plswbeQ5jjznR52z8knUY+b6jrwf4TVW2u7b7fI5gfBtbIf8gmcnPmSZzx3z16P0HQ1rWzN51n+6mP7uPpLMM/JJ0wvH4ZHBxwTinas39pS/upj/olj/y1m/56y/7Pftjgfw5NDvdHUnH3tHsuq7+gJe2u6X/R5P8AWJ/zB5z/AMtmHpxxxjuPl6iqljd2yWNwDbvndfHK6TP/AM92xzjgj1/g6HmtdGO6X91N/rE/5azf89m/2fw55zyPmyKp6ezfYLj91MPnv/8AlrN/z3b1Xt3zwf4sGjW4Jx5Xo911XZ+R4d8U7mNfjF4dlWRYY2u9MQpJE0J2C9unLbWHyqNgzkg8jGRnHuN9e2oW4xbyDEjdNHnTH7nPdePXHY/N0rxH4pzRj47aJFJCsjmwa4VJAXAMZvSM7h83JHBHbmver5iVuP3UwzI3WWY4/c+6/jzzjj7vNCvdnFhYpVJyaerfVdPl5mfeXVq2qWOLdsLfHIOjTjj7M/AXGTyc7ev8XSpLa9tTLZg28hzHHnOjztn5JOox831HXg/wmp752/tXTv3E/wDx/njzrjP/AB6ycfdznvnrjjGOaltmbzrP91Mf3cfSWYZ+STphePwyODjgnAr6nXJrkWj+Huu78jJtru2+3yOYHwbWyH/IJnJz5kmc8d89ej9B0NWkvbXdL/o8n+sT/mDzn/lsw9OOOMdx8vUUWrN/aUv7qY/6JY/8tZv+esv+z37Y4H8OTVxGO6X91N/rE/5azf8APZv9n8Oec8j5sihXKqtXej6dV2XkZFjd2yWNwDbvndfHK6TP/wA92xzjgj1/g6HmvIP2i9Qt4dR8MyrEFBs9eiPmWMkH37fYMb8biM8Afd4Br2rT2b7Bcfuph89//wAtZv8Anu3qvbvng/xYNeGftV2p1DUPAtoRPEs11exM4LyEBpYVOA+0ZGfXk9cGlrynNmDXJKye76rv6Hs9slrpGjRactmYfsaC3CRabcOqbLfGFcg5AxwT/v8ASrF5dWrapY4t2wt8cg6NOOPsz8BcZPJzt6/xdK0L5iVuP3UwzI3WWY4/c+6/jzzjj7vNRXzt/aunfuJ/+P8APHnXGf8Aj1k4+7nPfPXHGMc03exvSsklZ/C+q7ehBbXtqZbMG3kOY4850eds/JJ1GPm+o68H+E1Vtru2+3yOYHwbWyH/ACCZyc+ZJnPHfPXo/QdDWtbM3nWf7qY/u4+kswz8knTC8fhkcHHBOKdqzf2lL+6mP+iWP/LWb/nrL/s9+2OB/Dk0O90UnH3tHsuq7+gJe2u6X/R5P9Yn/MHnP/LZh6cccY7j5eoqpY3dsljcA2753Xxyukz/APPdsc44I9f4Oh5rXRjul/dTf6xP+Ws3/PZv9n8Oec8j5siqens32C4/dTD57/8A5azf8929V7d88H+LBo1uCceV6PddV2fkc98Sbm3k+HvidY4XVjpeoYJ02aIcA/xMMDjj2+71NZHwzij0/RfEk9yk7zX/AIi1O5b/AIlkjbCC8eA65BGY84wCCemFyeg+JzE/DjxRmOVf+JXqHLSSkdD/AHlA/wDr8nBwKxfgmw/4U5oR2ytJIbmZ2BkVQXaZ8AAYyA3P5dMkGtzh0+tR0ez7d35HXXl1atqlji3bC3xyDo044+zPwFxk8nO3r/F0qS2vbUy2YNvIcxx5zo87Z+STqMfN9R14P8Jqe+dv7V079xP/AMf54864z/x6ycfdznvnrjjGOaltmbzrP91Mf3cfSWYZ+STphePwyODjgnAr6nZJrkWj+Huu78jz34S3MP2PxfLIjSB/E0oXFjJORhLfIO0fL1wQeT0rtkvbXdL/AKPJ/rE/5g85/wCWzD0444x3Hy9RXJ/CT5IfHISNyP8AhMLsfI0igYaEAYQEdsDPI7ZNdwjHdL+6m/1if8tZv+ezf7P4c855HzZFCvY5sNKMqV7Pfuu/oZFjd2yWNwDbvndfHK6TP/z3bHOOCPX+DoeaNbu7Z9F1FVt3DG1vACdJnXBzxyRgY9TwvQ1b09m+wXH7qYfPf/8ALWb/AJ7t6r2754P8WDRrzN/YWp/upv8Aj0vOss3r/u9u+eD/ABYNLXlO9Ne2Wj+J9V3fkZWuafpV54gstZuIbs3GmLdxW0a6XcRxq00MeXxjqFjZcHP393YVo3l1atqlji3bC3xyDo044+zPwFxk8nO3r/F0rQvmJW4/dTDMjdZZjj9z7r+PPOOPu81FfO39q6d+4n/4/wA8edcZ/wCPWTj7uc989ccYxzTadjCkoR2T1T6rt6EFte2plswbeQ5jjznR52z8knUY+b6jrwf4TVW2u7b7fI5gfBtbIf8AIJnJz5kmc8d89ej9B0Na1szedZ/upj+7j6SzDPySdMLx+GRwccE4p2rN/aUv7qY/6JY/8tZv+esv+z37Y4H8OTQ73Racfe0ey6rv6Al7a7pf9Hk/1if8wec/8tmHpxxxjuPl6iqljd2yWNwDbvndfHK6TP8A892xzjgj1/g6HmtdGO6X91N/rE/5azf89m/2fw55zyPmyKp6ezfYLj91MPnv/wDlrN/z3b1Xt3zwf4sGjW4Jx5Xo911XZ+RU1u7tn0XUVW3cMbW8AJ0mdcHPHJGBj1PC9DVu+vbULcYt5BiRumjzpj9znuvHrjsfm6Ua8zf2Fqf7qb/j0vOss3r/ALvbvng/xYNXL5iVuP3UwzI3WWY4/c+6/jzzjj7vNCvcE48q0e8uq8vI5qx0+y0zxBcXKG6na/1g3LrLo8+2MfYyoRV25I4+716HoK2ba9tTLZg28hzHHnOjztn5JOox831HXg/wmp752/tXTv3E/wDx/njzrjP/AB6ycfdznvnrjjGOaltmbzrP91Mf3cfSWYZ+STphePwyODjgnAk9SLRjTSSfw913fkZNtd232+RzA+Da2Q/5BM5OfMkznjvnr0foOhq0l7a7pf8AR5P9Yn/MHnP/AC2YenHHGO4+XqKLVm/tKX91Mf8ARLH/AJazf89Zf9nv2xwP4cmriMd0v7qb/WJ/y1m/57N/s/hzznkfNkUK5dVq70fTquy8jw/xIVbxFqhQbVN1KQPLMeBvP8J5X6HkUUvifnxLqxII/wBLm4JJI+c9zz+fNFcb3P0PD/wo+i/I9fvLi5/tSwLJp4/04lcaxKQf9Gcct5fA6/N1z8vTmpLa4vBLZ5i08YjjznVpVx8knU+X8v0HTIH8Rqe+uZf7V08/b4M/byd32hMZ+yyDOfL6ds4xnjGealtp5BNZkXkK7Y4wCZ0G3CScH5OMZxznGR1yCOxJ66n51J+4vdXw95d2ZFtPdC/k/d2G/wCy2QIOqyADEkn+x165H8PUZzVtLi83S/utP/1if8xaUf8ALZj/AM8+eOc9h83U0Ws8g1KUC8hGLSxGPPTjEsuB9zt1Pp33dKuJPJul/wBMhGZEP+vTn98xz9z15+hzyDgCTKqvV+6unV9kZNjcXX2GcJHYMN1911WTOTO3GNnPfA/jHJxSa3PdHRdRDx2AU2t4CV1WRjyew2cn0H8XU1b0+eQ2FwDeQnL34x56HOZ2yPud+o9e23pRr08h0LUx9shObS8GPPTnJ5H3O/Uevbb0pWfKaJ/vl7q+J9X3YX1xeFbjEWnnMjYxq0r5/c47x8+me5+XpUd5cXP9qWBZNPH+nErjWJSD/ozjlvL4HX5uufl6c1oX08jLcZvIXzIx4nQ5/c4zwgzxx254681FfXMv9q6eft8Gft5O77QmM/ZZBnPl9O2cYzxjPNNp23Mab0+FfC+suxBbXF4JbPMWnjEcec6tKuPkk6ny/l+g6ZA/iNVLae6F/J+7sN/2WyBB1WQAYkk/2OvXI/h6jOa17aeQTWZF5Cu2OMAmdBtwknB+TjGcc5xkdcginazyDUpQLyEYtLEY89OMSy4H3O3U+nfd0oad9yk/i91bLq+4JcXm6X91p/8ArE/5i0o/5bMf+efPHOew+bqaq2NxdfYZwkdgw3X3XVZM5M7cY2c98D+McnFayTybpf8ATIRmRD/r05/fMc/c9efoc8g4FPT55DYXAN5CcvfjHnoc5nbI+536j17belFncE/dfurddX2ZU1ue6Oi6iHjsAptbwErqsjHk9hs5PoP4upq3fXF4VuMRaecyNjGrSvn9zjvHz6Z7n5elGvTyHQtTH2yE5tLwY89Ocnkfc79R69tvSrl9PIy3GbyF8yMeJ0Of3OM8IM8cdueOvNCTuCfur3VvLq/Iz7y4uf7UsCyaeP8ATiVxrEpB/wBGcct5fA6/N1z8vTmkZryeOGEx6coeBEJOqSYXKSDn93x16dBwP4jVy+uZf7V08/b4M/byd32hMZ+yyDOfL6ds4xnjGealtp5BNZkXkK7Y4wCZ0G3CScH5OMZxznGR1yCBJ66ky+Be6vh7y7s5DwNpMnhjSrXR7ZrOZbWys13PqboT++lYnCx4ByxyMfLwckk10aXF5ul/daf/AKxP+YtKP+WzH/nnzxznsPm6mi1nkGpSgXkIxaWIx56cYllwPudup9O+7pVxJ5N0v+mQjMiH/Xpz++Y5+568/Q55BwCKdhzSjoor7PWXZeZk2NxdfYZwkdgw3X3XVZM5M7cY2c98D+McnFJrc90dF1EPHYBTa3gJXVZGPJ7DZyfQfxdTVvT55DYXAN5CcvfjHnoc5nbI+536j17belGvTyHQtTH2yE5tLwY89Ocnkfc79R69tvSlZ8pqn++Xur4n1fdhfXF4VuMRaecyNjGrSvn9zjvHz6Z7n5elR3lxc/2pYFk08f6cSuNYlIP+jOOW8vgdfm65+XpzWhfTyMtxm8hfMjHidDn9zjPCDPHHbnjrzUV9cy/2rp5+3wZ+3k7vtCYz9lkGc+X07ZxjPGM802nbcxpvT4V8L6y7EFtcXgls8xaeMRx5zq0q4+STqfL+X6DpkD+I1Utp7oX8n7uw3/ZbIEHVZABiST/Y69cj+HqM5rXtp5BNZkXkK7Y4wCZ0G3CScH5OMZxznGR1yCKdrPINSlAvIRi0sRjz04xLLgfc7dT6d93Shp33KT+L3Vsur7glxebpf3Wn/wCsT/mLSj/lsx/5588c57D5upqrY3F19hnCR2DDdfddVkzkztxjZz3wP4xycVrJPJul/wBMhGZEP+vTn98xz9z15+hzyDgU9PnkNhcA3kJy9+Meehzmdsj7nfqPXtt6UWdwT91+6t11fZlTW57o6LqIeOwCm1vASuqyMeT2Gzk+g/i6mrd9cXhW4xFp5zI2MatK+f3OO8fPpnufl6Ua9PIdC1MfbITm0vBjz05yeR9zv1Hr229KuX08jLcZvIXzIx4nQ5/c4zwgzxx254680JO4J+6vdW8ur8jPvLi5/tSwLJp4/wBOJXGsSkH/AEZxy3l8Dr83XPy9Oaktri8EtnmLTxiOPOdWlXHySdT5fy/QdMgfxGp765l/tXTz9vgz9vJ3faExn7LIM58vp2zjGeMZ5qW2nkE1mReQrtjjAJnQbcJJwfk4xnHOcZHXIIEnrqTJ+4vdXw95d2ZFtPdC/k/d2G/7LZAg6rIAMSSf7HXrkfw9RnNW0uLzdL+60/8A1if8xaUf8tmP/PPnjnPYfN1NFrPINSlAvIRi0sRjz04xLLgfc7dT6d93SriTybpf9MhGZEP+vTn98xz9z15+hzyDgCTKqvV+6unV9kZNjcXX2GcJHYMN1911WTOTO3GNnPfA/jHJxSa3PdHRdRDx2AU2t4CV1WRjyew2cn0H8XU1b0+eQ2FwDeQnL34x56HOZ2yPud+o9e23pRr08h0LUx9shObS8GPPTnJ5H3O/Uevbb0pWfKaJ/vl7q+J9X3YX1xeFbjEWnnMjYxq0r5/c47x8+me5+XpWbewXh8baVqvn6dGsQubLyF1B287zY4pMmYoGVV+z9QDknbwMmt6+nkZbjN5C+ZGPE6HP7nGeEGeOO3PHXmor65l/tXTz9vgz9vJ3faExn7LIM58vp2zjGeMZ5ptOxzciqRScVs3u+mpBbXF4JbPMWnjEcec6tKuPkk6ny/l+g6ZA/iNVLae6F/J+7sN/2WyBB1WQAYkk/wBjr1yP4eozmte2nkE1mReQrtjjAJnQbcJJwfk4xnHOcZHXIIp2s8g1KUC8hGLSxGPPTjEsuB9zt1Pp33dKGnfc1T+L3Vsur7glxebpf3Wn/wCsT/mLSj/lsx/5588c57D5upqrY3F19hnCR2DDdfddVkzkztxjZz3wP4xycVrJPJul/wBMhGZEP+vTn98xz9z15+hzyDgU9PnkNhcA3kJy9+Meehzmdsj7nfqPXtt6UWdwT91+6t11fZnjXjW2N38erSeWFDJb+G7uX5LsmNcvcpu3FMuMPwONzEZOM59lvri8K3GItPOZGxjVpXz+5x3j59M9z8vSvNtbMj/G3WH8xcL4NuSX3jDZunHXGDnOOgz2x29Vvp5GW4zeQvmRjxOhz+5xnhBnjjtzx15pJO7OfDvR+79qXV/3TPvLi5/tSwLJp4/04lcaxKQf9Gcct5fA6/N1z8vTmpLa4vBLZ5i08YjjznVpVx8knU+X8v0HTIH8Rqe+uZf7V08/b4M/byd32hMZ+yyDOfL6ds4xnjGealtp5BNZkXkK7Y4wCZ0G3CScH5OMZxznGR1yCGk9dTaT9xe6vh7y7syLae6F/J+7sN/2WyBB1WQAYkk/2OvXI/h6jOatpcXm6X91p/8ArE/5i0o/5bMf+efPHOew+bqaLWeQalKBeQjFpYjHnpxiWXA+526n077ulXEnk3S/6ZCMyIf9enP75jn7nrz9DnkHAEmVVer91dOr7IybG4uvsM4SOwYbr7rqsmcmduMbOe+B/GOTivIvj2s9743+F1u62ytJq0yr5N48/W4g5IKjb9Rnd1Nez6fPIbC4BvITl78Y89DnM7ZH3O/Uevbb0ryT4+wtqHi/4fRNPHLsm1ObAkDY2hHzwoxnbkdc+g6UrNRuY4yHtLwta8rXu+563fXF4VuMRaecyNjGrSvn9zjvHz6Z7n5elR3lxc/2pYFk08f6cSuNYlIP+jOOW8vgdfm65+XpzWhfTyMtxm8hfMjHidDn9zjPCDPHHbnjrzUV9cy/2rp5+3wZ+3k7vtCYz9lkGc+X07ZxjPGM802nbc0pvT4V8L6y7EFtcXgls8xaeMRx5zq0q4+STqfL+X6DpkD+I1Utp7oX8n7uw3/ZbIEHVZABiST/AGOvXI/h6jOa17aeQTWZF5Cu2OMAmdBtwknB+TjGcc5xkdcginazyDUpQLyEYtLEY89OMSy4H3O3U+nfd0oad9yk/i91bLq+4JcXm6X91p/+sT/mLSj/AJbMf+efPHOew+bqaq2NxdfYZwkdgw3X3XVZM5M7cY2c98D+McnFayTybpf9MhGZEP8Ar05/fMc/c9efoc8g4FPT55DYXAN5CcvfjHnoc5nbI+536j17belFncE/dfurddX2Zz3xImuX+HnidZUswn9l6hkx6jJK3Q4wpQA/nyPm6iq3w5E9r8MvD8dtb2axtZRShXvnjb57UMTsCEdW6556d60vidM7fDjxQDdROP7L1D5VlVjyCegQdevXkDPA4Ojou228L2FvbSwQ28UEaRwJMCEUWoUAAqTgD5eSTnjr81OzucsP94vyrbu+4+8uLn+1LAsmnj/TiVxrEpB/0Zxy3l8Dr83XPy9Oaktri8EtnmLTxiOPOdWlXHySdT5fy/QdMgfxGp765l/tXTz9vgz9vJ3faExn7LIM58vp2zjGeMZ5qW2nkE1mReQrtjjAJnQbcJJwfk4xnHOcZHXIIST11OiT9xe6vh7y7s4/wVpt9oE/iGFptMuBqWpjW8C+eEwm4k5jOFO4r5YycDHXvx0iXF5ul/daf/rE/wCYtKP+WzH/AJ588c57D5upotZ5BqUoF5CMWliMeenGJZcD7nbqfTvu6VcSeTdL/pkIzIh/16c/vmOfuevP0OeQcASdglCNP3YwVtOr7LzMmxuLr7DOEjsGG6+66rJnJnbjGznvgfxjk4pNbnujouoh47AKbW8BK6rIx5PYbOT6D+Lqat6fPIbC4BvITl78Y89DnM7ZH3O/Uevbb0o16eQ6FqY+2QnNpeDHnpzk8j7nfqPXtt6UrPlNk/3y91fE+r7sL64vCtxiLTzmRsY1aV8/ucd4+fTPc/L0qO8uLn+1LAsmnj/TiVxrEpB/0Zxy3l8Dr83XPy9Oa0L6eRluM3kL5kY8Toc/ucZ4QZ447c8deaivrmX+1dPP2+DP28nd9oTGfssgzny+nbOMZ4xnmm07bmNN6fCvhfWXYgtri8EtnmLTxiOPOdWlXHySdT5fy/QdMgfxGqltPdC/k/d2G/7LZAg6rIAMSSf7HXrkfw9RnNa9tPIJrMi8hXbHGATOg24STg/JxjOOc4yOuQRTtZ5BqUoF5CMWliMeenGJZcD7nbqfTvu6UNO+5Sfxe6tl1fcEuLzdL+60/wD1if8AMWlH/LZj/wA8+eOc9h83U1Vsbi6+wzhI7BhuvuuqyZyZ24xs574H8Y5OK1knk3S/6ZCMyIf9enP75jn7nrz9DnkHAp6fPIbC4BvITl78Y89DnM7ZH3O/Uevbb0os7gn7r91brq+zKmtz3R0XUQ8dgFNreAldVkY8nsNnJ9B/F1NW764vCtxiLTzmRsY1aV8/ucd4+fTPc/L0o16eQ6FqY+2QnNpeDHnpzk8j7nfqPXtt6Vcvp5GW4zeQvmRjxOhz+5xnhBnjjtzx15oSdwT91e6t5dX5GfeXFz/algWTTx/pxK41iUg/6M45by+B1+brn5enNSW1xeCWzzFp4xHHnOrSrj5JOp8v5foOmQP4jU99cy/2rp5+3wZ+3k7vtCYz9lkGc+X07ZxjPGM81LbTyCazIvIV2xxgEzoNuEk4PycYzjnOMjrkECT11Jk/cXur4e8u7Mi2nuhfyfu7Df8AZbIEHVZABiST/Y69cj+HqM5q2lxebpf3Wn/6xP8AmLSj/lsx/wCefPHOew+bqaLWeQalKBeQjFpYjHnpxiWXA+526n077ulXEnk3S/6ZCMyIf9enP75jn7nrz9DnkHAEmVVer91dOr7I8P8AEhLeItULbdxupSdkhkX756MQCw9yOaKXxOS3iXVmLBybuYlgQQfnPOQBn8hRXG9z9Dw/8KPovyPZ7y1vxq1gDf6uWOoEAlbXcD9lfkfJjdj8MH1p9paX3n2G3UdWz5UW3atrnGyXGMp064zzjOecUX1iv9q6ev2Wf/j/ACuPLt8/8eshx6Z7+mPepba0VprMfZ5jujjOAkPOUkPGfp354OecV1qK1PziU1yL4fh7LuzPtbW9+3OovtV4tLA7gttyPNk2jlOmenfJO7jFW47S+3z/APEx1b/Wx5wtr1+0P1+TrnPtnOeMVBa2gOpSn7PMc2lichIed0so7+vbuf4uKuJaAtL/AKPMcSIPuQ8ZmYf0xxxkc/Limkiqs1d/D9nouyM+ytb1rC4P27VVGdQBG22x/rzuJ+TPXlsd/u8Ua5a3q6JqTNf6qyi0vSVZbbBGeQcJnHrjn+7Umn2iiwuD9nmGHvzkpDxtnYdvTvjkfw8Ua9aKNC1M/Z5hi0vDnZDxtOO3p37j+HilZcpopr2y+H4n0Xdk+o2l9sud2o6t/rWzvW16/Zz1wnXHpxj3pl5a341awBv9XLHUCAStruB+yvyPkxux+GD61YvrMItx/o8y7ZGHKQjH7nd2/PjjH+1UV9Yr/aunr9ln/wCP8rjy7fP/AB6yHHpnv6Y96JJWMYTVvs/C+i7BaWl959ht1HVs+VFt2ra5xslxjKdOuM84znnFVLW1vftzqL7VeLSwO4LbcjzZNo5Tpnp3yTu4xWhbWitNZj7PMd0cZwEh5ykh4z9O/PBzziqdraA6lKfs8xzaWJyEh53Syjv69u5/i4ptK5Smve+HZdF/MTx2l9vn/wCJjq3+tjzhbXr9ofr8nXOfbOc8YqpZWt61hcH7dqqjOoAjbbY/153E/Jnry2O/3eK0EtAWl/0eY4kQfch4zMw/pjjjI5+XFU9PtFFhcH7PMMPfnJSHjbOw7enfHI/h4osrgqis/h3XRdmR65a3q6JqTNf6qyi0vSVZbbBGeQcJnHrjn+7VvUbS+2XO7UdW/wBa2d62vX7OeuE649OMe9Qa9aKNC1M/Z5hi0vDnZDxtOO3p37j+Hirl9ZhFuP8AR5l2yMOUhGP3O7t+fHGP9qhJXBVFyr4d5dF5Fe8tb8atYA3+rljqBAJW13A/ZX5HyY3Y/DB9afaWl959ht1HVs+VFt2ra5xslxjKdOuM84znnFF9Yr/aunr9ln/4/wArjy7fP/HrIceme/pj3qW2tFaazH2eY7o4zgJDzlJDxn6d+eDnnFJRWpMprkXw/D2Xdmfa2t79udRfarxaWB3BbbkebJtHKdM9O+Sd3GKtx2l9vn/4mOrf62POFtev2h+vydc59s5zxioLW0B1KU/Z5jm0sTkJDzullHf17dz/ABcVcS0BaX/R5jiRB9yHjMzD+mOOMjn5cU0kVVmrv4fs9F2Rn2VretYXB+3aqozqAI222P8AXncT8mevLY7/AHeKNctb1dE1Jmv9VZRaXpKsttgjPIOEzj1xz/dqTT7RRYXB+zzDD35yUh42zsO3p3xyP4eKNetFGhamfs8wxaXhzsh42nHb079x/DxSsuU0U17ZfD8T6LuyfUbS+2XO7UdW/wBa2d62vX7OeuE649OMe9MvLW/GrWAN/q5Y6gQCVtdwP2V+R8mN2PwwfWrF9ZhFuP8AR5l2yMOUhGP3O7t+fHGP9qor6xX+1dPX7LP/AMf5XHl2+f8Aj1kOPTPf0x70SSsYwmrfZ+F9F2C0tL7z7DbqOrZ8qLbtW1zjZLjGU6dcZ5xnPOKqWtre/bnUX2q8WlgdwW25HmybRynTPTvkndxitC2tFaazH2eY7o4zgJDzlJDxn6d+eDnnFU7W0B1KU/Z5jm0sTkJDzullHf17dz/FxTaVylNe98Oy6L+YnjtL7fP/AMTHVv8AWx5wtr1+0P1+TrnPtnOeMVUsrW9awuD9u1VRnUARttsf687ifkz15bHf7vFaCWgLS/6PMcSIPuQ8ZmYf0xxxkc/Liqen2iiwuD9nmGHvzkpDxtnYdvTvjkfw8UWVwVRWfw7rouzI9ctb1dE1Jmv9VZRaXpKsttgjPIOEzj1xz/dq3qNpfbLndqOrf61s71tev2c9cJ1x6cY96g160UaFqZ+zzDFpeHOyHjacdvTv3H8PFXL6zCLcf6PMu2RhykIx+53dvz44x/tUJK4KouVfDvLovIr3lrfjVrAG/wBXLHUCAStruB+yvyPkxux+GD60+0tL7z7DbqOrZ8qLbtW1zjZLjGU6dcZ5xnPOKL6xX+1dPX7LP/x/lceXb5/49ZDj0z39Me9S21orTWY+zzHdHGcBIecpIeM/Tvzwc84pKK1JlNci+H4ey7sz7W1vftzqL7VeLSwO4LbcjzZNo5Tpnp3yTu4xVuO0vt8//Ex1b/Wx5wtr1+0P1+TrnPtnOeMVBa2gOpSn7PMc2lichIed0so7+vbuf4uKuJaAtL/o8xxIg+5DxmZh/THHGRz8uKaSKqzV38P2ei7Iz7K1vWsLg/btVUZ1AEbbbH+vO4n5M9eWx3+7xRrlrerompM1/qrKLS9JVltsEZ5BwmceuOf7tSafaKLC4P2eYYe/OSkPG2dh29O+OR/DxRr1oo0LUz9nmGLS8OdkPG047enfuP4eKVlymimvbL4fifRd2T6jaX2y53ajq3+tbO9bXr9nPXCdcenGPemXlrfjVrAG/wBXLHUCAStruB+yvyPkxux+GD61YvrMItx/o8y7ZGHKQjH7nd2/PjjH+1UV9Yr/AGrp6/ZZ/wDj/K48u3z/AMeshx6Z7+mPeiSVjGE1b7PwvouwWlpfefYbdR1bPlRbdq2ucbJcYynTrjPOM55xVS1tb37c6i+1Xi0sDuC23I82TaOU6Z6d8k7uMVoW1orTWY+zzHdHGcBIecpIeM/Tvzwc84qna2gOpSn7PMc2lichIed0so7+vbuf4uKbSuUpr3vh2XRfzE8dpfb5/wDiY6t/rY84W16/aH6/J1zn2znPGKqWVretYXB+3aqozqAI222P9edxPyZ68tjv93itBLQFpf8AR5jiRB9yHjMzD+mOOMjn5cVT0+0UWFwfs8ww9+clIeNs7Dt6d8cj+HiiyuCqKz+HddF2ZxOq6RqS/EbX9QaLUjbDwvNEb0wx4dvtMxaNm27OmCQmGwARXe6jaX2y53ajq3+tbO9bXr9nPXCdcenGPeoNetFGhamfs8wxaXhzsh42nHb079x/DxVy+swi3H+jzLtkYcpCMfud3b8+OMf7VCirkU7QjutXJ7LyK95a341awBv9XLHUCAStruB+yvyPkxux+GD60+0tL7z7DbqOrZ8qLbtW1zjZLjGU6dcZ5xnPOKL6xX+1dPX7LP8A8f5XHl2+f+PWQ49M9/THvUttaK01mPs8x3RxnASHnKSHjP0788HPOKSitRymuRfD8PZd2Z9ra3v251F9qvFpYHcFtuR5sm0cp0z075J3cYq3HaX2+f8A4mOrf62POFtev2h+vydc59s5zxiobSzVtRmJglz9jsW+5DzulkHHHftn0+araWgLS/6PMcSIPuQ8ZmYf0xxxkc/LimkiqtRXfw/Z6LsjPsrW9awuD9u1VRnUARttsf687ifkz15bHf7vFedfFe1l/wCE98CLdzX1yvk68yibyRtZbcnI2Be4yc56cV6Tp9oosLg/Z5hh785KQ8bZ2Hb0745H8PFc9468Hrqd/pmuiSeE6Lbao3keRCRMJIzH94EbdvHY/wCzjFTZcoqj5qiirfH2X8x1Go2l9sud2o6t/rWzvW16/Zz1wnXHpxj3pl5a341awBv9XLHUCAStruB+yvyPkxux+GD61YvrMItx/o8y7ZGHKQjH7nd2/PjjH+1Ud/YqNU01RbzHN+V2iODI/wBFkOOmM9/TH+1TaVhQqK32fhfRdhLS0vvPsNuo6tnyotu1bXONkuMZTp1xnnGc84qpa2t79udRfarxaWB3BbbkebJtHKdM9O+Sd3GK0La0VprMfZ5jujjOAkPOUkPGfp354OecVTtbQHUpT9nmObSxOQkPO6WUd/Xt3P8AFxTaVylNe98Oy6L+YnjtL7fP/wATHVv9bHnC2vX7Q/X5Ouc+2c54xVSytb1rC4P27VVGdQBG22x/rzuJ+TPXlsd/u8VoJaAtL/o8xxIg+5DxmZh/THHGRz8uKp6faKLC4P2eYYe/OSkPG2dh29O+OR/DxRZXBVFZ/Duui7MwfihBdQ/DjxO817qMiDTNQBWUW4U5OOdqg9cZweuMcZFdNqlreH7WRe6pGhmc7CtsQv7g8fdJ6e54/wBqsP4iaTNe+AvEVtaWshnk0+9CBlhUHBx1H5fXpxmugvrMItx/o8y7ZGHKQjH7nd2/PjjH+1QkrnPCX71y027Lu/6ZXvLW/GrWAN/q5Y6gQCVtdwP2V+R8mN2PwwfWn2lpfefYbdR1bPlRbdq2ucbJcYynTrjPOM55xRfWK/2rp6/ZZ/8Aj/K48u3z/wAeshx6Z7+mPepba0VprMfZ5jujjOAkPOUkPGfp354OecUlFam0prkXw/D2Xdmfa2t79udRfarxaWB3BbbkebJtHKdM9O+Sd3GKtx2l9vn/AOJjq3+tjzhbXr9ofr8nXOfbOc8YqC1tAdSlP2eY5tLE5CQ87pZR39e3c/xcVcS0BaX/AEeY4kQfch4zMw/pjjjI5+XFNJFVZq7+H7PRdkZ9la3rWFwft2qqM6gCNttj/XncT8mevLY7/d4o1y1vV0TUma/1VlFpekqy22CM8g4TOPXHP92pNPtFFhcH7PMMPfnJSHjbOw7enfHI/h4o160UaFqZ+zzDFpeHOyHjacdvTv3H8PFKy5TRTXtl8PxPou7J9RtL7Zc7tR1b/Wtnetr1+znrhOuPTjHvTLy1vxq1gDf6uWOoEAlbXcD9lfkfJjdj8MH1qxfWYRbj/R5l2yMOUhGP3O7t+fHGP9qor6xX+1dPX7LP/wAf5XHl2+f+PWQ49M9/THvRJKxjCat9n4X0XYLS0vvPsNuo6tnyotu1bXONkuMZTp1xnnGc84qpa2t79udRfarxaWB3BbbkebJtHKdM9O+Sd3GK0La0VprMfZ5jujjOAkPOUkPGfp354OecVTtbQHUpT9nmObSxOQkPO6WUd/Xt3P8AFxTaVylNe98Oy6L+YnjtL7fP/wATHVv9bHnC2vX7Q/X5Ouc+2c54xVSytb1rC4P27VVGdQBG22x/rzuJ+TPXlsd/u8VoJaAtL/o8xxIg+5DxmZh/THHGRz8uKp6faKLC4P2eYYe/OSkPG2dh29O+OR/DxRZXBVFZ/Duui7Mj1y1vV0TUma/1VlFpekqy22CM8g4TOPXHP92reo2l9sud2o6t/rWzvW16/Zz1wnXHpxj3qDXrRRoWpn7PMMWl4c7IeNpx29O/cfw8VcvrMItx/o8y7ZGHKQjH7nd2/PjjH+1Qkrgqi5V8O8ui8iveWt+NWsAb/Vyx1AgEra7gfsr8j5Mbsfhg+tPtLS+8+w26jq2fKi27Vtc42S4xlOnXGecZzzii+sV/tXT1+yz/APH+Vx5dvn/j1kOPTPf0x71Nb2SlrI+TId6R/KEhyfkc554wccZ54OeQtJJakyqJQXw/D2XmZ1ra3v251F9qvFpYHcFtuR5sm0cp0z075J3cYq3HaX2+f/iY6t/rY84W16/aH6/J1zn2znPGKgtbQHUpT9nmObSxOQkPO6WUd/Xt3P8AFxVxLQFpf9HmOJEH3IeMzMP6Y44yOflxTSRVWau/h+z0XZHiHicMviXVlkaRnF3KGaTbuJ3nk7eM/Tj0oo8Trs8S6sgUrtu5hggAj5z6cflxRXE9z9Fw/wDCj6L8j1+80nTV1SxVdN08K18VYDSjgj7M5wV9MgHb6jdUK22gQanpNlcW+jx3d3ErQQSWA3z7UcuVTrJjIJI9j2qa8urVtUscW7YW+OQdGnHH2Z+AuMnk529f4ulcdr9lPffFL4d6pbafPJp2nwXf2uX+zJdqGWAqmUxukJKn5l9M9BXWuXU/PKkq6pq3Nsuj7vyNbTbzwpd6jaRW8/h+f7dbW32NEtlf7QySyiXy8H5yu3Dlc5xjjFb6aPpm6X/iWaf/AKxP+YYT/wAtmH4emO4+XqK8G+H/AIV1vTNZ+GEl9o91HHo8F3/aH+is/k+dLP5RYDmQMGGCufTsa95S9td0v+jyf6xP+YPOf+WzD0444x3Hy9RTjy2G5YiWr5l8PfsvIqWWlac9jcM2nWBYNfAE6YcjE5A57YHAP8I4NGt6Vp0ei6i8enWCutreMrLphUgg8EHsR2P8PQ0WN3bJY3ANu+d18crpM/8Az3bHOOCPX+DoeaNbu7Z9F1FVt3DG1vACdJnXBzxyRgY9TwvQ0vd5TZOt7Zay+J9H3fkW77R9MC3GNM08YkbpphTH7nPfpzzjsfm6VHeaTpq6pYqum6eFa+KsBpRwR9mc4K+mQDt9RuqS+vbULcYt5BiRumjzpj9znuvHrjsfm6VHeXVq2qWOLdsLfHIOjTjj7M/AXGTyc7ev8XSm+WxlB1rby+F9H29CS20fTDLZ50zTzmOPOdMLZ+STqP4vqOvB/hNVLbSdON/Ip06wKi1smAOmE8mSTJ9ycDJ/ixgVbtr21MtmDbyHMcec6PO2fkk6jHzfUdeD/Caq213bfb5HMD4NrZD/AJBM5OfMkznjvnr0foOhofLcpOt72stl0ff0LSaPpm6X/iWaf/rE/wCYYT/y2Yfh6Y7j5eoqpZaVpz2NwzadYFg18ATphyMTkDntgcA/wjg1bS9td0v+jyf6xP8AmDzn/lsw9OOOMdx8vUVUsbu2SxuAbd87r45XSZ/+e7Y5xwR6/wAHQ80e7cE61nrLddH2fkGt6Vp0ei6i8enWCutreMrLphUgg8EHsR2P8PQ1bvtH0wLcY0zTxiRummFMfuc9+nPOOx+bpVTW7u2fRdRVbdwxtbwAnSZ1wc8ckYGPU8L0NW769tQtxi3kGJG6aPOmP3Oe68euOx+bpQuW4J1uVay3l0fl5Ed5pOmrqliq6bp4Vr4qwGlHBH2Zzgr6ZAO31G6pLbR9MMtnnTNPOY4850wtn5JOo/i+o68H+E1HeXVq2qWOLdsLfHIOjTjj7M/AXGTyc7ev8XSpLa9tTLZg28hzHHnOjztn5JOox831HXg/wmhcupMnW5FrL4ez7vyKltpOnG/kU6dYFRa2TAHTCeTJJk+5OBk/xYwKtpo+mbpf+JZp/wDrE/5hhP8Ay2Yfh6Y7j5eoqrbXdt9vkcwPg2tkP+QTOTnzJM547569H6DoaxfHtzeTeHLuHQtMmu7iS4hWREsbqCRYvtDbjGVaMlsADYZY8j5d2VwwuWw60qyu05dOj7LyLkJ8Owpe290NFjuoIb+6kjkswrxwLcMokIJyqDaQHPCYwaztZ13wMLG6t4dT8LC+ltZ/IjSOMSO0mGh2DdnLAgoR0BHXNeVXfhPxVd+CvDE8K3kPiSa3u9E16R9OM7ixe4Ys7O2VZk7lMSfPgtkV0+geGJ9F8YeO7qGHUbDQHsIoNPjNi0kVykNsYsMXVpI/LOMMWXn7xYUtOUmnUxMqydpJc3+f9f5nq99o+mBbjGmaeMSN00wpj9znv055x2PzdKjvNJ01dUsVXTdPCtfFWA0o4I+zOcFfTIB2+o3VJfXtqFuMW8gxI3TR50x+5z3Xj1x2PzdKjvLq1bVLHFu2FvjkHRpxx9mfgLjJ5OdvX+LpTfLYcHWtvL4X0fb0JLbR9MMtnnTNPOY4850wtn5JOo/i+o68H+E1UttJ0438inTrAqLWyYA6YTyZJMn3JwMn+LGBVu2vbUy2YNvIcxx5zo87Z+STqMfN9R14P8JqrbXdt9vkcwPg2tkP+QTOTnzJM547569H6DoaHy3KTre9rLZdH39C0mj6Zul/4lmn/wCsT/mGE/8ALZh+HpjuPl6iqllpWnPY3DNp1gWDXwBOmHIxOQOe2BwD/CODVtL213S/6PJ/rE/5g85/5bMPTjjjHcfL1FVLG7tksbgG3fO6+OV0mf8A57tjnHBHr/B0PNHu3BOtZ6y3XR9n5BreladHouovHp1grra3jKy6YVIIPBB7Edj/AA9DVu+0fTAtxjTNPGJG6aYUx+5z36c847H5ulVNbu7Z9F1FVt3DG1vACdJnXBzxyRgY9TwvQ1bvr21C3GLeQYkbpo86Y/c57rx647H5ulC5bgnW5VrLeXR+XkR3mk6auqWKrpunhWvirAaUcEfZnOCvpkA7fUbqkttH0wy2edM085jjznTC2fkk6j+L6jrwf4TUd5dWrapY4t2wt8cg6NOOPsz8BcZPJzt6/wAXSpLa9tTLZg28hzHHnOjztn5JOox831HXg/wmhcupMnW5FrL4ez7vyKltpOnG/kU6dYFRa2TAHTCeTJJk+5OBk/xYwKtpo+mbpf8AiWaf/rE/5hhP/LZh+HpjuPl6iqttd232+RzA+Da2Q/5BM5OfMkznjvnr0foOhq0l7a7pf9Hk/wBYn/MHnP8Ay2YenHHGO4+XqKFylVXWu7OXTo+y8ipZaVpz2NwzadYFg18ATphyMTkDntgcA/wjg0a3pWnR6LqLx6dYK62t4ysumFSCDwQexHY/w9DRY3dsljcA2753Xxyukz/892xzjgj1/g6HmjW7u2fRdRVbdwxtbwAnSZ1wc8ckYGPU8L0NL3eUtOt7Zay+J9H3fkW77R9MC3GNM08YkbpphTH7nPfpzzjsfm6VHeaTpq6pYqum6eFa+KsBpRwR9mc4K+mQDt9RuqS+vbULcYt5BiRumjzpj9znuvHrjsfm6VHeXVq2qWOLdsLfHIOjTjj7M/AXGTyc7ev8XSm+WxlB1rby+F9H29BrWGi2cUNzeWelQW0MCSzSzadhEURyFmYnggAZLdDjP8JrGN94RtLh3vp/D8MB0yxvEaW3RV8ppmUzZJwVO5FLjhsqAelat0NN1SyGn31pNLaXdqsE6f2VcjejxyhhlQCSR/EpGeCPu15B4C0TxJotl4kvdRs7i+12wsINJ0H/AEDyWkslkYoylUdAzkAgzIxJXaTgtQ+W5E5YlSaXNbS++mvoeraFP4U103Z0R/D+pLDJF5htLVZhHumfGdpO3IHQ9QNo5FWLLStOexuGbTrAsGvgCdMORicgc9sDgH+EcGuL+EFle6FBr1pqGn6hFppvopbJtS0wzX8pZv3zzvCCpy+QMkuQCpOAuO0sbu2SxuAbd87r45XSZ/8Anu2OccEev8HQ80e7cunKu4NvmvddH2fkGt6Vp0ei6i8enWCutreMrLphUgg8EHsR2P8AD0NW77R9MC3GNM08YkbpphTH7nPfpzzjsfm6VwfgO78z4e6sbtri4neTVcPLbTXG0CZlUB+QgAHsF5J+9XeX17ahbjFvIMSN00edMfuc9149cdj83ShctxUqlapSjNOWt/08iO80nTV1SxVdN08K18VYDSjgj7M5wV9MgHb6jdUlto+mGWzzpmnnMcec6YWz8knUfxfUdeD/AAmo7y6tW1Sxxbthb45B0accfZn4C4yeTnb1/i6VJbXtqZbMG3kOY4850eds/JJ1GPm+o68H+E0Ll1HJ1uRay+Hs+78ipbaTpxv5FOnWBUWtkwB0wnkySZPuTgZP8WMCraaPpm6X/iWaf/rE/wCYYT/y2Yfh6Y7j5eoqrbXdt9vkcwPg2tkP+QTOTnzJM547569H6DoatJe2u6X/AEeT/WJ/zB5z/wAtmHpxxxjuPl6ihcpVV1ruzl06PsvIqWWlac9jcM2nWBYNfAE6YcjE5A57YHAP8I4NUdQPh64h1+wsotKfUtOtLhriKLTyJLcvloy390kAkH+EdavWN3bJY3ANu+d18crpM/8Az3bHOOCPX+Doea848PSxN8SPjFJ5TGM21sqg2Uh2n7O+PlxmPofmbgUvd5RTqVoVo6ys52/F+R6lfaPpgW4xpmnjEjdNMKY/c579Oecdj83So7zSdNXVLFV03TwrXxVgNKOCPsznBX0yAdvqN1SX17ahbjFvIMSN00edMfuc9149cdj83So7y6tW1Sxxbthb45B0accfZn4C4yeTnb1/i6U3y2FB1rby+F9H29CS20fTDLZ50zTzmOPOdMLZ+STqP4vqOvB/hNVLbSdON/Ip06wKi1smAOmE8mSTJ9ycDJ/ixgVbtr21MtmDbyHMcec6PO2fkk6jHzfUdeD/AAmqttd232+RzA+Da2Q/5BM5OfMkznjvnr0foOhofLcpOt72stl0ff0LSaPpm6X/AIlmn/6xP+YYT/y2Yfh6Y7j5eoqpZaVpz2NwzadYFg18ATphyMTkDntgcA/wjg1bS9td0v8Ao8n+sT/mDzn/AJbMPTjjjHcfL1FVLG7tksbgG3fO6+OV0mf/AJ7tjnHBHr/B0PNHu3BOtZ6y3XR9n5FXxVFoel6NI1zbaZbS3fn2dpnTirSXDk+Wif7Z2nb/AHeh5IrVvtH0wLcY0zTxiRummFMfuc9+nPOOx+bpXCfF64glh8DCKMxn/hL7Mc2Ulvn55O7j5seg+70Nd3fXtqFuMW8gxI3TR50x+5z3Xj1x2PzdKFy3OelXrzqSpXl7vr176fcR3mk6auqWKrpunhWvirAaUcEfZnOCvpkA7fUbqkttH0wy2edM085jjznTC2fkk6j+L6jrwf4TUd5dWrapY4t2wt8cg6NOOPsz8BcZPJzt6/xdKktr21MtmDbyHMcec6PO2fkk6jHzfUdeD/CaFy6m0nW5FrL4ez7vyM9rLR7SW6nvbXTILSCxs5pJJtPwka75d7sx4AwOW6MBjtS2X/CM3l0sFouhTzzxR3kMcdmrtJAZ2AlUA58s5Az0OQuciorpNO1NL6yvrSSS0vNPtbeZBpdwGZWeVXGVAIyDjcMbuinIrxeDwF4iPgzxlBcvd3Otw20WhaJIdOkgaXT4p93Bj4Uy4K4ky3G0tgmknEnETxEZe7zPbv2XkeyeHP8AhHda0m5udLXRdQhSS9Qy21mJVUiXKjcCQDsZSP7qkeoq7reladHouovHp1grra3jKy6YVIIPBB7Edj/D0Ncf8MJdYtLPWrbWrGaHSYnmXSln0kC5VBjeHFuvlKFbIXHKHeDgba7DW7u2fRdRVbdwxtbwAnSZ1wc8ckYGPU8L0NHu8prCVd1E3zfF2fd+RbvtH0wLcY0zTxiRummFMfuc9+nPOOx+bpUd5pOmrqliq6bp4Vr4qwGlHBH2Zzgr6ZAO31G6pL69tQtxi3kGJG6aPOmP3Oe68euOx+bpUd5dWrapY4t2wt8cg6NOOPsz8BcZPJzt6/xdKb5bEQda28vhfR9vQkttH0wy2edM085jjznTC2fkk6j+L6jrwf4TVS20nTjfyKdOsCotbJgDphPJkkyfcnAyf4sYFW7a9tTLZg28hzHHnOjztn5JOox831HXg/wmqttd232+RzA+Da2Q/wCQTOTnzJM547569H6DoaHy3KTre9rLZdH39C0mj6Zul/4lmn/6xP8AmGE/8tmH4emO4+XqKqWWlac9jcM2nWBYNfAE6YcjE5A57YHAP8I4NW0vbXdL/o8n+sT/AJg85/5bMPTjjjHcfL1FVLG7tksbgG3fO6+OV0mf/nu2OccEev8AB0PNHu3BOtZ6y3XR9n5BreladHouovHp1grra3jKy6YVIIPBB7Edj/D0NW77R9MC3GNM08YkbpphTH7nPfpzzjsfm6VU1u7tn0XUVW3cMbW8AJ0mdcHPHJGBj1PC9DVu+vbULcYt5BiRumjzpj9znuvHrjsfm6ULluCdblWst5dH5eRHeaTpq6pYqum6eFa+KsBpRwR9mc4K+mQDt9RuqS20fTDLZ50zTzmOPOdMLZ+STqP4vqOvB/hNR3l1atqlji3bC3xyDo044+zPwFxk8nO3r/F0qS2vbUy2YNvIcxx5zo87Z+STqMfN9R14P8JoXLqTJ1uRay+Hs+78ipbaTpxv5FOnWBUWtkwB0wnkySZPuTgZP8WMCraaPpm6X/iWaf8A6xP+YYT/AMtmH4emO4+XqKq213bfb5HMD4NrZD/kEzk58yTOeO+evR+g6GrSXtrul/0eT/WJ/wAwec/8tmHpxxxjuPl6ihcpVV1ruzl06PsvI8b8SIkXiLVI40VI1upVVUTYFAc4AX+Ee3aijxIVbxFqhQbVN1KQPLMeBvP8J5X6HkUVxvc/QKH8KN+y/I9rvnb+1dO/cT/8f54864z/AMesnH3c575644xjmpbZm86z/dTH93H0lmGfkk6YXj8Mjg44Jxn3lxc/2pYFk08f6cSuNYlIP+jOOW8vgdfm65+XpzUltcXgls8xaeMRx5zq0q4+STqfL+X6DpkD+I12p7n5zKk+RafZ7ru/MLVm/tKX91Mf9Esf+Ws3/PWX/Z79scD+HJq4jHdL+6m/1if8tZv+ezf7P4c855HzZFZFtPdC/k/d2G/7LZAg6rIAMSSf7HXrkfw9RnNYvh7xPqeoeNvF+jy2+mrDpMtl5Z/tCZC3mlpD820hx0O4KuAc8k5oTQVo2kk+tuq7LzOl09m+wXH7qYfPf/8ALWb/AJ7t6r2754P8WDRrzN/YWp/upv8Aj0vOss3r/u9u+eD/ABYNVbG4uvsM4SOwYbr7rqsmcmduMbOe+B/GOTik1ue6Oi6iHjsAptbwErqsjHk9hs5PoP4uppX902VJ+2Tt9p9V3fma98xK3H7qYZkbrLMcfufdfx55xx93mor52/tXTv3E/wDx/njzrjP/AB6ycfdznvnrjjGOagvri8K3GItPOZGxjVpXz+5x3j59M9z8vSo7y4uf7UsCyaeP9OJXGsSkH/RnHLeXwOvzdc/L05pt6GNOk7bfZfVdvU0LZm86z/dTH93H0lmGfkk6YXj8Mjg44JxTtWb+0pf3Ux/0Sx/5azf89Zf9nv2xwP4cmi2uLwS2eYtPGI4851aVcfJJ1Pl/L9B0yB/EaqW090L+T93Yb/stkCDqsgAxJJ/sdeuR/D1Gc0N6lqk/e06Lqu/qa6Md0v7qb/WJ/wAtZv8Ans3+z+HPOeR82RVPT2b7Bcfuph89/wD8tZv+e7eq9u+eD/Fg1zfiXxddaDrugWUlnayJq9+LUumpSEJ88jAltowM7ecHjLDk1tWNxdfYZwkdgw3X3XVZM5M7cY2c98D+McnFF1ciMb80Vumuq7PzLWvM39han+6m/wCPS86yzev+72754P8AFg1cvmJW4/dTDMjdZZjj9z7r+PPOOPu81ka3PdHRdRDx2AU2t4CV1WRjyew2cn0H8XU1bvri8K3GItPOZGxjVpXz+5x3j59M9z8vShPUpUnyrTrLqvLzJ752/tXTv3E//H+ePOuM/wDHrJx93Oe+euOMY5qG9vm06w+2rZ3Vyba0Ewhilm3y7Y5TtX5eCe2OPTgtiK8uLn+1LAsmnj/TiVxrEpB/0Zxy3l8Dr83XPy9Oaw/HV3cxeBdakmtdPljTR5S8Z1OUhgLebKkBAfbaCMZABG4mhPcipTapr/D3Xn5mr4e1KLVY7fUbWC6Fvd6bp1xGJJJlbazyMMgAgHB6AkA/dJNa6Md0v7qb/WJ/y1m/57N/s/hzznkfNkVxXw3nuB4T8P7EsT/xI9JHzapIvADdthweuV6J1BOa6lLi83S/utP/ANYn/MWlH/LZj/zz545z2HzdTRF6DcJSSb/u9V2XmGns32C4/dTD57//AJazf8929V7d88H+LBo15m/sLU/3U3/HpedZZvX/AHe3fPB/iwaq2NxdfYZwkdgw3X3XVZM5M7cY2c98D+McnFJrc90dF1EPHYBTa3gJXVZGPJ7DZyfQfxdTSv7psqT9snb7T6ru/M175iVuP3UwzI3WWY4/c+6/jzzjj7vNVdXuo7W8s7i6DwQRXrSSSS3E6qii0kJLMV4AHJJ5x/s802+uLwrcYi085kbGNWlfP7nHePn0z3Py9K5X4t3Ui+CtdN0lsEMF2AbfUZJ2JNhKo4KrkZPLZ/2cYpt6GCg4xu/5X1Xb1Ow0q8ivYdNurPfPbzQRSRyRzTYdSkhBBC9DntkdccE4htWb+0pf3Ux/0Sx/5azf89Zf9nv2xwP4cmuI+Bl5dyfDXws6xWvliDYrTajJCSFadegQ7Rxjg+n9411ltPdC/k/d2G/7LZAg6rIAMSSf7HXrkfw9RnNDewUYucHK26XVd15mujHdL+6m/wBYn/LWb/ns3+z+HPOeR82RVPT2b7Bcfuph89//AMtZv+e7eq9u+eD/ABYNCXF5ul/daf8A6xP+YtKP+WzH/nnzxznsPm6mqtjcXX2GcJHYMN1911WTOTO3GNnPfA/jHJxRfUtUnZ6dV1XZ+Za15m/sLU/3U3/HpedZZvX/AHe3fPB/iwauXzErcfuphmRussxx+591/HnnHH3eayNbnujouoh47AKbW8BK6rIx5PYbOT6D+Lqat31xeFbjEWnnMjYxq0r5/c47x8+me5+XpQnqCpPlWnWXVeXmT3zt/aunfuJ/+P8APHnXGf8Aj1k4+7nPfPXHGMc1LbM3nWf7qY/u4+kswz8knTC8fhkcHHBOM+8uLn+1LAsmnj/TiVxrEpB/0Zxy3l8Dr83XPy9Oa4D4G+I9X13T9XnvZo7nyNangja61GSLy49rMEXCthF34HpwMYNCe5lNNKMLbx7ro35+Z6Has39pS/upj/olj/y1m/56y/7Pftjgfw5NXEY7pf3U3+sT/lrN/wA9m/2fw55zyPmyKyLae6F/J+7sN/2WyBB1WQAYkk/2OvXI/h6jOatpcXm6X91p/wDrE/5i0o/5bMf+efPHOew+bqaEzWrSd3p26rsvMNPZvsFx+6mHz3//AC1m/wCe7eq9u+eD/Fg0a8zf2Fqf7qb/AI9LzrLN6/7vbvng/wAWDVWxuLr7DOEjsGG6+66rJnJnbjGznvgfxjk4pNbnujouoh47AKbW8BK6rIx5PYbOT6D+LqaV/dNFSftk7fafVd35mvfMStx+6mGZG6yzHH7n3X8eeccfd5rC1HxJaL8R9M8M/Zr7+0WT+1N3my+X5flyxbc/f3ZAOdvQ4zgVo31xeFbjEWnnMjYxq0r5/c47x8+me5+XpXE3yzN8frS88qxLpo8Me86k4Vdz3fAlxuIIXk7DggLkZ5JPQ5HGUeXzTW6/lfn+P4noVszedZ/upj+7j6SzDPySdMLx+GRwccE4p2rN/aUv7qY/6JY/8tZv+esv+z37Y4H8OTRbXF4JbPMWnjEcec6tKuPkk6ny/l+g6ZA/iNVLae6F/J+7sN/2WyBB1WQAYkk/2OvXI/h6jOabep0Kk/e06Lqu/qa6Md0v7qb/AFif8tZv+ezf7P4c855HzZFU9PZvsFx+6mHz3/8Ay1m/57t6r2754P8AFg0JcXm6X91p/wDrE/5i0o/5bMf+efPHOew+bqaq2NxdfYZwkdgw3X3XVZM5M7cY2c98D+McnFF9RKk7PTquq7PzOQ+HJI+GWr4SRv3mr8q8gH+vbsoI/Pg98cZ9FvmJW4/dTDMjdZZjj9z7r+PPOOPu815p8PZJV+HGqKi2xjMmrbi948TDM79ECkN7AkbuQcYFd/fXF4VuMRaecyNjGrSvn9zjvHz6Z7n5elKL1McLTboQfr1Xl5k987f2rp37if8A4/zx51xn/j1k4+7nPfPXHGMc1LbM3nWf7qY/u4+kswz8knTC8fhkcHHBOOFsPiDb618SpPDVrZMlzp88k73UuoyLbSOkRjeNJNu4kCRDu25OSvQAnrra4vBLZ5i08YjjznVpVx8knU+X8v0HTIH8RpprUcbVYe50Vt1vd+f4has39pS/upj/AKJY/wDLWb/nrL/s9+2OB/Dk1cRjul/dTf6xP+Ws3/PZv9n8Oec8j5sisi2nuhfyfu7Df9lsgQdVkAGJJP8AY69cj+HqM5q2lxebpf3Wn/6xP+YtKP8Alsx/5588c57D5upoTNatJ3enbquy8w09m+wXH7qYfPf/APLWb/nu3qvbvng/xYNeX6C7D4p/GNfLkIaytycPJlf9HPUgZPX+IAeuK9Gsbi6+wzhI7BhuvuuqyZyZ24xs574H8Y5OK830Mzx/E34webHbLI9pak/6a23abdiNr7cyEjB2kDPc1LfukVoNVof4+67vzPXr5iVuP3UwzI3WWY4/c+6/jzzjj7vNRXzt/aunfuJ/+P8APHnXGf8Aj1k4+7nPfPXHGMc1BfXF4VuMRaecyNjGrSvn9zjvHz6Z7n5elcPr3xGex+Jdnob6M08EWoWttLdwaq5SO6uoXWFMlcsu0ElgARnHIADU2rGcpRoRTn1TW/dev4nolszedZ/upj+7j6SzDPySdMLx+GRwccE4p2rN/aUv7qY/6JY/8tZv+esv+z37Y4H8OTRbXF4JbPMWnjEcec6tKuPkk6ny/l+g6ZA/iNVLae6F/J+7sN/2WyBB1WQAYkk/2OvXI/h6jOaG9ToVJ+9p0XVd/U10Y7pf3U3+sT/lrN/z2b/Z/DnnPI+bIqnp7N9guP3Uw+e//wCWs3/PdvVe3fPB/iwaEuLzdL+60/8A1if8xaUf8tmP/PPnjnPYfN1NVbG4uvsM4SOwYbr7rqsmcmduMbOe+B/GOTii+olSdnp1XVdn5nA/HC6Ya98NLYxuqyeJUkyzyNysyjHzAf3+3J74NeqXzErcfuphmRussxx+591/HnnHH3ea8S+OEs0nxD+E/nLbLjWpMeTevcdbm36hlG32P8XU17DfXF4VuMRaecyNjGrSvn9zjvHz6Z7n5elCepxUKbeIqL9V/mT3zt/aunfuJ/8Aj/PHnXGf+PWTj7uc989ccYxzUtszedZ/upj+7j6SzDPySdMLx+GRwccE48/8f+OtQ0TxHY6dpOgDXNVHm6kbey1WVtkKQ7NxJTncWZVxyWG30DdZourPqdrpV/YpZmzubaGaJptTliYo0blSw2HYcEZAJAyACQ1Ca1NuaM/3a3Ue/r1v5mV8P/E0Hi3S4dasrS7hguLW1VUkml3Dy7mdD90EclDgA8duciupRjul/dTf6xP+Ws3/AD2b/Z/DnnPI+bIryz4BefbfDvSEjW0ObWFv3moPEcG7uG+6EPqc+gwwyScejpcXm6X91p/+sT/mLSj/AJbMf+efPHOew+bqaIvQtQlOKk+qj1XZeYaezfYLj91MPnv/APlrN/z3b1Xt3zwf4sGjXmb+wtT/AHU3/HpedZZvX/d7d88H+LBqrp9xcrZzbYtPcb77htVl5JnPGNnPfH98cnBo1y4u30bUvMSwAa1vNxTVJCeT2XywD7DgN1OKV/dN1Tft1p9p9V3fmVtM8Ryazq/iaxOmzW8el3f2cTm8kkEzG3LH5doK4BH3uucdAcbV87f2rp37if8A4/zx51xn/j1k4+7nPfPXHGMc15r8NbuabUfiC8EECt/wkV0jpLftwyw7TtYJ84JBxkA8gc7ia7+8uLn+1LAsmnj/AE4lcaxKQf8ARnHLeXwOvzdc/L05ob0OXCxlOnzPXSXVf5mhbM3nWf7qY/u4+kswz8knTC8fhkcHHBOKdqzf2lL+6mP+iWP/AC1m/wCesv8As9+2OB/Dk0W1xeCWzzFp4xHHnOrSrj5JOp8v5foOmQP4jVS2nuhfyfu7Df8AZbIEHVZABiST/Y69cj+HqM5pt6nQqT97Touq7+prox3S/upv9Yn/AC1m/wCezf7P4c855HzZFU9PZvsFx+6mHz3/APy1m/57t6r2754P8WDQlxebpf3Wn/6xP+YtKP8Alsx/5588c57D5upqrY3F19hnCR2DDdfddVkzkztxjZz3wP4xycUX1EqTs9Oq6rs/Mta8zf2Fqf7qb/j0vOss3r/u9u+eD/Fg1cvWyJ90cqKZGyzyzkL+575X8eeccfd5rI1ue6Oi6iHjsAptbwErqsjHk9hs5PoP4upqzqWq3GnQ3V9NDYNFbO87BNWkclVgJOMx89MZPU/L0ovqTOEo07pbc3VeXmZfhXxRbeMdL0HXtOtL2G1u7+QpHNNKXG2CVCCUDDOVJyCTjjAFdFbM3nWf7qY/u4+kswz8knTC8fhkcHHBOPJ/gDPMPhd4P2LabRe3O3zNQeEn5ZxyoU7R1+YEk8Dvx6ZbXF4JbPMWnjEcec6tKuPkk6ny/l+g6ZA/iNCe5KpuVGL/ALq6rz8wtWb+0pf3Ux/0Sx/5azf89Zf9nv2xwP4cmriMd0v7qb/WJ/y1m/57N/s/hzznkfNkVkW090L+T93Yb/stkCDqsgAxJJ/sdeuR/D1Gc1bS4vN0v7rT/wDWJ/zFpR/y2Y/88+eOc9h83U0JmlWk7vTt1XZeZ454n58S6sSCP9Lm4JJI+c9zz+fNFJ4kJbxFqhbbuN1KTskMi/fPRiAWHuRzRXG9z9Dw/wDCj6L8j2u+uZf7V08/b4M/byd32hMZ+yyDOfL6ds4xnjGealtp5BNZkXkK7Y4wCZ0G3CScH5OMZxznGR1yCK95a341awBv9XLHUCAStruB+yvyPkxux+GD60sFveRvZu2p6oirDEd2LUYASXkZTGMZ69s55xXWnvofnEow5FrH4fPu/IitZ5BqUoF5CMWliMeenGJZcD7nbqfTvu6V5V8JdXN38YfiiUlEYa+gUs0yhWMUroWztwckbs4HH5H0+whupbotDqOpshtLAiRBakMPNk24+Xpkcd8k7uMV5J8IrRo/it4xeK8v0n1OSS9jeNIC0iLqU0RZt3AO5V4C9fQDkT8jDFqHtoWa3X5LyPYdPnkNhcA3kJy9+Meehzmdsj7nfqPXtt6Ua9PIdC1MfbITm0vBjz05yeR9zv1Hr229KrxJPb6TeXF1quoWttF/aDSyyfZQiKJ23sx2cDjLe/3eK8K1weJr6xufik82rRaaJwttaSyIHm0lmMcrFFUqGczbvugKNzDd8pBf3bWNa1anRqp6P3m9O13rsfRN9PIy3GbyF8yMeJ0Of3OM8IM8cdueOvNRX1zL/aunn7fBn7eTu+0JjP2WQZz5fTtnGM8YzzUU8dxdWclxBqupywTMZEkxalXU2+QcqnOV9ONvvTry1vxq1gDf6uWOoEAlbXcD9lfkfJjdj8MH1ob02KhGFt4/C+/b0LFtPIJrMi8hXbHGATOg24STg/JxjOOc4yOuQRTtZ5BqUoF5CMWliMeenGJZcD7nbqfTvu6VPaWl959ht1HVs+VFt2ra5xslxjKdOuM84znnFVLS2vTfOq3+qcWlh8wW25HmybR93p6d8n5uMU29VoUow97WOy7/AM3oeafF68/4uj8LIVvEMn9qTyyYlBAAlTYxO3A5MhBweCT04Hp+nzyGwuAbyE5e/GPPQ5zO2R9zv1Hr229K8i8bfbI/jhpsgutQnSGGxtWbzYlaKWbVcgFVXa3CFsMMbgD0AFes2VretYXB+3aqozqAI222P9edxPyZ68tjv93ikn72xzYdRcql2viX5S8iTXp5DoWpj7ZCc2l4MeenOTyPud+o9e23pVy+nkZbjN5C+ZGPE6HP7nGeEGeOO3PHXmvMvGM/ifxLqmseH9C1S/0/S9KiuG1XUpTBv37RIII0RQSvzxM57jcoxyG2/h5rWo+LPANtql5f6il8ZJYLyNRblUnjiZH6pnnbuxzhW6luaaeuxcKkJS5NFa+vR7baHW31zL/aunn7fBn7eTu+0JjP2WQZz5fTtnGM8YzzXO/EeZz8OfEI+1RHGiTjHnLwPs04x9zryRjryBnkEb95a341awBv9XLHUCAStruB+yvyPkxux+GD61zfxFtrtfh3rzPfXzoNDmO2ZYdhH2af+4obpnHPrnPApJ76FVVBUr3j8P8An5FfwRqkeleA9Lvby/iS1s/DmlzSssoYqkaux+URknaATgZI/wBrpXTaDrtrrmmpqWk6pb3FlcMjxyrMo3YnfsY8gg5JBAx1I/hHj00N94q0Pwr4F0u+nkhv9D0yTWcGINZ2ibWVVIUDc7SIEBJbBYuNpDDovCdjdeDPiNqfhiOW6s9J16Y6npnkLbhmmjdVnjbcp5GA4VcKBnjGcEXboc/tYuSSty+6r+dl5eXY9B0+eQ2FwDeQnL34x56HOZ2yPud+o9e23pRr08h0LUx9shObS8GPPTnJ5H3O/Uevbb0qOytb1rC4P27VVGdQBG22x/rzuJ+TPXlsd/u8Ua5a3q6JqTNf6qyi0vSVZbbBGeQcJnHrjn+7Rf3dj0FGHtlrH4n37vyNC+nkZbjN5C+ZGPE6HP7nGeEGeOO3PHXmuC+Pl/5Hw71d57qOVGd0wkquSXtnQNgKuR8wGcj0x3ruNRtL7Zc7tR1b/Wtnetr1+znrhOuPTjHvXC/tA2V03wq8Rxz3epTeZdWsapMYFBYywjnywCTgnjle+MjIbd1scdRwp0+a6+FrTzVuwfAF3t/ht4fgFxFE9u00LFpFQZWe5GeVb/JHqCOztZ5BqUoF5CMWliMeenGJZcD7nbqfTvu6Vx3wcnvtUtNTl+1XcEq65ehltEiCljLO5IEoJH3z36Z74NP8d+Irnwrp0rW99qUutXlpZW2lW2y3Y3Nyzy+Uu0LnYGGex6gnJUUm9tAo8kaDlJr4V67+h2VlqkF1NeJa6rZTSQTokyx3cbFHEzHDYTgjO7twc4IOBHp88hsLgG8hOXvxjz0Ocztkfc79R69tvSvK/BPhOf4f/EPTNKhv71F1rS83UqyRySXV/BdAu+HBAXbIdvfjknkn1Cytb1rC4P27VVGdQBG22x/rzuJ+TPXlsd/u8U767F0HGpTblZPm/R+RJr08h0LUx9shObS8GPPTnJ5H3O/Uevbb0q5fTyMtxm8hfMjHidDn9zjPCDPHHbnjrzWfrlrerompM1/qrKLS9JVltsEZ5BwmceuOf7tW9RtL7Zc7tR1b/Wtnetr1+znrhOuPTjHvQnrsaqMOVax3l38vIL65l/tXTz9vgz9vJ3faExn7LIM58vp2zjGeMZ5rx39kx518FahNJOkLSay7bnlVMn7Ohzyp7N1/2h65Hrmpw3sN/aO+o6qMXzHe4tRsItHOeExnA9xt/wBqvKP2cEnWLULC2nvIGiGm3J+yiEhvN09SP9YD83yn0755xUp67HJW5VOmk1rF+nXyPVrWeQalKBeQjFpYjHnpxiWXA+526n077ulNs9esrrVb7TrbWrCXULdkea3S7jMiDzydxXZnALqc9PmHXO0c54x1y58K6XdXiXepT6g1pYQ2Frttibu4aSURRBQAxXcM/L82NxOcAVwer+Cbv4f6FovjCzku31fRZhda7L+4Z7hZnK3RU7fnIYDZvyBgnrjLT8i8VUUJtKztZv7l5b/oew6fPIbC4BvITl78Y89DnM7ZH3O/Uevbb0o16eQ6FqY+2QnNpeDHnpzk8j7nfqPXtt6VW0hZ73RmurXU9Te2mW+eN1W22uhmJ3cpnB6n3Py4FS65a3q6JqTNf6qyi0vSVZbbBGeQcJnHrjn+7Rf3djsUYe2TvH4n37vyNC+nkZbjN5C+ZGPE6HP7nGeEGeOO3PHXmvJNb1a50/8Aah0q4aTdZ3NjFp0l0siNGs0onMI3bMBmKFR8ucbuvf0bxje/2Bomp6prGr6rBZW7kyySLa9TDtA4TliSAAOuRj5q+dLiO+k8Z3viPX7m6gkfUNL1wC+RVkghN28cKvs4GIWVjgDHTHFDZ5OMlGMYKLTfl/wyPqC2nkE1mReQrtjjAJnQbcJJwfk4xnHOcZHXIIp2s8g1KUC8hGLSxGPPTjEsuB9zt1Pp33dKntLS+8+w26jq2fKi27Vtc42S4xlOnXGecZzziqlra3v251F9qvFpYHcFtuR5sm0cp0z075J3cYpt67HpKMPe1jsu/wDN6Ggk8m6X/TIRmRD/AK9Of3zHP3PXn6HPIOBU02aV7KdVu4mLSXyhRMpJzcNwBs53dh37belTR2l9vn/4mOrf62POFtev2h+vydc59s5zxiqMRvLLSby8bUNVjS3GoythbXACzsWPK+2T7/d4ob12E1BQk7x3Xf8AlfkeU/APUEu/hR4kktmjto2udQOxpwXYNHE3zZU5bBA+XaDt7HJPp3xD8Tf8Iz4T1nWZp4roWxysSzK3myPGI0HCA4LMqkjpzxxuryb9nS1uY/hJ4gVbm8jVXu3MMaxbWVra3bLbgTggjODnAGMHNdXrdrfeNfiJJarfXdx4c8NTNLdm4SE+dqBgbYiFF2MYQAzZOVJxjOCUmckGlhoWau7rrfp5fPc5yx8Nt4BvPhtqdxepPqT61NDqEyzf6y4voAGYkggBSgXPfaeM5r2y2nkE1mReQrtjjAJnQbcJJwfk4xnHOcZHXII474sebYaTYXV7dXsvk+ItNdDdR2xVHEsR3ZRQVbaCMjjBIPU11lpaX3n2G3UdWz5UW3atrnGyXGMp064zzjOecU0/IKVKMOZNq1l+Xp5EFrPINSlAvIRi0sRjz04xLLgfc7dT6d93SriTybpf9MhGZEP+vTn98xz9z15+hzyDgZ9ra3v251F9qvFpYHcFtuR5sm0cp0z075J3cYq3HaX2+f8A4mOrf62POFtev2h+vydc59s5zxihPyOyrGF3rHp37LyINPnkNhcA3kJy9+Meehzmdsj7nfqPXtt6V5d4enLfFD4ySLfQS7rOBTKsgw/7hgUBwQSOhA28j+HpXptla3rWFwft2qqM6gCNttj/AF53E/Jnry2O/wB3ivD/AIRztqHib4m31v8AaYRqNrc3zGPZ86m4uBht+fl6A7eeOD1qW/dMayisVTtb4n+foe6+JNWj0zSdT1C+vUa2thJPL5cqOxVbc5IGwZ4G0cjnjg/NXg/iaHVoPgNe63LK413WNXXXLmIyKxjOd6YXbnYsaIcE8HIxxXoPxWd9YvoPArPf6jc6pOl5eRTtEq21nD5bySOYVDAtsMa8hTu67hW38StEvdV8N6jpxu9Qla5M8SC4FuFVzYyYJ2KD6dONvbNOTuZKMZt6q0Yu3rbpp007HUxTstza+XeRKqpGFJuE+UBZMAnZxjOO/UdcgijazyDUpQLyEYtLEY89OMSy4H3O3U+nfd0rG+G13da54R8L6jDquoyNNYW+4w/ZSA6xyq6jKdmDjB5GGzzitW1tb37c6i+1Xi0sDuC23I82TaOU6Z6d8k7uMUN7aHRSUHBtuO0e/deRoJPJul/0yEZkQ/69Of3zHP3PXn6HPIOBT0+eQ2FwDeQnL34x56HOZ2yPud+o9e23pU8dpfb5/wDiY6t/rY84W16/aH6/J1zn2znPGKqWVretYXB+3aqozqAI222P9edxPyZ68tjv93infXYtRhZ6x3Xfs/I8W+M1y938bvAVq0qSC0uILkEPvGZL8KcbQBk7c8jGMeoFe8308jLcZvIXzIx4nQ5/c4zwgzxx2546814L8S1S4+NOjySveS3VhdaXa+ZIEC4kv5pG37QBu4TG3jhvavU/iLrV94c09hb3Gq3usXt0bewsnS2InmMGPnKqNqgHLNkAJnkGknqedRcI1aknbT/Ppoc3piXXiPxz4p1W9O2znu/7FtPtLiPzI4La5SYj5QGQyO43EDBBUHrjU+BeqT33wz8KTyTRW5S2FuoaYDAiaeIH5lbH3fcDdgYBAW/4M8K3fhXQfDWjLc6jHLb3OJhC0Dr57WsjyspcEkli55OMN0BwBz3wlkkRvF1ql7e240/X7pkgt/JOyB1eWM/vFOCd0nQ44PfGUna5ryxioNtaxf5t9v8AM0/hDCNP8FaFBBdoqNo+mzEPMgIZ5JZDxs6BnJ9hgnPSu2SeTdL/AKZCMyIf9enP75jn7nrz9DnkHA4n4Ux38/g3Qi11ewkaPpigWwgK7Q8iqPnUntn/AHi2flwB2Mdpfb5/+Jjq3+tjzhbXr9ofr8nXOfbOc8Ypxemx0RjBwV3HaP5R8iDT55DYXAN5CcvfjHnoc5nbI+536j17belO1h55tH1CKK5jlkktbtFRJlZmLH7oATJLHoO/bHSobK1vWsLg/btVUZ1AEbbbH+vO4n5M9eWx3+7xVuaxuZIJUur3VJLdoroSI4tgrJvG4EqoIH97BB/u0J+7sazdOFTnvHRt/n5HiP7Ol9JJdePIY7gi0+3i4RWKgbpBcqxyQSciNQB/InNe3X1zL/aunn7fBn7eTu+0JjP2WQZz5fTtnGM8YzzXz3+zLazWh8QWZmngmns7S7Vowm5kaK5b+IEY/eD3x0r2/wAX6nF4Zjh1XXtb1OzsIL/95PIlsShNswGAqHLHOMAEYPTdRfQ48FyeyvJraW//AAxs21y6z2Q+2wK3lR7czoMAI4/ucYzg9cbh1yCKlrPINSlAvIRi0sRjz04xLLgfc7dT6d93SvIL3TNa8Paba/EnV2uk1sXNrcTr5rb7XSpFaP7NtAUF0BVzmPG9GLKR971y2tL0X8ii/wBT4tLD5lFqQR5smMfLjGR8vfJ+bjFDeq0NaFSNTnvZbfddeRfSeTdL/pkIzIh/16c/vmOfuevP0OeQcCnp88hsLgG8hOXvxjz0Ocztkfc79R69tvSp47S+3z/8THVv9bHnC2vX7Q/X5Ouc+2c54xVSytb1rC4P27VVGdQBG22x/rzuJ+TPXlsd/u8U767GyjCz1juu/Z+RJr08h0LUx9shObS8GPPTnJ5H3O/Uevbb0rL+KF1IvgDxWxuo5f8AQrokJMjE5tGGeEHGOM/hjPNaGuWt6uiakzX+qsotL0lWW2wRnkHCZx645/u1zPxwmu9K+GPim6uLzUpIypgZZkg25liEQzsUHPzjocYx3pX12M6ygqLs4/a/TyMP9nqZ0+FXgwLdRRAX90cNKqYOLgZ5Q8ds9O2O9epW87rLZFb2IERx9ZkGzCycZ2Hpnv03Y5yCOJ+GejS6X4d0mxsbu9jhg17UoEjthb7Yikl2uF3rnOF78YPAzirPjvWtU8L6Ba3WnXGq3esXAgtdNtfKgYTXDpKEGFTOwAMxyR8qtkglaE9yL0/YRk2vh8+78jo7aScXryfaoxGbayQEzKBlZJDt+51XcCR2BBOc4q0k8m6X/TIRmRD/AK9Of3zHP3PXn6HPIOB4pomjXXwv8V+HALm7Frr9vb2ut3zTI+6+eWSWGZd+c7ikiDcAAOWwTk+zR2l9vn/4mOrf62POFtev2h+vydc59s5zximn5BCaqpuaUXdaP5W6HiviclvEurMWDk3cxLAgg/OecgDP5CijxOGXxLqyyNIzi7lDNJt3E7zydvGfpx6UVxPc/TMP/Cj6L8jtLj4PeDIdStFTQtTE0t4Ymm/tObzf9Q0mc+djdlc56YJ71JH8KdEvJbKHVJvE2qWTLG4s7zVWlhyVcghC2MZQEBvQ5HQV095pOmrqliq6bp4Vr4qwGlHBH2Zzgr6ZAO31G6pLbR9MMtnnTNPOY4850wtn5JOo/i+o68H+E12JPU/MnhcOoJ+X8r8/M4i3+GkdlqK/8Ivq/iHRIYILeaK0jnjuLRWnaRZCIJSy4YgEejZ6cYwE+El6njqwhstR8R2Wh2GlNAdRtb6OK6lme/kby2YdSfMc5xjIHNel22k6cb+RTp1gVFrZMAdMJ5MkmT7k4GT/ABYwKtpo+mbpf+JZp/8ArE/5hhP/AC2Yfh6Y7j5eooSY62FoX0bVrdH1S8+pwtl8LbO8t0/t/Ude1mwsp7ue3sr2WExeZHIU3y7QDLjBOG/vEAEM2e18Q6ZbSeGtUt5rBntjZXitEY4QpUcY+XBAA4OMEfw4FQ2Wlac9jcM2nWBYNfAE6YcjE5A57YHAP8I4NGt6Vp0ei6i8enWCutreMrLphUgg8EHsR2P8PQ0a8p0Ro0lV5e7a2fn1uca/ww1vQl8jwt4212xsIVEBi1O1ttRKbYsgISVCKE4CgEDAwc4AdffDXWtR1DTl8R+MvEVxN9pa3zpkVtpwH7l5AQqZG7gDknjPPOB3d9o+mBbjGmaeMSN00wpj9znv055x2PzdKjvNJ01dUsVXTdPCtfFWA0o4I+zOcFfTIB2+o3UO9jCnRpW+J7Po+3+I42w+FlxK9r9u8Y+N3kZEKm0v4rfgoxHQEk/IeSQTznHfNt/hlquh3k7eBNf1CxllW3vJ49RhgvI55Ji6Ekt83JQEZyck5xnNekW2j6YZbPOmaecxx5zphbPySdR/F9R14P8ACaqW2k6cb+RTp1gVFrZMAdMJ5MkmT7k4GT/FjAoadx/V6PvO72XR9/8AEeeaz8MNeu9J1lpNTuL7xDqd/p+byCKG0SzjinZd6oH+Yj5zwwyQAMY+a/afCsvbXjf8Jb47SHNxsRNUjXBikKlmwMNk5J4zzxnqe/TR9M3S/wDEs0//AFif8wwn/lsw/D0x3Hy9RVSy0rTnsbhm06wLBr4AnTDkYnIHPbA4B/hHBos7ijhqKu7vddH2b7lO18JaX4X8HajYaNYXENuLa9lYyGORnccF2ZssTwMnOf7vFYut/DvUrbV9bvfDPiLUtEt765a5ltDa29xGLgw7mkG48biAzBeD69AOm1vStOj0XUXj06wV1tbxlZdMKkEHgg9iOx/h6Grd9o+mBbjGmaeMSN00wpj9znv055x2PzdKetzT2VJwim3o5W0fl5nGv4d8f2l1awNrmk38guysUtzosSOX8lmwwSUKBsBHAxznqM1znxI8NeNbjwNrE2o+JLKOzSwe5ktrTSI182MQs3l72kLAHy3O773zHOcKo9RvNJ01dUsVXTdPCtfFWA0o4I+zOcFfTIB2+o3Vz/xBsLC1+H+vSw2VrFJ/Ys4DxWJRgWtphncB78noRz0U0lfUxq0oKlfmfw+fn5kHwn8IWHhrQbeGysJ0nutP025u5GMcjSzMXUnL5IXjCrwBzkDJzf8AHvgt/FWmxxWdzdabqNjexXVpdJFC4jlEsiDcmRuBBIxnGRz8oFWNC0rT2jt1ksLF8afp7HdpzPli8m45PUnAyf48YrUTR9M3S/8AEs0//WJ/zDCf+WzD8PTHcfL1FEb2L9nT9mo9Pd+z5LzOFi034kmzmW2m8KrEj3J81rBw7bJSJCR5hAy2enIH3ak1S0+Jot75Xg8BmwWK4ZpZoLmNjGpw+QjOQR7EkZ+U11dlpWnPY3DNp1gWDXwBOmHIxOQOe2BwD/CODRreladHouovHp1grra3jKy6YVIIPBB7Edj/AA9DRry3L9hB1UueXxefd+f4nEn4Za7dabc3viDxRrMHic3JlWawlVbK2xEWCLb5AZcHJ6E465yGoaho3xH1a70Dw74k0fTGtl1a3kvNWs5oQlwsIMpTyiqsrMqK3GFzxgZOPUL7R9MC3GNM08YkbpphTH7nPfpzzjsfm6VHeaTpq6pYqum6eFa+KsBpRwR9mc4K+mQDt9Ruod7GCw1KS0k1dNvR66X6tnjXw+0zx3car4wk8K3+kLaQ67d28FjfWokjkkLOWfzOGAAOV5YEryBgZ7vwp4DltPEp1XxFqeoeINVgt7ZrWeSGGCKBZXZG2QglVLKignqec8E56620fTDLZ50zTzmOPOdMLZ+STqP4vqOvB/hNVLbSdON/Ip06wKi1smAOmE8mSTJ9ycDJ/ixgUO6saU8PSimnJu1t0+/qZPjrwhqGszabqXh2SOz17R7wS2r3aKYZFeR43hl2EEI4wDgE/KQMAgjDsLb4oNazGOx8GQxB7nd5xlZsrKRKQyqNo3Z28MQMYxXepo+mbpf+JZp/+sT/AJhhP/LZh+HpjuPl6iqllpWnPY3DNp1gWDXwBOmHIxOQOe2BwD/CODTd7lOlBtyU2rtdPJ+Zx2o6Z8S7fTr37VceFLi2e3uJJ2+wuGhAP7xIsONyryFZsN7Co7zwb4611TbeMdWtdPs7UMyS+Gybeea4EYZWlZh91VBO1MAk55IFdrreladHouovHp1grra3jKy6YVIIPBB7Edj/AA9DVu+0fTAtxjTNPGJG6aYUx+5z36c847H5ulLW5P1em4pSlJrXo/Lz/wCHPN9e074nafoz2s+maJ4iuWme3gltpI7Sfc0DgNJEy7G+Vt2I3GMZ4ILDnPBum+L9N+IWvaF4TXRpzBY6TBc3WpQMxRksVVTGqsFyVDNhvRc817PeaTpq6pYqum6eFa+KsBpRwR9mc4K+mQDt9RuqeHTbGQ6fFJY2TxpGm1G00sq5WQnjvk8kjqef4TQkzKeHi1GTm3p22Wvn3ON8O+C9Rk8Rwaj4u1J9buLCG3msUisbe2hhMzMhZlBJlbCnaXJ2l2OB1rt5tNiuoLy3ntZXhlxDImyHlWldGU/UZXjjqD8uKzLbSdON/Ip06wKi1smAOmE8mSTJ9ycDJ/ixgVbTR9M3S/8AEs0//WJ/zDCf+WzD8PTHcfL1FNXOiVOnC6TetujfReZwOleHPH+j6d/Z+gX3h670WzE8Fq+swut0kMTlNrGIMrbQFUNweOABV3Vbb4jDTbxWsPBSRrC/myzSzuhjAInIVIlYENgjnKjIG/qOmstK057G4ZtOsCwa+AJ0w5GJyBz2wOAf4RwaNb0rTo9F1F49OsFdbW8ZWXTCpBB4IPYjsf4ehpa8oo4eKmoRnJK9tvXre5zVr4F1m81Mat481D7dPaz+da6dYQrb2dnOiF1kGH3SMABgsPlDPjJIrnvGnhkeJ/il4l8OlJFW+0m3iVWwgSQJcvGW8sgELIqPjvt6HpXqN9o+mBbjGmaeMSN00wpj9znv055x2PzdK4m1sLM/G7VLf7La/ZhBZDyPsJ8vmK7P+p69efrzSlexhKnT91JvW99H/K/P8Cx4a17xCNL01fEHgrW31VYUW4a1SxaOVgr/ADr8wGG+9jHGCOcA1LaeIpJL/VJI/B3iphZ29ssga0s1LbZJctGDJ+9DYIUoW3EY5yM9TbaPphls86Zp5zHHnOmFs/JJ1H8X1HXg/wAJqpbaTpxv5FOnWBUWtkwB0wnkySZPuTgZP8WMCm+a5tGnZSSqPZfZ815nMWvxJ8P3t2ljpem+IL/V5ZIt2nRaUEmgVpTlpDIqxoBlFJ3Y3MByvTn/ABX440K5+Gfi22V7jT9XitryObT9QgW2uITPKRGGQLk5WQfdyPmAyBnHqSaPpm6X/iWaf/rE/wCYYT/y2Yfh6Y7j5eorK/4RrQtRgFxf6LpdzPbNerDJLpWWjC3D7QpPQDJI7JnnmnrfUipCbg1Gd7u2sbdH6nlZv28K6Bqfh3Qlijvb7WJNPgF2qymGBNPtvNnA4BZAo2qccsuScEH17RPCtn4X0I6dYwXZWKR2knuDE8s0hhLvJI5ySzNljzgDpggY8iv9OW4+Kd4YQix6fNrM3lrCVVVNhaRjC9h8/A/hxk9MV7RfaPpgW4xpmnjEjdNMKY/c579Oecdj83SlFu5lgox5VKTel0tL9vPzMX4n+Ex4n8PXOipZu091NJHAJDHGqzC0d4iWTBGHCsQOMDkE5B57TfiNFC8MHiXwr4ksNUiRPPht9MW5jbhxvjdVIZWOMH2PJwDXb3mk6auqWKrpunhWvirAaUcEfZnOCvpkA7fUbqkttH0wy2edM085jjznTC2fkk6j+L6jrwf4TQr6nRUgmoyU2vd/l835nGW/jzQYLt5tVsPEWmK8FvGPtehSjcY2kaQjER4CnOepwc5AqwPiX4GWC9ml1qOBYGRjHcQLBKVLFwVikUOwKFSNqkHOOmBXQW2k6cb+RTp1gVFrZMAdMJ5MkmT7k4GT/FjArQttPsoJJDBZWcZWVSpTTmGMzMDjHTgAY7gbeopq4VVON7Tu9N426LszmPB3i7wrrUVxDa6kiSRm6nkiuUitpFiZxIkmyRVbZ5bq24Dv8vQ14L4I1y503wvNJZLE+p6npcFjbLMoKCWfULoZPHACljkc5x2zXv8Ae+DfDmvaef7W0WwuDBJfGMnT3QricgcgjjAA54UDBryj4nQx6d8QbG3srYC0trrStttGDEnlRSXr7AP4RiPpzip6JnJjI1nV5k9eay3Wt/Pb7z1nwr4Gt/C1hdyT/adQ1ueVjeancJF5kx8ndt6nag7KpwB/tAV0d5ZhdW03bbXAI1AgYS3yP9Fc49M9/T8ar32j6YFuMaZp4xI3TTCmP3Oe/TnnHY/N0qO80nTV1SxVdN08K18VYDSjgj7M5wV9MgHb6jdVO9jtpRhGNot/C/s+XqeZ+EL+5+HM0/h/xB4f1qfR4pzcadqGm6eLmFoJd8mxsJwys4BHPfsq1u2PjrR31Jmk0jxPHFJBbxrK2gyFWdHYuoxGT0cY4553dq7O20fTDLZ50zTzmOPOdMLZ+STqP4vqOvB/hNVLbSdON/Ip06wKi1smAOmE8mSTJ9ycDJ/ixgUnciNNxTUajskvs9L+pyUHxY8F3U8sGly6rql15qqLez0h3k4kYngxjHy44/DGBiol+IOn6TpIvdd8N+J9K0u4kuRHfXOnw+XGzTNgShCWjIJC8jOcgYxXepo+mbpf+JZp/wDrE/5hhP8Ay2Yfh6Y7j5eoqvpmnWKW0syWNks0cl6UkGnFWUrOdpDdiMDB/g6U/euNxk02qj3X2fJ+Z4x4g1TSpPF+tazb32n3+nnX9FtoJreaJjAkbLM7tgFdpMjICpXlGGcAg9f8L9Jvde0+Hx54kmkuNVvoHitoIYo47azgKF9qL3ZgEYvjOOByMnM/aF0fS9J+FE40rSrKyMV15kf2K0FoEfzkBcgDD/KAMdRxnOK6/wAB6VZN8N/DrXFjbSTHTrbc01iWf/jzXguR27Dtjd0oV7nFh6a9t7789ut+2h1d9Yr/AGrp6/ZZ/wDj/K48u3z/AMeshx6Z7+mPevOvElnqvhTxFqWvaX4dudY03V7C3a98h4vPgljjkRWSMn51ZSM4G4eWScda7q80nTV1SxVdN08K18VYDSjgj7M5wV9MgHb6jdWX4o06wtvC9/cQafYrNHpryKy6fghhDMQc+uQPm6EgH+E0tdTtrxjOmnzPSP8AL6+ZxPgLUPFl1pGh2+keEk8gaTp6Ne6jewRxlcMI2VUV3IcnHIyNpDdcDoJbL4oebJ9nt/AwQuqlZPPkKZkYDkIo+8COMj2IxUvw30+yufCegNcWdpM39h6ScyWJlOSGBO76AA+oAXtXUpo+mbpf+JZp/wDrE/5hhP8Ay2Yfh6Y7j5eoojexmqacFeb2j08kcTb6T8RbixeA3HhfTov9KE15awNdShhKfMaON1jUBWOBuJPHHBrO8SW3xH0HRr+EWem+J9PaC5jW5URWV5GucNJIuDGQhIA2kHAzxya7yy0rTnsbhm06wLBr4AnTDkYnIHPbA4B/hHBo1vStOj0XUXj06wV1tbxlZdMKkEHgg9iOx/h6GjXluayw8ZT5XUlq2tvXzt+B5npXw28W2Gr6ZOuojSNObRbWy1IWsFu1wJ7eFSY9zAj5gWYSjcRtK4wFz2ekfDTQdA8R6Xfw2eq3urC5e1a+1G5W5mkU2ztg7yUDe4UfLx1zXSX2j6YFuMaZp4xI3TTCmP3Oe/TnnHY/N0qO80nTV1SxVdN08K18VYDSjgj7M5wV9MgHb6jdQ00jKlhqKXV6N6xfb1LZ0u3vY4La6snnt7iBFkieKBhIrJJkYIwQcfxehzzivNdC8M+OPDcs9hoT6NqmlQRW0lsNVdkuhAzMI4FcK6kAh1UtjggH5cKvodto+mGWzzpmnnMcec6YWz8knUfxfUdeD/CaqW2k6cb+RTp1gVFrZMAdMJ5MkmT7k4GT/FjApu9zaVOEnJ8zTSXTz9f63MC3j+ItxMZRo3ha1g3rvt57xmlBMhUDesBX7wI4GMDHTFQW1l8Qk0e4SG28JNdLPdSGbzJfK8sOfMQL5QYuHJAbIAAwB3rsU0fTN0v/ABLNP/1if8wwn/lsw/D0x3Hy9RVSy0rTnsbhm06wLBr4AnTDkYnIHPbA4B/hHBo1uKNNWf7yW66eTOW1jTviObKZ5T4NgtkgkaVBFNMHCribcwVGVNxyNoLKOATj5ud8e69fazoD+FPEfhHU9C1LVdQtbdpJGhezCiSOUqtzGADIVjJCAD2y3X0vW9K06PRdRePTrBXW1vGVl0wqQQeCD2I7H+Hoau3el6fFHeLFp9iiu7IwTTSmR5W7HsMgHB6EBu1LVuxnLDqUEvaS1v07Neen6nlHh7S/HOpi7t9LudK0uwPiTUI7e9a0F3dGQSzs52yME2Y3qAwJyCeDg12Xh34fi38Q6Vq+r6rrms39urfZlnaBIYlkSQArEoCl9gwWb73zHCkit+80nTV1SxVdN08K18VYDSjgj7M5wV9MgHb6jdUlto+mGWzzpmnnMcec6YWz8knUfxfUdeD/AAmhJiWGpRgryb0vs+76XMfxL4Zj8SaXq2lslzC91p1mI5k2L5cpklMcnysrHa4VgMjJUbuK57S9b8ewb4da+HhndCENzp+oWhSSQOwGI3GVRnVhkngYyGwAeuttJ0438inTrAqLWyYA6YTyZJMn3JwMn+LGBVtNH0zdL/xLNP8A9Yn/ADDCf+WzD8PTHcfL1FNXNq8IubkpNPT7PkvM8Y1KUT6jdTXel6xaXEkrvJb/AOgnymJJKZ+0rnB4+6vToOlFP8SIkXiLVI40VI1upVVUTYFAc4AX+Ee3aiuRtX2Ps6ODxbpxaxL2X2Y/5HsF5dWrapY4t2wt8cg6NOOPsz8BcZPJzt6/xdKktr21MtmDbyHMcec6PO2fkk6jHzfUdeD/AAmp752/tXTv3E//AB/njzrjP/HrJx93Oe+euOMY5qW2ZvOs/wB1Mf3cfSWYZ+STphePwyODjgnHWr6nx0muRaP4e67vyMm2u7b7fI5gfBtbIf8AIJnJz5kmc8d89ej9B0NWkvbXdL/o8n+sT/mDzn/lsw9OOOMdx8vUUWrN/aUv7qY/6JY/8tZv+esv+z37Y4H8OTVxGO6X91N/rE/5azf89m/2fw55zyPmyKFcqq1d6Pp1XZeRkWN3bJY3ANu+d18crpM//Pdsc44I9f4Oh5o1u7tn0XUVW3cMbW8AJ0mdcHPHJGBj1PC9DVvT2b7Bcfuph89//wAtZv8Anu3qvbvng/xYNGvM39han+6m/wCPS86yzev+72754P8AFg0teU0TXtlo/ifVd35BfXtqFuMW8gxI3TR50x+5z3Xj1x2PzdKjvLq1bVLHFu2FvjkHRpxx9mfgLjJ5OdvX+LpWhfMStx+6mGZG6yzHH7n3X8eeccfd5qK+dv7V079xP/x/njzrjP8Ax6ycfdznvnrjjGOabvYxptW2fwvqu3oQW17amWzBt5DmOPOdHnbPySdRj5vqOvB/hNVba7tvt8jmB8G1sh/yCZyc+ZJnPHfPXo/QdDWtbM3nWf7qY/u4+kswz8knTC8fhkcHHBOKdqzf2lL+6mP+iWP/AC1m/wCesv8As9+2OB/Dk0O90UnH3tHsuq7+gJe2u6X/AEeT/WJ/zB5z/wAtmHpxxxjuPl6iqljd2yWNwDbvndfHK6TP/wA92xzjgj1/g6HmtdGO6X91N/rE/wCWs3/PZv8AZ/DnnPI+bIqnp7N9guP3Uw+e/wD+Ws3/AD3b1Xt3zwf4sGjW4Jx5Xo911XZ+RU1u7tn0XUVW3cMbW8AJ0mdcHPHJGBj1PC9DVu+vbULcYt5BiRumjzpj9znuvHrjsfm6Ua8zf2Fqf7qb/j0vOss3r/u9u+eD/Fg1cvmJW4/dTDMjdZZjj9z7r+PPOOPu80K9wTjyrR7y6ry8jPvLq1bVLHFu2FvjkHRpxx9mfgLjJ5OdvX+LpXIfFy8hPwy1oRQyhzp6nP2CWH+F8kuwx+P8XGOld1fO39q6d+4n/wCP88edcZ/49ZOPu5z3z1xxjHNcx8To765+HesW2mW19LeT6d5McdtHJPJJujkUqqEYwQSOM4GSueaFfUyrNex2fw915+Ro6ZdQiZWlhkZzZWAZjpMxJbzJMk4HfPXo/QdKvpe2u6X/AEeT/WJ/zB5z/wAtmHpxxxjuPl6ipFdTrV0YoZvL+zWW3Ekw482XHAXAz2xwP4cmrCMd0v7qb/WJ/wAtZv8Ans3+z+HPOeR82RRG9inZRSaf2eq7LyMixu7ZLG4Bt3zuvjldJn/57tjnHBHr/B0PNGt3ds+i6iq27hja3gBOkzrg545IwMep4Xoat6ezfYLj91MPnv8A/lrN/wA929V7d88H+LBo15m/sLU/3U3/AB6XnWWb1/3e3fPB/iwaWvKbpr2y0fxPqu78gvr21C3GLeQYkbpo86Y/c57rx647H5ulR3l1atqlji3bC3xyDo044+zPwFxk8nO3r/F0rQvmJW4/dTDMjdZZjj9z7r+PPOOPu81FfO39q6d+4n/4/wA8edcZ/wCPWTj7uc989ccYxzTd7GNNq2z+F9V29CC2vbUy2YNvIcxx5zo87Z+STqMfN9R14P8ACaq213bfb5HMD4NrZD/kEzk58yTOeO+evR+g6Gta2ZvOs/3Ux/dx9JZhn5JOmF4/DI4OOCcU7Vm/tKX91Mf9Esf+Ws3/AD1l/wBnv2xwP4cmh3uik4+9o9l1Xf0BL213S/6PJ/rE/wCYPOf+WzD0444x3Hy9RVSxu7ZLG4Bt3zuvjldJn/57tjnHBHr/AAdDzWujHdL+6m/1if8ALWb/AJ7N/s/hzznkfNkVT09m+wXH7qYfPf8A/LWb/nu3qvbvng/xYNGtwTjyvR7rquz8iprd3bPouoqtu4Y2t4ATpM64OeOSMDHqeF6Grd9e2oW4xbyDEjdNHnTH7nPdePXHY/N0o15m/sLU/wB1N/x6XnWWb1/3e3fPB/iwauXzErcfuphmRussxx+591/HnnHH3eaFe4Jx5Vo95dV5eRn3l1atqlji3bC3xyDo044+zPwFxk8nO3r/ABdKktr21MtmDbyHMcec6PO2fkk6jHzfUdeD/Canvnb+1dO/cT/8f54864z/AMesnH3c575644xjmpbZm86z/dTH93H0lmGfkk6YXj8Mjg44JwK+pMmuRaP4e67vyMm2u7b7fI5gfBtbIf8AIJnJz5kmc8d89ej9B0NWkvbXdL/o8n+sT/mDzn/lsw9OOOMdx8vUUWrN/aUv7qY/6JY/8tZv+esv+z37Y4H8OTVxGO6X91N/rE/5azf89m/2fw55zyPmyKFcqq1d6Pp1XZeRkWN3bJY3ANu+d18crpM//Pdsc44I9f4Oh5o1u7tn0XUVW3cMbW8AJ0mdcHPHJGBj1PC9DVvT2b7Bcfuph89//wAtZv8Anu3qvbvng/xYNGvM39han+6m/wCPS86yzev+72754P8AFg0teU0TXtlo/ifVd35BfXtqFuMW8gxI3TR50x+5z3Xj1x2PzdK4TS7mOT43eIXMGIIvsCBBp8nzZtro58j7/Un8t3TmvR75iVuP3UwzI3WWY4/c+6/jzzjj7vNcHpFleQfGnxLfS6dexWtzPYLDM3n7ZmSzuAwWTbuJGRkAfoc0SvZHHKzcLJ7Pqv5X5f8AAOwtr21MtmDbyHMcec6PO2fkk6jHzfUdeD/Caq213bfb5HMD4NrZD/kEzk58yTOeO+evR+g6Gta2ZvOs/wB1Mf3cfSWYZ+STphePwyODjgnFO1Zv7Sl/dTH/AESx/wCWs3/PWX/Z79scD+HJpu90dCcfe0ey6rv6Al7a7pf9Hk/1if8AMHnP/LZh6cccY7j5eoqpY3dsljcA2753Xxyukz/892xzjgj1/g6HmtdGO6X91N/rE/5azf8APZv9n8Oec8j5siqens32C4/dTD57/wD5azf8929V7d88H+LBo1uCceV6PddV2fkeKaXPHJ8bfiAoSQxxaZdHaLWQqhdLfblMZT7h5bG3Az0r2u+vbULcYt5BiRumjzpj9znuvHrjsfm6V5D4aikPxe+L84jcxrYhGw7gqWjyM4GT90/ewPXFe1XzErcfuphmRussxx+591/HnnHH3eaUb3OXB2VJXT3l1X93yM+8urVtUscW7YW+OQdGnHH2Z+AuMnk529f4ulSW17amWzBt5DmOPOdHnbPySdRj5vqOvB/hNT3zt/aunfuJ/wDj/PHnXGf+PWTj7uc989ccYxzUtszedZ/upj+7j6SzDPySdMLx+GRwccE4avqdEmuRaP4e67vyMm2u7b7fI5gfBtbIf8gmcnPmSZzx3z16P0HQ1aS9td0v+jyf6xP+YPOf+WzD0444x3Hy9RRas39pS/upj/olj/y1m/56y/7Pftjgfw5NXEY7pf3U3+sT/lrN/wA9m/2fw55zyPmyKFcqq1d6Pp1XZeRkWN3bJY3ANu+d18crpM//AD3bHOOCPX+Doea8X+Il20vxwsrS3jYRzWEk5/cOhURJejGzG5R8/fpjnjmvc9PZvsFx+6mHz3//AC1m/wCe7eq9u+eD/Fg1414vBP7QpYI/Hhy7JG58j/j4HJxnv3HPfHNS78pliLOrBWfx+Xd+R7LfXtqFuMW8gxI3TR50x+5z3Xj1x2PzdKjvLq1bVLHFu2FvjkHRpxx9mfgLjJ5OdvX+LpWhfMStx+6mGZG6yzHH7n3X8eeccfd5qK+dv7V079xP/wAf54864z/x6ycfdznvnrjjGOap3sXTats/hfVdvQgtr21MtmDbyHMcec6PO2fkk6jHzfUdeD/Caq213bfb5HMD4NrZD/kEzk58yTOeO+evR+g6Gta2ZvOs/wB1Mf3cfSWYZ+STphePwyODjgnFO1Zv7Sl/dTH/AESx/wCWs3/PWX/Z79scD+HJod7opOPvaPZdV39AS9td0v8Ao8n+sT/mDzn/AJbMPTjjjHcfL1FVLG7tksbgG3fO6+OV0mf/AJ7tjnHBHr/B0PNa6Md0v7qb/WJ/y1m/57N/s/hzznkfNkVT09m+wXH7qYfPf/8ALWb/AJ7t6r2754P8WDRrcE48r0e66rs/I81/aMuIZPhXqAijeM+byTYy24x9oQDlhhuvQciu50u5toPDtpH5EmUhRcrpcx6Ww6MBjrz9fm6Vxv7TG4fCbUQ8cifvVPztIc5uEP8AGB+nJ74NelSr5dm0a2s8CKcLG0kmUHkcAgAqCB2z7fd5oV7nJTcfrD0e3dd/QqXl1atqlji3bC3xyDo044+zPwFxk8nO3r/F0rE8b31sPBGsEQyA/wBkSnJ0uZefs83JYjHp83TgHoprpr52/tXTv3E//H+ePOuM/wDHrJx93Oe+euOMY5rI8ZWl3qXg7VbHT7Waa8udKkggjEkvzu0EyqBkADJI77evOCxAr6nRUa9ktH8PdefkY/w4mhh8KeHxLCzN/YWkjI06Wbs38SjHQj6/d6g11CXtrul/0eT/AFif8wec/wDLZh6cccY7j5eorH8C2lxpuh6TY3VtMlxbaNpcMqiaY4dS4PRSOoOMEj+6Sa6RGO6X91N/rE/5azf89m/2fw55zyPmyKI3sJWUEmntHquy8jIsbu2SxuAbd87r45XSZ/8Anu2OccEev8HQ80a3d2z6LqKrbuGNreAE6TOuDnjkjAx6nhehq3p7N9guP3Uw+e//AOWs3/PdvVe3fPB/iwaNeZv7C1P91N/x6XnWWb1/3e3fPB/iwaWvKdCa9stH8T6ru/IL69tQtxi3kGJG6aPOmP3Oe68euOx+bpUd5dWrapY4t2wt8cg6NOOPsz8BcZPJzt6/xdK0L5iVuP3UwzI3WWY4/c+6/jzzjj7vNRXzt/aunfuJ/wDj/PHnXGf+PWTj7uc989ccYxzTd7GNNq2z+F9V29CC2vbUy2YNvIcxx5zo87Z+STqMfN9R14P8JqrbXdt9vkcwPg2tkP8AkEzk58yTOeO+evR+g6Gta2ZvOs/3Ux/dx9JZhn5JOmF4/DI4OOCcU7Vm/tKX91Mf9Esf+Ws3/PWX/Z79scD+HJod7opOPvaPZdV39AS9td0v+jyf6xP+YPOf+WzD0444x3Hy9RVSxu7ZLG4Bt3zuvjldJn/57tjnHBHr/B0PNa6Md0v7qb/WJ/y1m/57N/s/hzznkfNkVT09m+wXH7qYfPf/APLWb/nu3qvbvng/xYNGtwTjyvR7rquz8iprd3bPouoqtu4Y2t4ATpM64OeOSMDHqeF6Grd9e2oW4xbyDEjdNHnTH7nPdePXHY/N0o15m/sLU/3U3/HpedZZvX/d7d88H+LBq5fMStx+6mGZG6yzHH7n3X8eeccfd5oV7gnHlWj3l1Xl5GfeXVq2qWOLdsLfHIOjTjj7M/AXGTyc7ev8XSpLa9tTLZg28hzHHnOjztn5JOox831HXg/wmp752/tXTv3E/wDx/njzrjP/AB6ycfdznvnrjjGOaltmbzrP91Mf3cfSWYZ+STphePwyODjgnAr6kya5Fo/h7ru/Iyba7tvt8jmB8G1sh/yCZyc+ZJnPHfPXo/QdDVpL213S/wCjyf6xP+YPOf8Alsw9OOOMdx8vUUWrN/aUv7qY/wCiWP8Ay1m/56y/7Pftjgfw5NXEY7pf3U3+sT/lrN/z2b/Z/DnnPI+bIoVyqrV3o+nVdl5Hh/iQq3iLVCg2qbqUgeWY8Def4Tyv0PIopfE/PiXViQR/pc3BJJHznuefz5orje5+h4f+FH0X5Hr95cXP9qWBZNPH+nErjWJSD/ozjlvL4HX5uufl6c1JbXF4JbPMWnjEcec6tKuPkk6ny/l+g6ZA/iNT31zL/aunn7fBn7eTu+0JjP2WQZz5fTtnGM8YzzUttPIJrMi8hXbHGATOg24STg/JxjOOc4yOuQR2JPXU/OpP3F7q+HvLuzItp7oX8n7uw3/ZbIEHVZABiST/AGOvXI/h6jOatpcXm6X91p/+sT/mLSj/AJbMf+efPHOew+bqaLWeQalKBeQjFpYjHnpxiWXA+526n077ulXEnk3S/wCmQjMiH/Xpz++Y5+568/Q55BwBJlVXq/dXTq+yMmxuLr7DOEjsGG6+66rJnJnbjGznvgfxjk4pNbnujouoh47AKbW8BK6rIx5PYbOT6D+Lqat6fPIbC4BvITl78Y89DnM7ZH3O/Uevbb0o16eQ6FqY+2QnNpeDHnpzk8j7nfqPXtt6UrPlNE/3y91fE+r7sL64vCtxiLTzmRsY1aV8/ucd4+fTPc/L0qO8uLn+1LAsmnj/AE4lcaxKQf8ARnHLeXwOvzdc/L05rQvp5GW4zeQvmRjxOhz+5xnhBnjjtzx15qK+uZf7V08/b4M/byd32hMZ+yyDOfL6ds4xnjGeabTtuY03p8K+F9ZdiC2uLwS2eYtPGI4851aVcfJJ1Pl/L9B0yB/EaqW090L+T93Yb/stkCDqsgAxJJ/sdeuR/D1Gc1r208gmsyLyFdscYBM6DbhJOD8nGM45zjI65BFO1nkGpSgXkIxaWIx56cYllwPudup9O+7pQ077lJ/F7q2XV9wS4vN0v7rT/wDWJ/zFpR/y2Y/88+eOc9h83U1Vsbi6+wzhI7BhuvuuqyZyZ24xs574H8Y5OK1knk3S/wCmQjMiH/Xpz++Y5+568/Q55BwKenzyGwuAbyE5e/GPPQ5zO2R9zv1Hr229KLO4J+6/dW66vsyprc90dF1EPHYBTa3gJXVZGPJ7DZyfQfxdTVu+uLwrcYi085kbGNWlfP7nHePn0z3Py9KNenkOhamPtkJzaXgx56c5PI+536j17belXL6eRluM3kL5kY8Toc/ucZ4QZ447c8deaEncE/dXureXV+Rn3lxc/wBqWBZNPH+nErjWJSD/AKM45by+B1+brn5enNSW1xeCWzzFp4xHHnOrSrj5JOp8v5foOmQP4jU99cy/2rp5+3wZ+3k7vtCYz9lkGc+X07ZxjPGM81LbTyCazIvIV2xxgEzoNuEk4PycYzjnOMjrkECT11Jk/cXur4e8u7Mi2nuhfyfu7Df9lsgQdVkAGJJP9jr1yP4eozmraXF5ul/daf8A6xP+YtKP+WzH/nnzxznsPm6mi1nkGpSgXkIxaWIx56cYllwPudup9O+7pVxJ5N0v+mQjMiH/AF6c/vmOfuevP0OeQcASZVV6v3V06vsjJsbi6+wzhI7BhuvuuqyZyZ24xs574H8Y5OKTW57o6LqIeOwCm1vASuqyMeT2Gzk+g/i6mrenzyGwuAbyE5e/GPPQ5zO2R9zv1Hr229KNenkOhamPtkJzaXgx56c5PI+536j17belKz5TRP8AfL3V8T6vuwvri8K3GItPOZGxjVpXz+5x3j59M9z8vSo7y4uf7UsCyaeP9OJXGsSkH/RnHLeXwOvzdc/L05rQvp5GW4zeQvmRjxOhz+5xnhBnjjtzx15qK+uZf7V08/b4M/byd32hMZ+yyDOfL6ds4xnjGeabTtuY03p8K+F9ZdiC2uLwS2eYtPGI4851aVcfJJ1Pl/L9B0yB/EaqW090L+T93Yb/ALLZAg6rIAMSSf7HXrkfw9RnNa9tPIJrMi8hXbHGATOg24STg/JxjOOc4yOuQRTtZ5BqUoF5CMWliMeenGJZcD7nbqfTvu6UNO+5Sfxe6tl1fcEuLzdL+60//WJ/zFpR/wAtmP8Azz545z2HzdTVWxuLr7DOEjsGG6+66rJnJnbjGznvgfxjk4rWSeTdL/pkIzIh/wBenP75jn7nrz9DnkHAp6fPIbC4BvITl78Y89DnM7ZH3O/Uevbb0os7gn7r91brq+zKmtz3R0XUQ8dgFNreAldVkY8nsNnJ9B/F1NW764vCtxiLTzmRsY1aV8/ucd4+fTPc/L0o16eQ6FqY+2QnNpeDHnpzk8j7nfqPXtt6Vcvp5GW4zeQvmRjxOhz+5xnhBnjjtzx15oSdwT91e6t5dX5GfeXFz/algWTTx/pxK41iUg/6M45by+B1+brn5enNSW1xeCWzzFp4xHHnOrSrj5JOp8v5foOmQP4jU99cy/2rp5+3wZ+3k7vtCYz9lkGc+X07ZxjPGM81LbTyCazIvIV2xxgEzoNuEk4PycYzjnOMjrkECT11Jk/cXur4e8u7Mi2nuhfyfu7Df9lsgQdVkAGJJP8AY69cj+HqM5q2lxebpf3Wn/6xP+YtKP8Alsx/5588c57D5upotZ5BqUoF5CMWliMeenGJZcD7nbqfTvu6VcSeTdL/AKZCMyIf9enP75jn7nrz9DnkHAEmVVer91dOr7IybG4uvsM4SOwYbr7rqsmcmduMbOe+B/GOTik1ue6Oi6iHjsAptbwErqsjHk9hs5PoP4upq3p88hsLgG8hOXvxjz0Ocztkfc79R69tvSjXp5DoWpj7ZCc2l4MeenOTyPud+o9e23pSs+U0T/fL3V8T6vuwvri8K3GItPOZGxjVpXz+5x3j59M9z8vSo7y4uf7UsCyaeP8ATiVxrEpB/wBGcct5fA6/N1z8vTmtC+nkZbjN5C+ZGPE6HP7nGeEGeOO3PHXmor65l/tXTz9vgz9vJ3faExn7LIM58vp2zjGeMZ5ptO25jTenwr4X1l2ILa4vBLZ5i08YjjznVpVx8knU+X8v0HTIH8RqpbT3Qv5P3dhv+y2QIOqyADEkn+x165H8PUZzWvbTyCazIvIV2xxgEzoNuEk4PycYzjnOMjrkEU7WeQalKBeQjFpYjHnpxiWXA+526n077ulDTvuUn8XurZdX3BLi83S/utP/ANYn/MWlH/LZj/zz545z2HzdTVWxuLr7DOEjsGG6+66rJnJnbjGznvgfxjk4rWSeTdL/AKZCMyIf9enP75jn7nrz9DnkHAp6fPIbC4BvITl78Y89DnM7ZH3O/Uevbb0os7gn7r91brq+zPLPDKXSePfi9c7LXyJ444yxvWX5lgJIU7cycOMA43fy9Tvri8K3GItPOZGxjVpXz+5x3j59M9z8vSuUs9GvtKv/AIh391cWyxaqJZoSs6lnQQIpyNvcg4GBkcjArt76eRluM3kL5kY8Toc/ucZ4QZ447c8deaIp3McMuWjG8esur7oz7y4uf7UsCyaeP9OJXGsSkH/RnHLeXwOvzdc/L05qS2uLwS2eYtPGI4851aVcfJJ1Pl/L9B0yB/EanvrmX+1dPP2+DP28nd9oTGfssgzny+nbOMZ4xnmpbaeQTWZF5Cu2OMAmdBtwknB+TjGcc5xkdcggSeuppJ+4vdXw95d2ZFtPdC/k/d2G/wCy2QIOqyADEkn+x165H8PUZzVtLi83S/utP/1if8xaUf8ALZj/AM8+eOc9h83U0Ws8g1KUC8hGLSxGPPTjEsuB9zt1Pp33dKuJPJul/wBMhGZEP+vTn98xz9z15+hzyDgCTKqvV+6unV9kZNjcXX2GcJHYMN1911WTOTO3GNnPfA/jHJxXn17bmX4veJbydrZJovCsiJGLpyG33EnKvt+bAU8HG7IHTJHpenzyGwuAbyE5e/GPPQ5zO2R9zv1Hr229K4S5WU/E3xlcfaYwP+Ea8skyKN+6ac4B2/NnaegGfUVLT5SK2taCt9vu+7O7vri8K3GItPOZGxjVpXz+5x3j59M9z8vSo7y4uf7UsCyaeP8ATiVxrEpB/wBGcct5fA6/N1z8vTmtC+nkZbjN5C+ZGPE6HP7nGeEGeOO3PHXmor65l/tXTz9vgz9vJ3faExn7LIM58vp2zjGeMZ5qmnbcdN6fCvhfWXYgtri8EtnmLTxiOPOdWlXHySdT5fy/QdMgfxGqltPdC/k/d2G/7LZAg6rIAMSSf7HXrkfw9RnNa9tPIJrMi8hXbHGATOg24STg/JxjOOc4yOuQRTtZ5BqUoF5CMWliMeenGJZcD7nbqfTvu6UNO+5Sfxe6tl1fcEuLzdL+60//AFif8xaUf8tmP/PPnjnPYfN1NVbG4uvsM4SOwYbr7rqsmcmduMbOe+B/GOTitZJ5N0v+mQjMiH/Xpz++Y5+568/Q55BwKenzyGwuAbyE5e/GPPQ5zO2R9zv1Hr229KLO4J+6/dW66vszzL9o+Wd/hTqIlitQpmBJhvWnIP2hMZDKMD3HJ6mvTb64vCtxiLTzmRsY1aV8/ucd4+fTPc/L0rjvjdFFqHg22tr64hktJdTgSXL+YFRruMMSqBSQQc4zyOm2u9vp5GW4zeQvmRjxOhz+5xnhBnjjtzx15ppanLSdq0vdW3d92Z95cXP9qWBZNPH+nErjWJSD/ozjlvL4HX5uufl6c1JbXF4JbPMWnjEcec6tKuPkk6ny/l+g6ZA/iNT31zL/AGrp5+3wZ+3k7vtCYz9lkGc+X07ZxjPGM81LbTyCazIvIV2xxgEzoNuEk4PycYzjnOMjrkEJJ66nRJ+4vdXw95d2ZFtPdC/k/d2G/wCy2QIOqyADEkn+x165H8PUZzVtLi83S/utP/1if8xaUf8ALZj/AM8+eOc9h83U0Ws8g1KUC8hGLSxGPPTjEsuB9zt1Pp33dKuJPJul/wBMhGZEP+vTn98xz9z15+hzyDgCTKqvV+6unV9kZNjcXX2GcJHYMN1911WTOTO3GNnPfA/jHJxSa3PdHRdRDx2AU2t4CV1WRjyew2cn0H8XU1b0+eQ2FwDeQnL34x56HOZ2yPud+o9e23pRr08h0LUx9shObS8GPPTnJ5H3O/Uevbb0pWfKaJ/vl7q+J9X3YX1xeFbjEWnnMjYxq0r5/c47x8+me5+XpUd5cXP9qWBZNPH+nErjWJSD/ozjlvL4HX5uufl6c1oX08jLcZvIXzIx4nQ5/c4zwgzxx254681FfXMv9q6eft8Gft5O77QmM/ZZBnPl9O2cYzxjPNNp23Mab0+FfC+suxBbXF4JbPMWnjEcec6tKuPkk6ny/l+g6ZA/iNVLae6F/J+7sN/2WyBB1WQAYkk/2OvXI/h6jOa17aeQTWZF5Cu2OMAmdBtwknB+TjGcc5xkdcginazyDUpQLyEYtLEY89OMSy4H3O3U+nfd0oad9yk/i91bLq+4JcXm6X91p/8ArE/5i0o/5bMf+efPHOew+bqaq2NxdfYZwkdgw3X3XVZM5M7cY2c98D+McnFayTybpf8ATIRmRD/r05/fMc/c9efoc8g4FPT55DYXAN5CcvfjHnoc5nbI+536j17belFncE/dfurddX2ZU1ue6Oi6iHjsAptbwErqsjHk9hs5PoP4upq3fXF4VuMRaecyNjGrSvn9zjvHz6Z7n5elGvTyHQtTH2yE5tLwY89Ocnkfc79R69tvSrl9PIy3GbyF8yMeJ0Of3OM8IM8cdueOvNCTuCfur3VvLq/Iz7y4uf7UsCyaeP8ATiVxrEpB/wBGcct5fA6/N1z8vTmpLa4vBLZ5i08YjjznVpVx8knU+X8v0HTIH8Rqe+uZf7V08/b4M/byd32hMZ+yyDOfL6ds4xnjGealtp5BNZkXkK7Y4wCZ0G3CScH5OMZxznGR1yCBJ66kyfuL3V8PeXdmRbT3Qv5P3dhv+y2QIOqyADEkn+x165H8PUZzVtLi83S/utP/ANYn/MWlH/LZj/zz545z2HzdTRazyDUpQLyEYtLEY89OMSy4H3O3U+nfd0q4k8m6X/TIRmRD/r05/fMc/c9efoc8g4Akyqr1furp1fZHh/iQlvEWqFtu43UpOyQyL989GIBYe5HNFL4nJbxLqzFg5N3MSwIIPznnIAz+Qorje5+h4f8AhR9F+R7PeWt+NWsAb/Vyx1AgEra7gfsr8j5Mbsfhg+tPtLS+8+w26jq2fKi27Vtc42S4xlOnXGecZzzii+sV/tXT1+yz/wDH+Vx5dvn/AI9ZDj0z39Me9S21orTWY+zzHdHGcBIecpIeM/Tvzwc84rrUVqfnEprkXw/D2Xdmfa2t79udRfarxaWB3BbbkebJtHKdM9O+Sd3GKtx2l9vn/wCJjq3+tjzhbXr9ofr8nXOfbOc8YqC1tAdSlP2eY5tLE5CQ87pZR39e3c/xcVcS0BaX/R5jiRB9yHjMzD+mOOMjn5cU0kVVmrv4fs9F2Rn2VretYXB+3aqozqAI222P9edxPyZ68tjv93ijXLW9XRNSZr/VWUWl6SrLbYIzyDhM49cc/wB2pNPtFFhcH7PMMPfnJSHjbOw7enfHI/h4o160UaFqZ+zzDFpeHOyHjacdvTv3H8PFKy5TRTXtl8PxPou7J9RtL7Zc7tR1b/Wtnetr1+znrhOuPTjHvTLy1vxq1gDf6uWOoEAlbXcD9lfkfJjdj8MH1qxfWYRbj/R5l2yMOUhGP3O7t+fHGP8AaqK+sV/tXT1+yz/8f5XHl2+f+PWQ49M9/THvRJKxjCat9n4X0XYLS0vvPsNuo6tnyotu1bXONkuMZTp1xnnGc84qpa2t79udRfarxaWB3BbbkebJtHKdM9O+Sd3GK0La0VprMfZ5jujjOAkPOUkPGfp354OecVTtbQHUpT9nmObSxOQkPO6WUd/Xt3P8XFNpXKU173w7Lov5ieO0vt8//Ex1b/Wx5wtr1+0P1+TrnPtnOeMVUsrW9awuD9u1VRnUARttsf687ifkz15bHf7vFaCWgLS/6PMcSIPuQ8ZmYf0xxxkc/Liqen2iiwuD9nmGHvzkpDxtnYdvTvjkfw8UWVwVRWfw7rouzI9ctb1dE1Jmv9VZRaXpKsttgjPIOEzj1xz/AHat6jaX2y53ajq3+tbO9bXr9nPXCdcenGPeoNetFGhamfs8wxaXhzsh42nHb079x/DxVy+swi3H+jzLtkYcpCMfud3b8+OMf7VCSuCqLlXw7y6LyK95a341awBv9XLHUCAStruB+yvyPkxux+GD60+0tL7z7DbqOrZ8qLbtW1zjZLjGU6dcZ5xnPOKL6xX+1dPX7LP/AMf5XHl2+f8Aj1kOPTPf0x71LbWitNZj7PMd0cZwEh5ykh4z9O/PBzzikorUmU1yL4fh7LuzPtbW9+3OovtV4tLA7gttyPNk2jlOmenfJO7jFW47S+3z/wDEx1b/AFsecLa9ftD9fk65z7ZznjFQWtoDqUp+zzHNpYnISHndLKO/r27n+LiriWgLS/6PMcSIPuQ8ZmYf0xxxkc/Limkiqs1d/D9nouyM+ytb1rC4P27VVGdQBG22x/rzuJ+TPXlsd/u8Ua5a3q6JqTNf6qyi0vSVZbbBGeQcJnHrjn+7Umn2iiwuD9nmGHvzkpDxtnYdvTvjkfw8Ua9aKNC1M/Z5hi0vDnZDxtOO3p37j+HilZcpopr2y+H4n0Xdk+o2l9sud2o6t/rWzvW16/Zz1wnXHpxj3pl5a341awBv9XLHUCAStruB+yvyPkxux+GD61YvrMItx/o8y7ZGHKQjH7nd2/PjjH+1UV9Yr/aunr9ln/4/yuPLt8/8eshx6Z7+mPeiSVjGE1b7PwvouwWlpfefYbdR1bPlRbdq2ucbJcYynTrjPOM55xVS1tb37c6i+1Xi0sDuC23I82TaOU6Z6d8k7uMVoW1orTWY+zzHdHGcBIecpIeM/Tvzwc84qna2gOpSn7PMc2lichIed0so7+vbuf4uKbSuUpr3vh2XRfzE8dpfb5/+Jjq3+tjzhbXr9ofr8nXOfbOc8YqpZWt61hcH7dqqjOoAjbbY/wBedxPyZ68tjv8Ad4rQS0BaX/R5jiRB9yHjMzD+mOOMjn5cVT0+0UWFwfs8ww9+clIeNs7Dt6d8cj+HiiyuCqKz+HddF2ZHrlrerompM1/qrKLS9JVltsEZ5BwmceuOf7tW9RtL7Zc7tR1b/Wtnetr1+znrhOuPTjHvUGvWijQtTP2eYYtLw52Q8bTjt6d+4/h4q5fWYRbj/R5l2yMOUhGP3O7t+fHGP9qhJXBVFyr4d5dF5Fe8tb8atYA3+rljqBAJW13A/ZX5HyY3Y/DB9afaWl959ht1HVs+VFt2ra5xslxjKdOuM84znnFF9Yr/AGrp6/ZZ/wDj/K48u3z/AMeshx6Z7+mPepba0VprMfZ5jujjOAkPOUkPGfp354OecUlFakymuRfD8PZd2Z9ra3v251F9qvFpYHcFtuR5sm0cp0z075J3cYq3HaX2+f8A4mOrf62POFtev2h+vydc59s5zxioLW0B1KU/Z5jm0sTkJDzullHf17dz/FxVxLQFpf8AR5jiRB9yHjMzD+mOOMjn5cU0kVVmrv4fs9F2Rn2VretYXB+3aqozqAI222P9edxPyZ68tjv93ijXLW9XRNSZr/VWUWl6SrLbYIzyDhM49cc/3ak0+0UWFwfs8ww9+clIeNs7Dt6d8cj+HijXrRRoWpn7PMMWl4c7IeNpx29O/cfw8UrLlNFNe2Xw/E+i7sn1G0vtlzu1HVv9a2d62vX7OeuE649OMe9MvLW/GrWAN/q5Y6gQCVtdwP2V+R8mN2PwwfWrF9ZhFuP9HmXbIw5SEY/c7u358cY/2qivrFf7V09fss//AB/lceXb5/49ZDj0z39Me9EkrGMJq32fhfRdgtLS+8+w26jq2fKi27Vtc42S4xlOnXGecZzziqlra3v251F9qvFpYHcFtuR5sm0cp0z075J3cYrQtrRWmsx9nmO6OM4CQ85SQ8Z+nfng55xVO1tAdSlP2eY5tLE5CQ87pZR39e3c/wAXFNpXKU173w7Lov5ieO0vt8//ABMdW/1secLa9ftD9fk65z7ZznjFVLK1vWsLg/btVUZ1AEbbbH+vO4n5M9eWx3+7xWgloC0v+jzHEiD7kPGZmH9MccZHPy4qnp9oosLg/Z5hh785KQ8bZ2Hb0745H8PFFlcFUVn8O66LsyPXLW9XRNSZr/VWUWl6SrLbYIzyDhM49cc/3at6jaX2y53ajq3+tbO9bXr9nPXCdcenGPeoNetFGhamfs8wxaXhzsh42nHb079x/DxVy+swi3H+jzLtkYcpCMfud3b8+OMf7VCSuCqLlXw7y6LyK95a341awBv9XLHUCAStruB+yvyPkxux+GD60+0tL7z7DbqOrZ8qLbtW1zjZLjGU6dcZ5xnPOKL6xX+1dPX7LP8A8f5XHl2+f+PWQ49M9/THvUttaK01mPs8x3RxnASHnKSHjP0788HPOKSitSZTXIvh+Hsu7M+1tb37c6i+1Xi0sDuC23I82TaOU6Z6d8k7uMVbjtL7fP8A8THVv9bHnC2vX7Q/X5Ouc+2c54xUFraA6lKfs8xzaWJyEh53Syjv69u5/i4q4loC0v8Ao8xxIg+5DxmZh/THHGRz8uKaSKqzV38P2ei7Iz7K1vWsLg/btVUZ1AEbbbH+vO4n5M9eWx3+7xVPVtBS3j1vVo31Iahc6bcQXErNCRLHG8hAK4wBmQhtoB4GO5Ohp9oosLg/Z5hh785KQ8bZ2Hb0745H8PFGvWijQtTP2eYYtLw52Q8bTjt6d+4/h4pWXKU3GVZJ2+J9F3ZPqNpfbLndqOrf61s71tev2c9cJ1x6cY96ZeWt+NWsAb/Vyx1AgEra7gfsr8j5Mbsfhg+tWL6zCLcf6PMu2RhykIx+53dvz44x/tVFfWK/2rp6/ZZ/+P8AK48u3z/x6yHHpnv6Y96JJWM4TVvs/C+i7BaWl959ht1HVs+VFt2ra5xslxjKdOuM84znnFVLW1vftzqL7VeLSwO4LbcjzZNo5Tpnp3yTu4xWhbWitNZj7PMd0cZwEh5ykh4z9O/PBzziqdraA6lKfs8xzaWJyEh53Syjv69u5/i4ptK5Smve+HZdF/MTx2l9vn/4mOrf62POFtev2h+vydc59s5zxiqlla3rWFwft2qqM6gCNttj/XncT8mevLY7/d4rQS0BaX/R5jiRB9yHjMzD+mOOMjn5cVT0+0UWFwfs8ww9+clIeNs7Dt6d8cj+HiiyuCqKz+HddF2ZneMNBbU9CmGo3msyR2hlvk2PbxsHhnWXIZVyOUwTzjOVFbGo2l9sud2o6t/rWzvW16/Zz1wnXHpxj3qDXrRRoWpn7PMMWl4c7IeNpx29O/cfw8VcvrMItx/o8y7ZGHKQjH7nd2/PjjH+1Qkrkx5Vaa5bu/RdGv8AMr3lrfjVrAG/1csdQIBK2u4H7K/I+TG7H4YPrT7S0vvPsNuo6tnyotu1bXONkuMZTp1xnnGc84ovrFf7V09fss//AB/lceXb5/49ZDj0z39Me9S21orTWY+zzHdHGcBIecpIeM/Tvzwc84pKK1CU1yL4fh7LuzPtbW9+3OovtV4tLA7gttyPNk2jlOmenfJO7jFW47S+3z/8THVv9bHnC2vX7Q/X5Ouc+2c54xUFraA6lKfs8xzaWJyEh53Syjv69u5/i4q4loC0v+jzHEiD7kPGZmH9MccZHPy4ppIqrNXfw/Z6LsjPsrW9awuD9u1VRnUARttsf687ifkz15bHf7vFGuWt6uiakzX+qsotL0lWW2wRnkHCZx645/u1Jp9oosLg/Z5hh785KQ8bZ2Hb0745H8PFGvWijQtTP2eYYtLw52Q8bTjt6d+4/h4pWXKaKa9svh+J9F3ZPqNpfbLndqOrf61s71tev2c9cJ1x6cY96ZeWt+NWsAb/AFcsdQIBK2u4H7K/I+TG7H4YPrVi+swi3H+jzLtkYcpCMfud3b8+OMf7VRX1iv8Aaunr9ln/AOP8rjy7fP8Ax6yHHpnv6Y96JJWMYTVvs/C+i7BaWl959ht1HVs+VFt2ra5xslxjKdOuM84znnFVLW1vftzqL7VeLSwO4LbcjzZNo5Tpnp3yTu4xWhbWitNZj7PMd0cZwEh5ykh4z9O/PBzziqdraA6lKfs8xzaWJyEh53Syjv69u5/i4ptK5Smve+HZdF/MTx2l9vn/AOJjq3+tjzhbXr9ofr8nXOfbOc8YqpZWt61hcH7dqqjOoAjbbY/153E/Jnry2O/3eK0EtAWl/wBHmOJEH3IeMzMP6Y44yOflxVPT7RRYXB+zzDD35yUh42zsO3p3xyP4eKLK4KorP4d10XZkeuWt6uiakzX+qsotL0lWW2wRnkHCZx645/u1b1G0vtlzu1HVv9a2d62vX7OeuE649OMe9Qa9aKNC1M/Z5hi0vDnZDxtOO3p37j+Hirl9ZhFuP9HmXbIw5SEY/c7u358cY/2qElcFUXKvh3l0XkV7y1vxq1gDf6uWOoEAlbXcD9lfkfJjdj8MH1p9paX3n2G3UdWz5UW3atrnGyXGMp064zzjOecUX1iv9q6ev2Wf/j/K48u3z/x6yHHpnv6Y96ltrRWmsx9nmO6OM4CQ85SQ8Z+nfng55xSUVqTKa5F8Pw9l3Zn2tre/bnUX2q8WlgdwW25HmybRynTPTvkndxircdpfb5/+Jjq3+tjzhbXr9ofr8nXOfbOc8YqC1tAdSlP2eY5tLE5CQ87pZR39e3c/xcVcS0BaX/R5jiRB9yHjMzD+mOOMjn5cU0kVVmrv4fs9F2R4h4nDL4l1ZZGkZxdyhmk27id55O3jP049KKPE67PEurIFK7buYYIAI+c+nH5cUVxPc/RcP/Cj6L8jNooooNgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75&deg;.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_32_41482=[""].join("\n");
var outline_f40_32_41482=null;
var title_f40_32_41483="Pathogen malignancy-related gastroparesis";
var content_f40_32_41483=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F70134&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F70134&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pathogenesis of malignancy-related gastroparesis in various cancer types",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pathogenesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Pancreatic carcinoma",
"       </td>",
"       <td>",
"        Autovagotomy secondary to micrometastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Retroperitoneal nerve invasion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Production of tumor-related gastroparetic factor or hormonal secretion of inhibitory neurotransmitters, such as vasopressin, by the tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disruption of the neuroendocrine feedback inhibitory system",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paraneoplastic involvement with antineuronal antibodies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Gastric carcinoma",
"       </td>",
"       <td>",
"        Mass effect from the tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tumor infiltration into myenteric plexus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vagotomy post gastric surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leiomyosarcoma",
"       </td>",
"       <td>",
"        Paraneoplastic process",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cholangiocarcinoma",
"       </td>",
"       <td>",
"        Tumor infiltration of the vagus nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Small cell lung cancer",
"       </td>",
"       <td>",
"        Autoimmune antibodies (ANNA-1) causing paraneoplastic visceral neuropathy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ANNA-1: antineuronal nuclear antibody type 1, also known as anti-Hu.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Donthireddy K, Ailawadhi S, Nasser E,&nbsp;et al. Malignant gastroparesis: pathogenesis and management of an underrecognized disorder. J Support Oncol 2007; 5:355. Illustrations used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_32_41483=[""].join("\n");
var outline_f40_32_41483=null;
var title_f40_32_41484="Box and whiskers plot";
var content_f40_32_41484=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F57798&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F57798&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Box and whiskers plot",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 407px; height: 265px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A box and whiskers plot is a graphical depiction of the interquartile range, a measure of dispersion of the data.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_32_41484=[""].join("\n");
var outline_f40_32_41484=null;
var title_f40_32_41485="Stomatocyte EM";
var content_f40_32_41485=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F68313&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F68313&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scanning electron micrograph of a stomatocyte",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 343px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Scanning electron micrograph of a stomatocyte.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stanley L Schrier, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_32_41485=[""].join("\n");
var outline_f40_32_41485=null;
var title_f40_32_41486="Fingertip bruises";
var content_f40_32_41486=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F52863%7EEM%2F61566&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F52863%7EEM%2F61566&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fingertip bruises",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 216px; height: 141px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the oval shaped bruises on the child's trunk.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Joan E Shook, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fingertip bruises",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 216px; height: 144px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the oval shaped bruises on the child's upper arm and forearm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Joan E Shook, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_32_41486=[""].join("\n");
var outline_f40_32_41486=null;
var title_f40_32_41487="TTE with color Doppler post-ASD repair";
var content_f40_32_41487=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/54350/asdpopcd_conv.mp4?title=TTE+with+color+Doppler+post-ASD+repair\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transthoracic echocardiogram with color Doppler post-repair of an atrial septal defect showing a small residual defect",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 284px; height: 236px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Color flow Doppler demonstates that post-operatively, there is a small, residual atrial septal defect seen as a minimal amount of left to right atrial blood flow.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_32_41487=[""].join("\n");
var outline_f40_32_41487=null;
